UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
18817,Euroclear,Twitter API,Twitter,Facing the FCA armed with data #AAA Websites Euroclear Fintech https://t.co/BLgUGxg6qW #regtech,nan,Facing the FCA armed with data #AAA Websites Euroclear Fintech https://t.co/BLgUGxg6qW #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['FCA', 'data', 'Fintech', 'co', 'BLgUGxg6qW', 'FCA', 'data', 'Fintech', 'co', 'BLgUGxg6qW']",2023-02-20,2023-02-25,Unknown
18826,Deutsche Boerse,Twitter API,Twitter,German exchange Deutsche Boerse has selected Google Cloud to provide the backbone of its digital assets business‚Ä¶ https://t.co/HzsN8zH61r,nan,German exchange Deutsche Boerse has selected Google Cloud to provide the backbone of its digital assets business‚Ä¶ https://t.co/HzsN8zH61r,neutral,0.08,0.91,0.01,neutral,0.08,0.91,0.01,True,English,"['digital assets business', 'German exchange', 'Deutsche Boerse', 'Google Cloud', 'backbone', 'HzsN8zH61r', 'digital assets business', 'German exchange', 'Deutsche Boerse', 'Google Cloud', 'backbone', 'HzsN8zH61r']",2023-02-20,2023-02-25,Unknown
18827,Deutsche Boerse,Twitter API,Twitter,üì£ Deutsche B√∂rse has selected Google Cloud to provide the backbone for a new digital asset business platform that w‚Ä¶ https://t.co/cb7rTguWgi,nan,üì£ Deutsche B√∂rse has selected Google Cloud to provide the backbone for a new digital asset business platform that w‚Ä¶ https://t.co/cb7rTguWgi,neutral,0.08,0.91,0.01,neutral,0.08,0.91,0.01,True,English,"['new digital asset business platform', 'Deutsche B√∂rse', 'Google Cloud', 'backbone', 'new digital asset business platform', 'Deutsche B√∂rse', 'Google Cloud', 'backbone']",2023-02-20,2023-02-25,Unknown
18828,Deutsche Boerse,Twitter API,Twitter,Deutsche Boerse announced on Friday that #Commerzbank AG will rejoin the #DAX index.The lender will replace Linde‚Ä¶ https://t.co/eliKa4OCcQ,nan,Deutsche Boerse announced on Friday that #Commerzbank AG will rejoin the #DAX index.The lender will replace Linde‚Ä¶ https://t.co/eliKa4OCcQ,neutral,0.01,0.98,0.0,neutral,0.01,0.98,0.0,True,English,"['Deutsche Boerse', 'Friday', 'lender', 'Linde', 'eliKa4OCcQ', 'Deutsche Boerse', 'Friday', 'lender', 'Linde', 'eliKa4OCcQ']",2023-02-19,2023-02-25,Unknown
18894,Euroclear,Twitter API,Twitter,And obviously assumptions about the attribution of Belgium's holdings (the Euroclear custodial account  which the F‚Ä¶ https://t.co/9bqRqJpxHf,nan,And obviously assumptions about the attribution of Belgium's holdings (the Euroclear custodial account  which the F‚Ä¶ https://t.co/9bqRqJpxHf,neutral,0.08,0.9,0.02,neutral,0.08,0.9,0.02,True,English,"['Euroclear custodial account', 'assumptions', 'Belgium', 'holdings', 'Euroclear custodial account', 'assumptions', 'Belgium', 'holdings']",2023-02-21,2023-02-25,Unknown
18895,Euroclear,Twitter API,Twitter,State of play: neobanks #AAA Websites Euroclear Fintech https://t.co/lEE8n6h3zQ #regtech,nan,State of play: neobanks #AAA Websites Euroclear Fintech https://t.co/lEE8n6h3zQ #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['AAA Websites', 'State', 'play', 'neobanks', 'Fintech', 'AAA Websites', 'State', 'play', 'neobanks', 'Fintech']",2023-02-21,2023-02-25,Unknown
18897,Deutsche Boerse,Twitter API,Twitter,Trading Technologies facilitates access to Eurex EnLight - Deutsche B√∂rse‚Äôs derivatives-focused exchange  Eurex an‚Ä¶ https://t.co/aF4i9R9wtz,nan,Trading Technologies facilitates access to Eurex EnLight - Deutsche B√∂rse‚Äôs derivatives-focused exchange  Eurex an‚Ä¶ https://t.co/aF4i9R9wtz,neutral,0.04,0.96,0.01,neutral,0.04,0.96,0.01,True,English,"['Deutsche B√∂rse', 'Trading Technologies', 'derivatives-focused exchange', 'Eurex EnLight', 'access', 'Deutsche B√∂rse', 'Trading Technologies', 'derivatives-focused exchange', 'Eurex EnLight', 'access']",2023-02-21,2023-02-25,Unknown
18898,Deutsche Boerse,Twitter API,Twitter,Deutsche Boerse downgraded to Hold from Buy at Jefferies$DBOEY,nan,Deutsche Boerse downgraded to Hold from Buy at Jefferies$DBOEY,neutral,0.01,0.96,0.03,neutral,0.01,0.96,0.03,True,English,"['Deutsche Boerse', 'Buy', 'Jefferies', 'Deutsche Boerse', 'Buy', 'Jefferies']",2023-02-21,2023-02-25,Unknown
18899,Deutsche Boerse,Twitter API,Twitter,deutsche boerse plunge and everything else flat in the dax at the open was a little strange. escalated quickly :),nan,deutsche boerse plunge and everything else flat in the dax at the open was a little strange. escalated quickly :),negative,0.01,0.1,0.89,negative,0.01,0.1,0.89,True,English,"['deutsche boerse plunge', 'everything', 'dax', 'open', 'deutsche boerse plunge', 'everything', 'dax', 'open']",2023-02-21,2023-02-25,Unknown
18900,Deutsche Boerse,Twitter API,Twitter,what happened to deutsche boerse here? glitch? gm dax https://t.co/QCsbVd15Wu,nan,what happened to deutsche boerse here? glitch? gm dax https://t.co/QCsbVd15Wu,negative,0.01,0.05,0.93,negative,0.01,0.05,0.93,True,English,"['deutsche boerse', 'glitch', 'gm', 'QCsbVd15Wu', 'deutsche boerse', 'glitch', 'gm', 'QCsbVd15Wu']",2023-02-21,2023-02-25,Unknown
18965,Euroclear,Twitter API,Twitter,Wells Fargo plans financial planning upgrade to its mobile app #AAA Websites Euroclear Fintech https://t.co/0V0WVFHwzm #regtech,nan,Wells Fargo plans financial planning upgrade to its mobile app #AAA Websites Euroclear Fintech https://t.co/0V0WVFHwzm #regtech,neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['financial planning upgrade', 'Wells Fargo', 'mobile app', 'Fintech', 'financial planning upgrade', 'Wells Fargo', 'mobile app', 'Fintech']",2023-02-22,2023-02-25,Unknown
18966,Euroclear,Twitter API,Twitter,@Mousacisse1 How is that possible? When they pay don‚Äôt they have to pay via euroclear and euroclear is holding the‚Ä¶ https://t.co/U7QYM47S3C,nan,@Mousacisse1 How is that possible? When they pay don‚Äôt they have to pay via euroclear and euroclear is holding the‚Ä¶ https://t.co/U7QYM47S3C,neutral,0.05,0.92,0.03,neutral,0.05,0.92,0.03,True,English,"['Mousacisse1', 'euroclear', 'U7QYM47S3C', 'Mousacisse1', 'euroclear', 'U7QYM47S3C']",2023-02-22,2023-02-25,Unknown
18967,Euroclear,Twitter API,Twitter,National Australia Bank builds its own fintechs #AAA Websites Euroclear Fintech https://t.co/BV1abMYlfa #regtech,nan,National Australia Bank builds its own fintechs #AAA Websites Euroclear Fintech https://t.co/BV1abMYlfa #regtech,neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['National Australia Bank', 'fintechs', 'BV1abMYlfa', 'regtech', 'National Australia Bank', 'fintechs', 'BV1abMYlfa', 'regtech']",2023-02-22,2023-02-25,Unknown
18968,Euroclear,Twitter API,Twitter,Fintech backed by Citi  BofA takes on 'antiquated' syndicated loan trading #AAA Websites Euroclear Fintech https://t.co/1pLuoTjfUn #regtech,nan,Fintech backed by Citi  BofA takes on 'antiquated' syndicated loan trading #AAA Websites Euroclear Fintech https://t.co/1pLuoTjfUn #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"[""antiquated' syndicated loan trading"", 'Citi', 'BofA', 'Fintech', ""antiquated' syndicated loan trading"", 'Citi', 'BofA', 'Fintech']",2023-02-22,2023-02-25,Unknown
18971,Deutsche Boerse,Twitter API,Twitter,@ToffCap1 Maybe Deutsche Boerse steps in? Aligns nicely for them given they already have a fund biz.,nan,@ToffCap1 Maybe Deutsche Boerse steps in? Aligns nicely for them given they already have a fund biz.,positive,0.99,0.01,0.0,positive,0.99,0.01,0.0,True,English,"['Deutsche Boerse', 'fund biz', 'Aligns', 'Deutsche Boerse', 'fund biz', 'Aligns']",2023-02-22,2023-02-25,Unknown
18972,Deutsche Boerse,Twitter API,Twitter,We're excited to announce #GoogleCloud's partnership with Deutsche B√∂rse to enhance  economize  and concentrate Deu‚Ä¶ https://t.co/hS88ypbawd,nan,We're excited to announce #GoogleCloud's partnership with Deutsche B√∂rse to enhance  economize  and concentrate Deu‚Ä¶ https://t.co/hS88ypbawd,positive,0.68,0.31,0.01,positive,0.68,0.31,0.01,True,English,"['Deutsche B√∂rse', 'partnership', 'Deutsche B√∂rse', 'partnership']",2023-02-22,2023-02-25,Unknown
18973,Deutsche Boerse,Twitter API,Twitter,üì£ Deutsche B√∂rse has selected Google Cloud to provide the backbone for a new digital asset business platform that w‚Ä¶ https://t.co/CxboBmGTGW,nan,üì£ Deutsche B√∂rse has selected Google Cloud to provide the backbone for a new digital asset business platform that w‚Ä¶ https://t.co/CxboBmGTGW,neutral,0.08,0.91,0.02,neutral,0.08,0.91,0.02,True,English,"['new digital asset business platform', 'Deutsche B√∂rse', 'Google Cloud', 'backbone', 'new digital asset business platform', 'Deutsche B√∂rse', 'Google Cloud', 'backbone']",2023-02-22,2023-02-25,Unknown
19029,Deutsche Boerse,Twitter API,Twitter,The participating #exchange groups include Deutsche Boerse Group  Euronext  Nasdaq  and SIX Group  as well as the l‚Ä¶ https://t.co/aLjS1odRh8,nan,The participating #exchange groups include Deutsche Boerse Group  Euronext  Nasdaq  and SIX Group  as well as the l‚Ä¶ https://t.co/aLjS1odRh8,neutral,0.07,0.92,0.01,neutral,0.07,0.92,0.01,True,English,"['participating #exchange groups', 'Deutsche Boerse Group', 'SIX Group', 'Euronext', 'Nasdaq', 'participating #exchange groups', 'Deutsche Boerse Group', 'SIX Group', 'Euronext', 'Nasdaq']",2023-02-23,2023-02-25,Unknown
19030,Deutsche Boerse,Twitter API,Twitter,We're excited to announce #GoogleCloud's partnership with Deutsche B√∂rse to enhance  economize  and concentrate Deu‚Ä¶ https://t.co/grBSB3xX4z,nan,We're excited to announce #GoogleCloud's partnership with Deutsche B√∂rse to enhance  economize  and concentrate Deu‚Ä¶ https://t.co/grBSB3xX4z,positive,0.9,0.1,0.0,positive,0.9,0.1,0.0,True,English,"['Deutsche B√∂rse', 'partnership', 'grBSB3xX4z', 'Deutsche B√∂rse', 'partnership', 'grBSB3xX4z']",2023-02-23,2023-02-25,Unknown
19121,Deutsche Boerse,Twitter API,Twitter,I found you a Death Cross on the daily chart of Deutsche Boerse AG. $0H3T #0H3T #deathcross #bearish‚Ä¶ https://t.co/iT6QYU7tWe,nan,I found you a Death Cross on the daily chart of Deutsche Boerse AG. $0H3T #0H3T #deathcross #bearish‚Ä¶ https://t.co/iT6QYU7tWe,negative,0.0,0.48,0.52,negative,0.0,0.48,0.52,True,English,"['Deutsche Boerse AG', 'Death Cross', 'daily chart', 'Deutsche Boerse AG', 'Death Cross', 'daily chart']",2023-02-24,2023-02-25,Unknown
19195,EuroNext,Twitter API,Twitter,Euronext wheat fell to a new one-month low on Friday  pressured by export competition from Russia and expectations‚Ä¶ https://t.co/HisRAooTgw,nan,Euronext wheat fell to a new one-month low on Friday  pressured by export competition from Russia and expectations‚Ä¶ https://t.co/HisRAooTgw,negative,0.01,0.42,0.58,negative,0.01,0.42,0.58,True,English,"['Euronext wheat', 'new one', 'export competition', 'month', 'Friday', 'Russia', 'expectations', 'Euronext wheat', 'new one', 'export competition', 'month', 'Friday', 'Russia', 'expectations']",2023-02-24,2023-02-25,Unknown
19196,EuroNext,Twitter API,Twitter,Other European stock markets lower on Friday  02/24/2023: Euronext 100 -1.58% at 1 336.64  lower for the week  Euro‚Ä¶ https://t.co/Gj8OJblAKz,nan,Other European stock markets lower on Friday  02/24/2023: Euronext 100 -1.58% at 1 336.64  lower for the week  Euro‚Ä¶ https://t.co/Gj8OJblAKz,neutral,0.07,0.91,0.02,neutral,0.07,0.91,0.02,True,English,"['Other European stock markets', 'Friday', 'Euronext', 'week', 'Gj8OJblAKz', 'Other European stock markets', 'Friday', 'Euronext', 'week', 'Gj8OJblAKz']",2023-02-24,2023-02-25,Unknown
19197,EuroNext,Twitter API,Twitter,@osloboers Who's euronext. A startup or shutdown?,nan,@osloboers Who's euronext. A startup or shutdown?,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['osloboers', 'startup', 'shutdown', 'osloboers', 'startup', 'shutdown']",2023-02-24,2023-02-25,Unknown
19198,EuroNext,Twitter API,Twitter,Nice the #website #tech_eu #SlavaUkraini  #Volocopter tops up Series E round  #Euronext chases ‚Ç¨5.5 billion Allfu‚Ä¶ https://t.co/59wxAbsLmH,nan,Nice the #website #tech_eu #SlavaUkraini  #Volocopter tops up Series E round  #Euronext chases ‚Ç¨5.5 billion Allfu‚Ä¶ https://t.co/59wxAbsLmH,positive,1.0,0.0,0.0,positive,1.0,0.0,0.0,True,English,"['Series E round', 'website', 'eu', 'Volocopter', 'Series E round', 'website', 'eu', 'Volocopter']",2023-02-24,2023-02-25,Unknown
19199,EuroNext,Twitter API,Twitter,Digital Value starts listing process on Euronext Milan market https://t.co/8uLOOeZRj7 https://t.co/eQDfcFYHGD,nan,Digital Value starts listing process on Euronext Milan market https://t.co/8uLOOeZRj7 https://t.co/eQDfcFYHGD,neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['Euronext Milan market', 'Digital Value', 'listing process', '8uLOOeZRj7', 'Euronext Milan market', 'Digital Value', 'listing process', '8uLOOeZRj7']",2023-02-24,2023-02-25,Unknown
19207,Euroclear,NewsApi.org,https://finance.yahoo.com/news/lundin-gold-declares-quarterly-dividend-003000571.html,LUNDIN GOLD DECLARES QUARTERLY DIVIDEND,"Lundin Gold Inc. (TSX: LUG) (Nasdaq Stockholm: LUG) (OTCQX: LUGDF) (""Lundin Gold"" or the ""Company"") is pleased to announce that its Board of Directors has...","Lundin Gold Logo (CNW Group/Lundin Gold Inc.)VANCOUVER  BC  Feb. 23  2023 /CNW/ - Lundin Gold Inc. (TSX: LUG) (Nasdaq Stockholm: LUG) (OTCQX: LUGDF) (""Lundin Gold"" or the ""Company"") is pleased to announce that its Board of Directors has declared a quarterly cash dividend of US$0.10 per common share. The dividend will be payable on March 31  2023  to shareholders of record at the close of business on March 13  2023. This dividend qualifies as an ""eligible dividend"" for Canadian income tax purposes. View PDFBased on today's closing price of the Company's common shares on the Toronto Stock Exchange (""TSX"") of CAD$13.04  this dividend of US$0.10 per common share represents an estimated annual yield of approximately 4.2%.1Dividends for shares trading on the TSX and the OTCQX will be paid in Canadian dollars on March 31  2023  based on the prevailing exchange rate at the record date. Dividends for shares trading on Nasdaq Stockholm will be paid in Swedish kronor (SEK) in accordance with Euroclear principles on April 4  2023. To execute the payment of the dividend  a temporary administrative cross-border transfer closure will be applied by Euroclear from March 9  2023 up to and including March 13  2023 during which period shares of the Company cannot be transferred between TSX and Nasdaq Stockholm. Payments to shareholders who are not residents of Canada will be net of any Canadian withholding taxes that may be applicable. For further details  please visit: www.lundingold/investors/dividends.About Lundin GoldLundin Gold  headquartered in Vancouver  Canada  owns the Fruta del Norte gold mine in southeast Ecuador. Fruta del Norte is among the highest-grade operating gold mines in the world.The Company's board and management team have extensive expertise in mine operations and are dedicated to operating Fruta del Norte responsibly. The Company operates with transparency and in accordance with international best practices. Lundin Gold is committed to delivering value to its shareholders  while simultaneously providing economic and social benefits to impacted communities  fostering a healthy and safe workplace and minimizing the environmental impact. The Company believes that the value created through the development of Fruta del Norte will benefit its shareholders  the Government and the citizens of Ecuador.Story continuesAdditional InformationThe information in this release is subject to the disclosure requirements of Lundin Gold under the EU Market Abuse Regulation. This information was publicly communicated on February 23  2023 at 4:30 p.m. Pacific Time through the contact persons set out below.Caution Regarding Forward-Looking Information and StatementsCertain of the information and statements in this press release are considered ""forward-looking information"" or ""forward-looking statements"" as those terms are defined under Canadian securities laws (collectively referred to as ""forward-looking statements""). Any statements that express or involve discussions with respect to predictions  expectations  beliefs  plans  projections  objectives  assumptions or future events or performance (often  but not always  identified by words or phrases such as ""believes""  ""anticipates""  ""expects""  ""is expected""  ""scheduled""  ""estimates""  ""pending""  ""intends""  ""plans""  ""forecasts""  ""targets""  or ""hopes""  or variations of such words and phrases or statements that certain actions  events or results ""may""  ""could""  ""would""  ""will""  ""should"" ""might""  ""will be taken""  or ""occur"" and similar expressions) are not statements of historical fact and may be forward-looking statements. By their nature  forward-looking statements and information involve assumptions  inherent risks and uncertainties  many of which are difficult to predict  and are usually beyond the control of management  that could cause actual results to be materially different from those expressed by these forward-looking statements and information. Lundin Gold believes that the expectations reflected in this forward-looking information are reasonable  but no assurance can be given that these expectations will prove to be correct. Forward-looking information should not be unduly relied upon. This information speaks only as of the date of this press release  and the Company will not necessarily update this information  unless required to do so by securities laws.This press release contains forward-looking information in a number of places  such as in statements relating to the Company's declaration and payment of dividends pursuant to its dividend policy and the estimated annual yield. There can be no assurance that such statements will prove to be accurate  as Lundin Gold's actual results and future events could differ materially from those anticipated in this forward-looking information as a result of the factors discussed in the ""Risk Factors"" section in Lundin Gold's Management Discussion & Analysis dated February 23  2023  which is available at www.lundingold.com or on SEDAR.Lundin Gold's actual results could differ materially from those anticipated. Factors that could cause actual results to differ materially from any forward-looking statement or that could have a material impact on the Company or the trading price of its shares include: risks related to political and economic instability in Ecuador; risks associated with the Company's community relationships; risks related to estimates of production  cash flows and costs; risks inherent to mining operations; shortages of critical supplies; control of the Company's largest shareholders; volatility in the price of gold; failure of the Company to maintain its obligations under its debt facilities; risks related to Lundin Gold's compliance with environmental laws and liability for environmental contamination; the lack of availability of infrastructure; the Company's reliance on one mine; security risks to the Company  its assets and its personnel; risks related to illegal mining; exploration and development risks; the impacts of a pandemic virus outbreak; risks related to the Company's ability to obtain  maintain or renew regulatory approvals  permits and licenses; uncertainty with and changes to the tax regime in Ecuador; the reliance of the Company on its information systems and the risk of cyber-attacks on those systems; the imprecision of Mineral Reserve and Resource estimates; deficient or vulnerable title to concessions  easements and surface rights; inherent safety hazards and risk to the health and safety of the Company's employees and contractors; risks related to the Company's workforce and its labour relations; key talent recruitment and retention of key personnel; volatility in the market price of the Company's shares; measures to protect endangered species and critical habitats; social media and reputation; the cost of non-compliance and compliance costs; the adequacy of the Company's insurance; risks relating to the declaration of dividends; uncertainty as to reclamation and decommissioning; the ability of Lundin Gold to ensure compliance with anti-bribery and anti-corruption laws; the uncertainty regarding risks posed by climate change; limits of disclosure and internal controls; the potential for litigation; and risks due to conflicts of interest.________________________________ 1 Estimated yield has been calculated using today's CAD$ to US$ exchange rate of 1.3549 as provided by the Bank of Canada.LUNDIN GOLD DECLARES QUARTERLY DIVIDEND (CNW Group/Lundin Gold Inc.)SOURCE Lundin Gold Inc.CisionView original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2023/23/c4528.html",neutral,0.08,0.92,0.0,mixed,0.21,0.12,0.68,True,English,"['LUNDIN GOLD DECLARES', 'temporary administrative cross-border transfer closure', 'Fruta del Norte gold mine', 'EU Market Abuse Regulation', 'Canadian income tax purposes', 'highest-grade operating gold mines', 'Toronto Stock Exchange', 'prevailing exchange rate', 'Canadian withholding taxes', 'international best practices', 'quarterly cash dividend', 'Canadian securities laws', 'Lundin Gold Logo', 'Lundin Gold Inc.', 'Risk Factors"" section', 'mine operations', 'Canadian dollars', 'CNW Group', 'Nasdaq Stockholm', 'common share', 'eligible dividend', 'closing price', 'annual yield', 'Swedish kronor', 'extensive expertise', 'social benefits', 'safe workplace', 'environmental impact', 'disclosure requirements', 'Pacific Time', 'contact persons', 'similar expressions', 'historical fact', 'inherent risks', 'press release', 'actual results', 'management team', 'future events', 'Management Discussion', 'Euroclear principles', 'southeast Ecuador', 'Additional Information', 'Forward-Looking Information', 'looking statements', 'The Company', 'record date', 'shares', 'VANCOUVER', 'BC', 'Feb.', 'LUG', 'Board', 'Directors', 'March', 'shareholders', 'close', 'business', 'PDF', 'today', 'TSX', 'Dividends', 'OTCQX', 'SEK', 'accordance', 'April', 'payment', 'period', 'residents', 'Canada', 'details', 'world', 'transparency', 'value', 'economic', 'communities', 'healthy', 'development', 'Government', 'citizens', 'Story', 'February', 'Caution', 'terms', 'discussions', 'respect', 'predictions', 'expectations', 'beliefs', 'plans', 'projections', 'objectives', 'assumptions', 'performance', 'words', 'phrases', 'believes', 'expects', 'targets', 'hopes', 'variations', 'actions', 'nature', 'uncertainties', 'control', 'assurance', 'number', 'places', 'declaration', 'policy', 'Analysis', 'SEDAR.', '4:30']",2023-02-24,2023-02-25,finance.yahoo.com
19208,Euroclear,NewsApi.org,https://finance.yahoo.com/news/notice-attend-extraordinary-general-meeting-163000551.html,NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING IN MAHA ENERGY AB (PUBL),The shareholders in Maha Energy AB (publ)  reg. no. 559018-9543  (the ‚ÄúCompany‚Äù) are hereby given notice to attend the extraordinary general meeting on 29...,Maha Energy ABThe shareholders in Maha Energy AB (publ)  reg. no. 559018-9543  (the ‚ÄúCompany‚Äù) are hereby given notice to attend the extraordinary general meeting on 29 March 2023 at 10.00 CET at Setterwalls Advokatbyr√•‚Äôs offices at Sturegatan 10 in Stockholm  Sweden. Registration for the meeting commences at 09.30 CET.NoticeShareholders wishing to participate at the meeting must:(i) be entered in the shareholders‚Äô register  kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation)  on the record day which is 21 March 2023; and(ii) notify the Company of their attendance and any assistant no later than 23 March 2023. Notification can be made via letter to Setterwalls Advokatbyr√• AB  Attn: Magnus Melin  P.O. Box 1050  SE-101 39 Stockholm  Sweden or by e-mail to magnus.melin@setterwalls.se.Notification shall include full name  personal identification number or corporate registration number  address and daytime telephone number and  where appropriate  information about representative  proxy and assistants. The number of assistants may not be more than two. In order to facilitate entry to the meeting  notification should  where appropriate  be accompanied by powers of attorney  registration certificates and other documents of authority.Personal data obtained from the share register kept by Euroclear Sweden AB  notices and attendance at the meeting and information on representatives  proxies and assistants will be used for registration  preparation of the voting list for the meeting and  where appropriate  the minutes of the meeting.Nominee registered sharesShareholders who have their shares registered in the name of a nominee must request temporary entry in the transcription of the share register kept by Euroclear Sweden AB in order to be entitled to participate and vote for their shares at the meeting. The shareholder must inform the nominee well in advance of 21 March 2023 at which time the register entry must have been made. Voting rights registration that has been requested by the shareholder at such time that the registration has been completed by the nominee no later than 23 March 2023  will  however  be taken into account in the preparation of the share register.Story continuesProxyA shareholder represented by proxy shall issue a power of attorney which shall be dated and signed by the shareholder. If issued by a legal entity the power of attorney shall be accompanied by registration certificate or  if not applicable  equivalent documents of authority. Power of attorney forms for those shareholders wishing to participate by proxy are available on the Company‚Äôs website www.mahaenergy.ca. The original version of the power of attorney shall also be presented at the meeting.Proposed agendaOpening of the meeting and election of chairman of the meeting; Preparation and approval of the voting list; Approval of the agenda; Election of one (1) or two (2) persons who shall approve the minutes of the meeting; Determination of whether the meeting has been duly convened; Resolution on changes to the articles of association; Resolution on issue of new shares against payment in kind; Resolution on changes to the board composition; Closing of the meeting.Proposed resolutionsItem 1. Election of chairman of the meetingThe board of directors proposes that attorney Marcus Nivinger is appointed chairman of the extraordinary general meeting.Item 6. Resolution on changes to the articles of associationIn view of the investment agreement signed with the shareholders of DBO 2.0 S.A. (referenced to in item 7 below)  the board of directors proposes to change the limits in the articles of association with respect to share capital and number of shares in ¬ß¬ß 4 and 5. ¬ß 4 is proposed to be changed from ‚ÄúThe company‚Äôs share capital shall be not less than SEK 517 000 and not more than SEK 2 068 000‚Äù to ‚ÄúThe company‚Äôs share capital shall be not less than SEK 1 980 000 and not more than SEK 7 920 000‚Äù. ¬ß 5 is proposed to be changed from ‚ÄúThe number of shares in the company shall be no less than 47 000 000 and no more than 188 000 000‚Äù to ‚ÄúThe number of shares in the company shall be no less than 180 000 000 and no more than 720 000 000‚Äù.The chairman of the board of directors  the CEO or a person appointed by the board of directors shall be authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office. A valid resolution requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast as well as of all shares represented at the meeting.Item 7. Resolution on issue of new shares against payment in kindThe board of directors of Maha Energy AB (publ) (the ‚ÄúCompany‚Äù)  proposes that the general meeting resolves to increase the Company‚Äôs share capital by not more than SEK 404 529.51 through a new issue of not more than 36 775 410 shares. The resolution shall otherwise be governed by the following terms and conditions.1. The Company and its subsidiary Nova Maha Energy Brasil Ltda. (‚ÄúMaha Brasil‚Äù) have entered into an investment agreement with the shareholders (the ‚ÄúSellers‚Äù) of DBO 2.0 S.A.  reg. no. 40.070.729/0001-59 (the ‚ÄúTarget‚Äù) regarding the acquisition of all 188 427 shares in the Target  of which 188 426 shares in the Target (the ‚ÄúShares‚Äù) are acquired by the Company against payment of 36 775 410 new shares in the Company and one (1) share in the Target is acquired by Maha Brasil against payment of BRL 1.00. Before entering into said investment agreement  the Company has engaged SpareBank 1 Markets AS (‚ÄúSB1M‚Äù) to provide a fairness opinion regarding the proposed acquisition of Shares (the ‚ÄùIndependent Fairness Opinion Statement‚Äù). SB1M‚Äôs conclusions on the attractiveness of the transaction from a financial point of view have supported the board of directors‚Äô decision to submit the resolution in reference to Company‚Äôs shareholders. For more information on whether the acquisition of all Shares constitutes a fair transaction from a financial point of view and its overall attractiveness for the Company‚Äôs shareholders  please refer to the Independent Fairness Opinion Statement provided by SB1M  Schedule 1 .2. Based on the current approximate share price  the board of directors estimates that the Shares will be included with SEK 352 308 427.8 in the Company‚Äôs balance sheet per the closing date upon full subscription. The value may change  as the value will be determined pursuant to applicable accounting rules as per share price on the closing of the transaction.3. The amount that exceeds the quotient value of the new shares in the Company shall be allocated to the free premium fund.4. The right to subscribe for the new shares shall only vest with the Sellers  with the right and obligation to pay for the new shares by the contribution of shares in the Target in accordance with the below.Maximum number of shares in the Company to be allocated to each Seller Number of Shares in the Target to be contributed by each Seller DBO Invest S.A. 22 706 658 116 342 Svein Harald √òygard 3 370 614 17 270 AGR AS 3 328 652 17 055 Tore Myrholt 2 938 699 15 057 GAESM PARTICIPA√á√ïES LTDA. 1 195 817 6 127 Sebastian Wurster 1 092 961 5 600 Luis Antonio Gomes Araujo 762 926 3 909 Aristeidis Athanasios Tsikouras 656 557 3 364 Andre Luiz de Oliveira Naslausky 481 684 2 468 Halvard Idland 120 421 617 Kjetil Solbr√¶kke 120 421 617 Total 36 775 410 188 4265. Subscription for the newly issued shares shall be made on a subscription list in connection with the completion of the acquisition of the Target  however no later than on 29 September 2023. Payment shall be made in connection with subscription.6. The new shares shall entitle to dividends from and including the first record date for dividends decided after the new shares have been registered with the Swedish Companies Registration Office.7. The chairman of the board of directors  the managing director or a person appointed by the board of directors shall be authorized to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.8. Documents as referred to in Chapter 13 Sections 6-8 of the Swedish Companies Act have been prepared and are kept available at the Company‚Äôs office.Item 8. Resolution on changes to the board compositionAt the extraordinary general meeting held on 3 November 2022  it was resolved to elect Fabio Vassel (chairman)  Paulo Thiago Mendon√ßa and Enrique Pe√±a as new ordinary board members. After the extraordinary general meeting  the board of directors consists of the following six (6) board members without deputy members until the end of the next annual general meeting: Fabio Vassel (chairman)  Paulo Thiago Mendon√ßa  Enrique Pe√±a  Harald Pousette  Viktor Modigh and Richard Norris.Pursuant to the investment agreement with the shareholders of DBO 2.0 S.A.  described under item 7 above  the board of directors proposes that the general meeting resolves on the following changes to the board composition and decision on board fees. The board of directors proposes that the board of directors shall consist of seven (7) ordinary board members with no deputy members until the end of the next annual general meeting. The board of directors proposes that Harald Pousette  upon his own request  is discharged from the board of directors. It is further proposed that Halvard Idland and Kjetil Solbraekke are elected as new ordinary board members until the end of the next annual general meeting (i.e. in addition to the remaining current board members).The new board members are to be entitled to remuneration (board fees) as resolved by the annual general meeting held on 31 May 2022 (i.e. SEK 300 000 reduced proportionally taking into account that the new board members will not serve the entire time period between the annual general meeting held on 31 May 2022 and the next annual general meeting).Presentation of proposed board membersHalvard Idland   born 6 August 1975Experience: Halvard Idland has more than 20 years of industrial and financial investment experience in the oil and gas industry in Norway and Brazil. Previous experience includes DNB  Pareto and Aker Yards prior to co-founding DBO Energy.Education: M.Sc. in Economics and Business Administration from Norwegian School of Economics (NHH).Current assignments: Co-founder and Director at DBO Invest and Janeiro Energy. Board member at Prosafe SE and 3R Offshore. Chairman of DreamLearnWork.Previous assignments (last five years): Co-founder and CFO at DBO Energy and DBO 2.0. Audit committee member at 3R Petroleum.Independent in relation to the Company and the Company management: Yes.Independent in relation to the major shareholders: No. Halvard is Director at DBO Invest which will be a major shareholder in the Company following completion of the issue of new shares proposed under item 7 of the agenda.Holdings of shares in Maha: Halvard does currently have any holdings in Maha. Halvard may subscribe for up to 120 421 new shares in Maha within the issue of new shares proposed under item 7 of the agenda.Kjetil Solbraekke   born 3 May 1962Experience: Kjetil Solbraekke has over 30 years of experience from the Norwegian Oil and gas sector in various positions as Assistant director general in the Ministry of Petroleum in Norway  SVP and CFO in Norsk Hydro  CEO in Panoro Energy and Sintef do Brazil  Founder and CEO in DBO Energy. He has lived in Brazil since 2006.Education: Cand. Oecon from the University of Oslo  Economist.Current assignments: Co-Founder and CEO at DBO Invest.Previous assignments (last five years): CEO in Sintef do Brasil. Co-founder and CEO at DBO Energy and DBO 2.0. Board Member of 3R Petroleum.Independent in relation to the Company and the Company management: Yes.Independent in relation to the major shareholders: No. Kjetil is CEO of DBO Invest which will be a major shareholder in the Company following completion of the issue of new shares proposed under item 7 of the agenda.Holdings of shares in Maha: Kjetil currently holds 100 000 shares in Maha. Kjetil may subscribe for up to 120 421 new shares in Maha within the issue of new shares proposed under item 7 of the agenda.Number of shares and votes in the CompanyThe total number of shares in the Company at the time of issuance of this notice is 143 615 696. The total number of votes for all issued shares in the Company is 143 615 696 votes. The Company does not hold any of its own shares.Shareholders‚Äô right to request informationPursuant to Chapter 7 section 32 of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) the board of directors and the managing director are under a duty to  if any shareholder so requests and the board of directors deems that it can be made without material damage to the Company  provide information  regarding circumstances which may affect the assessment of a matter on the agenda.DocumentationDocuments to be dealt with at the general meeting will be kept available at the Company‚Äôs office not later than three weeks before the meeting. The documents will be sent free of charge to shareholders who so request and state their postal address. The documents will also be made available not later than the aforementioned date on the Company‚Äôs website www.mahaenergy.ca. All the above mentioned documents will also be presented at the general meeting._____Stockholm  24 February 2023The board of directorsMiscellaneousThe information was submitted for publication  through the agency of the contact person set out above  17:30 P.M. CET on 24 February 2023.For more information  please contact:Paulo Thiago Mendon√ßa  CEOPhone: +46 8 611 05 11E-mail: info@mahaenergy.caBernardo Guterres  CFOPhone: +46 8 611 05 11E-mail: info@mahaenergy.caAbout MahaMaha Energy AB (publ) is a listed  international upstream oil and gas company whose business activities include exploration  development and production of crude oil and natural gas. The strategy is to target and develop underperforming hydrocarbon assets on global basis. Maha operates four oil fields: Tartaruga and Tie in Brazil  Powder River (LAK Ranch) and Illinois Basin in the United States. The shares are listed on Nasdaq Stockholm (MAHA-A). The head office is in Stockholm  Sweden with a technical office in Calgary  Canada  as well as operations offices in Grayville  Illinois  USA and Rio De Janeiro  Brazil. For more information  please visit our website www.mahaenergy.ca.Attachments,neutral,0.03,0.93,0.03,positive,0.54,0.36,0.09,True,English,"['EXTRAORDINARY GENERAL MEETING', 'MAHA ENERGY AB', 'NOTICE', 'PUBL', 'Nova Maha Energy Brasil L', 'Swedish Central Securities Depository', 'Swedish Companies Registration Office', 'Maha Energy AB', 'P.O. Box', 'DBO 2.0 S.A.', 'Euroclear Sweden AB', 'Setterwalls Advokatbyr√• AB', 'daytime telephone number', 'attorney Marcus Nivinger', 'Voting rights registration', 'personal identification number', 'corporate registration number', 'extraordinary general meeting', 'Nominee registered shares', 'Personal data', 'voting list', 'registration certificates', 'Clearing Organisation', 'record day', 'Magnus Melin', 'magnus.melin', 'other documents', 'share register', 'legal entity', 'equivalent documents', 'original version', 'two (2) persons', 'investment agreement', 'minor adjustments', 'following terms', 'share capital', 'temporary entry', 'register entry', 'full name', 'attorney forms', 'new shares', 'new issue', 'board composition', 'shareholders‚Äô register', 'valid resolution', 'The Company', '36,775,410 shares', 'publ', 'reg.', 'notice', '29 March', '10.00 CET', 'offices', 'Sturegatan', 'Stockholm', '09.30 CET', '21 March', 'attendance', 'assistant', '23 March', 'Notification', 'letter', 'Attn', 'mail', 'address', 'information', 'representative', 'proxy', 'order', 'powers', 'authority', 'proxies', 'preparation', 'minutes', 'transcription', 'advance', 'account', 'Story', 'website', 'mahaenergy', 'agenda', 'Opening', 'election', 'chairman', 'approval', 'Determination', 'changes', 'articles', 'association', 'payment', 'kind', 'Closing', 'resolutions', 'Item', 'directors', 'view', 'limits', 'respect', 'SEK', 'CEO', 'proposal', 'two-thirds', 'votes', 'conditions', 'subsidiary', '¬ß¬ß']",2023-02-24,2023-02-25,finance.yahoo.com
19209,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/FORTNOX-AB-PUBL-15672035/news/Fortnox-Postal-vote-form-and-notification-43075644/?utm_medium=RSS&utm_content=20230224,Fortnox : Postal vote form and notification,(marketscreener.com)    Notification and form for postal voting for the Annual General Meeting on 30 March 2023   The form must be received by Euroclear AB no later than 24 March 2023.   The shareholders set out below hereby register and exercise the‚Ä¶,The shareholders set out below hereby register and exercise their voting right for all of the shareholder's shares in Fortnox AB (publ)  reg.no 556469-6291  at the Annual General Meeting on 30 March 2023. The voting right is exercised in accordance with the voting options marked below.The form must be received by Euroclear AB no later than 24 March 2023.Notification and form for postal voting for the Annual General Meeting on 30 March 2023Name of the shareholderDeclaration (if the signatory is a deputy for shareholders who are legal entities):The undersigned is a board member  managing director or signatory of the shareholder and declares in good faith that I am authorised to cast this postal vote for the shareholder and that the content of the postal vote matches the shareholder's resolution.Declaration (if the signatory represents shareholders by proxy):The undersigned declares in good faith that the attached proxy corresponds to the original and has not been revoked.Date and placeSignatureClarification of signature,neutral,0.0,0.99,0.0,positive,0.72,0.24,0.04,True,English,"['Postal vote form', 'Fortnox', 'notification', 'Annual General Meeting', 'voting right', 'Fortnox AB', 'voting options', 'Euroclear AB', 'postal voting', 'legal entities', 'board member', 'managing director', 'good faith', 'postal vote', 'place Signature', 'shareholders', 'shares', 'publ', '30 March', 'accordance', 'form', '24 March', 'Notification', 'Name', 'Declaration', 'signatory', 'deputy', 'content', 'resolution', 'proxy', 'original', 'Date', 'Clarification']",2023-02-24,2023-02-25,marketscreener.com
19210,Euroclear,NewsApi.org,https://finance.yahoo.com/news/bbs-bioactive-bone-substitutes-plc-130000850.html,BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin  1 January ‚Äì 31 December 2022 (unaudited),BBS-Bioactive Bone Substitutes Plc  Financial Statements Bulletin  24 February 2023 at 3.00 p.m. BBS advances towards the CE marking of its first product...,BBS-Bioactive Bone Substitutes OyjBBS-Bioactive Bone Substitutes Plc  Financial Statements Bulletin  24 February 2023 at 3.00 p.m.BBS advances towards the CE marking of its first productThis is a summary of BBS-Bioactive Bone Substitutes Plc‚Äôs Financial Statements Bulletin for January‚ÄìDecember 2022. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc‚Äôs website at https://www.bbs-artebone.fi/.JULY-DECEMBER (H2) HIGHLIGHTSDuring the second half of the year  BBS-Bioactive Bone Substitutes Plc (BBS) continued to implement the actions required for the registration of the company's first product (ARTEBONE¬Æ Paste)  including ramping up production and preparing for the start of marketing measures.In November  the Notified Body conducted a successful audit  related to the company‚Äôs quality system. Only minor measures were needed to correct the issues in the inspection report. Quality system certification is a part of the CE marking process for BBS‚Äô first product  Artebone Paste. The final audit for the quality system is scheduled for early March.The company generated no revenue during the review period.The financial result in the review period was EUR -1.42 (-1.46) million.Cash flow from operations was EUR -1.320 (-1.156) million.Cash and cash equivalents on 31 December 2022 were EUR 1.52 (1.24) million.YEAR 2022Artebone Paste's CE marking application was submitted to the notified body on March 9  2022.In May ‚Äì June  the company arranged a rights issue  raising a total of approximately EUR 3.5 million in gross proceeds. Net proceeds after transaction costs related to the issue were approximately EUR 3.1 million.The company generated no revenue during the review period.The financial result in the review period was EUR ‚Äì3.09 (-2.77) million.Cash flow from operations was EUR ‚Äì2.82 (-2.52) million.Cash and cash equivalents on 31 December 2022 were EUR 1.52 (1.24) million.The figures in the review are rounded  so the sum of the individual figures may differ from the total presented. BBS's accounting period is a calendar year. Figures in parentheses refer to the corresponding period of the previous year  unless otherwise stated. The information in the review is unaudited.Story continuesOUTLOOKGuidance for 2023No revenue is expected during 2023.Board of Directors‚Äô outlook for 2023The company has submitted the CE marking application for its first product (ARTEBONE¬Æ Paste) to the notified body on 9 March 2022. Based on a survey* conducted for the Notified Body  the average application processing times increased in 2022. Due to this  the company estimates that  based on currently available information  it is unlikely to receive the final CE marking approval by the end of March 2023. The company expects authorities‚Äô decision on approving the application during 2023.Preparations for commercial operations will begin towards the end of 2023.Further measures are required to ensure the sufficiency of the company's financing in order to implement the company‚Äôs plans following the expected approval of the CE marking. The company continues discussions to secure additional funding to enable the continuation of the development work as well as initiating commercial activities.*MedTech Europe Survey Report:. https://www.medtecheurope.org/wp-content/uploads/2022/07/medtech-europe-survey-report-analysing-the-availability-of-medical-devices-in-2022-in-connection-to-the-medical-device-regulation-mdr-implementation.pdfKEY FIGURES1000 eur 7-12/2022 7-12/2021 1-12/2022 1-12/2021 Other operating income 9 16 64 61 Personnel expenses 587 720 1 315 1 199 Depreciationa and amortization 112 119 225 231 Other operational expenses 756 481 1 446 1 144 Profit/Loss for the period -1 416 -1 463 -3 093 -2 771 Cash flow for business operations -1 320 -1 155 -2 816 -2 520 Change in cash resources -1 872 -698 281 -2 202 Equity ratio1)  % 40.0 34.6 40.0 34.6 Earnings per share2)  EUR -0.15 -0.22 -0.38 -0.42 Earnings per share  EUR  diluted -0.14 -0.22 -0.35 -0.41 Number of shares at the end of period 9 668 351 6 737 889 9 668 351 6 737 889 Average number of shares in the period 9 450 846 6 615 855 8 211 650 6 593 872 Equity per share 3)  EUR 0.44 0.54 0.44 0.54 Cash and cash equivalents 1 517 1 236 1 517 1 236 Equity 4 271 3 634 4 271 3 634 Balance sheet total 10 688 10 506 10 688 10 5061) Equity ratio = Equity / (Balance sheet total ‚Äì Advances received)2 )EPS = Profit(Loss) / Average number of outstanding shares in the period3 )Equity / Total number of outstanding shares at the end of the periodCEO ILKKA KANGASNIEMIDuring the second half of the year  BBS focused on advancing the CE marking process with the Notified Body  aimed at facilitating the sales and marketing of our first product (ARTEBONE¬Æ Paste) in the EU region. During the autumn months  we continued to refine production lines and processes  while finalizing production validation procedures  ensuring the ability to produce products consistently for the upcoming launch.The CE marking procedure involves two key streams: quality system approval and product approval. With regards to the first  significant progress was made in the latter half of the year. In November  the Notified Body conducted a successful audit  and no critical non-conformities were reported regarding the quality system. The final audit for the quality system is scheduled for early March.It is also noteworthy that the Notified Body has already submitted the initial questions and supplemental requests regarding product approval  and there were no critical non-conformities in these submissions.Obtaining product approval requires close collaboration between the Notified Body and the Medicines Agency. So far  the process has progressed at a slower pace  and cooperation has yet to commence. Given the current backlog of application processing  as reported in public surveys  the company announced in December that it was unlikely to receive the final CE marking approval by the end of March 2023. Despite the delays in the regulatory process  the company still believes that receiving the approval is achievable in 2023.The product approval process for medical devices can be time-consuming and requires patience. Although progress has been slow  the company's financial situation remains stable until July-August. The management team is able to adjust the allocation of funds based on its decisions. Currently  the company is exploring multiple options for additional funding to secure the continuation of development work and well as preparations for commercial operations during the congested approval process..We are steadfastly advancing towards our objective: to bring a new generation of safe bone fillers to a thriving market  improving patients' lives and streamlining the overburdened healthcare system.EVENTS AFTER PERIOD-ENDThe company has on 13 February 2023 applied for The Delisting of Secondary Listing on Nasdaq First North Growth Market Sweden. When making the decision  the board has taken into account the low trading volumes of BBS shares after the company's listing in 2018  as well as the small number of shareholders registered with Euroclear Sweden AB. The board has also assessed the additional costs incurred by the company and the administrative responsibilities arising from compliance with the listing requirements in connection with the parallel listing. The last day of trading in the shares of BBS on Nasdaq First North Growth Market Sweden shall be March 3  2023.FINANCIAL CALENDAR FOR 2023Financial Statements Release for the year 2022 will be published on 24 February 2023The Annual Report for the year 2022 will be published during the week 13/2023 the latest.The Annual General Meeting is planned to be held on 28 April 2023Half-year financial report January-June 2023 will be published on 25 August 2023The company's previously published reports can be found on the BBS investor website at: https://www.bbs-artebone.fi/investors/financial-reports/.24 February 2023BBS-Bioactive Bone Substitutes PlcBoard of DirectorsDistributionNasdaq Helsinkihttps://www.bbs-artebone.fi/BBS in briefBBS-Bioactive Bone Substitutes Plc is a Finnish orthobiology company whose core competence is the development  commercialization and manufacture of easy-to-use bone implants that promote bone formation and healing. Bone substitutes  i.e. implants  are intended for the treatment of various bone damage  bone healing problems and bone diseases instead of autologous and bank bone grafts. BBS aims to become one of the leading players in the field of bioactive implants intended for bone healing problems.BBS was founded in 2003  and the company has been listed on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden since February 2018. The company's head office is located in Oulu  and it employs 20 people.Attachments,neutral,0.0,1.0,0.0,negative,0.0,0.24,0.76,True,English,"['BBS-Bioactive Bone Substitutes Plc', 'Financial Statements Bulletin', '1 January', '31 December', 'BBS-Bioactive Bone Substitutes Plc', 'average application processing times', 'MedTech Europe Survey Report', 'final CE marking approval', 'Other operating income', 'CE marking process', 'Financial Statements Bulletin', 'Other operational expenses', 'CE marking application', 'Balance sheet total', 'production validation procedures', 'Quality system certification', 'final audit', 'expected approval', 'financial result', 'Personnel expenses', 'Average number', 'entire report', 'inspection report', 'first product', 'second half', 'ARTEBONE¬Æ Paste', 'successful audit', 'minor measures', 'Artebone Paste', 'gross proceeds', 'Net proceeds', 'transaction costs', 'authorities‚Äô decision', 'Further measures', 'additional funding', 'development work', 'commercial activities', 'ILKKA KANGASNIEMI', 'EU region', 'autumn months', 'production lines', 'Total number', 'Cash flow', 'cash equivalents', 'cash resources', 'Notified Body', 'accounting period', 'corresponding period', 'marketing measures', 'rights issue', 'Directors‚Äô outlook', 'available information', 'commercial operations', 'business operations', 'outstanding shares', 'calendar year', 'previous year', 'January‚ÄìDecember', 'Equity ratio', 'early March', 'individual figures', 'review period', 'Company Announcement', '31 December', '9 March', 'Oyj', '24 February', 'summary', 'file', 'website', 'JULY-DECEMBER', 'HIGHLIGHTS', 'actions', 'registration', 'start', 'November', 'issues', 'part', 'revenue', 'May', 'June', 'parentheses', 'Story', 'Guidance', 'Board', 'Preparations', 'sufficiency', 'financing', 'order', 'plans', 'discussions', 'continuation', 'medtecheurope', 'uploads', 'medtech-europe-survey', 'availability', 'medical-devices', 'connection', 'medical-device-regulation', 'Depreciationa', 'amortization', 'Profit/Loss', 'Change', '6 Earnings', 'Advances', 'EPS', 'CEO', 'sales', 'processes', 'products', 'upcomi', '3.00', '2023', '1000']",2023-02-24,2023-02-25,finance.yahoo.com
19211,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/FORTNOX-AB-PUBL-15672035/news/Fortnox-Notice-AGM-30-march-2023-43075646/?utm_medium=RSS&utm_content=20230224,Fortnox : Notice AGM 30 march 2023,(marketscreener.com)   Notice of Annual General Meeting in Fortnox AB    The shareholders in Fortnox AB   reg. no. 556469-6291  are hereby invited to the Annual General Meeting to be held on Thursday 30 March 2023  at 2 p.m.  at Fortnox AB  Bollgatan 3 B‚Ä¶,"Fortnox : Notice AGM 30 march 2023 02/24/2023 | 05:27am EST Send by mail :Name : First name : From * : To * : (You can enter multiple email addresses separated by commas) Message : * Required fields Notice of Annual General Meeting in Fortnox AB (publ) The shareholders in Fortnox AB (publ)  reg. no. 556469-6291  are hereby invited to the Annual General Meeting (""AGM"") to be held on Thursday 30 March 2023  at 2 p.m.  at Fortnox AB  Bollgatan 3 B V√§xj√∂. The Board of Directors has resolved that shareholders also shall have the right to exercise their voting rights by postal voting ahead of the AGM in accordance with Chapter 7  Section 4 a of the Swedish Companies Act (2005:551) and the company's Articles of Association. Shareholders may therefore choose to exercise their voting rights at the meeting by postal voting  in person or through proxy. Participation through postal voting Shareholders who wish to participate in the AGM through postal voting must both be registered as shareholders in the register of shareholders maintained by Euroclear Sweden AB as per Wednesday 22 March 2023 be registered as shareholders in the register of shareholders maintained by Euroclear Sweden AB as per Wednesday 22 March 2023  and notify their participation by submitting their postal vote in accordance with the instructions below  so that the postal vote is received by Euroclear Sweden AB no later than Friday 24 March 2023. For postal voting  a special form must be used. The form is available on Fortnox's website  www.fortnox.se. The completed and signed form must be received by Euroclear Sweden AB no later than 24 March 2023. The completed and signed form must be sent to Fortnox AB (publ)  ""AGM""  c/o Euroclear Sweden AB  Box 191  101 23 Stockholm  Sweden. The completed and signed form may also be sent by e-mail  if so it shall be sent to GeneralMeetingService@euroclear.com (state ""Fortnox AB - Postal voting"" in the subject line). Shareholders who are a natural person may also submit his/her postal vote electronically through verification by BankID at Euroclear Sweden AB's website  https://anmalan.vpc.se/EuroclearProxy/. Such electronical postal votes must be submitted not later than 24 March 2023. Shareholders exercising their voting rights by postal voting and whose postal vote is received no later than 24 March 2023 as stated above do not need to register specifically for the meeting  the submitted voting form will be considered a notification to the AGM. Those who wish to withdraw a submitted postal vote and instead exercise their voting rights by participating in the AGM in person or through a proxy must give notice thereof to the AGM's secretariat prior to the opening of the AGM. Participation in person Shareholders who wish to participate in the AGM in person must both be registered as shareholder in the register of shareholders maintained by Euroclear Sweden AB as per Wednesday 22 March 2023 be registered as shareholder in the register of shareholders maintained by Euroclear Sweden AB as per Wednesday 22 March 2023  and notify their participation no later than Friday 24 March 2023. Notification of participation in the AGM shall be made to https://anmalan.vpc.se/EuroclearProxy/ or by e- mail to Fortnox AB (publ)  ""AGM""  c/o Euroclear Sweden AB  Box 191  101 23 Stockholm  Sweden. The notification must state the name  personal or organization number  address  and telephone number. Participation by proxy Shareholders who are represented by proxy must issue a written  signed and dated power of attorney. If the power of attorney is issued by a legal entity a certificate of registration for the legal entity (or 1 (10) Fortnox AB (publ) 556469-6291 corresponding authorization documents for a foreign legal entity) must be attached to the power of attorney. If participation takes place with the support of a power of attorney  the form should be submitted attached to the notification of participation in the AGM. A proxy form for shareholders who wish to participate in the meeting by proxy will be available at the company's website  www.fortnox.se  and at the company's premises at Bollgatan 3 B  V√§xj√∂  Sweden. Nominee-registered shares To be entitled to participate in the meeting  a shareholder whose shares are nominee-registered must  in addition to providing notification of participation (or submitting their postal vote) re-register the shares in their own name so that the shareholder is registered in the register of shareholder as of the record date on Wednesday 22 March 2023. Such re-registration may be temporary (so-called voting rights registration) and is requested from the nominee in accordance with the respective nominee's routines  at such a time in advance as the nominee determines. Voting rights registration that have been requested by the shareholder at such time that the registration has been completed by the nominee no later than Friday 24 March 2023 will be considered when preparing the share register. Proposed agenda The chairman of the Board of Directors greets welcome and opens the meeting Election of the chairman of the meeting Compilation and approval of the voting list Approval of the agenda Election of one or two persons to verify the minutes Determination of whether the meeting has been duly convened The CEO's presentation Presentation of the annual report and the auditor's report as well as the consolidated financial statements and the auditor's report for the group Resolutions on adoption of the income statement and balance sheet  as well as the consolidated income statement and consolidated balance sheet  appropriation of the company's profit or loss according to the adopted balance sheet  discharge from liability for the members of the Board of Directors and the CEO Determination of the number of members of the Board of Directors and auditors Determination of the remuneration for the Board of Directors  remuneration for committee work and fees to the auditor Election of members of the Board of Directors  Chairman of the Board of Directors and auditor Resolution on guidelines for appointment of the Nomination Committee and instructions for the Nomination Committee and its work Resolution on approval of the Remuneration Report Resolution on long-term share savings program as well as acquisition and transfer of shares under the program Resolution on authorization for the Board of Directors to resolve on new issues of shares Closing of the meeting Proposals for resolution Item 2 - Election of the chairman of the meeting The Nomination Committee for Fortnox AB (publ) has ahead of the AGM 2023 consisted of the Chairman of the Board of Directors  Olof Hallrup  Monica √Ösmyr  appointed by Swedbank Robur Fonder AB  Mathias Svensson  appointed by First Kraft AB (also the chairman of the Nomination Committee) and Peter Nichols  2 (10) Fortnox AB (publ) 556469-6291 appointed by Vor Capital LLP. First Kraft AB  Swedbank Robur Fonder AB and Vor Capital LLP together represent approximately 30 percent of the total number of votes in Fortnox AB. The Nomination Committee proposes that lawyer Maria Arnoldsson should be appointed chairman of the AGM. Item 9b - Appropriation of the company's profit or loss according to the adopted balance sheet The Board of Directors proposes a dividend to the shareholders of SEK 0.12 per share and that the record date for receipt of the dividend shall be 3 April 2023. If the AGM resolves in accordance with the proposal  the dividend is expected to be paid through Euroclear Sweden AB on 6 April 2023. Item 10 - Resolution on the number of members of the Board of Directors and the number of auditors The Nomination Committee proposes that the number of members of the Board of Directors elected by the general meeting shall be five (5)  and that the number of auditors shall be one (1). Item 11 - Determination of the remuneration for the Board of Directors  remuneration for committee work and fees to the auditor The Nomination Committee proposes that the remuneration for the Board of Directors  for the period up to and including the AGM 2024  should be paid in an amount that  including remuneration for committee work and based on the Nomination Committee's proposal and proposed composition of the committees  amounts to a total of SEK 2 297 000  [which is an increase of SEK 97 000 compared to the previous year.] The remuneration is proposed to be allocated as follows: Chairman of the Board of Directors SEK 720 000; each of the other members of the Board of Directors SEK 310 000; chairman of the Audit Committee SEK 129 000; member of the Audit Committee SEK 52 000; chairman of the Remuneration Committee SEK 52 000 and member of the Remuneration Committee SEK 26 000. The Nomination Committee proposes that the auditor's fee shall be paid according to invoice. Item 12 - Election of members of the Board of Directors  Chairman of the Board of Directors and auditor The Nomination Committee proposes re-election of Anna Frick  Lena Glader  Magnus Gud√©hn  Olof Hallrup and Per Bertland as members of the Board of Directors  for a period until the end of the next AGM. Furthermore  the Nomination Committee proposes re-election of Olof Hallrup as Chairman of the Board of Directors. The Nomination Committee proposes  in accordance with the Audit Committee's recommendation  to reelect the auditing firm KPMG AB as the company's auditor  for a period until the end of the next AGM. KPMG AB intends to appoint the authorised public accountant Dan Beitner as auditor in charge. Item 13 - Resolution on guidelines for appointment of the Nomination Committee and instructions for the Nomination Committee and its work The Nomination Committee proposes that the AGM resolves that the company should have a Nomination Committee ahead of the AGM 2024  consisting of members appointed by each of the three largest shareholders in terms of votes  together with the Chairman of the Board of Directors. If any of the three shareholders refrains from appointing a member to the Nomination Committee  further shareholders shall be consulted  in order of size  until three members have been appointed. The names of the members of the Nomination Committee and the names of the shareholders who appointed each member shall be published no later than six months before the AGM and shall be based on shareholder statistics from Euroclear Sweden AB as of the last banking day in August 2023. The chairman of the Nomination Committee shall  unless the members agree otherwise  be the member appointed by the largest shareholder in terms of 3 (10) Fortnox AB (publ) 556469-6291 votes. If a member no longer represents the current shareholder  or otherwise resign from the Nomination Committee before its work has been completed  the shareholder shall be given the opportunity to appoint a new member to the Nomination Committee. Shareholders who have appointed a member of the Nomination Committee have the right to dismiss such member and appoint a new member of the Nomination Committee. If a shareholder who appointed a member subsequently no longer is one of the three largest shareholders in terms of votes  the appointed member shall resign and a new member shall be appointed according to the procedure set out above. However  unless there are special reasons  no changes shall take place in the composition of the Nomination Committee if there is only a marginal change in the number of votes  or if the change occurs later than three months before the AGM. Changes in the composition of the Nomination Committee shall be made public as soon as they occur. The Nomination Committee shall prepare and submit the general meeting proposals for the chairman of the meeting  members of the Board of Directors  the Chairman of the Board of Directors  remuneration for each of the members of the Board of Directors and the Chairman  as well as any remuneration for committee work  remuneration to the company's auditor and  if applicable  proposal for the election of auditor. Furthermore  the Nomination Committee shall prepare and submit the AGM proposal on the principles for the appointment of the Nomination Committee ahead of the 2025 AGM. The Nomination Committee shall be entitled to charge the company with costs for consultants or other costs required for the Nomination Committee to fulfil its mandate. No remuneration shall be paid to the members of the Nomination Committee. The company shall pay the necessary expenses that the Nomination Committee may incur in the scope of its work. The Nomination Committee's mandate shall expire when a new Nomination Committee has been announced. Item 14 - Resolution on approval of the Remuneration Report The Board of Directors proposes that the AGM approves the Board of Directors' Remuneration Report for 2022 in accordance with Chapter 8  Section 53 a of the Swedish Companies Act. The Remuneration Report is available on the company's website  www.fortnox.se. Item 15 - Resolution on long-term share savings program as well as acquisition and transfer of shares under the program The Board of Directors of Fortnox AB (publ) (""Fortnox"" or the ""Company"") proposes that the AGM resolves to implement a long-term share savings plan for current and future permanent employees (""Employees"") within the Fortnox Group (Fortnox Employee Share Saving Program  ""ESSP 2023""). 1. Background and reasons An Extraordinary General Meeting held on 21 October 2022 resolved  in accordance with the Board of Directors' proposal  to implement a long-term share savings program ""ESSP 2022"" to all Employees of the Group. The program was well received and more than 60 percent of the Employees chose to participate in the program. The Board of Directors has evaluated the participation in and the initial impact of the share savings program and proposes that the AGM resolves on a new share savings program with similar conditions. The purpose of ESSP 2023 is to create shareholder value and strengthen the community of interest between the participants in the program and Fortnox's other shareholders. ESSP 2023  together with previous programs  is further expected to increase Fortnox's ability to retain and recruit qualified personnel to the Fortnox Group  as well as Employees' interest and commitment to Fortnox's operations and development. Against this background  the Board of Directors believes that ESSP 2023 will have a positive impact on the future development of the Fortnox Group and thus benefit both the shareholders and the Employees of Fortnox. 4 (10) Fortnox AB (publ) 556469-6291 After evaluating the participation in and the effect of the share saving programs  the Board of Directors will consider whether to propose new share savings programs with similar terms and conditions. The Board of Directors also intends  if necessary  to return to subsequent annual general meetings with a proposal that the Board of Directors shall be authorised to resolve on further acquisitions of own shares for transfer to the participants in both ESSP 2022 and ESSP 2023 and any additional share savings programs and related acquisitions and transfers of shares for hedging social security contributions for such programs. 2. Preparation of the proposal The Board of Directors' proposal to the AGM regarding ESSP 2023 has been prepared by the Remuneration Committee together with external advisors  in accordance with the Board of Directors' guidelines and following discussions with major shareholders. The Board of Directors has resolved  following the recommendation of the Remuneration Committee  to propose ESSP 2023 to the AGM for decision in accordance with the proposal below. 3. The Board of Directors' proposed resolution Therefore  in order to maintain the maximum flexibility  the Board of Directors therefore proposes  in accordance with the recommendation of the Remuneration Committee  that the AGM resolves: on a long-term share savings plan (ESSP 2023) in accordance with the conditions set out in section A. below; to authorize the Board of Directors to resolve on the acquisition of own shares in Fortnox on Nasdaq Stockholm and that acquired own shares may be i) transferred free of charge to participants in ESSP 2023 and ESSP 2022  and ii) transferred to secure thereto connected costs for social security contributions in accordance with the conditions set out in sections B.-D. below; and in the event that the required majority according to sections B.-D. below cannot be reached  that Fortnox may enter into share swap agreements with third parties in accordance with the conditions in section E. below. Resolution on long-term share savings plan (ESSP 2023) ESSP 2023 is addressed to Employees of the Fortnox Group  which is estimated to consist of approximately 764 employees. ESSP 2023 offers Employees the opportunity  subject to their own investment in Fortnox shares ("" Savings Shares "") during a period of twelve (12) months (the "" Savings Period "")  to receive from Fortnox or from another company within the Fortnox Group  or from a designated third party  an allotment of Fortnox shares free of charge. For each Savings Share  Employees participating in ESSP 2023 will have the opportunity  after a three-year holding period from the time the Savings Shares are acquired on behalf of the participants (the "" Holding Period "")  to receive an allocation of one share in Fortnox (the "" Matching Share ""). The maximum amount that each Employee participating in ESSP 2023 may invest on a monthly basis  normally through monthly savings  has been differentiated according to position  responsibility and work performance within the group and the participants have thus been divided into five different categories:Category A - EmployeesCategory B - Managers and key employees Category C - Members of group management 5 (10) Fortnox AB (publ) 556469-6291 Attachments Original LinkOriginal DocumentPermalink Disclaimer Fortnox AB published this content on 24 February 2023 and is solely responsible for the information contained therein. Distributed by Public  unedited and unaltered  on 24 February 2023 10:26:10 UTC.¬© Publicnow 2023 All news about FORTNOX AB (PUBL) 02/24 Fortnox : Notice AGM 30 march 2023 PU 02/24 Fortnox : Postal vote form and notification PU 02/24 Fortnox : Nomination Committee's proposal PU 02/24 Fortnox : Resolution regarding long-term share savings program PU 02/24 Fortnox : Resolution on authorisation for the Bord of Directors to resolve on new issues o.. PU 02/21 Fortnox Chairman Reduces Stake to 19% MT 02/21 Olof Hallrup divests shares in Fortnox AQ 02/21 Olof Hallrup contemplates to divest shares in Fortnox AQ 02/17 Fortnox - Strong Momentum in Complementing Segments AQ 02/16 Transcript : Fortnox AB  Q4 2022 Earnings Call  Feb 16  2023 CI",neutral,0.0,1.0,0.0,neutral,0.0,0.99,0.0,True,English,"['Notice AGM', 'Fortnox', 'march', 'Such electronical postal votes', 'Bollgatan 3 B V√§xj√∂', 'multiple email addresses', 'Swedish Companies Act', 'corresponding authorization documents', 'Euroclear Sweden AB', 'foreign legal entity', 'Annual General Meeting', 'voting rights registration', 'Such re-registration', 'Fortnox AB', 'postal voting', 'subject line', 'organization number', 'telephone number', 'record date', 'Thursday 30 March', 'Friday 24 March', 'voting form', 'Wednesday 22 March', 'special form', 'Nominee-registered shares', 'First name', 'dated power', 'respective nominee', 'natural person', 'share register', 'proxy form', 'Notice AGM', 'proxy Shareholders', 'commas', 'Message', 'fields', 'publ', 'Board', 'Directors', 'accordance', 'Chapter', 'Section', 'company', 'Articles', 'Association', 'Participation', 'instructions', 'website', 'Box', 'Stockholm', 'GeneralMeetingService', 'verification', 'BankID', 'EuroclearProxy', 'notification', 'secretariat', 'opening', 'vpc', 'personal', 'written', 'signed', 'attorney', 'certificate', 'place', 'support', 'premises', 'addition', 'routines', 'time', 'advance', 'agenda', 'chairman', 'Election']",2023-02-24,2023-02-25,marketscreener.com
19212,Euroclear,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2615432/0/en/NOTICE-TO-ATTEND-THE-EXTRAORDINARY-GENERAL-MEETING-IN-MAHA-ENERGY-AB-PUBL.html,NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING IN MAHA ENERGY AB (PUBL),The shareholders in Maha Energy AB (publ)  reg. no. 559018-9543  (the ‚ÄúCompany‚Äù) are hereby given notice to attend the extraordinary general meeting on 29 March 2023 at 10.00 CET at Setterwalls Advokatbyr√•‚Äôs offices at Sturegatan 10 in Stockholm  Sweden. Regi‚Ä¶,English SwedishThe shareholders in Maha Energy AB (publ)  reg. no. 559018-9543  (the ‚ÄúCompany‚Äù) are hereby given notice to attend the extraordinary general meeting on 29 March 2023 at 10.00 CET at Setterwalls Advokatbyr√•‚Äôs offices at Sturegatan 10 in Stockholm  Sweden. Registration for the meeting commences at 09.30 CET.NoticeShareholders wishing to participate at the meeting must:(i) be entered in the shareholders‚Äô register  kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation)  on the record day which is 21 March 2023; and(ii) notify the Company of their attendance and any assistant no later than 23 March 2023. Notification can be made via letter to Setterwalls Advokatbyr√• AB  Attn: Magnus Melin  P.O. Box 1050  SE-101 39 Stockholm  Sweden or by e-mail to magnus.melin@setterwalls.se.Notification shall include full name  personal identification number or corporate registration number  address and daytime telephone number and  where appropriate  information about representative  proxy and assistants. The number of assistants may not be more than two. In order to facilitate entry to the meeting  notification should  where appropriate  be accompanied by powers of attorney  registration certificates and other documents of authority.Personal data obtained from the share register kept by Euroclear Sweden AB  notices and attendance at the meeting and information on representatives  proxies and assistants will be used for registration  preparation of the voting list for the meeting and  where appropriate  the minutes of the meeting.Nominee registered sharesShareholders who have their shares registered in the name of a nominee must request temporary entry in the transcription of the share register kept by Euroclear Sweden AB in order to be entitled to participate and vote for their shares at the meeting. The shareholder must inform the nominee well in advance of 21 March 2023 at which time the register entry must have been made. Voting rights registration that has been requested by the shareholder at such time that the registration has been completed by the nominee no later than 23 March 2023  will  however  be taken into account in the preparation of the share register.ProxyA shareholder represented by proxy shall issue a power of attorney which shall be dated and signed by the shareholder. If issued by a legal entity the power of attorney shall be accompanied by registration certificate or  if not applicable  equivalent documents of authority. Power of attorney forms for those shareholders wishing to participate by proxy are available on the Company‚Äôs website www.mahaenergy.ca. The original version of the power of attorney shall also be presented at the meeting.Proposed agendaOpening of the meeting and election of chairman of the meeting; Preparation and approval of the voting list; Approval of the agenda; Election of one (1) or two (2) persons who shall approve the minutes of the meeting; Determination of whether the meeting has been duly convened; Resolution on changes to the articles of association; Resolution on issue of new shares against payment in kind; Resolution on changes to the board composition; Closing of the meeting.Proposed resolutionsItem 1. Election of chairman of the meetingThe board of directors proposes that attorney Marcus Nivinger is appointed chairman of the extraordinary general meeting.Item 6. Resolution on changes to the articles of associationIn view of the investment agreement signed with the shareholders of DBO 2.0 S.A. (referenced to in item 7 below)  the board of directors proposes to change the limits in the articles of association with respect to share capital and number of shares in ¬ß¬ß 4 and 5. ¬ß 4 is proposed to be changed from ‚ÄúThe company‚Äôs share capital shall be not less than SEK 517 000 and not more than SEK 2 068 000‚Äù to ‚ÄúThe company‚Äôs share capital shall be not less than SEK 1 980 000 and not more than SEK 7 920 000‚Äù. ¬ß 5 is proposed to be changed from ‚ÄúThe number of shares in the company shall be no less than 47 000 000 and no more than 188 000 000‚Äù to ‚ÄúThe number of shares in the company shall be no less than 180 000 000 and no more than 720 000 000‚Äù.The chairman of the board of directors  the CEO or a person appointed by the board of directors shall be authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office. A valid resolution requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast as well as of all shares represented at the meeting.Item 7. Resolution on issue of new shares against payment in kindThe board of directors of Maha Energy AB (publ) (the ‚ÄúCompany‚Äù)  proposes that the general meeting resolves to increase the Company‚Äôs share capital by not more than SEK 404 529.51 through a new issue of not more than 36 775 410 shares. The resolution shall otherwise be governed by the following terms and conditions.1. The Company and its subsidiary Nova Maha Energy Brasil Ltda. (‚ÄúMaha Brasil‚Äù) have entered into an investment agreement with the shareholders (the ‚ÄúSellers‚Äù) of DBO 2.0 S.A.  reg. no. 40.070.729/0001-59 (the ‚ÄúTarget‚Äù) regarding the acquisition of all 188 427 shares in the Target  of which 188 426 shares in the Target (the ‚ÄúShares‚Äù) are acquired by the Company against payment of 36 775 410 new shares in the Company and one (1) share in the Target is acquired by Maha Brasil against payment of BRL 1.00. Before entering into said investment agreement  the Company has engaged SpareBank 1 Markets AS (‚ÄúSB1M‚Äù) to provide a fairness opinion regarding the proposed acquisition of Shares (the ‚ÄùIndependent Fairness Opinion Statement‚Äù). SB1M‚Äôs conclusions on the attractiveness of the transaction from a financial point of view have supported the board of directors‚Äô decision to submit the resolution in reference to Company‚Äôs shareholders. For more information on whether the acquisition of all Shares constitutes a fair transaction from a financial point of view and its overall attractiveness for the Company‚Äôs shareholders  please refer to the Independent Fairness Opinion Statement provided by SB1M  Schedule 1 .2. Based on the current approximate share price  the board of directors estimates that the Shares will be included with SEK 352 308 427.8 in the Company‚Äôs balance sheet per the closing date upon full subscription. The value may change  as the value will be determined pursuant to applicable accounting rules as per share price on the closing of the transaction.3. The amount that exceeds the quotient value of the new shares in the Company shall be allocated to the free premium fund.4. The right to subscribe for the new shares shall only vest with the Sellers  with the right and obligation to pay for the new shares by the contribution of shares in the Target in accordance with the below.Maximum number of shares in the Company to be allocated to each Seller Number of Shares in the Target to be contributed by each Seller DBO Invest S.A. 22 706 658 116 342 Svein Harald √òygard 3 370 614 17 270 AGR AS 3 328 652 17 055 Tore Myrholt 2 938 699 15 057 GAESM PARTICIPA√á√ïES LTDA. 1 195 817 6 127 Sebastian Wurster 1 092 961 5 600 Luis Antonio Gomes Araujo 762 926 3 909 Aristeidis Athanasios Tsikouras 656 557 3 364 Andre Luiz de Oliveira Naslausky 481 684 2 468 Halvard Idland 120 421 617 Kjetil Solbr√¶kke 120 421 617 Total 36 775 410 188 4265. Subscription for the newly issued shares shall be made on a subscription list in connection with the completion of the acquisition of the Target  however no later than on 29 September 2023. Payment shall be made in connection with subscription.6. The new shares shall entitle to dividends from and including the first record date for dividends decided after the new shares have been registered with the Swedish Companies Registration Office.7. The chairman of the board of directors  the managing director or a person appointed by the board of directors shall be authorized to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.8. Documents as referred to in Chapter 13 Sections 6-8 of the Swedish Companies Act have been prepared and are kept available at the Company‚Äôs office.Item 8. Resolution on changes to the board compositionAt the extraordinary general meeting held on 3 November 2022  it was resolved to elect Fabio Vassel (chairman)  Paulo Thiago Mendon√ßa and Enrique Pe√±a as new ordinary board members. After the extraordinary general meeting  the board of directors consists of the following six (6) board members without deputy members until the end of the next annual general meeting: Fabio Vassel (chairman)  Paulo Thiago Mendon√ßa  Enrique Pe√±a  Harald Pousette  Viktor Modigh and Richard Norris.Pursuant to the investment agreement with the shareholders of DBO 2.0 S.A.  described under item 7 above  the board of directors proposes that the general meeting resolves on the following changes to the board composition and decision on board fees. The board of directors proposes that the board of directors shall consist of seven (7) ordinary board members with no deputy members until the end of the next annual general meeting. The board of directors proposes that Harald Pousette  upon his own request  is discharged from the board of directors. It is further proposed that Halvard Idland and Kjetil Solbraekke are elected as new ordinary board members until the end of the next annual general meeting (i.e. in addition to the remaining current board members).The new board members are to be entitled to remuneration (board fees) as resolved by the annual general meeting held on 31 May 2022 (i.e. SEK 300 000 reduced proportionally taking into account that the new board members will not serve the entire time period between the annual general meeting held on 31 May 2022 and the next annual general meeting).Presentation of proposed board membersHalvard Idland   born 6 August 1975Experience: Halvard Idland has more than 20 years of industrial and financial investment experience in the oil and gas industry in Norway and Brazil. Previous experience includes DNB  Pareto and Aker Yards prior to co-founding DBO Energy.Education: M.Sc. in Economics and Business Administration from Norwegian School of Economics (NHH).Current assignments: Co-founder and Director at DBO Invest and Janeiro Energy. Board member at Prosafe SE and 3R Offshore. Chairman of DreamLearnWork.Previous assignments (last five years): Co-founder and CFO at DBO Energy and DBO 2.0. Audit committee member at 3R Petroleum.Independent in relation to the Company and the Company management: Yes.Independent in relation to the major shareholders: No. Halvard is Director at DBO Invest which will be a major shareholder in the Company following completion of the issue of new shares proposed under item 7 of the agenda.Holdings of shares in Maha: Halvard does currently have any holdings in Maha. Halvard may subscribe for up to 120 421 new shares in Maha within the issue of new shares proposed under item 7 of the agenda.Kjetil Solbraekke   born 3 May 1962Experience: Kjetil Solbraekke has over 30 years of experience from the Norwegian Oil and gas sector in various positions as Assistant director general in the Ministry of Petroleum in Norway  SVP and CFO in Norsk Hydro  CEO in Panoro Energy and Sintef do Brazil  Founder and CEO in DBO Energy. He has lived in Brazil since 2006.Education: Cand. Oecon from the University of Oslo  Economist.Current assignments: Co-Founder and CEO at DBO Invest.Previous assignments (last five years): CEO in Sintef do Brasil. Co-founder and CEO at DBO Energy and DBO 2.0. Board Member of 3R Petroleum.Independent in relation to the Company and the Company management: Yes.Independent in relation to the major shareholders: No. Kjetil is CEO of DBO Invest which will be a major shareholder in the Company following completion of the issue of new shares proposed under item 7 of the agenda.Holdings of shares in Maha: Kjetil currently holds 100 000 shares in Maha. Kjetil may subscribe for up to 120 421 new shares in Maha within the issue of new shares proposed under item 7 of the agenda.Number of shares and votes in the CompanyThe total number of shares in the Company at the time of issuance of this notice is 143 615 696. The total number of votes for all issued shares in the Company is 143 615 696 votes. The Company does not hold any of its own shares.Shareholders‚Äô right to request informationPursuant to Chapter 7 section 32 of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) the board of directors and the managing director are under a duty to  if any shareholder so requests and the board of directors deems that it can be made without material damage to the Company  provide information  regarding circumstances which may affect the assessment of a matter on the agenda.DocumentationDocuments to be dealt with at the general meeting will be kept available at the Company‚Äôs office not later than three weeks before the meeting. The documents will be sent free of charge to shareholders who so request and state their postal address. The documents will also be made available not later than the aforementioned date on the Company‚Äôs website www.mahaenergy.ca. All the above mentioned documents will also be presented at the general meeting._____Stockholm  24 February 2023The board of directorsMiscellaneousThe information was submitted for publication  through the agency of the contact person set out above  17:30 P.M. CET on 24 February 2023.For more information  please contact:Paulo Thiago Mendon√ßa  CEOPhone: +46 8 611 05 11E-mail: info@mahaenergy.caBernardo Guterres  CFOPhone: +46 8 611 05 11E-mail: info@mahaenergy.caAbout MahaMaha Energy AB (publ) is a listed  international upstream oil and gas company whose business activities include exploration  development and production of crude oil and natural gas. The strategy is to target and develop underperforming hydrocarbon assets on global basis. Maha operates four oil fields: Tartaruga and Tie in Brazil  Powder River (LAK Ranch) and Illinois Basin in the United States. The shares are listed on Nasdaq Stockholm (MAHA-A). The head office is in Stockholm  Sweden with a technical office in Calgary  Canada  as well as operations offices in Grayville  Illinois  USA and Rio De Janeiro  Brazil. For more information  please visit our website www.mahaenergy.ca.Attachments,neutral,0.03,0.93,0.03,neutral,0.04,0.95,0.01,True,English,"['EXTRAORDINARY GENERAL MEETING', 'MAHA ENERGY AB', 'NOTICE', 'PUBL', 'Nova Maha Energy Brasil Ltda', 'Swedish Central Securities Depository', 'Swedish Companies Registration Office', 'Maha Energy AB', 'P.O. Box', 'DBO 2.0 S.A.', 'Euroclear Sweden AB', 'Setterwalls Advokatbyr√• AB', 'daytime telephone number', 'attorney Marcus Nivinger', 'Voting rights registration', 'personal identification number', 'corporate registration number', 'extraordinary general meeting', 'Nominee registered shares', 'English Swedish', 'Maha Bras', 'Personal data', 'voting list', 'registration certificates', 'Clearing Organisation', 'record day', 'Magnus Melin', 'magnus.melin', 'other documents', 'share register', 'legal entity', 'equivalent documents', 'original version', 'two (2) persons', 'investment agreement', 'minor adjustments', 'following terms', 'share capital', 'temporary entry', 'register entry', 'full name', 'attorney forms', 'new shares', 'new issue', 'board composition', 'shareholders‚Äô register', 'valid resolution', 'The Company', '36,775,410 shares', 'publ', 'reg.', 'notice', '29 March', '10.00 CET', 'offices', 'Sturegatan', 'Stockholm', '09.30 CET', '21 March', 'attendance', 'assistant', '23 March', 'Notification', 'letter', 'Attn', 'mail', 'address', 'information', 'representative', 'proxy', 'order', 'powers', 'authority', 'proxies', 'preparation', 'minutes', 'transcription', 'advance', 'account', 'website', 'mahaenergy', 'agenda', 'Opening', 'election', 'chairman', 'approval', 'Determination', 'changes', 'articles', 'association', 'payment', 'kind', 'Closing', 'resolutions', 'Item', 'directors', 'view', 'limits', 'respect', 'SEK', 'CEO', 'proposal', 'two-thirds', 'votes', 'conditions', 'subsidiary', '¬ß¬ß']",2023-02-24,2023-02-25,globenewswire.com
19213,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/MAHA-ENERGY-AB-PUBL-61747321/news/NOTICE-TO-ATTEND-THE-EXTRAORDINARY-GENERAL-MEETING-IN-MAHA-ENERGY-AB-PUBL-43081740/?utm_medium=RSS&utm_content=20230224,NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING IN MAHA ENERGY AB (PUBL),(marketscreener.com) The shareholders in Maha Energy AB   reg. no. 559018-9543  are hereby given notice to attend the extraordinary general meeting on 29 March 2023 at 10.00 CET at Setterwalls Advokatbyr√•‚Äôs offices at Sturegatan 10 in Stockholm  Sweden. Regis‚Ä¶,The shareholders in Maha Energy AB (publ)  reg. no. 559018-9543  (the ‚ÄúCompany‚Äù) are hereby given notice to attend the extraordinary general meeting on 29 March 2023 at 10.00 CET at Setterwalls Advokatbyr√•‚Äôs offices at Sturegatan 10 in Stockholm  Sweden. Registration for the meeting commences at 09.30 CET.NoticeShareholders wishing to participate at the meeting must:(i) be entered in the shareholders‚Äô register  kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation)  on the record day which is 21 March 2023; and(ii) notify the Company of their attendance and any assistant no later than 23 March 2023. Notification can be made via letter to Setterwalls Advokatbyr√• AB  Attn: Magnus Melin  P.O. Box 1050  SE-101 39 Stockholm  Sweden or by e-mail to magnus.melin@setterwalls.se.Notification shall include full name  personal identification number or corporate registration number  address and daytime telephone number and  where appropriate  information about representative  proxy and assistants. The number of assistants may not be more than two. In order to facilitate entry to the meeting  notification should  where appropriate  be accompanied by powers of attorney  registration certificates and other documents of authority.Personal data obtained from the share register kept by Euroclear Sweden AB  notices and attendance at the meeting and information on representatives  proxies and assistants will be used for registration  preparation of the voting list for the meeting and  where appropriate  the minutes of the meeting.Nominee registered sharesShareholders who have their shares registered in the name of a nominee must request temporary entry in the transcription of the share register kept by Euroclear Sweden AB in order to be entitled to participate and vote for their shares at the meeting. The shareholder must inform the nominee well in advance of 21 March 2023 at which time the register entry must have been made. Voting rights registration that has been requested by the shareholder at such time that the registration has been completed by the nominee no later than 23 March 2023  will  however  be taken into account in the preparation of the share register.ProxyA shareholder represented by proxy shall issue a power of attorney which shall be dated and signed by the shareholder. If issued by a legal entity the power of attorney shall be accompanied by registration certificate or  if not applicable  equivalent documents of authority. Power of attorney forms for those shareholders wishing to participate by proxy are available on the Company‚Äôs website www.mahaenergy.ca. The original version of the power of attorney shall also be presented at the meeting.Proposed agendaOpening of the meeting and election of chairman of the meeting; Preparation and approval of the voting list; Approval of the agenda; Election of one (1) or two (2) persons who shall approve the minutes of the meeting; Determination of whether the meeting has been duly convened; Resolution on changes to the articles of association; Resolution on issue of new shares against payment in kind; Resolution on changes to the board composition; Closing of the meeting.Proposed resolutionsItem 1. Election of chairman of the meetingThe board of directors proposes that attorney Marcus Nivinger is appointed chairman of the extraordinary general meeting.Item 6. Resolution on changes to the articles of associationIn view of the investment agreement signed with the shareholders of DBO 2.0 S.A. (referenced to in item 7 below)  the board of directors proposes to change the limits in the articles of association with respect to share capital and number of shares in ¬ß¬ß 4 and 5. ¬ß 4 is proposed to be changed from ‚ÄúThe company‚Äôs share capital shall be not less than SEK 517 000 and not more than SEK 2 068 000‚Äù to ‚ÄúThe company‚Äôs share capital shall be not less than SEK 1 980 000 and not more than SEK 7 920 000‚Äù. ¬ß 5 is proposed to be changed from ‚ÄúThe number of shares in the company shall be no less than 47 000 000 and no more than 188 000 000‚Äù to ‚ÄúThe number of shares in the company shall be no less than 180 000 000 and no more than 720 000 000‚Äù.The chairman of the board of directors  the CEO or a person appointed by the board of directors shall be authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office. A valid resolution requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast as well as of all shares represented at the meeting.Item 7. Resolution on issue of new shares against payment in kindThe board of directors of Maha Energy AB (publ) (the ‚ÄúCompany‚Äù)  proposes that the general meeting resolves to increase the Company‚Äôs share capital by not more than SEK 404 529.51 through a new issue of not more than 36 775 410 shares. The resolution shall otherwise be governed by the following terms and conditions.1. The Company and its subsidiary Nova Maha Energy Brasil Ltda. (‚ÄúMaha Brasil‚Äù) have entered into an investment agreement with the shareholders (the ‚ÄúSellers‚Äù) of DBO 2.0 S.A.  reg. no. 40.070.729/0001-59 (the ‚ÄúTarget‚Äù) regarding the acquisition of all 188 427 shares in the Target  of which 188 426 shares in the Target (the ‚ÄúShares‚Äù) are acquired by the Company against payment of 36 775 410 new shares in the Company and one (1) share in the Target is acquired by Maha Brasil against payment of BRL 1.00. Before entering into said investment agreement  the Company has engaged SpareBank 1 Markets AS (‚ÄúSB1M‚Äù) to provide a fairness opinion regarding the proposed acquisition of Shares (the ‚ÄùIndependent Fairness Opinion Statement‚Äù). SB1M‚Äôs conclusions on the attractiveness of the transaction from a financial point of view have supported the board of directors‚Äô decision to submit the resolution in reference to Company‚Äôs shareholders. For more information on whether the acquisition of all Shares constitutes a fair transaction from a financial point of view and its overall attractiveness for the Company‚Äôs shareholders  please refer to the Independent Fairness Opinion Statement provided by SB1M  Schedule 1 .2. Based on the current approximate share price  the board of directors estimates that the Shares will be included with SEK 352 308 427.8 in the Company‚Äôs balance sheet per the closing date upon full subscription. The value may change  as the value will be determined pursuant to applicable accounting rules as per share price on the closing of the transaction.3. The amount that exceeds the quotient value of the new shares in the Company shall be allocated to the free premium fund.4. The right to subscribe for the new shares shall only vest with the Sellers  with the right and obligation to pay for the new shares by the contribution of shares in the Target in accordance with the below.Maximum number of shares in the Company to be allocated to each Seller Number of Shares in the Target to be contributed by each Seller DBO Invest S.A. 22 706 658 116 342 Svein Harald √òygard 3 370 614 17 270 AGR AS 3 328 652 17 055 Tore Myrholt 2 938 699 15 057 GAESM PARTICIPA√á√ïES LTDA. 1 195 817 6 127 Sebastian Wurster 1 092 961 5 600 Luis Antonio Gomes Araujo 762 926 3 909 Aristeidis Athanasios Tsikouras 656 557 3 364 Andre Luiz de Oliveira Naslausky 481 684 2 468 Halvard Idland 120 421 617 Kjetil Solbr√¶kke 120 421 617 Total 36 775 410 188 4265. Subscription for the newly issued shares shall be made on a subscription list in connection with the completion of the acquisition of the Target  however no later than on 29 September 2023. Payment shall be made in connection with subscription.6. The new shares shall entitle to dividends from and including the first record date for dividends decided after the new shares have been registered with the Swedish Companies Registration Office.7. The chairman of the board of directors  the managing director or a person appointed by the board of directors shall be authorized to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.8. Documents as referred to in Chapter 13 Sections 6-8 of the Swedish Companies Act have been prepared and are kept available at the Company‚Äôs office.Item 8. Resolution on changes to the board compositionAt the extraordinary general meeting held on 3 November 2022  it was resolved to elect Fabio Vassel (chairman)  Paulo Thiago Mendon√ßa and Enrique Pe√±a as new ordinary board members. After the extraordinary general meeting  the board of directors consists of the following six (6) board members without deputy members until the end of the next annual general meeting: Fabio Vassel (chairman)  Paulo Thiago Mendon√ßa  Enrique Pe√±a  Harald Pousette  Viktor Modigh and Richard Norris.Pursuant to the investment agreement with the shareholders of DBO 2.0 S.A.  described under item 7 above  the board of directors proposes that the general meeting resolves on the following changes to the board composition and decision on board fees. The board of directors proposes that the board of directors shall consist of seven (7) ordinary board members with no deputy members until the end of the next annual general meeting. The board of directors proposes that Harald Pousette  upon his own request  is discharged from the board of directors. It is further proposed that Halvard Idland and Kjetil Solbraekke are elected as new ordinary board members until the end of the next annual general meeting (i.e. in addition to the remaining current board members).The new board members are to be entitled to remuneration (board fees) as resolved by the annual general meeting held on 31 May 2022 (i.e. SEK 300 000 reduced proportionally taking into account that the new board members will not serve the entire time period between the annual general meeting held on 31 May 2022 and the next annual general meeting).Presentation of proposed board membersHalvard Idland   born 6 August 1975Experience: Halvard Idland has more than 20 years of industrial and financial investment experience in the oil and gas industry in Norway and Brazil. Previous experience includes DNB  Pareto and Aker Yards prior to co-founding DBO Energy.Education: M.Sc. in Economics and Business Administration from Norwegian School of Economics (NHH).Current assignments: Co-founder and Director at DBO Invest and Janeiro Energy. Board member at Prosafe SE and 3R Offshore. Chairman of DreamLearnWork.Previous assignments (last five years): Co-founder and CFO at DBO Energy and DBO 2.0. Audit committee member at 3R Petroleum.Independent in relation to the Company and the Company management: Yes.Independent in relation to the major shareholders: No. Halvard is Director at DBO Invest which will be a major shareholder in the Company following completion of the issue of new shares proposed under item 7 of the agenda.Holdings of shares in Maha: Halvard does currently have any holdings in Maha. Halvard may subscribe for up to 120 421 new shares in Maha within the issue of new shares proposed under item 7 of the agenda.Kjetil Solbraekke   born 3 May 1962Experience: Kjetil Solbraekke has over 30 years of experience from the Norwegian Oil and gas sector in various positions as Assistant director general in the Ministry of Petroleum in Norway  SVP and CFO in Norsk Hydro  CEO in Panoro Energy and Sintef do Brazil  Founder and CEO in DBO Energy. He has lived in Brazil since 2006.Education: Cand. Oecon from the University of Oslo  Economist.Current assignments: Co-Founder and CEO at DBO Invest.Previous assignments (last five years): CEO in Sintef do Brasil. Co-founder and CEO at DBO Energy and DBO 2.0. Board Member of 3R Petroleum.Independent in relation to the Company and the Company management: Yes.Independent in relation to the major shareholders: No. Kjetil is CEO of DBO Invest which will be a major shareholder in the Company following completion of the issue of new shares proposed under item 7 of the agenda.Holdings of shares in Maha: Kjetil currently holds 100 000 shares in Maha. Kjetil may subscribe for up to 120 421 new shares in Maha within the issue of new shares proposed under item 7 of the agenda.Number of shares and votes in the CompanyThe total number of shares in the Company at the time of issuance of this notice is 143 615 696. The total number of votes for all issued shares in the Company is 143 615 696 votes. The Company does not hold any of its own shares.Shareholders‚Äô right to request informationPursuant to Chapter 7 section 32 of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) the board of directors and the managing director are under a duty to  if any shareholder so requests and the board of directors deems that it can be made without material damage to the Company  provide information  regarding circumstances which may affect the assessment of a matter on the agenda.DocumentationDocuments to be dealt with at the general meeting will be kept available at the Company‚Äôs office not later than three weeks before the meeting. The documents will be sent free of charge to shareholders who so request and state their postal address. The documents will also be made available not later than the aforementioned date on the Company‚Äôs website www.mahaenergy.ca. All the above mentioned documents will also be presented at the general meeting._____Stockholm  24 February 2023The board of directorsMiscellaneousThe information was submitted for publication  through the agency of the contact person set out above  17:30 P.M. CET on 24 February 2023.For more information  please contact:Paulo Thiago Mendon√ßa  CEOPhone: +46 8 611 05 11E-mail: info@mahaenergy.caBernardo Guterres  CFOPhone: +46 8 611 05 11E-mail: info@mahaenergy.caAbout MahaMaha Energy AB (publ) is a listed  international upstream oil and gas company whose business activities include exploration  development and production of crude oil and natural gas. The strategy is to target and develop underperforming hydrocarbon assets on global basis. Maha operates four oil fields: Tartaruga and Tie in Brazil  Powder River (LAK Ranch) and Illinois Basin in the United States. The shares are listed on Nasdaq Stockholm (MAHA-A). The head office is in Stockholm  Sweden with a technical office in Calgary  Canada  as well as operations offices in Grayville  Illinois  USA and Rio De Janeiro  Brazil. For more information  please visit our website www.mahaenergy.ca.Attachments,neutral,0.03,0.93,0.03,positive,0.67,0.32,0.01,True,English,"['EXTRAORDINARY GENERAL MEETING', 'MAHA ENERGY AB', 'NOTICE', 'PUBL', 'Nova Maha Energy Brasil Ltda', 'Swedish Central Securities Depository', 'Swedish Companies Registration Office', 'Maha Energy AB', 'P.O. Box', 'DBO 2.0 S.A.', 'Euroclear Sweden AB', 'Setterwalls Advokatbyr√• AB', 'daytime telephone number', 'attorney Marcus Nivinger', 'Voting rights registration', 'personal identification number', 'corporate registration number', 'extraordinary general meeting', 'Maha Brasil', 'Nominee registered shares', 'Personal data', 'voting list', 'registration certificates', 'Clearing Organisation', 'record day', 'Magnus Melin', 'magnus.melin', 'other documents', 'share register', 'legal entity', 'equivalent documents', 'original version', 'two (2) persons', 'investment agreement', 'minor adjustments', 'following terms', 'share capital', 'temporary entry', 'register entry', 'full name', 'attorney forms', 'new shares', 'new issue', 'board composition', 'shareholders‚Äô register', 'valid resolution', 'The Company', '36,775,410 shares', 'publ', 'reg.', 'notice', '29 March', '10.00 CET', 'offices', 'Sturegatan', 'Stockholm', '09.30 CET', '21 March', 'attendance', 'assistant', '23 March', 'Notification', 'letter', 'Attn', 'mail', 'address', 'information', 'representative', 'proxy', 'order', 'powers', 'authority', 'proxies', 'preparation', 'minutes', 'transcription', 'advance', 'account', 'website', 'mahaenergy', 'agenda', 'Opening', 'election', 'chairman', 'approval', 'Determination', 'changes', 'articles', 'association', 'payment', 'kind', 'Closing', 'resolutions', 'Item', 'directors', 'view', 'limits', 'respect', 'SEK', 'CEO', 'proposal', 'two-thirds', 'votes', 'conditions', 'subsidiary', '¬ß¬ß']",2023-02-24,2023-02-25,marketscreener.com
19214,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/BBS-BIOACTIVE-BONE-SUBSTI-41648091/news/BBS-Bioactive-Bone-Substitutes-Plc-Financial-Statements-Bulletin-1-January-ndash-31-December-202-43077121/?utm_medium=RSS&utm_content=20230224,BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin  1 January ‚Äì 31 December 2022 (unaudited),(marketscreener.com) BBS-Bioactive Bone Substitutes Plc  Financial Statements Bulletin  24 February 2023 at 3.00 p.m. BBS advances towards the CE marking of its first product This is a summary of BBS-Bioactive Bone Substitutes Plc‚Äôs Financial Statements Bulle‚Ä¶,BBS-Bioactive Bone Substitutes Plc  Financial Statements Bulletin  24 February 2023 at 3.00 p.m.BBS advances towards the CE marking of its first productThis is a summary of BBS-Bioactive Bone Substitutes Plc‚Äôs Financial Statements Bulletin for January‚ÄìDecember 2022. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc‚Äôs website at https://www.bbs-artebone.fi/.JULY-DECEMBER (H2) HIGHLIGHTSDuring the second half of the year  BBS-Bioactive Bone Substitutes Plc (BBS) continued to implement the actions required for the registration of the company's first product (ARTEBONE¬Æ Paste)  including ramping up production and preparing for the start of marketing measures.In November  the Notified Body conducted a successful audit  related to the company‚Äôs quality system. Only minor measures were needed to correct the issues in the inspection report. Quality system certification is a part of the CE marking process for BBS‚Äô first product  Artebone Paste. The final audit for the quality system is scheduled for early March.The company generated no revenue during the review period.The financial result in the review period was EUR -1.42 (-1.46) million.Cash flow from operations was EUR -1.320 (-1.156) million.Cash and cash equivalents on 31 December 2022 were EUR 1.52 (1.24) million.YEAR 2022Artebone Paste's CE marking application was submitted to the notified body on March 9  2022.In May ‚Äì June  the company arranged a rights issue  raising a total of approximately EUR 3.5 million in gross proceeds. Net proceeds after transaction costs related to the issue were approximately EUR 3.1 million.The company generated no revenue during the review period.The financial result in the review period was EUR ‚Äì3.09 (-2.77) million.Cash flow from operations was EUR ‚Äì2.82 (-2.52) million.Cash and cash equivalents on 31 December 2022 were EUR 1.52 (1.24) million.The figures in the review are rounded  so the sum of the individual figures may differ from the total presented. BBS's accounting period is a calendar year. Figures in parentheses refer to the corresponding period of the previous year  unless otherwise stated. The information in the review is unaudited.OUTLOOKGuidance for 2023No revenue is expected during 2023.Board of Directors‚Äô outlook for 2023The company has submitted the CE marking application for its first product (ARTEBONE¬Æ Paste) to the notified body on 9 March 2022. Based on a survey* conducted for the Notified Body  the average application processing times increased in 2022. Due to this  the company estimates that  based on currently available information  it is unlikely to receive the final CE marking approval by the end of March 2023. The company expects authorities‚Äô decision on approving the application during 2023.Preparations for commercial operations will begin towards the end of 2023.Further measures are required to ensure the sufficiency of the company's financing in order to implement the company‚Äôs plans following the expected approval of the CE marking. The company continues discussions to secure additional funding to enable the continuation of the development work as well as initiating commercial activities.*MedTech Europe Survey Report:. https://www.medtecheurope.org/wp-content/uploads/2022/07/medtech-europe-survey-report-analysing-the-availability-of-medical-devices-in-2022-in-connection-to-the-medical-device-regulation-mdr-implementation.pdfKEY FIGURES1000 eur 7-12/2022 7-12/2021 1-12/2022 1-12/2021 Other operating income 9 16 64 61 Personnel expenses 587 720 1 315 1 199 Depreciationa and amortization 112 119 225 231 Other operational expenses 756 481 1 446 1 144 Profit/Loss for the period -1 416 -1 463 -3 093 -2 771 Cash flow for business operations -1 320 -1 155 -2 816 -2 520 Change in cash resources -1 872 -698 281 -2 202 Equity ratio1)  % 40.0 34.6 40.0 34.6 Earnings per share2)  EUR -0.15 -0.22 -0.38 -0.42 Earnings per share  EUR  diluted -0.14 -0.22 -0.35 -0.41 Number of shares at the end of period 9 668 351 6 737 889 9 668 351 6 737 889 Average number of shares in the period 9 450 846 6 615 855 8 211 650 6 593 872 Equity per share 3)  EUR 0.44 0.54 0.44 0.54 Cash and cash equivalents 1 517 1 236 1 517 1 236 Equity 4 271 3 634 4 271 3 634 Balance sheet total 10 688 10 506 10 688 10 5061) Equity ratio = Equity / (Balance sheet total ‚Äì Advances received)2 )EPS = Profit(Loss) / Average number of outstanding shares in the period3 )Equity / Total number of outstanding shares at the end of the periodCEO ILKKA KANGASNIEMIDuring the second half of the year  BBS focused on advancing the CE marking process with the Notified Body  aimed at facilitating the sales and marketing of our first product (ARTEBONE¬Æ Paste) in the EU region. During the autumn months  we continued to refine production lines and processes  while finalizing production validation procedures  ensuring the ability to produce products consistently for the upcoming launch.The CE marking procedure involves two key streams: quality system approval and product approval. With regards to the first  significant progress was made in the latter half of the year. In November  the Notified Body conducted a successful audit  and no critical non-conformities were reported regarding the quality system. The final audit for the quality system is scheduled for early March.It is also noteworthy that the Notified Body has already submitted the initial questions and supplemental requests regarding product approval  and there were no critical non-conformities in these submissions.Obtaining product approval requires close collaboration between the Notified Body and the Medicines Agency. So far  the process has progressed at a slower pace  and cooperation has yet to commence. Given the current backlog of application processing  as reported in public surveys  the company announced in December that it was unlikely to receive the final CE marking approval by the end of March 2023. Despite the delays in the regulatory process  the company still believes that receiving the approval is achievable in 2023.The product approval process for medical devices can be time-consuming and requires patience. Although progress has been slow  the company's financial situation remains stable until July-August. The management team is able to adjust the allocation of funds based on its decisions. Currently  the company is exploring multiple options for additional funding to secure the continuation of development work and well as preparations for commercial operations during the congested approval process..We are steadfastly advancing towards our objective: to bring a new generation of safe bone fillers to a thriving market  improving patients' lives and streamlining the overburdened healthcare system.EVENTS AFTER PERIOD-ENDThe company has on 13 February 2023 applied for The Delisting of Secondary Listing on Nasdaq First North Growth Market Sweden. When making the decision  the board has taken into account the low trading volumes of BBS shares after the company's listing in 2018  as well as the small number of shareholders registered with Euroclear Sweden AB. The board has also assessed the additional costs incurred by the company and the administrative responsibilities arising from compliance with the listing requirements in connection with the parallel listing. The last day of trading in the shares of BBS on Nasdaq First North Growth Market Sweden shall be March 3  2023.FINANCIAL CALENDAR FOR 2023Financial Statements Release for the year 2022 will be published on 24 February 2023The Annual Report for the year 2022 will be published during the week 13/2023 the latest.The Annual General Meeting is planned to be held on 28 April 2023Half-year financial report January-June 2023 will be published on 25 August 2023The company's previously published reports can be found on the BBS investor website at: https://www.bbs-artebone.fi/investors/financial-reports/.24 February 2023BBS-Bioactive Bone Substitutes PlcBoard of DirectorsDistributionNasdaq Helsinkihttps://www.bbs-artebone.fi/BBS in briefBBS-Bioactive Bone Substitutes Plc is a Finnish orthobiology company whose core competence is the development  commercialization and manufacture of easy-to-use bone implants that promote bone formation and healing. Bone substitutes  i.e. implants  are intended for the treatment of various bone damage  bone healing problems and bone diseases instead of autologous and bank bone grafts. BBS aims to become one of the leading players in the field of bioactive implants intended for bone healing problems.BBS was founded in 2003  and the company has been listed on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden since February 2018. The company's head office is located in Oulu  and it employs 20 people.Attachments,neutral,0.0,1.0,0.0,mixed,0.1,0.35,0.56,True,English,"['BBS-Bioactive Bone Substitutes Plc', 'Financial Statements Bulletin', '1 January', '31 December', 'BBS-Bioactive Bone Substitutes Plc', 'average application processing times', 'MedTech Europe Survey Report', 'final CE marking approval', 'Other operating income', 'CE marking process', 'CE marking procedure', 'Financial Statements Bulletin', 'CE marking application', 'Other operational expenses', 'Balance sheet total', 'production validation procedures', 'Quality system certification', 'final audit', 'expected approval', 'financial result', 'Personnel expenses', 'Average number', 'entire report', 'inspection report', 'first product', 'second half', 'ARTEBONE¬Æ Paste', 'successful audit', 'minor measures', 'Artebone Paste', 'gross proceeds', 'Net proceeds', 'transaction costs', 'authorities‚Äô decision', 'Further measures', 'additional funding', 'development work', 'commercial activities', 'ILKKA KANGASNIEMI', 'EU region', 'autumn months', 'production lines', 'upcoming launch', 'two key', 'Total number', 'Cash flow', 'cash equivalents', 'cash resources', 'Notified Body', 'accounting period', 'corresponding period', 'marketing measures', 'rights issue', 'calendar year', 'previous year', 'Directors‚Äô outlook', 'available information', 'commercial operations', 'business operations', 'outstanding shares', 'January‚ÄìDecember', 'Equity ratio', 'early March', 'individual figures', 'review period', 'Company Announcement', '31 December', '9 March', '24 February', 'summary', 'file', 'website', 'bbs-artebone', 'JULY-DECEMBER', '2) HIGHLIGHTS', 'actions', 'registration', 'start', 'November', 'issues', 'part', 'revenue', 'May', 'June', 'parentheses', 'Guidance', 'Board', 'Preparations', 'sufficiency', 'financing', 'order', 'plans', 'discussions', 'continuation', 'medtecheurope', 'uploads', 'medtech-europe-survey', 'availability', 'medical-devices', 'connection', 'medical-device-regulation', 'Depreciationa', 'amortization', 'Profit/Loss', 'Change', '6 Earnings', 'Advances', 'EPS', 'CEO', 'sales', 'processes', 'products', '3.00', '2023']",2023-02-24,2023-02-25,marketscreener.com
19215,Euroclear,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2615197/0/en/BBS-Bioactive-Bone-Substitutes-Plc-Financial-Statements-Bulletin-1-January-31-December-2022-unaudited.html,BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin  1 January ‚Äì 31 December 2022 (unaudited),BBS-Bioactive Bone Substitutes Plc  Financial Statements Bulletin  24 February 2023 at 3.00 p.m.        BBS advances towards the CE marking of its...,English FinnishBBS-Bioactive Bone Substitutes Plc  Financial Statements Bulletin  24 February 2023 at 3.00 p.m.BBS advances towards the CE marking of its first productThis is a summary of BBS-Bioactive Bone Substitutes Plc‚Äôs Financial Statements Bulletin for January‚ÄìDecember 2022. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc‚Äôs website at https://www.bbs-artebone.fi/.JULY-DECEMBER (H2) HIGHLIGHTSDuring the second half of the year  BBS-Bioactive Bone Substitutes Plc (BBS) continued to implement the actions required for the registration of the company's first product (ARTEBONE¬Æ Paste)  including ramping up production and preparing for the start of marketing measures.In November  the Notified Body conducted a successful audit  related to the company‚Äôs quality system. Only minor measures were needed to correct the issues in the inspection report. Quality system certification is a part of the CE marking process for BBS‚Äô first product  Artebone Paste. The final audit for the quality system is scheduled for early March.The company generated no revenue during the review period.The financial result in the review period was EUR -1.42 (-1.46) million.Cash flow from operations was EUR -1.320 (-1.156) million.Cash and cash equivalents on 31 December 2022 were EUR 1.52 (1.24) million.YEAR 2022Artebone Paste's CE marking application was submitted to the notified body on March 9  2022.In May ‚Äì June  the company arranged a rights issue  raising a total of approximately EUR 3.5 million in gross proceeds. Net proceeds after transaction costs related to the issue were approximately EUR 3.1 million.The company generated no revenue during the review period.The financial result in the review period was EUR ‚Äì3.09 (-2.77) million.Cash flow from operations was EUR ‚Äì2.82 (-2.52) million.Cash and cash equivalents on 31 December 2022 were EUR 1.52 (1.24) million.The figures in the review are rounded  so the sum of the individual figures may differ from the total presented. BBS's accounting period is a calendar year. Figures in parentheses refer to the corresponding period of the previous year  unless otherwise stated. The information in the review is unaudited.OUTLOOKGuidance for 2023No revenue is expected during 2023.Board of Directors‚Äô outlook for 2023The company has submitted the CE marking application for its first product (ARTEBONE¬Æ Paste) to the notified body on 9 March 2022. Based on a survey* conducted for the Notified Body  the average application processing times increased in 2022. Due to this  the company estimates that  based on currently available information  it is unlikely to receive the final CE marking approval by the end of March 2023. The company expects authorities‚Äô decision on approving the application during 2023.Preparations for commercial operations will begin towards the end of 2023.Further measures are required to ensure the sufficiency of the company's financing in order to implement the company‚Äôs plans following the expected approval of the CE marking. The company continues discussions to secure additional funding to enable the continuation of the development work as well as initiating commercial activities.*MedTech Europe Survey Report:. https://www.medtecheurope.org/wp-content/uploads/2022/07/medtech-europe-survey-report-analysing-the-availability-of-medical-devices-in-2022-in-connection-to-the-medical-device-regulation-mdr-implementation.pdfKEY FIGURES1000 eur 7-12/2022 7-12/2021 1-12/2022 1-12/2021 Other operating income 9 16 64 61 Personnel expenses 587 720 1 315 1 199 Depreciationa and amortization 112 119 225 231 Other operational expenses 756 481 1 446 1 144 Profit/Loss for the period -1 416 -1 463 -3 093 -2 771 Cash flow for business operations -1 320 -1 155 -2 816 -2 520 Change in cash resources -1 872 -698 281 -2 202 Equity ratio1)  % 40.0 34.6 40.0 34.6 Earnings per share2)  EUR -0.15 -0.22 -0.38 -0.42 Earnings per share  EUR  diluted -0.14 -0.22 -0.35 -0.41 Number of shares at the end of period 9 668 351 6 737 889 9 668 351 6 737 889 Average number of shares in the period 9 450 846 6 615 855 8 211 650 6 593 872 Equity per share 3)  EUR 0.44 0.54 0.44 0.54 Cash and cash equivalents 1 517 1 236 1 517 1 236 Equity 4 271 3 634 4 271 3 634 Balance sheet total 10 688 10 506 10 688 10 5061) Equity ratio = Equity / (Balance sheet total ‚Äì Advances received)2 )EPS = Profit(Loss) / Average number of outstanding shares in the period3 )Equity / Total number of outstanding shares at the end of the periodCEO ILKKA KANGASNIEMIDuring the second half of the year  BBS focused on advancing the CE marking process with the Notified Body  aimed at facilitating the sales and marketing of our first product (ARTEBONE¬Æ Paste) in the EU region. During the autumn months  we continued to refine production lines and processes  while finalizing production validation procedures  ensuring the ability to produce products consistently for the upcoming launch.The CE marking procedure involves two key streams: quality system approval and product approval. With regards to the first  significant progress was made in the latter half of the year. In November  the Notified Body conducted a successful audit  and no critical non-conformities were reported regarding the quality system. The final audit for the quality system is scheduled for early March.It is also noteworthy that the Notified Body has already submitted the initial questions and supplemental requests regarding product approval  and there were no critical non-conformities in these submissions.Obtaining product approval requires close collaboration between the Notified Body and the Medicines Agency. So far  the process has progressed at a slower pace  and cooperation has yet to commence. Given the current backlog of application processing  as reported in public surveys  the company announced in December that it was unlikely to receive the final CE marking approval by the end of March 2023. Despite the delays in the regulatory process  the company still believes that receiving the approval is achievable in 2023.The product approval process for medical devices can be time-consuming and requires patience. Although progress has been slow  the company's financial situation remains stable until July-August. The management team is able to adjust the allocation of funds based on its decisions. Currently  the company is exploring multiple options for additional funding to secure the continuation of development work and well as preparations for commercial operations during the congested approval process..We are steadfastly advancing towards our objective: to bring a new generation of safe bone fillers to a thriving market  improving patients' lives and streamlining the overburdened healthcare system.EVENTS AFTER PERIOD-ENDThe company has on 13 February 2023 applied for The Delisting of Secondary Listing on Nasdaq First North Growth Market Sweden. When making the decision  the board has taken into account the low trading volumes of BBS shares after the company's listing in 2018  as well as the small number of shareholders registered with Euroclear Sweden AB. The board has also assessed the additional costs incurred by the company and the administrative responsibilities arising from compliance with the listing requirements in connection with the parallel listing. The last day of trading in the shares of BBS on Nasdaq First North Growth Market Sweden shall be March 3  2023.FINANCIAL CALENDAR FOR 2023Financial Statements Release for the year 2022 will be published on 24 February 2023The Annual Report for the year 2022 will be published during the week 13/2023 the latest.The Annual General Meeting is planned to be held on 28 April 2023Half-year financial report January-June 2023 will be published on 25 August 2023The company's previously published reports can be found on the BBS investor website at: https://www.bbs-artebone.fi/investors/financial-reports/.24 February 2023BBS-Bioactive Bone Substitutes PlcBoard of DirectorsDistributionNasdaq Helsinkihttps://www.bbs-artebone.fi/BBS in briefBBS-Bioactive Bone Substitutes Plc is a Finnish orthobiology company whose core competence is the development  commercialization and manufacture of easy-to-use bone implants that promote bone formation and healing. Bone substitutes  i.e. implants  are intended for the treatment of various bone damage  bone healing problems and bone diseases instead of autologous and bank bone grafts. BBS aims to become one of the leading players in the field of bioactive implants intended for bone healing problems.BBS was founded in 2003  and the company has been listed on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden since February 2018. The company's head office is located in Oulu  and it employs 20 people.Attachments,neutral,0.0,1.0,0.0,negative,0.0,0.24,0.76,True,English,"['BBS-Bioactive Bone Substitutes Plc', 'Financial Statements Bulletin', '1 January', '31 December', 'BBS-Bioactive Bone Substitutes Plc', 'The CE marking procedure', 'average application processing times', 'MedTech Europe Survey Report', 'final CE marking approval', 'CE marking process', 'Other operating income', 'CE marking application', 'Financial Statements Bulletin', 'Other operational expenses', 'Balance sheet total', 'production validation procedures', 'Quality system certification', 'final audit', 'expected approval', 'financial result', 'Personnel expenses', 'Average number', 'entire report', 'inspection report', 'English Finnish', 'first product', 'second half', 'ARTEBONE¬Æ Paste', 'successful audit', 'minor measures', 'Artebone Paste', 'gross proceeds', 'Net proceeds', 'transaction costs', 'authorities‚Äô decision', 'Further measures', 'additional funding', 'development work', 'commercial activities', 'ILKKA KANGASNIEMI', 'EU region', 'autumn months', 'production lines', 'upcoming launch', 'Total number', 'Cash flow', 'cash equivalents', 'cash resources', 'Notified Body', 'accounting period', 'corresponding period', 'marketing measures', 'rights issue', 'Directors‚Äô outlook', 'available information', 'commercial operations', 'business operations', 'outstanding shares', 'calendar year', 'previous year', 'January‚ÄìDecember', 'Equity ratio', 'early March', 'individual figures', 'review period', 'Company Announcement', '31 December', '9 March', '24 February', 'summary', 'file', 'website', 'JULY-DECEMBER', 'HIGHLIGHTS', 'actions', 'registration', 'start', 'November', 'issues', 'part', 'revenue', 'May', 'June', 'parentheses', 'Guidance', 'Board', 'Preparations', 'sufficiency', 'financing', 'order', 'plans', 'discussions', 'continuation', 'medtecheurope', 'uploads', 'medtech-europe-survey', 'availability', 'medical-devices', 'connection', 'medical-device-regulation', 'Depreciationa', 'amortization', 'Profit/Loss', 'Change', '6 Earnings', 'Advances', 'EPS', 'CEO', 'sales', 'processes', 'products', '3.00', '2023']",2023-02-24,2023-02-25,globenewswire.com
19216,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/KATORO-GOLD-PLC-22033612/news/Katoro-Gold-GM-Notice-Final-Proxy-Form-clean-FINAL-43074829/?utm_medium=RSS&utm_content=20230224,Katoro Gold : GM Notice Final + Proxy Form - clean FINAL,(marketscreener.com)   THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document  or the action you should take  you are recommended to seek your own independent financial advice immediatel‚Ä¶,"Katoro Gold : GM Notice Final + Proxy Form - clean FINAL 02/24/2023 | 03:27am EST Send by mail :Name : First name : From * : To * : (You can enter multiple email addresses separated by commas) Message : * Required fields THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document  or the action you should take  you are recommended to seek your own independent financial advice immediately from your stockbroker  bank manager  solicitor  accountant or other independent professional adviser who  if you are taking advice in the United Kingdom  is duly authorised under the Financial Services and Markets Act 2000  or from an appropriately authorised independent financial adviser if you are in a territory outside the United Kingdom. If you have sold or otherwise transferred all of your ordinary shares in Katoro Gold PLC  please forward this document and the accompanying Form of Proxy at once to the purchaser or transferee or to the stockbroker or other agent through whom the sale or transfer was effected for delivery to the purchaser or transferee. However  such documents should not be forwarded to  or transmitted in or into  any jurisdiction where to do so might violate the relevant laws and regulations in that jurisdiction. If you have sold or transferred only part of your holding in the shares  you should retain this document and consult the stockbroker  bank or other agent through whom the sale of transfer was effected. The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. NOTICE OF GENERAL MEETING Katoro Gold PLC (Incorporated in England and Wales with registered number 09306219) (the ""Company"") Notice is hereby given that the General Meeting of the Company will be held at offices of Shakespeare Martineau LLP  6th Floor  60 Gracechurch Street  London  EC3V 0HR at 10.00 a.m. GMT on 15th March 2023 for the purposes of considering  and if thought fit  passing the resolutions set out below. Resolutions 1 and 3 will be proposed as ordinary resolutions and resolutions 2 and 4 will be proposed as special resolutions. Ordinary Resolution 1. THAT  subject and conditional on the passing of resolutions 2 and 3 below  with effect from 23.59 hours on the date of the passing of this resolution: each of the existing Ordinary Shares of ¬£ 0.01 each (""Existing Ordinary Share(s)"") be subdivided into one Deferred Share ¬£0.009 each and one Ordinary Share of ¬£0.001 each (""New Ordinary Share(s)""); the New Ordinary Shares will have the same rights and be subject to the same restrictions as the Existing Ordinary Shares in the Company's articles of association and the Deferred Shares will have the rights and be subject to the restrictions set out in the Articles; and the Directors are hereby authorised to settle any difficulty which occurs  in particular (but without limitation)  between the holders of shares consolidated and may  in the case of any shares registered in the name or names of one or more members being consolidated with shares registered in the name or names of another member or -1- members  make such arrangements for the sale of such consolidated shares or fractional shares as they see fit with the proceeds of sale to be retained by the Company. Special Resolution 2. THAT  subject and conditional on the passing of resolution 1 above and resolution 3 below  the articles of association be amended by: 2.1. inserting in article 2 the following definition: ""Deferred Shares: the deferred shares in the capital of the Company with the rights set out in Article 7"" 2.2. by inserting the following as article 7: ""7. The rights and restrictions attached to the Deferred Shares shall be as follows: As regards income the holders of the Deferred Shares shall not be entitled to receive any dividend out of the profits of the Company available for distribution and resolved to be distributed in respect of any financial year or any other income or right to participate therein. As regards capital on a distribution of assets on a winding-up or other return of capital (otherwise than on conversion or redemption on purchase by the Company of any of its shares) the holders of the Deferred Shares shall be entitled to receive the amount paid up on their shares after there shall have been distributed (in cash or in specie) to the holders of the Ordinary Shares the amount of ¬£100 000 000 in respect of each Ordinary Share held by them respectively. For this purpose distributions in currency other than sterling shall be treated as converted into sterling  and the value for any distribution in specie shall be ascertained in sterling  in each case in such manner as the Directors of the Company in general meeting may approve. The Deferred Shares shall not entitle the holders thereof to any further or other right of participation in the assets of the Company. As regards voting the holders of Deferred Shares shall not be entitled to receive notice of or to attend (either personally or by proxy) any general meeting of the Company or to vote (either personally or by proxy) on any resolution to be proposed thereat. The rights attached to the Deferred Shares shall not be deemed to be varied or abrogated by the creation or issue of any new shares ranking in priority to or pari passu with or subsequent to such shares. In addition neither the passing by the Company of any resolution for the cancellation of the Deferred Shares for no consideration by means of a reduction of capital requiring the confirmation of the Court nor the obtaining by the Company nor the making by the Court of any order confirming any such reduction of capital nor the becoming effective of any such order shall constitute a variation  modification or abrogation of the rights attaching to the Deferred Shares and accordingly the Deferred Shares may at any time be cancelled for no consideration by means of a reduction of capital effected in accordance with applicable legislation without sanction on the part of the holders of the Deferred Shares. Notwithstanding any other provision of these Articles  the Company shall have the power and authority at any time to purchase all or any of the Deferred Shares for an aggregate consideration of ¬£1. -2- The Company shall have irrevocable authority to appoint any person to execute on behalf of the holders of the Deferred Shares a transfer/cancellation of the Deferred Shares and/or an agreement to transfer/cancel the same  without making any payment to the holders of the Deferred Shares to such person or persons as the Company may determine as custodian thereof and  pending such transfer and/or cancellation and/or purchase  to retain the certificate(s) if any  for such shares. The Company may  at its option and subject to compliance with the provisions of applicable legislation  at any time after the adoption of this Article  cancel such shares by way of reduction of capital for no consideration. Notwithstanding any other provision of these Articles  and unless specifically required by the provisions of applicable legislation  the Company shall not be required to issue any certificates or other documents of title in respect of the Deferred Shares."" 2.3. for subsequent numbering of the articles of association to be sequentially amended. Ordinary Resolution 3. That in substitution for all existing and unexercised authorities  the directors of the Company be and they are hereby generally and unconditionally authorised for the purpose of section 551 of the Companies Act 2006 (""the Act"") to exercise all or any of the powers of the Company to allot Relevant Securities (as defined in this Resolution) up to a maximum nominal amount of ¬£3 222 888.15 provided that this authority shall  unless previously revoked or varied by the company in general meeting  expire on the earlier of the conclusion of the next Annual General Meeting of the Company or 15 months after the passing of this Resolution  unless renewed or extended prior to such time except that the directors of the Company may before the expiry of such period make an offer or agreement which would or might require Relevant Securities to be allotted after the expiry of such period and the directors of the Company may allot Relevant Securities in pursuance of such offer or agreement as if the authority conferred hereby had not expired. In this Resolution  ""Relevant Securities"" means any shares in the capital of the Company and the grant of any right to subscribe for  or to convert any security into  shares in the capital of the Company (""Shares"") but does not include the allotment of Shares or the grant of a right to subscribe for Shares in pursuance of an employee's share scheme or the allotment of Shares pursuant to any right to subscribe for  or to convert any security into  Shares. Special Resolution 4. That in substitution for all existing and unexercised authorities and subject to the passing of the preceding Resolution  the directors of the Company be and they are hereby empowered pursuant to section 570 of the Act to allot equity securities (as defined in section 560 of the Act) for cash pursuant to the authority conferred upon them by the preceding Resolution as if section 561(1) of the Act did not apply to any such allotment provided that the power conferred by this Resolution  unless previously revoked or varied by special resolution of the Company in general meeting  shall be limited to: 4.1. the allotment of equity securities in connection with a rights issue in favour of ordinary shareholders where the equity securities respectively attributable to the interest of all such shareholders are proportionate (as nearly as may be) to the respective numbers of the ordinary shares held by them subject only to such exclusions or other arrangements as the directors of the Company may consider appropriate to deal with fractional entitlements or legal and practical difficulties under the laws of  or the requirements of any recognised regulatory body in  any territory; and -3- 4.2. the allotment (otherwise than pursuant to sub-paragraphs (a) and (b) above) of equity securities up to an aggregate nominal amount of ¬£3 222 888.15; and shall expire on the earlier of the date of the next Annual General Meeting of the Company or on the anniversary of the General meeting being convened by this Notice save that the Company may before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry and the directors may allot equity securities in pursuance of such offer or agreement as if the power conferred hereby had not expired. By order of the Board Ben Harber Company Secretary 6th Floor  60 Gracechurch Street London EC3V 0HR Date: 24th February 2023 -4- Notes to the notice of General Meeting: Entitlement to vote 1. Only those members entered on the register of members of the Company at close of business on 13th March 2023 or  in the event that this meeting is adjourned  at close of business on the day two days prior to the adjourned meeting shall be entitled to attend or vote at the meeting in respect of the number of ordinary shares held in the capital of the Company registered in their name at that time. Changes to entries on the relevant register of securities after that time will be disregarded in determining the rights of any person to attend or vote at the meeting. Appointment of proxies If you are a member of the Company at the time set out in note 1 above  you are entitled to appoint a proxy to exercise all or any of your rights to speak and vote at the meeting and you should have received a proxy form with this notice of meeting. You can only appoint a proxy using the procedures set out in these notes and the notes to the proxy form. A proxy does not need to be a member of the Company however  we encourage shareholders to appoint the Chair of the meeting as proxy. This will ensure that your vote will be counted even though physical attendance at the meeting is prohibited. Details of how to appoint the Chairman of the meeting or another person as your proxy using the proxy form are set out in the notes to the proxy form. If you wish your proxy to speak on your behalf at the meeting you must appoint your own choice of proxy (not the Chairman) and give your instructions directly to the relevant person. Details of how to appoint the Chairman of the meeting or another person as your proxy using the proxy form are set out in the notes to the proxy form. If you wish your proxy to speak on your behalf at the meeting you must appoint your own choice of proxy (not the Chairman) and give your instructions directly to the relevant person. You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy  you must complete a separate proxy form for each proxy and specify against the proxy's name the number of shares over which the proxy has rights. If you are in any doubt as to the procedure to be followed for the purpose of appointing more than one proxy you must contact the Company's Registrars  Link Group  on 0371 664 0300 calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30  Monday to Friday excluding public holidays in England and Wales  or you may photocopy the Form of Proxy. If you fail to specify the number of shares to which each proxy relates  or specify a number of shares greater than that held by you on the record date  your proxy appointments will be invalid. A vote withheld is not a vote in law  which means that the vote will not be counted in the calculation of votes for or against the resolution. If no voting indication is given  your proxy will vote or abstain from voting at their discretion. Your proxy will vote (or abstain from voting) as they think fit in relation to any other matter which is put before the meeting. Appointment of proxy through CREST 7. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the Meeting and any adjournment thereof by using the procedures described in the CREST manual. The CREST manual can be found at www.euroclear.com. CREST personal members or other CREST sponsored members  and those CREST members who have appointed a voting service provider  should refer to their CREST sponsor or voting service provider  who will be able to take the appropriate action on their behalf. In order for a proxy appointment or instruction made using the CREST service to be valid  the appropriate CREST message (a ""CREST proxy instruction"") must be properly authenticated in accordance with Euroclear UK & Ireland Limited's (""EUI"") specification and must contain the information required for such instructions  as described in the CREST manual. All messages regarding the appointment of a proxy or an instruction to a previously appointed proxy must be -5- Attachments Original LinkOriginal DocumentPermalink Disclaimer Katoro Gold plc published this content on 24 February 2023 and is solely responsible for the information contained therein. Distributed by Public  unedited and unaltered  on 24 February 2023 08:26:07 UTC.¬© Publicnow 2023 All news about KATORO GOLD PLC 02/24 FTSE 100 Ends Week Down as US Inflation Rise Hits Stocks Globally DJ 02/24 Katoro seeks shareholder approval to subdivide share capital AN 02/24 GBP/USD Could Stabilize as Implied Volatility Falls DJ 02/24 Katoro Gold Proposes to Subdivide Share Capital MT 02/24 FTSE 100 Rises as Oil Stocks Gain; IAG Falls DJ 02/24 Katoro Gold : GM Notice Final + Proxy Form - clean FINAL PU 2022 TRADING UPDATES: Hardide confirms annual revenue guidance AN 2022 AIM WINNERS & LOSERS: Katoro Gold plummets on delisting warning AN 2022 LONDON MARKET OPEN: Stocks feeling festive despite gloomy UK GDP prin.. AN 2022 Katoro Gold Eyes Fundraise In FY23 Q1 To Progress Namibia Iron Ore Project; Shares Plun.. MT",neutral,0.07,0.92,0.01,negative,0.0,0.15,0.85,True,English,"['GM Notice Final', 'clean FINAL', 'Katoro Gold', 'Proxy Form', 'GENERAL MEETING Katoro Gold PLC', 'other independent professional adviser', 'independent financial adviser', 'multiple email addresses', 'Shakespeare Martineau LLP', 'Existing Ordinary Share', 'New Ordinary Share', 'independent financial advice', 'one Ordinary Share', 'one Deferred Share', 'GM Notice Final', 'The Deferred Shares', 'clean FINAL', 'Financial Services', 'financial year', 'other agent', 'other return', 'ordinary shares', 'IMMEDIATE ATTENTION', 'United Kingdom', 'Markets Act', 'accompanying Form', 'relevant laws', 'securities laws', 'registered number', '6th Floor', '60 Gracechurch Street', '15th March', 'following definition', 'Ordinary Resolution', 'consolidated shares', 'fractional shares', 'other income', 'other right', 'Proxy Form', 'bank manager', 'Special Resolution', 'First name', 'same rights', 'same restrictions', 'resolutions', 'commas', 'Message', 'Required', 'fields', 'DOCUMENT', 'doubt', 'contents', 'stockbroker', 'solicitor', 'accountant', 'territory', 'purchaser', 'transferee', 'sale', 'delivery', 'jurisdiction', 'regulations', 'part', 'holding', 'distribution', 'persons', 'possession', 'failure', 'violation', 'England', 'Wales', 'offices', 'London', 'EC3V', '10.00 a', 'purposes', 'passing', 'effect', '23.59 hours', 'articles', 'association', 'Directors', 'difficulty', 'limitation', 'holders', 'case', 'names', 'members', 'arrangements', 'proceeds', 'capital', 'profits', 'respect', 'assets', 'winding-up', 'conversion', 'redemption', 'amount', 'cash', 'specie', 'currency', 'sterling', 'value', 'manner']",2023-02-24,2023-02-25,marketscreener.com
19217,Euroclear,Twitter API,Twitter,Visa aims to get business owners to upgrade from consumer cards #AAA Websites Euroclear Fintech https://t.co/1Yd6NGMBu6 #regtech,nan,Visa aims to get business owners to upgrade from consumer cards #AAA Websites Euroclear Fintech https://t.co/1Yd6NGMBu6 #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['business owners', 'consumer cards', 'Visa', 'Fintech', 'business owners', 'consumer cards', 'Visa', 'Fintech']",2023-02-24,2023-02-25,Unknown
19218,Euroclear,Twitter API,Twitter,MidWest America Federal Credit Union in Indiana names new CEO #AAA Websites Euroclear Fintech https://t.co/VgUCkfzA2V #regtech,nan,MidWest America Federal Credit Union in Indiana names new CEO #AAA Websites Euroclear Fintech https://t.co/VgUCkfzA2V #regtech,neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['MidWest America Federal Credit Union', 'Indiana names', 'new CEO', 'Fintech', 'VgUCkfzA2V', 'MidWest America Federal Credit Union', 'Indiana names', 'new CEO', 'Fintech', 'VgUCkfzA2V']",2023-02-24,2023-02-25,Unknown
19219,Deutsche Boerse,NewsApi.org,https://www.investing.com/news/stock-market-news/germany-stocks-lower-at-close-of-trade-dax-down-172-3014369,Germany stocks lower at close of trade; DAX down 1.72% By Investing.com,Germany stocks lower at close of trade; DAX down 1.72%,¬© Reuters Germany stocks lower at close of trade; DAX down 1.72%Investing.com ‚Äì Germany stocks were lower after the close on Friday  as losses in the   and sectors led shares lower.At the close in Frankfurt  the fell 1.72%  while the index fell 0.98%  and the index declined 1.68%.The best performers of the session on the were Linde PLC (ETR: )  which rose 1.98% or 6.20 points to trade at 319.00 at the close. Meanwhile  Deutsche Boerse AG (ETR: ) added 0.89% or 1.45 points to end at 165.05 and Munich Reinsurance (ETR: ) was up 0.28% or 0.90 points to 319.50 in late trade.The worst performers of the session were BASF SE NA O.N. (ETR: )  which fell 7.86% or 4.10 points to trade at 48.07 at the close. Vonovia SE (ETR: ) declined 5.03% or 1.26 points to end at 23.80 and Infineon Technologies AG NA O.N. (ETR: ) was down 3.50% or 1.22 points to 33.60.The top performers on the MDAX were Gerresheimer AG (ETR: ) which rose 4.30% to 82.45  K&S AG (ETR: ) which was up 2.78% to settle at 22.53 and Knorr-Bremse AG (ETR: ) which gained 2.11% to close at 66.78.The worst performers were Siltronic AG (ETR: ) which was down 8.95% to 68.15 in late trade  Aroundtown Property Holdings PLC (ETR: ) which lost 5.09% to settle at 2.37 and Delivery Hero AG (ETR: ) which was down 4.07% to 37.22 at the close.The top performers on the TecDAX were Hensoldt Ag (ETR: ) which rose 2.87% to 30.50  ADTRAN Holdingsa Inc (ETR: ) which was up 1.82% to settle at 16.80 and Telefonica Deutschland Holding AG (ETR: ) which gained 0.77% to close at 2.89.The worst performers were Nagarro SE (ETR: ) which was down 10.96% to 96.70 in late trade  Siltronic AG (ETR: ) which lost 8.95% to settle at 68.15 and Verbio Vereinigte Bioenergie AG (ETR: ) which was down 3.87% to 47.72 at the close.Falling stocks outnumbered advancing ones on the Frankfurt Stock Exchange by 495 to 179 and 84 ended unchanged.Shares in Gerresheimer AG (ETR: ) rose to 52-week highs; up 4.30% or 3.40 to 82.45. Shares in Hensoldt Ag (ETR: ) rose to all time highs; rising 2.87% or 0.85 to 30.50.The   which measures the implied volatility of DAX options  was up 7.34% to 20.47 a new 1-month high.Gold Futures for April delivery was down 0.54% or 9.95 to $1 816.85 a troy ounce. Elsewhere in commodities trading  Crude oil for delivery in April rose 1.06% or 0.80 to hit $76.19 a barrel  while the April Brent oil contract rose 0.86% or 0.71 to trade at $82.92 a barrel.EUR/USD was unchanged 0.46% to 1.05  while EUR/GBP unchanged 0.14% to 0.88.The US Dollar Index Futures was up 0.63% at 105.20.,neutral,0.0,0.98,0.02,mixed,0.17,0.04,0.8,True,English,"['Germany stocks', 'Investing.com', 'close', 'trade', 'DAX', 'The US Dollar Index Futures', 'BASF SE NA O.N.', 'Aroundtown Property Holdings PLC', 'Telefonica Deutschland Holding AG', 'Verbio Vereinigte Bioenergie AG', 'April Brent oil contract', 'ADTRAN Holdingsa Inc', 'Deutsche Boerse AG', 'Infineon Technologies AG', 'K&S AG', 'Frankfurt Stock Exchange', 'Delivery Hero AG', 'Gold Futures', 'Linde PLC', 'Vonovia SE', 'Nagarro SE', 'Crude oil', 'Gerresheimer AG', 'Knorr-Bremse AG', 'Siltronic AG', 'Hensoldt Ag', 'April delivery', 'Reuters Germany', 'Investing.com', 'Germany stocks', 'best performers', 'Munich Reinsurance', 'worst performers', 'top performers', 'Falling stocks', '52-week highs', 'time highs', 'troy ounce', 'commodities trading', 'late trade', 'DAX options', 'close', 'Friday', 'losses', 'sectors', 'shares', 'session', 'were', 'ETR', '1.45 points', 'MDAX', 'TecDAX', 'implied', 'volatility', '1-month', 'EUR/USD', 'EUR/GBP', '¬©', '6.20', '0.', '4.10', '1.26', '1.22']",2023-02-24,2023-02-25,investing.com
19220,Deutsche Boerse,NewsApi.org,https://www.marketscreener.com/quote/stock/SILTRONIC-AG-22412985/news/Siltronic-resolves-upon-forecast-of-financial-year-2023-43076957/?utm_medium=RSS&utm_content=20230224,Siltronic resolves upon forecast of financial year 2023,(marketscreener.com) EQS-Ad-hoc: Siltronic AG / Key word: ForecastSiltronic resolves upon forecast of financial year 2023 24-Feb-2023 / 13:45 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation No 596/2014  transmitted‚Ä¶,"EQS-Ad-hoc: Siltronic AG / Key word(s): ForecastSiltronic resolves upon forecast of financial year 202324-Feb-2023 / 13:45 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014  transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad-hoc announcement / Disclosure of an inside information according to Article 17 MAR Siltronic AGEinsteinstra√üe 17281677 Munichwww.siltronic.com Siltronic resolves upon forecast of financial year 2023 Munich  Germany  February 24  2023 - The Executive Board of Siltronic AG today resolved upon the forecast for 2023. Due to expected inventory adjustments for the next quarters in the value chain after us as well as short-term postponement of delivery volumes of some customers in H1 2023  the Executive Board assumes that sales in Q1 2023 will be approximately 15 percent below Q4 2022. The EBITDA margin in Q1 2023 is expected to be between 30 and 33 percent. For the entire year  the Executive Board anticipates the following development: Sales significantly below previous year due to lower volumes and exchange rate effects; an average exchange rate of the Euro against the US dollar of 1.10 instead of 1.05 (average for the year 2022) would have a negative impact on sales of around EUR 65 million. On the other hand  there is a positive effect from slightly rising prices.EBITDA margin significantly below previous year; in addition to the above-mentioned influences  inflation-related increases in unit costs of around EUR 50 million contributed to the declineDepreciation and amortization due to investments at approximately EUR 220 millionSignificant decline in EBITTax rate in the mid-single-digit percentage rangeCapital expenditure slightly above previous year. Projects that have already started are to be completed on schedule. The capital expenditures in 2024 will materially decrease in comparison to the ongoing year.Net cash flow significantly below previous yearEarnings per share will be significantly lower The complete and audited Annual Report 2022 will be published on March 9  2023. Additional information: ISIN: DE000WAF3001WKN: WAF300Deutsche Boerse: WAFTrading: Amtlicher Markt (Prime Standard)  Frankfurter Wertpapierboerse Contact: Verena St√ºtzeHead of Investor Relations & CommunicationsTel.: +49 (0)89 8564 3133E-Mail: investor.relations@siltronic.com Important Information This adhoc announcement contains statements related to our future business and financial performance and future events or developments involving Siltronic that may constitute forward-looking statements. These statements may be identified by words such as ""expect "" ""look forward to "" ""anticipate"" ""intend "" ""plan "" ""believe "" ""seek "" ""estimate "" ""will "" ""project"" or words of similar meaning. Such statements are based on the current expectations and certain assumptions of the Siltronic-management  of which many are beyond the control of Siltronic. These are subject to a number of risks  uncertainties and factors. Should one or more of these risks or uncertainties materialize  or should underlying expectations not occur or assumptions prove incorrect  actual results  performance or achievements of Siltronic may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Siltronic neither intends  nor assumes any obligation  to update or revise these forward-looking statements in light of developments which differ from those anticipated. This document contains supplementary financial measures that are  or may be  alternative performance measures not specifically identified in the applicable financial reporting frameworks. For the purpose of assessing Siltronic's financial position and performance  these supplementary financial measures should not be used in isolation or as an alternative to the financial measures presented in the consolidated financial statements and determined in accordance with relevant accounting frameworks. Other companies that present or report alternative performance measures with a similar title may calculate them differently. Explanations of financial measures used can be found in the Annual Report 2022 of Siltronic AG. 24-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements  Financial/Corporate News and Press Releases.Archive at www.eqs-news.com",neutral,0.01,0.99,0.0,negative,0.0,0.13,0.87,True,English,"['financial year', 'Siltronic', 'forecast', 'Article 17 MAR Siltronic AG Einsteinstra√üe', 'The EQS Distribution Services', 'applicable financial reporting frameworks', 'relevant accounting frameworks', 'EQS Group AG', 'exchange rate effects', 'EBIT Tax rate', 'mid-single-digit percentage range', 'Net cash flow', 'Frankfurter Wertpapierboerse Contact', 'Verena St√ºtze', 'incorrect, actual results', 'relevant forward-looking statement', 'supplementary financial measures', 'average exchange rate', 'consolidated financial statements', 'alternative performance measures', 'EQS News', 'financial performance', 'financial position', 'financial year', 'forward-looking statements', 'Key word', 'inside information', 'Executive Board', 'inventory adjustments', 'next quarters', 'value chain', 'short-term postponement', 'EBITDA margin', 'following development', 'US dollar', 'negative impact', 'other hand', 'positive effect', 'rising prices', 'inflation-related increases', 'unit costs', 'Capital expenditure', 'Annual Report', 'Additional information', 'Deutsche Boerse', 'WAF Trading', 'Amtlicher Markt', 'Prime Standard', 'Investor Relations', 'Important Information', 'future business', 'future events', 'similar meaning', 'current expectations', 'underlying expectations', 'Other companies', 'similar title', 'Regulatory Announcements', 'Financial/Corporate News', 'Press Releases', 'entire year', 'previous year', 'ongoing year', 'Such statements', 'Ad-hoc announcement', 'adhoc announcement', 'lower volumes', 'Significant decline', 'Forecast', 'Feb', 'CET', 'CEST', 'Disclosure', 'Regulation', 'issuer', 'content', 'Munich', 'Germany', 'delivery', 'customers', 'H1', 'sales', 'Q1', 'Q4', '33 percent', 'Euro', 'influences', 'Depreciation', 'amortization', 'investments', 'Projects', 'schedule', 'comparison', 'Earnings', 'share', 'complete', 'March', 'WKN', 'WAF300', 'Head', 'Communications', 'Tel.', 'Mail', 'developments', 'words', 'plan', 'assumptions', 'Siltronic-management', 'control', 'number', 'risks', 'uncertainties', 'factors', 'achievements', 'obligation', 'light', 'document', 'purpose', 'isolation', 'accordance', 'Archive']",2023-02-24,2023-02-25,marketscreener.com
19221,Deutsche Boerse,Twitter API,Twitter,@DeutscheBoerse has partnered with @googlecloud to boost its outsourcing capabilities and better serve clients. Le‚Ä¶ https://t.co/TlaOFVL0vW,nan,@DeutscheBoerse has partnered with @googlecloud to boost its outsourcing capabilities and better serve clients. Le‚Ä¶ https://t.co/TlaOFVL0vW,positive,0.69,0.31,0.0,positive,0.69,0.31,0.0,True,English,"['outsourcing capabilities', 'clients', 'TlaOFVL0vW', 'outsourcing capabilities', 'clients', 'TlaOFVL0vW']",2023-02-25,2023-02-25,Unknown
19222,EuroNext,NewsApi.org,https://finance.yahoo.com/news/oxurion-receives-transparency-notifications-negma-180000301.html,Oxurion Receives Transparency Notifications from Negma Group,Oxurion Receives Transparency Notifications from Negma Group Leuven  BELGIUM  Boston  MA  US ‚Äì February 24  2022 ‚Äì 7.00 PM CET Oxurion NV (Euronext Brussels:...,"Oxurion NVOxurion Receives Transparency Notifications from Negma GroupLeuven  BELGIUM  Boston  MA  US ‚Äì February 24  2022 ‚Äì 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with clinical stage assets in vascular retinal disorders  today announced that  pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:Oxurion received a transparency notification on February 21  2023 from Negma Group Ltd. indicating that as of February 16  2023  it held no shares of the then outstanding 564 210 937 shares  and therefore crossed below the threshold (3%) by virtue of disposal of voting securities. See Annex 1Oxurion received a transparency notification on February 21  2023 from Negma Group Ltd. indicating that as of February 15  2023  it held 35 314 661 shares of the then outstanding 564 210 937 shares  and therefore crossed above the threshold (5%) by virtue of acquisition of voting securities. See Annex 2About OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered ‚Äúforward-looking‚Äù. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company‚Äôs Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.Story continuesFor further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10"" tom.graney@oxurion.comMichael DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.comU SConway CommunicationsMary T. Conwaymtconway@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com________1. Article 14  first paragraph  of the Law of 2 May 2007 on disclosure of major holdings.ANNEX 1ANNEX 2Attachments",neutral,0.01,0.99,0.0,mixed,0.21,0.19,0.6,True,English,"['Transparency Notifications', 'Negma Group', 'Oxurion', 'applicable U.S. state securities laws', 'potent plasma kallikrein inhibitor', 'U.S. Securities Act', 'next generation standard', 'Negma Group Ltd.', 'diabetic macular edema', 'Chief Executive Officer', 'potential new standard', 'Mary T. Conway', 'Belgian Transparency legislation1', 'Negma Group Leuven', 'clinical stage assets', 'Chief Business Officer', 'U S', 'vascular retinal disorders', 'Such forward-looking statements', 'care ophthalmic therapies', 'CET Oxurion NV', 'voting securities', 'Conway Communications', 'new information', 'Transparency Notifications', 'Euronext Brussels', 'leading cause', 'working-age people', 'other conditions', 'important role', 'successful development', 'novel therapeutic', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'press release', 'current expectations', 'future events', 'other reason', 'other factors', 'actual results', 'Annual Report', 'United States', 'first paragraph', 'major holdings', 'More information', 'Important information', 'Additional information', 'biopharmaceutical company', 'The Company', 'outstanding 564,210,937 shares', 'vision loss', 'various risks', 'Tom Graney', 'Michael Dillen', 'ICR Westwicke', 'Christopher Brinzey', 'ANNEX 2 Attachments', 'DME patients', '35,314,661 shares', 'Annex 1', 'BELGIUM', 'Boston', 'February', 'threshold', 'virtue', 'disposal', 'acquisition', 'treatment', 'THR-149', 'uncertainties', 'assurance', 'obligation', 'offer', 'invitation', 'sale', 'purchase', 'jurisdiction', 'registration', 'compliance', 'exemption', 'accordance', 'Story', 'Tel', 'Article', '2 May', 'disclosure', '7.00', '32']",2023-02-24,2023-02-25,finance.yahoo.com
19223,EuroNext,NewsApi.org,https://finance.yahoo.com/news/gtt-2023-financial-agenda-180000586.html,GTT: 2023 financial agenda,2023 financial agenda Paris ‚Äì February 24  2023. GTT  the technological expert in membrane containment systems used to transport and store liquefied gases...,GTT2023 financial agendaParis ‚Äì February 24  2023. GTT  the technological expert in membrane containment systems used to transport and store liquefied gases  announces that the publication of the 2023 third-quarter activity update  originally planned on 23 October 2023  has been rescheduled to 25 October 2023. In addition  the ex-dividend date and payment date of the dividend balance have been set on 12 June 2023 and 14 June 2023 respectively (instead of 10 June 2023 and 12 June 2023 as announced in the annual results press release).The financial agenda for the 2023 financial year is therefore as follows:2023 first-quarter activity update: April 20  2023 (after close of trading)Shareholders‚Äô Meeting: June 7  2023Ex-dividend date of the dividend balance for financial year 2022: June 12  2023Payment of the dividend balance for financial year 2022: June 14  2023Publication of 2023 half-year results: July 27  2023 (after close of trading)2023 third-quarter activity update: October 25  2023 (after close of trading)About GTTGTT is a technological expert in containment systems with cryogenic membranes used to transport and store liquefied gases. For over 50 years  GTT has been designing and providing cutting-edge technologies for a better energy performance  which combine operational efficiency and safety  to equip LNG carriers  floating terminals  land storage  and multi-gas carriers. GTT also develops systems dedicated to the use of LNG as fuel  as well as a full range of services  including digital services in the field of Smart Shipping. The Group is also active in hydrogen through its subsidiary Elogen  which designs and assembles electrolysers notably for the production of green hydrogen.GTT is listed on Euronext Paris  Compartment A (ISIN FR0011726835 Euronext Paris: GTT) and is notably included in SBF 120  Stoxx Europe 600 and MSCI Small Cap indicesInvestor relations contact:information-financiere@gtt.fr / +33 1 30 23 20 87Media contact:press@gtt.fr / +33 1 30 23 48 45For more information  visit www.gtt.fr.Attachment,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['2023 financial agenda', 'GTT', 'MSCI Small Cap indices', 'annual results press release', '2023 third-quarter activity update', '2023 first-quarter activity update', 'Investor relations contact', 'membrane containment systems', '2023 half-year results', 'Media contact', '2023 financial agenda', 'technological expert', 'liquefied gases', 'ex-dividend date', '2023 financial year', 'Shareholders‚Äô Meeting', 'cryogenic membranes', 'cutting-edge technologies', 'energy performance', 'operational efficiency', 'floating terminals', 'land storage', 'multi-gas carriers', 'full range', 'Smart Shipping', 'The Group', 'subsidiary Elogen', 'Compartment A', 'Stoxx Europe', 'Euronext Paris', 'payment date', 'LNG carriers', 'digital services', 'green hydrogen', 'dividend balance', 'GTT', 'February', 'publication', '23 October', '25 October', 'addition', '12 June', '14 June', '10 June', 'April', 'close', 'trading', 'July', '50 years', 'safety', 'use', 'fuel', 'field', 'electrolysers', 'production', 'SBF', 'financiere', 'information', 'fr', 'Attachment', '1 30']",2023-02-24,2023-02-25,finance.yahoo.com
19224,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bekaert-liquidity-agreement-071500394.html,Bekaert - Update on the Liquidity Agreement,Update on the Liquidity Agreement Period from 16 February 2023 to 22 February 2023 Liquidity agreement In relation to the renewed liquidity agreement with...,BekaertUpdate on the Liquidity AgreementPeriod from 16 February 2023 to 22 February 2023Liquidity agreementIn relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 2 September 2022   Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 9 600 shares during the period from 16 February 2023 to 22 February 2023 on Euronext Brussels. During the same period  Kepler Cheuvreux on behalf of Bekaert has sold 6 872 shares on Euronext Brussels.The tables below provide an overview of the transactions under the liquidity agreement during the period from16 February 2023 to 22 February 2023:Purchase of shares Date Number of Shares Average Price (‚Ç¨) Highest Price (‚Ç¨) Lowest Price (‚Ç¨) Total Amount (‚Ç¨) 16 February 2023 0 0.00 0.00 0.00 0 17 February 2023 400 40.10 40.10 40.10 16 040 20 February 2023 400 40.40 40.40 40.40 16 160 21 February 2023 4 000 40.71 40.84 40.50 162 840 22 February 2023 4 800 40.21 40.40 39.98 193 008 Total 9 600 388 048Sale of shares Date Number of Shares Average Price (‚Ç¨) Highest Price (‚Ç¨) Lowest Price (‚Ç¨) Total Amount (‚Ç¨) 16 February 2023 1 600 40.58 40.60 40.50 64 928 17 February 2023 400 40.60 40.60 40.60 16 240 20 February 2023 1 111 40.59 40.70 40.50 45 095 21 February 2023 3 361 40.88 41.00 40.70 137 398 22 February 2023 400 40.26 40.26 40.26 16 104 Total 6 872 279 765The balance held by Bekaert under the liquidity agreement at the end of the period is 40 364 shares.On 22 February 2023 after closing of the market  Bekaert holds 4 753 017 own shares  or 8.05% of the total number of the outstanding shares.This information is also made available on the investor relations pages of our website.Story continuesAttachment,neutral,0.03,0.96,0.0,positive,0.54,0.34,0.12,True,English,"['Liquidity Agreement', 'Bekaert', 'Update', 'investor relations pages', 'Shares Average Price', 'Liquidity Agreement Period', 'Highest Price', 'Lowest Price', 'Kepler Cheuvreux', 'Euronext Brussels', 'Date Number', 'Total Amount', 'total number', 'same period', 'outstanding shares', '9 600 shares', '6 872 shares', '40 364 shares', 'Bekaert', 'Update', '16 February', '22 February', '2 September', 'behalf', 'tables', 'overview', 'transactions', 'Purchase', '17 February', 'Sale', 'balance', 'end', 'closing', 'market', 'information', 'website', 'Story', 'Attachment', '4 753 017']",2023-02-24,2023-02-25,finance.yahoo.com
19225,EuroNext,NewsApi.org,https://finance.yahoo.com/news/press-release-biocartis-group-nv-060000347.html,Press release Biocartis Group NV: Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option Plans,PRESS RELEASE - REGULATED INFORMATION 24 February 2023  07:00 CET Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share...,Biocartis NVPRESS RELEASE - REGULATED INFORMATION24 February 2023  07:00 CETBiocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option PlansMechelen  Belgium  24 February 2023 ‚Äì Biocartis Group NV (the ‚ÄòCompany‚Äô or ‚ÄòBiocartis‚Äô)  an innovative molecular diagnostics company (Euronext Brussels: BCART)  today announces that its board of directors created  within the framework of the authorized capital  8.3 million share options (each share option having the form of a subscription right) under a new share option plan  called the ‚ÄòShare Option Plan 2023‚Äô  in order to enable the Company to offer the share options to current and future personnel members and members of the executive management of the Company and/or its subsidiaries.The purpose of the Share Option Plan 2023 is to create a plan of subscription rights for shares of the Company which will allow the Company to attract  encourage  motivate and retain personnel and executives  and to align their interests with the interests of the Company and its shareholders by giving them the opportunity to share in the potential increase in the value of the Company. At the same time  the Company will cancel 435.270 share options which have not yet been offered to  and accepted by  the beneficiaries under the existing share option plans of the Company.The share options under the Share Option Plan 2023 have a term of ten years (unless contractually reduced in the offer to a beneficiary)  are generally not transferable and can in principle not be exercised prior to the first day of the fourth calendar year following the calendar year in which the offer of share options is made to a beneficiary. The share options of the members of the executive management will vest on the third anniversary of the date of offer  while the share options of the personnel members will in principle vest gradually over a period over approximately four years unless decided otherwise. Each share option gives the right to subscribe to one new ordinary Biocartis share. Should the share options be exercised  Biocartis will apply for the admission to trading of the resulting new shares on Euronext Brussels. The share option as such will not be listed on any stock market.Story continuesThe reports prepared by the board of directors and the Company‚Äôs statutory auditor (in accordance with Article 7:198 juncto Articles 7:180 and 7:191 of the Belgian Companies and Associations Code) in the framework of the creation of the Share Option Plan 2023 can be consulted on the website of the Company.--- END ---More information:e-mail: ir@biocartis.com@Biocartis_www.linkedin.com/BiocartisAbout BiocartisWith its revolutionary and proprietary Idylla‚Ñ¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idylla‚Ñ¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idylla‚Ñ¢'s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idylla‚Ñ¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idylla‚Ñ¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.0,1.0,0.0,mixed,0.18,0.14,0.68,True,English,"['New Share Option Plan', 'Share Option Plans', 'Biocartis Group NV', 'Press release', 'Outstanding Pool', 'one new ordinary Biocartis share', 'faster, informed treatment decisions', 'key unmet clinical needs', 'U.S. Securities Act', 'existing share option plans', 'New Share Option Plan', 'innovative molecular diagnostics company', 'resulting new shares', 'Polymerase Chain Reaction', 'fastest growing segment', 'molecular diagnostics market', 'fourth calendar year', 'proprietary Idylla‚Ñ¢ platform', '8.3 million share options', 'accurate molecular information', 'molecular diagnostic tests', 'The Idylla‚Ñ¢ platform', 'Biocartis Group NV', 'individual Biocartis product', 'United States Securities', 'future personnel members', '435.270 share options', 'molecular testing', 'stock market', 'product labeling', 'future events', 'Biocartis NV', 'The Biocartis', 'PRESS RELEASE', 'REGULATED INFORMATION', 'Outstanding Pool', 'Euronext Brussels', 'authorized capital', 'executive management', 'subscription rights', 'potential increase', 'ten years', 'first day', 'third anniversary', 'four years', 'statutory auditor', 'Belgian Companies', 'Associations Code', 'More information', 'personalized medicine', 'real-time PCR', 'based system', 'minimum amount', 'expanding menu', 'liver cancer', 'other countries', 'Idylla‚Ñ¢ trademark', 'Exchange Commission', 'financial condition', 'same time', 'universal access', 'Forward-looking statements', 'current expectations', 'Company directors', '24 February', '07:00 CET', 'Mechelen', 'Belgium', 'BCART', 'board', 'framework', 'order', 'subsidiaries', 'purpose', 'executives', 'interests', 'shareholders', 'opportunity', 'value', 'beneficiaries', 'term', 'offer', 'beneficiary', 'principle', 'date', 'period', 'trading', 'Story', 'reports', 'accordance', 'Article', '198 juncto', 'creation', 'website', 'mail', 'revolutionary', 'patients', 'world', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'trademarks', 'Europe', 'logo', 'applicable', 'uses', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibility', 'violation', 'invitation', 'sale', 'purchase', 'America', 'registration', 'exemption', 'beliefs', 'opinions', 'projections', 'results', 'operations', 'liquidity', 'performance', 'prospects', 'growth', 'strategies', 'industry']",2023-02-24,2023-02-25,finance.yahoo.com
19226,EuroNext,NewsApi.org,https://finance.yahoo.com/news/information-total-number-voting-rights-180000222.html,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA Negma Group Investment Ltd. has converted 80...,Oxurion NVInformation on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMANegma Group Investment Ltd. has converted 80 convertible bonds in Oxurion resulting in a EUR 200 000 capital increase. This is part of Negma Group Investment Ltd.‚Äôs EUR 15 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven  BELGIUM  Boston  MA  US ‚Äì February 24  2023 ‚Äì 07.00 PM CET ‚Äì In accordance with article 15 of the Belgian Act of May 2  2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions  Oxurion NV (Euronext Brussels: OXUR) (the ‚ÄúCompany‚Äù or ‚ÄúOxurion‚Äù)  announces the below information  following the issuance of 20 491 803 new ordinary shares on February 20  2023  for a total amount of EUR 200 000  as the result of the conversion of 80 class B convertible bonds  pursuant to the Capital Commitment entered into with Negma Group Investment Ltd.Following completion of the capital increase through the conversion of the convertible bonds  the total number of shares issued by Oxurion amounts to 584 702 740  outstanding ordinary shares carrying voting rights (compared to 564 210 937 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.Therefore  Oxurion publishes the following updated information:Share capital (EUR) 77 706 161.32 Total number of securities with voting rights (all ordinary shares) 584 702 740 Total number of ordinary shares (= denominator) 584 702 740 Number of outstanding  granted rights to subscribe to securities carrying voting rights not yet issued: 694 000 subscription rights (‚ÄúSRs‚Äù) issued on November 20  2017  entitling their holders to subscribe to a total number of 694 000 securities carrying voting rights (all ordinary shares);60 000 SRs issued on December 23  2020  entitling their holders to subscribe to a total number of 60 000 securities carrying voting rights (all ordinary shares);976 874 SRs issued on April 14  2021  entitling their holders to subscribe to a total number of 976 874 securities carrying voting rights (all ordinary shares);534 688 SRs issued on September 22  2021  entitling their holders to subscribe to a total number of 534 688 securities carrying voting rights (all ordinary shares);582 248 SRs issued on December 30  2021  entitling their holders to subscribe to a total number of 582 248 securities carrying voting rights (all ordinary shares); and100 convertible bonds issued on December 20  2021  entitling their holders (Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company  Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.  on November 21  2021.ENDAbout OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Story continuesImportant information about forward-looking statementsCertain statements in this press release may be considered ‚Äúforward-looking‚Äù. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company‚Äôs Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMicha√´l DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com USConway CommunicationsMary T. Conwaymtconway@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com1 Press release Oxurion  06/04/2021  Press release Oxurion  02/09/2022 and Press release Oxurion  25/01/2023Attachments,neutral,0.0,1.0,0.0,mixed,0.26,0.27,0.48,True,English,"['Total Number', 'Voting Rights', 'Conversion Notice', 'Information', 'Denominator', 'NEGMA', 'potent plasma kallikrein inhibitor', 'Negma Group Investment Ltd.', 'EUR 15 million Capital Commitment1', '80 class B convertible bonds', 'Pontifax Medison Finance', 'next generation standard', 'diabetic macular edema', 'EUR 200,000 capital increase', 'Kreos Capital VI', 'potential new standard', 'potential market opportunities', 'care ophthalmic therapies', 'outstanding ordinary shares', 'Such forward-looking statements', '20,491,803 new ordinary shares', 'Israel) L.P.', 'Oxurion NV Information', '80 convertible bonds', '100 convertible bonds', 'Share capital', 'new information', 'regulated market', 'drug candidate', 'Belgian Act', 'major participations', 'miscellaneous provisions', 'Euronext Brussels', 'total amount', 'updated information', 'Loan Facility', 'retinal disorders', 'leading cause', 'working-age people', 'important role', 'successful development', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'More information', 'Important information', 'press release', 'current expectations', 'future events', 'other reason', 'Additional information', 'other factors', 'actual results', 'Annual Report', 'Voting Rights', '694,000 subscription rights', 'Total Number', 'vision loss', 'other conditions', 'novel therapeutic', 'various risks', 'biopharmaceutical company', 'The Company', 'Conversion Notice', 'DME patients', 'Denominator', 'back', 'eye', 'Leuven', 'BELGIUM', 'Boston', 'February', '07.00 PM', 'accordance', 'article', 'May', 'disclosure', 'issuers', 'issuance', 'completion', 'calculation', 'percentages', 'shareholdings', 'securities', 'SRs', 'November', 'holders', 'December', 'April', 'September', 'UK', 'Cayman', 'terms', 'Agreement', 'Limited', 'treatment', 'THR-149', 'Story', 'uncertainties', 'assurance', 'obligation', 'business', 'offer', 'invitation', 'sale', 'purchase', 'assets', 'jurisdiction']",2023-02-24,2023-02-25,finance.yahoo.com
19227,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/DIGITAL-VALUE-S-P-A-47080611/news/Digital-Value-starts-listing-process-on-Euronext-Milan-market-43082719/?utm_medium=RSS&utm_content=20230224,Digital Value starts listing process on Euronext Milan market,(marketscreener.com) The board of directors of Digital Value Spa announced on Friday that it has approved the start of the project to list the company's shares on Euronext Milan  the regulated market organized and managed by Borsa Italiana Spa that caters to ‚Ä¶,"(Alliance News) - The board of directors of Digital Value Spa announced on Friday that it has approved the start of the project to list the company's shares on Euronext Milan  the regulated market organized and managed by Borsa Italiana Spa that caters to mid- and large-cap companies.The project will be submitted for approval at the next shareholders' meeting scheduled for April 5  2023 on first call and April 6  2023 on second call.""The translisting operation on the regulated market Euronext Milan is aimed at enabling the company to benefit from greater liquidity of its securities and visibility by the market and institutional investors. At the same time  the move to the regulated market will strengthen the well-established relationships with its strategic partners  as well as enable the company to engage additional institutional investors with a view to a progressive enhancement of the Digital Value group  its brand and its competitive positioning "" the company explained in a note.Digital Value closedBy Claudia Cavaliere  Alliance News reporterComments and questions to redazione@alliancenews.comCopyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.",neutral,0.0,1.0,0.0,negative,0.0,0.24,0.76,True,English,"['Euronext Milan market', 'Digital Value', 'listing process', 'Alliance News IS Italian Service Ltd', 'Alliance News reporter', 'Borsa Italiana Spa', ""next shareholders' meeting"", 'Digital Value Spa', 'Digital Value group', 'additional institutional investors', 'Euronext Milan', 'large-cap companies', 'first call', 'second call', 'translisting operation', 'greater liquidity', 'same time', 'strategic partners', 'progressive enhancement', 'competitive positioning', 'Claudia Cavaliere', 'regulated market', 'board', 'directors', 'Friday', 'start', 'project', 'company', 'shares', 'approval', 'April', 'securities', 'visibility', 'move', 'relationships', 'view', 'brand', 'note', 'Comments', 'questions', 'Copyright', 'rights']",2023-02-24,2023-02-25,marketscreener.com
19228,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ROCKET-SHARING-COMPANY-S-133985246/news/RSC-Integrae-SIM-takes-over-from-Banca-Profilo-as-Euronext-advisor-43082637/?utm_medium=RSS&utm_content=20230224,RSC  Integrae SIM takes over from Banca Profilo as Euronext advisor,(marketscreener.com) Rocket Sharing Company Spa announced Friday that it has appointed Euronext growth advisor and specialist Integrae SIM Spa  which will take over from Banca Profilo Spa  effective Feb. 28  2023  inclusive. Rocket Sharing Company closed in t‚Ä¶,(Alliance News) - Rocket Sharing Company Spa announced Friday that it has appointed Euronext growth advisor and specialist Integrae SIM Spa  which will take over from Banca Profilo Spa  effective Feb. 28  2023  inclusive.Rocket Sharing Company closed in the green by 14 percent at EUR0.75 per share.By Chiara Bruschi  Alliance News reporterComments and questions to redazione@alliancenews.comCopyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.,neutral,0.0,1.0,0.0,neutral,0.01,0.98,0.0,True,English,"['Integrae SIM', 'Banca Profilo', 'Euronext advisor', 'RSC', 'Alliance News IS Italian Service Ltd', 'Rocket Sharing Company Spa', 'Alliance News reporter', 'Integrae SIM Spa', 'Banca Profilo Spa', 'Euronext growth advisor', 'Chiara Bruschi', 'specialist', 'green', '14 percent', 'share', 'Comments', 'questions', 'redazione', 'Copyright', 'rights']",2023-02-24,2023-02-25,marketscreener.com
19229,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-eur-nav-063000495.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 23 Feb 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.2812 ¬£ 24.0467 Estimated MTD return 0.06 % 0.15 % Estimated YTD return -1.76 % -1.55 % Estimated ITD return 172.81 % 140.47 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 22.00 N/A Premium/discount to estimated NAV -19.36 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.99 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 297 058 126 294 Held in treasury 800 N/A Shares Issued 12 297 858 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 239.4131 Class GBP A Shares (estimated) ¬£ 128.3609The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comStory continuesThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.16,0.84,True,English,"['BGHL', 'EUR', 'NAV', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'London Stock Exchange plc', 'A N/A Average Price', 'Euro Shares Sterling Shares', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'N/A Sterling Shares Amsterdam', 'US Investment Company Act', 'Euro Shares Amsterdam', 'A N/A Range', 'Sterling Shares Shares', 'GAVAUDAN HOLDING LIMITED', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', '800 N/A Shares', 'The Shares', 'Dutch Authority', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Emmanuel Gavaudan', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'returns', 'AEX', 'Transactions', 'treasury', 'Number', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'Story', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-02-24,2023-02-25,finance.yahoo.com
19230,EuroNext,NewsApi.org,https://finance.yahoo.com/news/legrand-north-america-announces-opening-172500331.html,LEGRAND NORTH AMERICA ANNOUNCES OPENING OF NEWEST DISTRIBUTION CENTER IN DAYTON,Legrand¬Æ  a world leader in electrical  digital infrastructure  and connected solutions  has officially opened a larger operations facility in the Dayton...,"Electrical Giant Expands Footprint In Centrally Located Western Ohio. The Resulting New Distribution Network Will Allow For The Majority Of Customer Base To Be Within A 2-Day Transit Time.DAYTON  Ohio  Feb. 24  2023 /PRNewswire/ -- Legrand¬Æ   a world leader in electrical  digital infrastructure  and connected solutions  has officially opened a larger operations facility in the Dayton area. This latest opening will provide over 200 new jobs to the Dayton area and enhance the company's ability to serve its customers quicker in shipment times across all of America.LEGRAND NORTH AMERICA ANNOUNCES OPENING OF NEWEST DISTRIBUTION CENTER IN DAYTONThe 625 000 square-feet operations facility  located at 2200 Douglas Way  Union OH  is a state-of-the-art distribution center that will enhance the company's ability to meet the growing demand for electrical and digital building infrastructures as well as connected solutions across America. The facility features technology and equipment that will increase production and maintain quality control  ensuring that customers receive the best products available.Legrand is committed to sustainability  and the opening of the Dayton facility supports that commitment through various approaches. Notably  the building is on track to receive Green Globes Level One Certification. In addition  the new centrally located facility  coupled with existing West Coast and Southern Distribution centers will service customers more efficiently reducing freight and carbon emissions.This latest expansion will bring new jobs to Dayton  with Legrand hiring for positions ranging from production and warehouse to office and management. This growth is a testament to Legrand's commitment to providing exceptional customer service and delivering high-quality solutions to customers.Each aspect of the facility features and highlights Legrand's notable brands including:Architectural and industrial lighting from Kenall  Finelite  OCL  and Pinnacle.Automated window shades from Legrand Commercial Shading.Electrical wiring devices from Legrand's radiant Collection and Cablofil wire management.Data room outfitted with Legrand Minkels technology.Productivity enabling technologies from Legrand's AV division  such as Middle Atlantic  Chief  Vaddio  Da-Lite  C2G.Story continuesAs a result  this facility truly showcases Legrand's deep expertise in the space and creates a highly functional environment for its employees.""We are thrilled to expand our footprint in Dayton and continue to support the thriving community "" said Dan Carsten  Vice President of Operational Excellence and Logistics of Legrand North America. ""Our goal is to provide our customers with the highest quality products and exceptional customer service  and this our newest facility will allow us to do this.""""Our investment into Montgomery County worked to develop the site for long-term sustainability by putting the site into production  generating taxes into the community  and further strengthening the economy through job creation "" said Matt Gaston  Vice President of Development at NorthPoint Development. ""The expansion of Legrand's operations into Montgomery County further supports the thriving community here in Dayton  as well as the region as a whole.""About Legrand and Legrand  North and Central AmericaLegrand is the global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for commercial  industrial  and residential markets makes it a benchmark for customers worldwide. The Group harnesses technological and societal trends with lasting impacts on buildings with the purpose of improving life by transforming the spaces where people live  work and meet with electrical  digital infrastructures and connected solutions that are simple  innovative and sustainable. Drawing on an approach that involves all teams and stakeholders  Legrand is pursuing its strategy of profitable and responsible growth driven by acquisitions and innovation  with a steady flow of new offerings‚Äîincluding products with enhanced value in use (faster expanding segments: data centers  connected offerings and energy efficiency programs). Legrand reported sales of ‚Ç¨7.0 billion in 2021. The company is listed on Euronext Paris and is notably a component stock of the CAC 40 and CAC 40 ESG indexes. (code ISIN FR0010307819). https://www.legrand.us/CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/legrand-north-america-announces-opening-of-newest-distribution-center-in-dayton-301755606.htmlSOURCE Legrand",neutral,0.0,1.0,0.0,positive,0.79,0.19,0.02,True,English,"['LEGRAND NORTH AMERICA ANNOUNCES', 'NEWEST DISTRIBUTION CENTER', 'OPENING', 'DAYTON', 'Green Globes Level One Certification', 'LEGRAND NORTH AMERICA ANNOUNCES', '2-Day Transit Time', 'art distribution center', 'existing West Coast', 'faster expanding segments', 'energy efficiency programs', 'exceptional customer service', 'NEWEST DISTRIBUTION CENTER', 'Southern Distribution centers', 'digital building infrastructures', 'New Distribution Network', 'electrical, digital infrastructure', 'Electrical wiring devices', 'Cablofil wire management', 'CAC 40 ESG indexes', 'Legrand Commercial Shading', 'highest quality products', 'larger operations facility', '625,000 square-feet operations facility', 'Central America Legrand', 'Legrand Minkels technology', 'Customer Base', 'quality control', 'data centers', 'newest facility', '200 new jobs', 'new offerings', 'Electrical Giant', 'world leader', 'shipment times', '2200 Douglas Way', 'Union OH', 'growing demand', 'best products', 'various approaches', 'carbon emissions', 'notable brands', 'industrial lighting', 'window shades', 'radiant Collection', 'Data room', 'AV division', 'Middle Atlantic', 'deep expertise', 'functional environment', 'Dan Carsten', 'Vice President', 'Operational Excellence', 'Montgomery County', 'job creation', 'Matt Gaston', 'global specialist', 'comprehensive offering', 'residential markets', 'The Group', 'societal trends', 'lasting impacts', 'steady flow', 'enhanced value', 'connected offerings', 'Euronext Paris', 'component stock', 'code ISIN', 'original content', 'facility features', 'connected solutions', 'high-quality solutions', 'thriving community', 'SOURCE Legrand', 'Western Ohio', 'latest expansion', 'long-term sustainability', 'NorthPoint Development', 'responsible growth', 'Dayton area', 'latest opening', 'Dayton facility', 'Legrand¬Æ', 'Footprint', 'Majority', 'Feb.', 'PRNewswire', 'company', 'customers', 'equipment', 'production', 'commitment', 'track', 'addition', 'freight', 'positions', 'warehouse', 'office', 'testament', 'aspect', 'highlights', 'Architectural', 'Kenall', 'Finelite', 'OCL', 'Pinnacle', 'Productivity', 'technologies', 'Chief', 'Vaddio', 'Da-Lite', 'C2G', 'Story', 'result', 'space', 'employees', 'Logistics', 'goal', 'investment', 'site', 'taxes', 'economy', 'region', 'benchmark', 'technological', 'buildings', 'purpose', 'life', 'people', 'teams', 'stakeholders', 'strategy', 'profitable', 'acquisitions', 'innovation', 'sales', 'Cision', 'multimedia', 'news-releases', 'newest-distribution']",2023-02-24,2023-02-25,finance.yahoo.com
19231,EuroNext,NewsApi.org,https://finance.yahoo.com/news/altuviiio-approved-u-fda-positive-161600954.html,ALTUVIIIO‚Ñ¢ approved by the U.S. FDA: this positive event triggers impairment reversal  positively impacting 2022 IFRS net income; no change on business net income (non-IFRS),FDA approves once-weekly ALTUVIIIO‚Ñ¢  a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event...,Sanofi - Aventis GroupeFDA approves once-weekly ALTUVIIIO‚Ñ¢  a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal  impacting 2022 IFRS net income; no change on business net income (non-IFRS)Filing of the 2022 U.S. Form 20-F and French ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù containing the Annual Financial ReportParis  February 24  2023. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù containing its Annual Financial Report with the French market regulator Autorit√© des march√©s financiers (AMF).On February 22  2023  the US Food and Drug Administration (FDA) approved ALTUVIIIOTM. This confirms the significant increase of value of the asset. That decision  which occurred prior to the filing of the French Document d‚Äôenregistrement universel and of the Annual Report on Form 20-F  resulted in an adjustment to IFRS net income for the year ended December 31  2022 as presented in the Sanofi press release issued on February 3  2023. The adjustment consisted of the reversal of ‚Ç¨2 154 million of impairment losses against the intangible assets associated with the Eloctate franchise  in accordance with IAS 36 (Impairment of Assets); the assets had been partially written down in 2019. The adjustment is presented within the line item Impairment of intangible assets in the consolidated income statement; the net impact after tax is a gain of ‚Ç¨1 651 million. Cash flows are not impacted by the adjustment. Following the adjustment  for the year ended December 31  2022  IFRS net income amounts to ‚Ç¨8 371 million (versus ‚Ç¨6 720 million as per the press release of February 3  2023); earnings per share (IFRS EPS) amounts to ‚Ç¨6.69 (versus ‚Ç¨5.37 as per the press release of February 3  2023); and total equity amounts to ‚Ç¨75 152 million (versus ‚Ç¨73 512 million as per the press release of February 3  2023).Story continuesBusiness net income (a non-IFRS financial measure) for the year ended December 31  2022 is unchanged  as is the amount of the dividend proposed by the Board of Directors held on February 2  2023.Updated IFRS figures for 2022 Financial Statements1Q4 2022 Change Changeat CER 2022 Change Changeat CER IFRS net sales reported ‚Ç¨10 725m +7.3% +2.6% ‚Ç¨42 997m +13.9% +7.0% IFRS net income reported ‚Ç¨3 111m +175.1% _ ‚Ç¨8 371m +34.5% ‚Äî IFRS EPS reported ‚Ç¨2.48 +175.9% _ ‚Ç¨6.69 +34.6% ‚Äî Free cash flow(2) ‚Ç¨2 546m +0.2% _ ‚Ç¨8 483m +4.8% ‚Äî Business operating income ‚Ç¨2 724m +20.7% +15.0% ‚Ç¨13 040m +21.7% +13.3% Business net income(1) ‚Ç¨2 141m +23.8% +17.6% ‚Ç¨10 341m +25.9% +17.0% Business EPS(1) ‚Ç¨1.71 +23.9% +17.4% ‚Ç¨8.26 +25.9% +17.1%Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9 of February 3  2023 Press Release). (1) In order to facilitate an understanding of operational performance  Sanofi comments on the business net income statement. Business net income is a non-IFRS financial measure (definition in Appendix 9 of February 3  2023 Press Release). The reconciliation of reported IFRS net income to business net income is set forth in the 2022 U.S. Form 20-F page 62 and French ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù page 142; (2) Free cash flow is a non-IFRS financial measure (definition in Appendix 9 of February 3  2023 Press Release).These documents are available on the company‚Äôs website: https://www.sanofi.com/en/investors/reports-and-publications/financial-and-csr-reports.In addition  the Form 20-F is available on the website of the SEC (www.sec.gov) and the ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù is available on the website of the AMF (www.amf-france.org). A hard copy of these documents  each of which contains our complete audited financial statements  may be received free of charge  upon request.About SanofiWe are an innovative global healthcare company  driven by one purpose: we chase the miracles of science to improve people‚Äôs lives. Our team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comEvan Berland | +1 215 432 0234 | evan.berland@sanofi.comKate Conway | + 1 508 364 4931 | kate.conway@sanofi.comInvestor RelationsEva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.comArnaud Del√©pine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comCorentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comTarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comUpdated vs. February 3  2023 press releaseAttachment,neutral,0.25,0.57,0.18,mixed,0.39,0.25,0.37,True,English,"['U.S. FDA', 'business net income', '2022 IFRS net income', 'positive event', 'impairment reversal', 'ALTUVIIIO‚Ñ¢', 'change', 'des march√©s financiers', 'innovative global healthcare company', 'business net income statement', 'CER IFRS net sales', 'consolidated income statement', 'U.S. Securities', 'factor VIII therapy', 'life-changing treatment options', 'life-saving vaccine protection', 'Arnaud Del√©pine', 'Business operating income', 'Free cash flow', 'significant bleed protection', 'constant exchange rates', 'SNY Media Relations', '2022 U.S. Form', 'French market regulator', 'Q4 2022 Change Change', '2022 IFRS net income', 'IFRS financial measure', 'Annual Financial Report', 'CER 2022 Change Change', 'Sanofi press release', 'Annual Report', 'Business EPS', 'net impact', '2022 Financial Statements1', 'Cash flows', 'Exchange Commission', 'significant increase', 'Investor Relations', 'IFRS EPS', 'IFRS figures', 'Form 20-F', 'Aventis Groupe', 'new class', 'hemophilia A', 'positive event', 'Enregistrement Universel', 'US Food', 'Drug Administration', 'Eloctate franchise', 'line item', 'total equity', 'operational performance', 'F page', 'hard copy', 'one purpose', 'social responsibility', 'Corentine Driancourt', 'Nathalie Pham', 'French ‚ÄúDocument', 'French Document', 'impairment losses', 'intangible assets', 'Sandrine Guendoul', 'Evan Berland', 'Kate Conway', 'Eva Schaefer-Jansen', 'Tarik Elgoutni', 'sec.gov', 'impairment reversal', 'Victor Rouault', 'Felix Lauscher', 'FDA', 'ALTUVIIIO‚Ñ¢', 'Filing', 'Paris', 'February', 'AMF', 'ALTUVIIIOTM', 'value', 'decision', 'adjustment', 'year', 'December', 'accordance', 'IAS', 'tax', 'gain', 'earnings', 'share', 'Story', 'amount', 'Board', 'Directors', 'Changes', 'definition', 'Appendix', 'order', 'understanding', 'reconciliation', 'documents', 'website', 'investors', 'reports', 'publications', 'csr', 'addition', 'org', 'complete', 'charge', 'request', 'miracles', 'science', 'people', 'lives', 'team', '100 countries', 'practice', 'medicine', 'millions', 'sustainability', 'center', 'ambitions', 'EURONEXT', 'NASDAQ']",2023-02-24,2023-02-25,finance.yahoo.com
19232,EuroNext,NewsApi.org,https://finance.yahoo.com/news/fda-approves-once-weekly-efanesoctocog-063000288.html,FDA approves once-weekly efanesoctocog alfa  a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB,Sobi¬Æ today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion...,"STOCKHOLM  Feb. 24  2023 /PRNewswire/ -- Sobi¬Æ today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl]  a first-in-class  high-sustained factor VIII replacement therapy for adults and children with haemophilia A. Efanesoctocog alfa is the first and only haemophilia A treatment that provides patients with normal to near-normal factor VIII activity levels for a significant part of the week with once-weekly dosing  resulting in superior protection from bleeds compared to existing factor VIII prophylaxis.Haemophilia A is a rare  genetic disorder in which the ability of a person's blood to clot is impaired due to a lack of factor VIII. Haemophilia A occurs in about one in 5 000 male births annually  and more rarely in females. People with haemophilia can experience bleeding episodes that can cause pain  irreversible joint damage and life-threatening haemorrhages. Despite advancements in treatment made in recent years  a large unmet medical need still exists and requires further improvement in the standard of care.""This approval marks an important clinical advancement for the haemophilia community because we have an option that can achieve higher levels of factor activity with a single weekly dose "" said Lynn Malec  MD  Medical Director of Comprehensive Center for Bleeding Disorders and Associate Investigator at Versiti Blood Research Institute  and Associate Professor of Medicine and Pediatrics at The Medical College of Wisconsin  US. ""By maintaining high levels of factor activity throughout the week  patients can be confident in the bleed protection efanesoctocog alfa offers.""""On behalf of Sobi I'd like to congratulate our co-development partner Sanofi on this great achievement "" said Anders Ullman  Head of Research & Development and Medical Affairs  Chief Medical Officer at Sobi. ""This is a major milestone in our collaboration as we work towards providing access to this important new treatment for people living with haemophilia A around the world.""The FDA approval is primarily based on data from the pivotal XTEND-1 phase 3 study recently published in The New England Journal of Medicine. Once-weekly efanesoctocog alfa met the primary endpoint  providing significant improvements in bleed protection for people with severe haemophilia A with median and mean annualised bleeding rates (ABR) of 0.00 (interquartile range: 0.00-1.04) and 0.71 (95% confidence interval: 0.52-0.97)  respectively. Efanesoctocog alfa met the key secondary endpoint with a significant reduction of 77% in ABR versus prior factor prophylaxis based on an intra-patient comparison. Efanesoctocog alfa prophylaxis with 50IU/kg/week provided mean factor VIII activity greater than 40% for the majority of the week with a trough activity of 15% on day seven  and these levels were associated with a low bleed risk.Additional data showed prevention of joint bleeds with a median annualised joint bleeding rate of 0 (Q1  Q3: 0.0  1.0). Treatment with efanesoctocog alfa provided 100% resolution of target joints  which are joints that have recurrent bleeds (e.g.  knee  ankle  or elbow). In adults and adolescents  efanesoctocog alfa had a favourable safety profile and there were no signs of factor VIII inhibitor development.Efanesoctocog alfa is indicated in the US for routine prophylaxis  on-demand treatment and control of bleeding episodes  and perioperative management of bleeding. The recommended weekly dose of 50 IU/kg is intended for prophylaxis in patients of all ages and the same dose can be administered according to needs in different clinical settings. Efanesoctocog alfa is expected to be commercially available in the US starting in the second quarter of 2023 and will be marketed as ALTUVIIIO‚Ñ¢ in Sanofi territories.The FDA evaluated the application under Priority Review  which is granted to therapies that have the potential to provide significant improvements in the treatment  diagnosis  or prevention of serious conditions.Regulatory submission in the EU will follow the availability of final data from the XTEND-Kids paediatric study in the first half of 2023. The European Commission granted orphan designation in June 2019.About efanesoctocog alfaEfanesoctocog alfa (formerly BIVV001) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for most of the week  extending bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN¬Æ polypeptides to potentially extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling  which is believed to impose a half-life limitation on current factor VIII therapies. It is approved as ALTUVIIIO [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the US. It is not approved in any country outside the US.About the Sanofi and Sobi collaborationSobi and Sanofi collaborate on the development and commercialisation of Alprolix¬Æ and Elocta¬Æ/Eloctate¬Æ. The companies also collaborate on the development and commercialisation of efanesoctocog alfa or ALTUVIIIO in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe  North Africa  Russia and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.SanofiSanofi are an innovative global healthcare company  driven by one purpose: to chase the miracles of science to improve people's lives. Their team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the centre of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.Sobi¬ÆSobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology  immunology and specialty care  Sobi has approximately 1 600 employees across Europe  North America  the Middle East  Asia and Australia. In 2022  revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com  LinkedIn and YouTube.ContactsFor details on how to contact the Sobi Investor Relations Team  please click here. For Sobi Media contacts  click here.Swedish Orphan Biovitrum AB (publ)Postal address SE-112 76 Stockholm  SwedenPhone: 46 8 697 20 00www.sobi.comThe following files are available for download:https://mb.cision.com/Main/14266/3722707/1872777.pdf FDA approves once-weekly efanesoctocog alfaCisionView original content:https://www.prnewswire.co.uk/news-releases/fda-approves-once-weekly-efanesoctocog-alfa-a-new-class-of-high-sustained-factor-viii-therapy-for-haemophilia-a-swedish-orphan-biovitrum-ab-301755196.html",neutral,0.0,1.0,0.0,mixed,0.17,0.16,0.67,True,English,"['high-sustained factor VIII therapy', 'Swedish Orphan Biovitrum AB', 'efanesoctocog alfa', 'new class', 'haemophilia A', 'FDA', 'high-sustained factor VIII replacement therapy', 'investigational recombinant factor VIII therapy', 'median annualised joint bleeding rate', 'normal factor VIII activity levels', 'pivotal XTEND-1 phase 3 study', 'current factor VIII therapies', 'innovative Fc fusion technology', 'mean annualised bleeding rates', 'large unmet medical need', 'mean factor VIII activity', 'The New England Journal', 'von Willebrand factor ceiling', 'existing factor VIII prophylaxis', 'factor VIII inhibitor development', 'near-normal factor activity levels', 'Versiti Blood Research Institute', 'haemophilia A. Efanesoctocog alfa', 'Fc-VWF-XTEN Fusion Protein-ehtl', 'irreversible joint damage', 'prior factor prophylaxis', 'rare, genetic disorder', 'important clinical advancement', 'low bleed risk', 'favourable safety profile', 'different clinical settings', 'The European Commission', 'The Medical College', 'Chief Medical Officer', 'key secondary endpoint', 'important new treatment', 'efanesoctocog alfa offers', 'single weekly dose', 'Efanesoctocog alfa prophylaxis', 'weekly efanesoctocog alfa', 'The FDA approval', 'Antihemophilic Factor', 'joint bleeds', 'trough activity', 'higher levels', 'Medical Director', 'high levels', 'Medical Affairs', 'bleeding episodes', 'Bleeding Disorders', 'routine prophylaxis', 'primary endpoint', 'weekly dosing', 'development partner', 'same dose', 'Drug Administration', 'significant part', '5,000 male births', 'life-threatening haemorrhages', 'recent years', 'Lynn Malec', 'Comprehensive Center', 'Associate Investigator', 'Associate Professor', 'great achievement', 'Anders Ullman', 'major milestone', 'significant improvements', 'interquartile range', 'significant reduction', 'intra-patient comparison', 'recurrent bleeds', 'perioperative management', 'second quarter', 'Priority Review', 'serious conditions', 'Regulatory submission', 'orphan designation', 'XTEN¬Æ polypeptides', 'half-life limitation', 'haemophilia community', 'severe haemophilia', 'Additional data', 'final data', 'target joints', 'demand treatment', 'first half', 'Sanofi territories', 'superior protection', 'US Food', 'PRNewswire', 'Sobi¬Æ', 'adults', 'children', 'only', 'patients', 'ability', 'person', 'lack', 'females', 'People', 'pain', 'advancements', 'standard', 'care', 'option', 'MD', 'Medicine', 'Pediatrics', 'Wisconsin', 'behalf', 'Head', 'collaboration', 'access', 'world', 'ABR', '50IU/kg', 'majority', 'day', 'seven', 'prevention', '100% resolution', 'knee', 'ankle', 'elbow', 'adolescents', 'signs', 'control', '50 IU', 'needs', 'ALTUVIIIO‚Ñ¢', 'application', 'potential', 'diagnosis', 'June', 'novel', 'region', 'time', 'circulation', 'country']",2023-02-24,2023-02-25,finance.yahoo.com
19233,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/TME-PHARMA-N-V-31472058/news/TME-Pharma-N-CEO-message-43074843/?utm_medium=RSS&utm_content=20230224,TME Pharma N : CEO message,(marketscreener.com)   TME PHARMA CEO MESSAGE   Berlin  Germany  February 24  2023  08.00 a.m. CET - TME Pharma N.V. (Euronext Growth Paris:   ALTME)  a biotechnology company focused on developing novel therapies for treatment of cancer by targeting t‚Ä¶,TME PHARMA CEO MESSAGE Berlin  Germany  February 24  2023  08.00 a.m. CET - TME Pharma N.V. (Euronext Growth Paris: ALTME)  a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME)  released today a message from Aram Mangasarian  CEO of TME Pharma  to its shareholders with the following key highlights: Exceptional clinical results generated in brain cancer trial evaluating NOX-A12 in combination with radiotherapy and bevacizumabNOX-A12 in combination with radiotherapy and bevacizumab Maturing brain cancer survival data confirmed 83% of patients still alive at 10 months12-month median follow-up survival data expected in early Q2 2023median follow-up survival data expected in early Q2 2023 Intensified partnering and financing discussions to secure future clinical development of NOX-A12 without reliance on convertible debt financingNOX-A12 without reliance on convertible debt financing Cash runway projected into September 2023 Dear Shareholders  I would like to take a moment to both look back at 2022 and to look ahead to the 2023 catalysts that can move TME Pharma forward. With the exceptional clinical results emerging from our brain cancer program throughout last year  it was time to make our transformation into an oncology biotech with a focus on therapeutics altering the tumor microenvironment - TME - visible with our new name. Our current strategy focuses all facets of our and collaborators' expertise on the development of our lead asset NOX-A12 in brain cancer as the opportunity with the fastest path to approval. Indeed  recent work has revealed a potential biomarker that may predict clinical response of brain cancer patients to NOX-A12-based therapy. Being able to select patients who will benefit most strongly from our therapy should increase chances of regulatory approval and commercial success while at the same time reducing cost and duration of associated trials. At TME Pharma we pride ourselves on taking on one of the most difficult to treat and underserved cancer indications - brain cancer (glioblastoma multiforme  GBM). GBM is one of the most aggressive forms of brain cancer and the most common malignant central nervous system tumor in adults. Patients with this devastating orphan disease are faced with extremely poor prognosis and a staggering 95% of them will not survive beyond 5 years. There is a huge unmet medical need for an effective approach to treat GBM where the standard of care - a combination treatment including surgery  radiotherapy and chemotherapy - unfortunately is not curative  and provides only a minimal survival benefit despite its heavy toll on the last few months of the patients' and their families' lives. Moreover  not all patients will benefit clinically from the chemotherapy  which limits the efficacy of the treatment while adding side effects for patients. Our approach  built on research into the tumor microenvironment  has delivered a series of highly encouraging results in the clinic and demonstratesthat NOX-A12 combinations  granted orphan drug designation in the US and Europe  have the potential to considerably improve therapy of this disease. Although we were confident that NOX-A12 could generate clinical benefit for patients  the data generated from the GLORIA study in newly diagnosed glioblastoma patients surpassed our expectations  in particular the interim results in the expansion arm evaluating the triple combination of NOX-A12  radiotherapy and bevacizumab  the antibody also known as Avastin¬Æ from Roche. These results were reported in November at the Society for Neuro-Oncology (SNO) Annual Meeting in Tampa  US and showed that almost all patients responded to the NOX-A12 triple combination in an impressive manner: 100% of targeted lesions treated with the NOX-A12 combination shrank by more than 50% with 83% of patients achieving durable partial responses lasting longer than six months. Two of the six patients experienced tumor size reduction greater than 99%. These are exceptionally positive treatment outcomes for this patient group: a matched historical cohort treated with the standard of care showed only 25% of patients with tumor size reduction and 10% of patients with a reduction of 50% or more in tumor size. The GLORIA study continues to generate important data  and we have not yet reached median overall survival (mOS). We recently reported that 83% of patients are still alive with the median time on study of 10 months. The 10-month timepoint is an important landmark for assessment since this is the expected median survival for our patient population with chemorefractory tumors and incomplete surgical removal. We are now keenly awaiting the 12-month median follow-up survival data which are due in early Q2 2023. More mature survival data will allow us to initiate discussions with the regulators and design the optimal regulatory path forward for NOX-A12. As announced in June 2022  in response to the emerging positive data we have decided to focus our strategy so that our capabilities and resources advance the glioblastoma program. Over the last months we have been considering different options to maximize availability of mature data from the GLORIA brain cancer trial with available funds and we have now made the decision to pause the recruitment of additional patients in the other expansion arms. These changes provide additional cash runway with funding of TME Pharma projected into early September 2023. As such  to execute on its plans and meet its future financial obligations  the company will need to access additional financing in May 2023. The goal of these actions is to enable us to deliver the datapoints needed to attract an industry partner or long-term investors. Throughout the last year  the TME Pharma team has participated in a range of industry events and conferences. Key clinical readouts were accepted for presentation at two of the most high-profile congresses related to novel cancer therapies  the American Society of Clinical Oncology (ASCO) and Society for Neuro-Oncology (SNO) annual meetings. This was a welcome validation of the importance of our research and development and contributed to raising awareness of the work we are doing in brain cancer among the wider scientific community. However  despite the recognition of our promising data  glioblastoma is generally perceived as one of the riskiest indications both by industrial partners and investors. Reluctance to invest in this particularly challenging indication has left patients without effective therapies for decades and made the pursuit for a new treatment so much more critical. Advancing and financing of the glioblastoma program remains our priority for as long as data continues to show positive efficacy signals and generates interest among potential partners. In order to drive clinical development into the next phase we need long-term support from a strategic or financialpartner. Prospective partners and investors would like to wait though for more mature survival data and feedback from the regulatory agencies to advance the discussions. The agreement put in place with Atlas Special Opportunities (ASO) in 2020 has served the company for more than 2.5 years as a predominant source of financing  however it is dilutive for our shareholders and puts downward pressure on the share price. It is our goal to bring long-term investors on board and to end reliance of the company on convertible debt financing. We are actively pursuing multiple alternatives to secure funding for TME Pharma and our clinical programs. We are optimistic that with more mature data and the potential to select patients that will respond to treatment with NOX-A12 we will be able to attract needed financial support to our program. Although I am writing to you during a challenging time for the biotech industry  especially for a small company such as ours  I remain proud of our achievements at TME Pharma and convinced that investors and partners will ultimately see significant value in our NOX-A12 program. I would like to thank the entire TME Pharma team for their diligence and dedication. I know they share my excitement and expectations for the year ahead. I would also like to express my gratitude to our shareholders for their belief in the company and I look forward to updating you on our progress in 2023. We have entered 2023 with enthusiasm and determination for the busy time ahead of us  which contains a great promise for TME Pharma. Yours sincerely  Aram Mangasarian CEO  TME Pharma February 24  2023 For more information  please contact: TME Pharma N.V. Aram Mangasarian  Ph.D.  CEO Tel. +49 (0) 30 726247 0 investors@tmepharma.com Investor and Media Relations: LifeSci Advisors Guillaume van Renterghem Tel. +41 (0) 76 735 01 31 gvanrenterghem@lifesciadvisors.com NewCap Arthur Rouill√© Tel. +33 (0) 1 44 71 00 15 arouille@newcap.frAbout TME Pharma TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focusedpipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME  TME Pharma's approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial  TME Pharma is studying its lead drug candidate NOX-A12in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-linedata from the NOX-A12three dose-escalationcohorts combined with radiotherapy of the GLORIA clinical trial  observing consistent tumor reductions and objective tumor responses. Additionally  GLORIA expansion arms evaluate safety and efficacy of NOX-A12in other combinations where the interim results from the triple combination of NOX-A12 radiotherapy and bevacizumab suggest even deeper and more durable responses. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-linedata with encouraging overall survival and safety profile from its NOX- A12 combination trial with Keytruda¬Æ in metastatic colorectal and pancreatic cancer patients  which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study  OPTIMUS  to further evaluate safety and efficacy of NOX-A12in combination with Merck's Keytruda¬Æ and two different chemotherapy regimens as second-linetherapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in France and Spain and is in discussion with regulatory authorities in the United States. The company's second clinical-stagedrug candidate  NOX-E36 is designed to target the innate immune system. TME Pharma is considering several solid tumors for further clinical development. Further information can be found at: www.tmepharma.com. TME Pharma¬Æ and the TME Pharma logo are registered trademarks. Keytruda¬Æ is a registered trademark of Merck Sharp & Dohme Corp. Visit TME Pharma on LinkedInand Twitter. About the GLORIA Study GLORIA (NCT04121455) is TME Pharma's dose-escalation  Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.,neutral,0.01,0.99,0.0,mixed,0.29,0.11,0.6,True,English,"['TME Pharma N', 'CEO message', 'common malignant central nervous system tumor', '10 months 12-month median follow-up survival data', 'convertible debt financing Cash runway', 'huge unmet medical need', 'More mature survival data', 'TME Pharma N.V.', 'brain cancer survival data', 'median overall survival', 'emerging positive data', 'minimal survival benefit', 'Euronext Growth Paris', 'following key highlights', 'orphan drug designation', 'SNO) Annual Meeting', 'durable partial responses', 'incomplete surgical removal', 'brain cancer trial', 'brain cancer program', 'devastating orphan disease', 'optimal regulatory path', 'tumor size reduction', 'Exceptional clinical results', 'positive treatment outcomes', 'future clinical development', 'median survival', 'The GLORIA study', 'TME PHARMA CEO', 'brain cancer patients', 'NOX-A12 triple combination', 'important data', 'median time', 'clinical benefit', 'tumor microenvironment', 'financing discussions', 'fastest path', 'six months', 'cancer indications', 'encouraging results', 'interim results', 'clinical response', 'biotechnology company', 'novel therapies', 'Aram Mangasarian', 'early Q2', 'oncology biotech', 'new name', ""collaborators' expertise"", 'lead asset', 'recent work', 'regulatory approval', 'commercial success', 'associated trials', 'glioblastoma multiforme', 'aggressive forms', 'poor prognosis', 'heavy toll', ""families' lives"", 'side effects', 'expansion arm', 'impressive manner', 'patient group', 'historical cohort', '10-month timepoint', 'important landmark', 'patient population', 'chemorefractory tumors', 'same time', 'combination treatment', 'MESSAGE Berlin', 'Dear Shareholders', 'last year', 'current strategy', 'potential biomarker', 'effective approach', 'NOX-A12 combinations', 'NOX-A12-based therapy', 'glioblastoma patients', 'six patients', 'NOX-A12.', 'Germany', 'February', 'CET', 'ALTME', 'radiotherapy', 'bevacizumab', 'partnering', 'reliance', 'September', 'moment', '2023 catalysts', 'transformation', 'focus', 'therapeutics', 'opportunity', 'chances', 'cost', 'duration', 'GBM', 'adults', '5 years', 'standard', 'care', 'surgery', 'chemotherapy', 'efficacy', 'research', 'series', 'Europe', 'expectations', 'antibody', 'Avastin¬Æ', 'Roche', 'November', 'Society', 'Neuro-Oncology', 'Tampa', 'lesions', 'mOS', 'assessment', 'regulators', 'June', 'capabilities', 'resource', '08.00']",2023-02-24,2023-02-25,marketscreener.com
19234,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/KTESIOS-REAL-ESTATE-SOCIM-123269049/news/Ktesios-Real-Estate-SOCIMI-S-A-SOCIMI-Asset-Acquisition-Toledo-43080482/?utm_medium=RSS&utm_content=20230224,Ktesios Real Estate SOCIMI S A : SOCIMI - Asset Acquisition- Toledo,(marketscreener.com)   KTESIOS SOCIMI   Madrid  24 February 2023   Pursuant to Article 17 of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse   Article 61004/2 of Euronext Rule Book I Harmonized Ru‚Ä¶,"KTESIOS SOCIMIMadrid  24 February 2023Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)  Article 61004/2 of Euronext Rule Book I Harmonized Rules and concordant provisions  on ongoing obligations of companies listed on Euronext  Ktesios Real Estate SOCIMI  S.A. (the ""Company"") hereby notifies the following:RELEVANT INFORMATIONWe are pleased to announce that  on 22 of February 2023  the Company acquired a total of 81 assets (of which 52 are dwellings)  with an occupancy ratio above 70%  for a total value of 1.7M euros  with an estimated market value of 3.3M euros. The transaction has been financed by Unicaja Bank (60% LTV).These assets are located in the municipalities of Toledo  Borox  Caba√±as de la Sagra  Fuensalida  Villaseca de la Sagra and Yuncler  all in the province of Toledo.The Company's asset portfolio totals 609 properties  of which 373 are dwellings  with an estimated market value of 36M euros and occupancy ratio of 85 6%.We remain at your disposal for any clarification you may need Henry GallegoCEOKtesios Real Estate SOCIMI  S.A.Ktesios Real Estate SOCIMI S.A. CIF: A88346614 - C/ Sagasta 15  7¬∫ Izda.- 28004 - MadridRegistrada en el Registro Mercantil de Madrid al Tomo 38.976  Folio 30  Secci√≥n 1  Hoja M-692614Email: info@ktesios-socimi.es | Tel: +34 910 638 011 | www.ktesios-socimi.es",neutral,0.0,1.0,0.0,positive,0.59,0.39,0.01,True,English,"['Ktesios Real Estate SOCIMI S A', 'Asset Acquisition- Toledo', 'Ktesios Real Estate SOCIMI S.A.', 'Caba√±as de la Sagra', 'Villaseca de la Sagra', 'Henry Gallego CEO', 'KTESIOS SOCIMI', 'Euronext Rule Book', 'Market Abuse Regulation', 'market value', 'European Parliament', 'concordant provisions', 'ongoing obligations', 'RELEVANT INFORMATION', 'occupancy ratio', '1.7M euros', '3.3M euros', 'Unicaja Bank', 'asset portfolio', '36M euros', 'C/ Sagasta', 'Registro Mercantil', 'Secci√≥n', 'total value', 'The Company', 'Madrid', '24 February', 'Article', 'No.', 'Council', '16 April', 'Rules', 'companies', '81 assets', 'dwellings', 'transaction', '60% LTV', 'municipalities', 'Toledo', 'Borox', 'Fuensalida', 'Yuncler', 'province', '609 properties', 'disposal', 'clarification', 'CIF', '7¬∫ Izda.', 'Tomo', 'Hoja', 'Email', 'ktesios-socimi', 'Tel', '34']",2023-02-24,2023-02-25,marketscreener.com
19235,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/KTESIOS-REAL-ESTATE-SOCIM-123269049/news/Ktesios-Real-Estate-SOCIMI-S-A-24-02-2023-ndash-Ktesios-SOCIMI-ndash-Asset-Acquisition-Toledo-43080656/?utm_medium=RSS&utm_content=20230224,Ktesios Real Estate SOCIMI S A : 24.02.2023 ‚Äì Ktesios SOCIMI ‚Äì Asset Acquisition- Toledo,(marketscreener.com)   KTESIOS SOCIMI   Madrid  24 February 2023   Pursuant to Article 17 of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse   Article 61004/2 of Euronext Rule Book I Harmonized Ru‚Ä¶,"KTESIOS SOCIMIMadrid  24 February 2023Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)  Article 61004/2 of Euronext Rule Book I Harmonized Rules and concordant provisions  on ongoing obligations of companies listed on Euronext  Ktesios Real Estate SOCIMI  S.A. (the ""Company"") hereby notifies the following:RELEVANT INFORMATIONWe are pleased to announce that  on 22 of February 2023  the Company acquired a total of 81 assets (of which 52 are dwellings)  with an occupancy ratio above 70%  for a total value of 1.7M euros  with an estimated market value of 3.3M euros. The transaction has been financed by Unicaja Bank (60% LTV).These assets are located in the municipalities of Toledo  Borox  Caba√±as de la Sagra  Fuensalida  Villaseca de la Sagra and Yuncler  all in the province of Toledo.The Company's asset portfolio totals 609 properties  of which 373 are dwellings  with an estimated market value of 36M euros and occupancy ratio of 85 6%.We remain at your disposal for any clarification you may need Henry GallegoCEOKtesios Real Estate SOCIMI  S.A.Ktesios Real Estate SOCIMI S.A. CIF: A88346614 - C/ Sagasta 15  7¬∫ Izda.- 28004 - MadridRegistrada en el Registro Mercantil de Madrid al Tomo 38.976  Folio 30  Secci√≥n 1  Hoja M-692614Email: info@ktesios-socimi.es | Tel: +34 910 638 011 | www.ktesios-socimi.es",neutral,0.0,1.0,0.0,positive,0.59,0.39,0.01,True,English,"['Ktesios Real Estate SOCIMI', 'Ktesios SOCIMI', 'Toledo', 'Ktesios Real Estate SOCIMI S.A.', 'Caba√±as de la Sagra', 'Villaseca de la Sagra', 'Henry Gallego CEO', 'KTESIOS SOCIMI', 'Euronext Rule Book', 'Market Abuse Regulation', 'market value', 'European Parliament', 'concordant provisions', 'ongoing obligations', 'RELEVANT INFORMATION', 'occupancy ratio', '1.7M euros', '3.3M euros', 'Unicaja Bank', 'asset portfolio', '36M euros', 'C/ Sagasta', 'Registro Mercantil', 'Secci√≥n', 'total value', 'The Company', 'Madrid', '24 February', 'Article', 'No.', 'Council', '16 April', 'Rules', 'companies', '81 assets', 'dwellings', 'transaction', '60% LTV', 'municipalities', 'Toledo', 'Borox', 'Fuensalida', 'Yuncler', 'province', '609 properties', 'disposal', 'clarification', 'CIF', '7¬∫ Izda.', 'Tomo', 'Hoja', 'Email', 'ktesios-socimi', 'Tel', '34']",2023-02-24,2023-02-25,marketscreener.com
19236,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/KTESIOS-REAL-ESTATE-SOCIM-123269049/news/Ktesios-Real-Estate-SOCIMI-S-A-24-02-2023-ndash-Ktesios-SOCIMI-ndash-Valuation-Report-2022-43080655/?utm_medium=RSS&utm_content=20230224,Ktesios Real Estate SOCIMI S A : 24.02.2023 ‚Äì Ktesios SOCIMI ‚Äì Valuation Report 2022,(marketscreener.com)   KTESIOS SOCIMI   Madrid  24 Feb. 2023   Pursuant to Article 17 of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse   Article 61004/2 of Euronext Rule Book I Harmonized Rules ‚Ä¶,"KTESIOS SOCIMIMadrid  24 Feb. 2023Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)  Article 61004/2 of Euronext Rule Book I Harmonized Rules and concordant provisions  on ongoing obligations of companies listed on Euronext  Ktesios Real Estate SOCIMI  S.A. (the ""Company"") hereby notifies the following:RELEVANT INFORMATIONThe Company has requested from the independent expert  Gesvalt Sociedad de Tasaci√≥n  S.A.  an updated valuation of the real estate portfolio as of December 31  2022  under the methodology ""RICS Valuation Standards"" included in the ""Red Book"" current edition  published by the Royal Institution of Chartered Surveyors.According to the assumptions reflected in the valuation report issued by Gesvalt and based on the market value approach by the methods of capitalization of future income from rentals according to contractual and / or market income  and comparison method  the total market value is 32 588 988 euros.The assets have been valued individually and not as part of a real estate portfolio. The value opinion is based on the General Principles and Methodology detailed in the report submitted to the Company.We remain at your disposal for any clarification you may need Henry GallegoCEOKtesios Real Estate SOCIMI  S.A.Ktesios Real Estate SOCIMI S.A. CIF: A88346614 - C/ Sagasta 15  7¬∫ Izda.- 28004 - MadridRegistrada en el Registro Mercantil de Madrid al Tomo 38.976  Folio 30  Secci√≥n 1  Hoja M-692614Email: info@ktesios-socimi.es | Tel: +34 910 638 011 | www.ktesios-socimi.es",neutral,0.0,1.0,0.0,neutral,0.05,0.92,0.03,True,English,"['Ktesios Real Estate SOCIMI S A', 'Ktesios SOCIMI', 'Valuation Report', '24.', 'Ktesios Real Estate SOCIMI S.A.', 'Gesvalt Sociedad de Tasaci√≥n', 'Red Book"" current edition', 'real estate portfolio', 'RICS Valuation Standards', 'Henry Gallego CEO', 'Euronext Rule Book', 'market value approach', 'total market value', 'KTESIOS SOCIMI', 'Market Abuse Regulation', 'Secci√≥n', 'value opinion', 'market income', 'European Parliament', 'concordant provisions', 'ongoing obligations', 'RELEVANT INFORMATION', 'independent expert', 'Royal Institution', 'Chartered Surveyors', 'future income', 'comparison method', 'General Principles', 'C/ Sagasta', 'Registro Mercantil', 'Madrid', 'Article', 'No.', 'Council', '16 April', 'Rules', 'companies', 'Company', 'December', 'methodology', 'assumptions', 'report', 'methods', 'capitalization', 'rentals', 'contractual', '2,588,988 euros', 'assets', 'part', 'disposal', 'clarification', 'CIF', '7¬∫ Izda.', 'Tomo', 'Hoja', 'Email', 'ktesios-socimi', 'Tel', '24', '34']",2023-02-24,2023-02-25,marketscreener.com
19237,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/KTESIOS-REAL-ESTATE-SOCIM-123269049/news/Ktesios-Real-Estate-SOCIMI-S-A-SOCIMI-Update-Offer-QPQ-43080483/?utm_medium=RSS&utm_content=20230224,Ktesios Real Estate SOCIMI S A : SOCIMI- Update Offer QPQ,(marketscreener.com)   KTESIOS SOCIMI   Madrid  24 February 2023   Pursuant to Article 17 of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse   Article 61004/2 of Euronext Rule Book I Harmonized Ru‚Ä¶,"KTESIOS SOCIMIMadrid  24 February 2023Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)  Article 61004/2 of Euronext Rule Book I Harmonized Rules and concordant provisions  on ongoing obligations of companies listed on Euronext  Ktesios Real Estate SOCIMI  S.A. (the ""Company"") hereby notifies the following:RELEVANT INFORMATIONWe are pleased to inform that  in connection with the ANNOUNCEMENT OF OFFER FOR THE SUBSCRIPTION OF OPTIONS ON THE SHARES OF QUID PRO QUO ALQUILER SEGURO SOCIMI S.A  published on 14 February 2023  the acceptance of such offer as of to date stands at 62.15%  above the threshold defined by the Company at 60%.We remain at your disposal for any clarification you may need Henry GallegoCEOKtesios Real Estate SOCIMI  S.A.Ktesios Real Estate SOCIMI S.A. CIF: A88346614 - C/ Sagasta 15  7¬∫ Izda.- 28004 - MadridRegistrada en el Registro Mercantil de Madrid al Tomo 38.976  Folio 30  Secci√≥n 1  Hoja M-692614Email: info@ktesios-socimi.es | Tel: +34 910 638 011 | www.ktesios-socimi.es",neutral,0.0,1.0,0.0,positive,0.59,0.39,0.01,True,English,"['Ktesios Real Estate SOCIMI S A', 'SOCIMI- Update Offer', 'QPQ', 'QUID PRO QUO ALQUILER SEGURO SOCIMI S.A', 'Ktesios Real Estate SOCIMI S.A.', 'Henry Gallego CEO', 'KTESIOS SOCIMI', 'Euronext Rule Book', 'Market Abuse Regulation', 'European Parliament', 'concordant provisions', 'ongoing obligations', 'RELEVANT INFORMATION', 'C/ Sagasta', 'Registro Mercantil', 'Secci√≥n', 'Madrid', '24 February', 'Article', 'No.', 'Council', '16 April', 'Rules', 'companies', 'Company', 'connection', 'ANNOUNCEMENT', 'OFFER', 'SUBSCRIPTION', 'OPTIONS', 'SHARES', '14 February', 'acceptance', 'date', 'threshold', 'disposal', 'clarification', 'CIF', '7¬∫ Izda.', 'Tomo', 'Folio', 'Hoja', 'Email', 'ktesios-socimi', 'Tel', '34']",2023-02-24,2023-02-25,marketscreener.com
19238,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/KTESIOS-REAL-ESTATE-SOCIM-123269049/news/Ktesios-Real-Estate-SOCIMI-S-A-SOCIMI-Valuation-Report-2022-43080561/?utm_medium=RSS&utm_content=20230224,Ktesios Real Estate SOCIMI S A : SOCIMI- Valuation Report 2022,(marketscreener.com)   KTESIOS SOCIMI   Madrid  24 Feb. 2023   Pursuant to Article 17 of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse   Article 61004/2 of Euronext Rule Book I Harmonized Rules ‚Ä¶,"KTESIOS SOCIMIMadrid  24 Feb. 2023Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)  Article 61004/2 of Euronext Rule Book I Harmonized Rules and concordant provisions  on ongoing obligations of companies listed on Euronext  Ktesios Real Estate SOCIMI  S.A. (the ""Company"") hereby notifies the following:RELEVANT INFORMATIONThe Company has requested from the independent expert  Gesvalt Sociedad de Tasaci√≥n  S.A.  an updated valuation of the real estate portfolio as of December 31  2022  under the methodology ""RICS Valuation Standards"" included in the ""Red Book"" current edition  published by the Royal Institution of Chartered Surveyors.According to the assumptions reflected in the valuation report issued by Gesvalt and based on the market value approach by the methods of capitalization of future income from rentals according to contractual and / or market income  and comparison method  the total market value is 32 588 988 euros.The assets have been valued individually and not as part of a real estate portfolio. The value opinion is based on the General Principles and Methodology detailed in the report submitted to the Company.We remain at your disposal for any clarification you may need Henry GallegoCEOKtesios Real Estate SOCIMI  S.A.Ktesios Real Estate SOCIMI S.A. CIF: A88346614 - C/ Sagasta 15  7¬∫ Izda.- 28004 - MadridRegistrada en el Registro Mercantil de Madrid al Tomo 38.976  Folio 30  Secci√≥n 1  Hoja M-692614Email: info@ktesios-socimi.es | Tel: +34 910 638 011 | www.ktesios-socimi.es",neutral,0.0,1.0,0.0,neutral,0.05,0.92,0.03,True,English,"['Ktesios Real Estate SOCIMI S A', 'SOCIMI- Valuation Report', 'Ktesios Real Estate SOCIMI S.A.', 'Gesvalt Sociedad de Tasaci√≥n', 'Red Book"" current edition', 'real estate portfolio', 'RICS Valuation Standards', 'Henry Gallego CEO', 'Euronext Rule Book', 'market value approach', 'total market value', 'KTESIOS SOCIMI', 'Market Abuse Regulation', 'Secci√≥n', 'value opinion', 'market income', 'European Parliament', 'concordant provisions', 'ongoing obligations', 'RELEVANT INFORMATION', 'independent expert', 'Royal Institution', 'Chartered Surveyors', 'future income', 'comparison method', 'General Principles', 'C/ Sagasta', 'Registro Mercantil', 'Madrid', 'Article', 'No.', 'Council', '16 April', 'Rules', 'companies', 'Company', 'December', 'methodology', 'assumptions', 'report', 'methods', 'capitalization', 'rentals', 'contractual', '2,588,988 euros', 'assets', 'part', 'disposal', 'clarification', 'CIF', '7¬∫ Izda.', 'Tomo', 'Hoja', 'Email', 'ktesios-socimi', 'Tel', '24', '34']",2023-02-24,2023-02-25,marketscreener.com
19239,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/KTESIOS-REAL-ESTATE-SOCIM-123269049/news/Ktesios-Real-Estate-SOCIMI-S-A-24-02-2023-ndash-Ktesios-SOCIMI-ndash-QPQ-Offer-Update-43080657/?utm_medium=RSS&utm_content=20230224,Ktesios Real Estate SOCIMI S A : 24.02.2023 ‚Äì Ktesios SOCIMI ‚Äì QPQ Offer Update,(marketscreener.com)   KTESIOS SOCIMI   Madrid  24 February 2023   Pursuant to Article 17 of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse   Article 61004/2 of Euronext Rule Book I Harmonized Ru‚Ä¶,"KTESIOS SOCIMIMadrid  24 February 2023Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)  Article 61004/2 of Euronext Rule Book I Harmonized Rules and concordant provisions  on ongoing obligations of companies listed on Euronext  Ktesios Real Estate SOCIMI  S.A. (the ""Company"") hereby notifies the following:RELEVANT INFORMATIONWe are pleased to inform that  in connection with the ANNOUNCEMENT OF OFFER FOR THE SUBSCRIPTION OF OPTIONS ON THE SHARES OF QUID PRO QUO ALQUILER SEGURO SOCIMI S.A  published on 14 February 2023  the acceptance of such offer as of to date stands at 62.15%  above the threshold defined by the Company at 60%.We remain at your disposal for any clarification you may need Henry GallegoCEOKtesios Real Estate SOCIMI  S.A.Ktesios Real Estate SOCIMI S.A. CIF: A88346614 - C/ Sagasta 15  7¬∫ Izda.- 28004 - MadridRegistrada en el Registro Mercantil de Madrid al Tomo 38.976  Folio 30  Secci√≥n 1  Hoja M-692614Email: info@ktesios-socimi.es | Tel: +34 910 638 011 | www.ktesios-socimi.es",neutral,0.0,1.0,0.0,positive,0.59,0.39,0.01,True,English,"['Ktesios Real Estate SOCIMI S A', 'QPQ Offer Update', 'Ktesios SOCIMI', '24.', 'QUID PRO QUO ALQUILER SEGURO SOCIMI S.A', 'Ktesios Real Estate SOCIMI S.A.', 'Henry Gallego CEO', 'KTESIOS SOCIMI', 'Euronext Rule Book', 'Market Abuse Regulation', 'European Parliament', 'concordant provisions', 'ongoing obligations', 'RELEVANT INFORMATION', 'C/ Sagasta', 'Registro Mercantil', 'Secci√≥n', 'Madrid', '24 February', 'Article', 'No.', 'Council', '16 April', 'Rules', 'companies', 'Company', 'connection', 'ANNOUNCEMENT', 'OFFER', 'SUBSCRIPTION', 'OPTIONS', 'SHARES', '14 February', 'acceptance', 'date', 'threshold', 'disposal', 'clarification', 'CIF', '7¬∫ Izda.', 'Tomo', 'Folio', 'Hoja', 'Email', 'ktesios-socimi', 'Tel', '34']",2023-02-24,2023-02-25,marketscreener.com
19240,EuroNext,NewsApi.org,https://finance.yahoo.com/news/press-release-phase-3-data-153100416.html,Press release: New Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease,New Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ (avalglucosidase alfa) as potential new standard of care for all people living with late-...,Sanofi - Aventis GroupeNew Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe diseaseParis  February 24  2023. Today  at WORLDSymposiumTM  data from the Phase 3 COMET study long-term extension showed sustained treatment effect of Nexviazyme¬Æ (avalglucosidase alfa) over nearly three years in late-onset Pompe disease (LOPD) patients who were treatment-na√Øve as well as those who switched from long-time standard of care  alglucosidase alfa  during the 96-week extension period. Additionally  a separate analysis of respiratory function showed clinical benefit over two years for patients who switched to Nexviazyme regardless of prior response to alglucosidase alfa.Priya S. Kishnani  MDC.L. and Su Chen Professor of Pediatrics; Medical Director  YT and Alice Chen Pediatrics Genetics and Genomics Center; and Division Chief  Medical Genetics  Duke University Medical Center‚ÄúThe results presented at the 2023 WORLDSymposium continue to build on the data from the clinical trials on the value and long-term impact Nexviazyme may provide for a wide variety of people living with late-onset Pompe disease  from newly diagnosed patients to those who have been previously treated with alglucosidase alfa. Further  when examining patients treated with Nexviazyme who switched from using alglucosidase alfa  these data show clinical benefit both for patients who were stable on alglucosidase alfa and those who experienced sub-optimal response or decline.‚ÄùBill SiboldGlobal Head of Specialty Care  Sanofi‚ÄúThese long-term data over nearly three years add to the robust body of evidence that consistently shows the clinical benefit and durability of effect of treatment with Nexviazyme for both treatment-experienced and treatment-na√Øve people living with late-onset Pompe disease. We continue to learn from our 20 years of experience in Pompe disease and build on our findings in an effort to advance the standard of care.‚ÄùStory continuesNexviazyme is a monotherapy approved in the US and other markets for the treatment of LOPD. It is also approved for infantile-onset Pompe disease (IOPD) in certain markets outside of the US.Nexviazyme maintained treatment effect at 145 weeksThe Phase 3 COMET trial enrolled 100 previously untreated LOPD patients who were randomized to receive either Nexviazyme (20 mg/kg) or alglucosidase alfa (20 mg/kg) every two weeks for 49 weeks during the double-blind primary analysis period. During the open-label extension period  long-term efficacy and safety outcomes were assessed up to 145 weeks in patients who continued their treatment with Nexviazyme (n=51)  as well as those who switched to treatment with Nexviazyme from alglucosidase alfa (n=44) at the conclusion of the primary analysis period (Week 49).After nearly three years (145 weeks)  changes from baseline (least squares mean [standard error]) showed:Patients who received continuous Nexviazyme treatment for 145 weeks experienced sustained improvements in respiratory and motor function  showing a 1.40 (1.21) point improvement in forced vital capacity (FVC) percent-predicted and an average increase of 20.65 (9.60) meters in walking distance as measured by the six-minute walk test (6MWT)  respectively  compared to baseline.Patients who switched from alglucosidase alfa to Nexviazyme treatment during the extension period experienced stabilization of treatment effect  showing a 1.18 (1.32) point improvement in FVC percent-predicted and an average increase of 0.29 (10.42) meters in walking distance (6MWT)  compared to baseline.The safety profile during treatment with Nexviazyme was comparable between both study groups (those who started Nexviazyme in the primary analysis period and those who switched to Nexviazyme during the extension period). No new safety signals were observed in patients who switched from alglucosidase alfa to Nexviazyme during the extension period. Across both Nexviazyme treatment groups  five patients discontinued treatment during the extension period due to six adverse events (AEs); four were treatment-related (ocular hyperemia  erythema  urticaria  respiratory distress)  and two were non-treatment-related (acute myocardial infarction  pancreatic adenocarcinoma).Clinical benefits seen over two years for patients who switched to NexviazymeSubgroup analyses were also performed to assess respiratory function outcomes for the 44 patients who switched to Nexviazyme in the long-term extension period of the Phase 3 COMET study. Patients were divided into two subgroups  responders (n=14) and non-responders (n=30) based on individual responses to initial treatment with alglucosidase alfa  as measured by the change in FVC percent-predicted (ŒîFVC %predicted/year) pre- (baseline-week 49) and post-switch (week 49-week 145). Findings showed clinical benefits over two years following switch to Nexviazyme regardless of prior response to alglucosidase alfa:Patients who responded to alglucosidase alfa treatment in the primary analysis period had increased respiratory function (ŒîFVC slope  4.67¬±1.28%/yr  p<0.001)  which was maintained throughout the extension period with Nexviazyme treatment (ŒîFVC slope  0.14¬±0.94%/yr  p=0.88).Patients who did not respond to alglucosidase alfa treatment in the primary analysis period had reduced respiratory function while taking alglucosidase alfa (ŒîFVC slope  -2.12¬±0.87%/yr  p=0.016); however  switching to Nexviazyme halted this decline in the extension period (ŒîFVC slope  0.15¬±0.61%/yr  p=0.81).About Pompe diseasePeople living with Pompe disease have low levels of the enzyme acid alpha-glucosidase (GAA)  which results in build-up of glycogen in muscle cells throughout the body  leading to irreversible damage to skeletal and cardiac muscles.Pompe disease can present as infantile-onset Pompe disease (IOPD)  the most severe form of the disease with rapid onset in infancy  or late-onset Pompe disease (LOPD)  which progressively damages muscles over time. If left untreated  IOPD can lead to heart failure and death within the first year of life  while people living with LOPD may require mechanical ventilation to help with breathing or a wheelchair to assist with mobility as the disease progresses.About Nexviazyme (avalglucosidase alfa)Nexviazyme (avalglucosidase alfa) is an enzyme replacement therapy (ERT) designed to target the mannose-6-phosphate (M6P) receptor  the key pathway for uptake and transport of ERT. Nexviazyme aims to help improve uptake and enhance glycogen clearance in target tissues with an average 15-fold higher level of M6P moieties as compared to alglucosidase alfa  the comparator therapy in the pivotal study. Nexviazyme is approved in multiple markets around the world for the treatment of people living with Pompe disease  including the United States  the European Union  Japan  Canada  Switzerland  Australia  Brazil  Argentina  Taiwan  the United Arab Emirates  South Korea and the United Kingdom  with specific indications varying by country. In Europe  the medicine is marketed under the brand name Nexviadyme.About SanofiWe are an innovative global healthcare company  driven by one purpose: we chase the miracles of science to improve people‚Äôs lives. Our team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comKate Conway | + 1 508 364 4931 | kate.conway@sanofi.comInvestor RelationsEva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.comArnaud Del√©pine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comCorentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comTarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comSanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995  as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions  statements regarding plans  objectives  intentions  and expectations with respect to future financial results  events  operations  services  product development and potential  and statements regarding future performance. Forward-looking statements are generally identified by the words ‚Äúexpects‚Äù  ‚Äúanticipates‚Äù  ‚Äúbelieves‚Äù  ‚Äúintends‚Äù  ‚Äúestimates‚Äù  ‚Äúplans‚Äù and similar expressions. Although Sanofi‚Äôs management believes that the expectations reflected in such forward-looking statements are reasonable  investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties  many of which are difficult to predict and generally beyond the control of Sanofi  that could cause actual results and developments to differ materially from those expressed in  or implied or projected by  the forward-looking information and statements. These risks and uncertainties include among other things  the uncertainties inherent in research and development  future clinical data and analysis  including post marketing  decisions by regulatory authorities  such as the FDA or the EMA  regarding whether and when to approve any drug  device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates  the fact that product candidates if approved may not be commercially successful  the future approval and commercial success of therapeutic alternatives  Sanofi‚Äôs ability to benefit from external growth opportunities  to complete related transactions and/or obtain regulatory clearances  risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation  trends in exchange rates and prevailing interest rates  volatile economic and market conditions  cost containment initiatives and subsequent changes thereto  and the impact that COVID-19 will have on us  our customers  suppliers  vendors  and other business partners  and the financial condition of any one of them  as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly  and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi  including those listed under ‚ÄúRisk Factors‚Äù and ‚ÄúCautionary Statement Regarding Forward-Looking Statements‚Äù in Sanofi‚Äôs annual report on Form 20-F for the year ended December 31  2022. Other than as required by applicable law  Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.Attachment,neutral,0.0,0.96,0.04,mixed,0.25,0.07,0.68,True,English,"['New Phase 3 data', 'potential new standard', 'late-onset Pompe disease', 'Press release', 'avalglucosidase alfa', 'WORLDSymposium‚Ñ¢', 'Nexviazyme¬Æ', 'care', 'people', 'Duke University Medical Center', 'Alice Chen Pediatrics Genetics', 'double-blind primary analysis period', '100 previously untreated LOPD patients', 'Su Chen Professor', 'Priya S. Kishnani', 'Phase 3 COMET trial', 'six-minute walk test', 'six adverse events', 'acute myocardial infarction', 'late-onset Pompe disease', 'infantile-onset Pompe disease', 'Phase 3 COMET study', 'new safety signals', '96-week extension period', 'open-label extension period', 'potential new standard', 'treatment-na√Øve people', 'New Phase 3 data', 'up to 145 weeks', 'long-term extension period', 'respiratory function outcomes', 'sustained treatment effect', 'continuous Nexviazyme treatment', 'alglucosidase alfa treatment', 'Medical Genetics', 'Nexviazyme treatment groups', 'study groups', 'Genomics Center', 'safety outcomes', 'separate analysis', 'Medical Director', 'sustained improvements', 'motor function', 'safety profile', 'long-term impact', 'long-term efficacy', 'avalglucosidase alfa', 'Aventis Groupe', 'long-time standard', 'clinical benefit', 'prior response', 'C.L.', 'Division Chief', 'clinical trials', 'wide variety', 'sub-optimal response', 'Bill Sibold', 'Global Head', 'robust body', 'least squares', 'standard error', '1.40 (1.21) point improvement', 'vital capacity', 'average increase', 'walking distance', '1.18 (1.32) point improvement', 'ocular hyperemia', 'respiratory distress', 'Subgroup analyses', 'two subgroups', 'individual responses', 'three years', 'two years', 'long-term data', 'initial treatment', 'other markets', 'five patients', 'Specialty Care', 'FVC percent', '20 years', '49 weeks', '44 patients', 'Nexviazyme¬Æ', 'Nexviazyme (20', 'Sanofi', 'WORLDSymposium‚Ñ¢', 'Paris', 'February', 'WORLDSymposiumTM', 'MD', 'YT', 'results', '2023 WORLDSymposium', 'value', 'decline', 'evidence', 'durability', 'treatment-experienced', 'findings', 'effort', 'Story', 'monotherapy', 'IOPD', 'conclusion', 'changes', 'baseline', '20.65 (9.60) meters', 'stabilization', '0.29 (10.42) meters', 'AEs', 'urticaria', 'pancreatic', 'responders', 'switch']",2023-02-24,2023-02-25,finance.yahoo.com
19241,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/GAZTRANSPORT-TECHNIGAZ-15821825/news/GTT-2023-financial-agenda-43082494/?utm_medium=RSS&utm_content=20230224,GTT: 2023 financial agenda,(marketscreener.com) 2023 financial agenda Paris ‚Äì February 24  2023. GTT  the technological expert in membrane containment systems used to transport and store liquefied gases  announces that the publication of the 2023 third-quarter activity update  original‚Ä¶,2023 financial agendaParis ‚Äì February 24  2023. GTT  the technological expert in membrane containment systems used to transport and store liquefied gases  announces that the publication of the 2023 third-quarter activity update  originally planned on 23 October 2023  has been rescheduled to 25 October 2023. In addition  the ex-dividend date and payment date of the dividend balance have been set on 12 June 2023 and 14 June 2023 respectively (instead of 10 June 2023 and 12 June 2023 as announced in the annual results press release).The financial agenda for the 2023 financial year is therefore as follows:2023 first-quarter activity update: April 20  2023 (after close of trading)Shareholders‚Äô Meeting: June 7  2023Ex-dividend date of the dividend balance for financial year 2022: June 12  2023Payment of the dividend balance for financial year 2022: June 14  2023Publication of 2023 half-year results: July 27  2023 (after close of trading)2023 third-quarter activity update: October 25  2023 (after close of trading)About GTTGTT is a technological expert in containment systems with cryogenic membranes used to transport and store liquefied gases. For over 50 years  GTT has been designing and providing cutting-edge technologies for a better energy performance  which combine operational efficiency and safety  to equip LNG carriers  floating terminals  land storage  and multi-gas carriers. GTT also develops systems dedicated to the use of LNG as fuel  as well as a full range of services  including digital services in the field of Smart Shipping. The Group is also active in hydrogen through its subsidiary Elogen  which designs and assembles electrolysers notably for the production of green hydrogen.GTT is listed on Euronext Paris  Compartment A (ISIN FR0011726835 Euronext Paris: GTT) and is notably included in SBF 120  Stoxx Europe 600 and MSCI Small Cap indicesInvestor relations contact:information-financiere@gtt.fr / +33 1 30 23 20 87Media contact:press@gtt.fr / +33 1 30 23 48 45For more information  visit www.gtt.fr.Attachment,neutral,0.01,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['2023 financial agenda', 'GTT', 'MSCI Small Cap indices', 'annual results press release', '2023 third-quarter activity update', '2023 first-quarter activity update', 'Investor relations contact', 'membrane containment systems', '2023 half-year results', 'Media contact', '2023 financial agenda', 'technological expert', 'ex-dividend date', '2023 financial year', 'Shareholders‚Äô Meeting', 'cryogenic membranes', 'cutting-edge technologies', 'energy performance', 'operational efficiency', 'floating terminals', 'land storage', 'multi-gas carriers', 'full range', 'Smart Shipping', 'The Group', 'Compartment A', 'Stoxx Europe', 'Euronext Paris', 'payment date', 'LNG carriers', 'digital services', 'green hydrogen', 'dividend balance', 'liquefied gases', 'February', 'GTT', 'publication', '23 October', '25 October', 'addition', '12 June', '14 June', '10 June', 'April', 'close', 'trading', 'July', '50 years', 'safety', 'use', 'fuel', 'field', 'subsidiary', 'Elogen', 'electrolysers', 'production', 'SBF', 'financiere', 'information', 'fr', 'Attachment', '30']",2023-02-24,2023-02-25,marketscreener.com
19242,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2615481/0/en/GTT-2023-financial-agenda.html,GTT: 2023 financial agenda,2023 financial agenda  Paris ‚Äì February 24  2023. GTT  the technological expert in membrane containment systems used to transport and store liquefied......,English French2023 financial agendaParis ‚Äì February 24  2023. GTT  the technological expert in membrane containment systems used to transport and store liquefied gases  announces that the publication of the 2023 third-quarter activity update  originally planned on 23 October 2023  has been rescheduled to 25 October 2023. In addition  the ex-dividend date and payment date of the dividend balance have been set on 12 June 2023 and 14 June 2023 respectively (instead of 10 June 2023 and 12 June 2023 as announced in the annual results press release).The financial agenda for the 2023 financial year is therefore as follows:2023 first-quarter activity update: April 20  2023 (after close of trading)Shareholders‚Äô Meeting: June 7  2023Ex-dividend date of the dividend balance for financial year 2022: June 12  2023Payment of the dividend balance for financial year 2022: June 14  2023Publication of 2023 half-year results: July 27  2023 (after close of trading)2023 third-quarter activity update: October 25  2023 (after close of trading)About GTTGTT is a technological expert in containment systems with cryogenic membranes used to transport and store liquefied gases. For over 50 years  GTT has been designing and providing cutting-edge technologies for a better energy performance  which combine operational efficiency and safety  to equip LNG carriers  floating terminals  land storage  and multi-gas carriers. GTT also develops systems dedicated to the use of LNG as fuel  as well as a full range of services  including digital services in the field of Smart Shipping. The Group is also active in hydrogen through its subsidiary Elogen  which designs and assembles electrolysers notably for the production of green hydrogen.GTT is listed on Euronext Paris  Compartment A (ISIN FR0011726835 Euronext Paris: GTT) and is notably included in SBF 120  Stoxx Europe 600 and MSCI Small Cap indicesInvestor relations contact:information-financiere@gtt.fr / +33 1 30 23 20 87Media contact:press@gtt.fr / +33 1 30 23 48 45For more information  visit www.gtt.fr.Attachment,neutral,0.01,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['2023 financial agenda', 'GTT', 'MSCI Small Cap indices', 'annual results press release', '2023 third-quarter activity update', '2023 first-quarter activity update', 'Investor relations contact', 'membrane containment systems', '2023 half-year results', 'Media contact', 'English French', '2023 financial agenda', 'technological expert', 'liquefied gases', 'ex-dividend date', '2023 financial year', 'Shareholders‚Äô Meeting', 'cryogenic membranes', 'cutting-edge technologies', 'energy performance', 'operational efficiency', 'floating terminals', 'land storage', 'multi-gas carriers', 'full range', 'Smart Shipping', 'The Group', 'subsidiary Elogen', 'Compartment A', 'Stoxx Europe', 'Euronext Paris', 'payment date', 'LNG carriers', 'digital services', 'green hydrogen', 'dividend balance', 'February', 'GTT', 'publication', '23 October', '25 October', 'addition', '12 June', '14 June', '10 June', 'April', 'close', 'trading', 'July', '50 years', 'safety', 'use', 'fuel', 'field', 'electrolysers', 'production', 'SBF', 'financiere', 'information', 'Attachment', '1 30']",2023-02-24,2023-02-25,globenewswire.com
19243,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/UCB-5963/news/UCB-Share-Repurchase-Program-2023-to-cover-UCB-s-Long-Term-Incentive-Plans-for-employees-43082742/?utm_medium=RSS&utm_content=20230224,UCB : Share Repurchase Program 2023 to cover UCB's Long Term Incentive Plans for employees,(marketscreener.com)  Share Repurchase Program 2023 to cover UCB's Long Term Incentive Plans for employees   Brussels   24 February 2023 - 20:00 - Regulated information  In application of article 7:215 of the Belgian Code of Companies and Associations  ‚Ä¶,"Brussels (Belgium)  24 February 2023 - 20:00 (CET) - Regulated informationIn application of article 7:215 of the Belgian Code of Companies and Associations  UCB SA/NV (""UCB"" or the ""Company"") (Euronext Brussels: UCB) announces the launch of a share buy-back program (the ""Share Repurchase Program 2023"")  effective as of 27 February 2023.The repurchase of UCB shares under this program intends to cover current and future obligations under UCB's Long Term Incentive Plans for its employees. UCB will continuously monitor both its current and future obligations under such plans in view of keeping an adequate level of treasury shares.Under this program  UCB may acquire from time to time its common stock  for a maximum of 500 000 UCB shares. The share repurchases will be conducted under the terms and conditions approved by the extraordinary general shareholders' meeting of the Company held on 28 April 2022. The timing of the repurchase of shares pursuant to the program will depend on a variety of factors  including market conditions. The Share Repurchase Program may be suspended or discontinued at any time.UCB has requested a financial intermediary to repurchase UCB shares on its behalf under the terms of a mandate agreement with initial validity until the earlier of 28 April 2023 or the mandate having been completed.During the Share Repurchase Program 2023  regular updates will be published in accordance with applicable legislation.In the framework of UCB's ongoing cash and treasury shares management  UCB may decide to enter into equity swap transactions  including during the term of this Share Repurchase Program 2023. Any such transaction will be reported in accordance with applicable legislation.This press release is available on UCB SA/NV's website via the followinglink.For further information  contact UCB:Investor RelationsAntje WitteT +32 2 559 94 14antje.witte@ucb.comCorporate CommunicationsLaurent SchotsT+32 2 559 92 64laurent.schots@ucb.comAbout UCBUCB  Brussels  Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 700 people in 36 countries  the company generated revenue of ‚Ç¨ 5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news",neutral,0.0,1.0,0.0,neutral,0.01,0.99,0.0,True,English,"['Long Term Incentive Plans', 'Share Repurchase Program', 'UCB', 'employees', ""extraordinary general shareholders' meeting"", 'Long Term Incentive Plans', 'The Share Repurchase Program', 'equity swap transactions', 'central nervous system', 'share buy-back program', 'treasury shares management', 'global biopharmaceutical company', 'share repurchases', 'immune system', 'Belgian Code', 'future obligations', 'adequate level', 'common stock', 'financial intermediary', 'initial validity', 'regular updates', 'applicable legislation', 'ongoing cash', 'press release', 'Investor Relations', 'Antje Witte', 'Corporate Communications', 'innovative medicines', 'severe diseases', 'Regulated information', 'Euronext Brussels', 'market conditions', 'mandate agreement', 'Laurent Schots', 'UCB SA/NV', 'UCB shares', 'Belgium', '24 February', 'CET', 'application', 'article', 'Companies', 'Associations', 'launch', '27 February', 'current', 'employees', 'view', 'time', 'maximum', 'terms', '28 April', 'timing', 'variety', 'factors', 'behalf', 'accordance', 'framework', 'website', 'followinglink', 'discovery', 'development', 'solutions', 'lives', 'people', '36 countries', 'revenue', 'symbol', 'Twitter', 'UCB_news', '32']",2023-02-24,2023-02-25,marketscreener.com
19244,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2614988/0/en/Bekaert-Update-on-the-Liquidity-Agreement.html,Bekaert - Update on the Liquidity Agreement,Update on the Liquidity Agreement    Period from 16¬†February 2023 to 22¬†February 2023      Liquidity agreement    In relation to the renewed......,English Dutch FrenchUpdate on the Liquidity AgreementPeriod from 16 February 2023 to 22 February 2023Liquidity agreementIn relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 2 September 2022   Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 9 600 shares during the period from 16 February 2023 to 22 February 2023 on Euronext Brussels. During the same period  Kepler Cheuvreux on behalf of Bekaert has sold 6 872 shares on Euronext Brussels.The tables below provide an overview of the transactions under the liquidity agreement during the period from16 February 2023 to 22 February 2023:Purchase of shares Date Number of Shares Average Price (‚Ç¨) Highest Price (‚Ç¨) Lowest Price (‚Ç¨) Total Amount (‚Ç¨) 16 February 2023 0 0.00 0.00 0.00 0 17 February 2023 400 40.10 40.10 40.10 16 040 20 February 2023 400 40.40 40.40 40.40 16 160 21 February 2023 4 000 40.71 40.84 40.50 162 840 22 February 2023 4 800 40.21 40.40 39.98 193 008 Total 9 600 388 048Sale of shares Date Number of Shares Average Price (‚Ç¨) Highest Price (‚Ç¨) Lowest Price (‚Ç¨) Total Amount (‚Ç¨) 16 February 2023 1 600 40.58 40.60 40.50 64 928 17 February 2023 400 40.60 40.60 40.60 16 240 20 February 2023 1 111 40.59 40.70 40.50 45 095 21 February 2023 3 361 40.88 41.00 40.70 137 398 22 February 2023 400 40.26 40.26 40.26 16 104 Total 6 872 279 765The balance held by Bekaert under the liquidity agreement at the end of the period is 40 364 shares.On 22 February 2023 after closing of the market  Bekaert holds 4 753 017 own shares  or 8.05% of the total number of the outstanding shares.This information is also made available on the investor relations pages of our website.Attachment,neutral,0.03,0.96,0.0,positive,0.5,0.49,0.01,True,English,"['Liquidity Agreement', 'Bekaert', 'Update', 'English Dutch French', 'investor relations pages', 'Shares Average Price', 'Liquidity Agreement Period', 'Highest Price', 'Lowest Price', 'Kepler Cheuvreux', 'Euronext Brussels', 'Date Number', 'Total Amount', 'total number', 'same period', 'outstanding shares', '9 600 shares', '6 872 shares', '40 364 shares', 'Update', '16 February', '22 February', '2 September', 'Bekaert', 'behalf', 'tables', 'overview', 'transactions', 'Purchase', '17 February', 'Sale', 'balance', 'end', 'closing', 'market', 'information', 'website', 'Attachment', '4 753 017']",2023-02-24,2023-02-25,globenewswire.com
19245,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BEKAERT-NV-5971/news/Bekaert-Update-on-the-Liquidity-Agreement-43074282/?utm_medium=RSS&utm_content=20230224,Bekaert - Update on the Liquidity Agreement,(marketscreener.com) ¬† ¬† ¬† ¬† Update on the Liquidity Agreement Period from 16¬†February 2023 to 22¬†February 2023 Liquidity agreement In relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 2 September 2022  Bekaert announces today tha‚Ä¶,Update on the Liquidity AgreementPeriod from 16 February 2023 to 22 February 2023Liquidity agreementIn relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 2 September 2022   Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 9 600 shares during the period from 16 February 2023 to 22 February 2023 on Euronext Brussels. During the same period  Kepler Cheuvreux on behalf of Bekaert has sold 6 872 shares on Euronext Brussels.The tables below provide an overview of the transactions under the liquidity agreement during the period from16 February 2023 to 22 February 2023:Purchase of shares Date Number of Shares Average Price (‚Ç¨) Highest Price (‚Ç¨) Lowest Price (‚Ç¨) Total Amount (‚Ç¨) 16 February 2023 0 0.00 0.00 0.00 0 17 February 2023 400 40.10 40.10 40.10 16 040 20 February 2023 400 40.40 40.40 40.40 16 160 21 February 2023 4 000 40.71 40.84 40.50 162 840 22 February 2023 4 800 40.21 40.40 39.98 193 008 Total 9 600 388 048Sale of shares Date Number of Shares Average Price (‚Ç¨) Highest Price (‚Ç¨) Lowest Price (‚Ç¨) Total Amount (‚Ç¨) 16 February 2023 1 600 40.58 40.60 40.50 64 928 17 February 2023 400 40.60 40.60 40.60 16 240 20 February 2023 1 111 40.59 40.70 40.50 45 095 21 February 2023 3 361 40.88 41.00 40.70 137 398 22 February 2023 400 40.26 40.26 40.26 16 104 Total 6 872 279 765The balance held by Bekaert under the liquidity agreement at the end of the period is 40 364 shares.On 22 February 2023 after closing of the market  Bekaert holds 4 753 017 own shares  or 8.05% of the total number of the outstanding shares.This information is also made available on the investor relations pages of our website.Attachment,neutral,0.03,0.96,0.0,neutral,0.01,0.99,0.0,True,English,"['Liquidity Agreement', 'Bekaert', 'Update', 'investor relations pages', 'Shares Average Price', 'Liquidity Agreement Period', 'Highest Price', 'Lowest Price', 'Kepler Cheuvreux', 'Euronext Brussels', 'Date Number', 'Total Amount', 'total number', 'same period', 'outstanding shares', '9 600 shares', '6 872 shares', '40 364 shares', 'Update', '16 February', '22 February', '2 September', 'Bekaert', 'behalf', 'tables', 'overview', 'transactions', 'Purchase', '17 February', '21 February', 'Sale', 'balance', 'end', 'closing', 'market', 'information', 'website', 'Attachment', '4 753 017']",2023-02-24,2023-02-25,marketscreener.com
19246,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/OXURION-NV-29715/news/Oxurion-Receives-Transparency-Notifications-from-Negma-Group-43082506/?utm_medium=RSS&utm_content=20230224,Oxurion Receives Transparency Notifications from Negma Group,(marketscreener.com) Oxurion Receives Transparency Notifications from Negma Group Leuven  BELGIUM  Boston  MA  US ‚Äì February 24  2022 ‚Äì 7.00 PM CET Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with c‚Ä¶,"Oxurion Receives Transparency Notifications from Negma GroupLeuven  BELGIUM  Boston  MA  US ‚Äì February 24  2022 ‚Äì 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with clinical stage assets in vascular retinal disorders  today announced that  pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:Oxurion received a transparency notification on February 21  2023 from Negma Group Ltd. indicating that as of February 16  2023  it held no shares of the then outstanding 564 210 937 shares  and therefore crossed below the threshold (3%) by virtue of disposal of voting securities. See Annex 1Oxurion received a transparency notification on February 21  2023 from Negma Group Ltd. indicating that as of February 15  2023  it held 35 314 661 shares of the then outstanding 564 210 937 shares  and therefore crossed above the threshold (5%) by virtue of acquisition of voting securities. See Annex 2About OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered ‚Äúforward-looking‚Äù. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company‚Äôs Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10"" tom.graney@oxurion.comMichael DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.comU SConway CommunicationsMary T. Conwaymtconway@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com________1. Article 14  first paragraph  of the Law of 2 May 2007 on disclosure of major holdings.ANNEX 1ANNEX 2Attachments",neutral,0.01,0.99,0.0,mixed,0.28,0.21,0.52,True,English,"['Transparency Notifications', 'Negma Group', 'Oxurion', 'applicable U.S. state securities laws', 'Tom Graney Chief Executive Officer', 'potent plasma kallikrein inhibitor', 'U.S. Securities Act', 'Chief Business Officer', 'next generation standard', 'Negma Group Ltd.', 'diabetic macular edema', 'potential new standard', 'Mary T. Conway', 'Belgian Transparency legislation1', 'Negma Group Leuven', 'clinical stage assets', 'U S', 'vascular retinal disorders', 'Such forward-looking statements', 'CET Oxurion NV', 'care ophthalmic therapies', 'voting securities', 'Conway Communications', 'new information', 'Transparency Notifications', 'Euronext Brussels', 'leading cause', 'working-age people', 'other conditions', 'important role', 'successful development', 'novel therapeutic', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'press release', 'current expectations', 'future events', 'other reason', 'other factors', 'actual results', 'Annual Report', 'United States', 'first paragraph', 'major holdings', 'More information', 'Important information', 'Additional information', 'biopharmaceutical company', 'The Company', 'outstanding 564,210,937 shares', 'vision loss', 'various risks', 'ICR Westwicke', 'Christopher Brinzey', 'ANNEX 2 Attachments', 'Michael Dillen', 'DME patients', '35,314,661 shares', 'Annex 1', 'BELGIUM', 'Boston', 'February', 'threshold', 'virtue', 'disposal', 'acquisition', 'treatment', 'THR-149', 'uncertainties', 'assurance', 'obligation', 'offer', 'invitation', 'sale', 'purchase', 'jurisdiction', 'registration', 'compliance', 'exemption', 'accordance', 'Tel', 'Article', '2 May', 'disclosure', '7.00', '32']",2023-02-24,2023-02-25,marketscreener.com
19247,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BONYF-135043902/news/24-February-2023-Trading-Suspension-43082392/?utm_medium=RSS&utm_content=20230224,24 February 2023: Trading Suspension,(marketscreener.com)   PRESS RELEASE   Paris  24 February 2023  6:00 p.m.   Trading Suspension   Ghent   24 February 2023  6:00 p.m.; bonyf NV   the next-   generation oral comfort expert  announces the suspension of the listing of its shares at‚Ä¶,PRESS RELEASEParis  24 February 2023  6:00 p.m.Trading SuspensionGhent (Belgium)  24 February 2023  6:00 p.m.; bonyf NV (Mnemonic: MLBON)  the next-generation oral comfort expert  announces the suspension of the listing of its shares at the request of the company.bonyf is currently pursuing discussions with potential strategic partners and investors with the objective to strengthen the company's financial position and extend its cash runway beyond its current term (March 2023).The company requested Euronext Access in Paris to suspend trading of its shares at the commencement of trading today and it remains suspended pending further announcement. bonyf will inform the market of progress made in the evolution of its financial status.bonyf's strengthsProducts with patented formulationsProduced in Switzerland compliant with stringent international quality regulationsProven clinical efficacyCommercial presence in 37 countriesProspects for solid growth and rapid profitabilityA fast-growing oral and dental care marketPage 1Page 1,neutral,0.0,1.0,0.0,mixed,0.49,0.25,0.26,True,English,"['Trading Suspension', '24 February', 'next- generation oral comfort expert', 'stringent international quality regulations', 'potential strategic partners', 'Proven clinical efficacy', 'dental care market', 'growing oral', 'PRESS RELEASE', 'financial position', 'cash runway', 'current term', 'Euronext Access', 'financial status', 'patented formulations', 'Commercial presence', 'solid growth', 'rapid profitability', 'bonyf NV', 'Trading Suspension', 'Paris', '24 February', 'Ghent', 'Belgium', 'Mnemonic', 'MLBON', 'listing', 'shares', 'request', 'company', 'discussions', 'investors', 'objective', 'March', 'commencement', 'announcement', 'progress', 'evolution', 'strengths', 'Products', 'Switzerland', '37 countries', 'Prospects', 'Page', '6:00']",2023-02-24,2023-02-25,marketscreener.com
19248,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BIOCARTIS-GROUP-NV-22033639/news/Press-release-Biocartis-Group-NV-Biocartis-Creates-New-Share-Option-Plan-and-Cancels-Outstanding-Po-43073810/?utm_medium=RSS&utm_content=20230224,Press release Biocartis Group NV: Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option Plans,(marketscreener.com) PRESS RELEASE - REGULATED INFORMATION 24 February 2023  07:00 CET Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option Plans Mechelen  Belgium  24 February 2023 ‚Äì Biocartis Group NV   an innovat‚Ä¶,PRESS RELEASE - REGULATED INFORMATION24 February 2023  07:00 CETBiocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option PlansMechelen  Belgium  24 February 2023 ‚Äì Biocartis Group NV (the ‚ÄòCompany‚Äô or ‚ÄòBiocartis‚Äô)  an innovative molecular diagnostics company (Euronext Brussels: BCART)  today announces that its board of directors created  within the framework of the authorized capital  8.3 million share options (each share option having the form of a subscription right) under a new share option plan  called the ‚ÄòShare Option Plan 2023‚Äô  in order to enable the Company to offer the share options to current and future personnel members and members of the executive management of the Company and/or its subsidiaries.The purpose of the Share Option Plan 2023 is to create a plan of subscription rights for shares of the Company which will allow the Company to attract  encourage  motivate and retain personnel and executives  and to align their interests with the interests of the Company and its shareholders by giving them the opportunity to share in the potential increase in the value of the Company. At the same time  the Company will cancel 435.270 share options which have not yet been offered to  and accepted by  the beneficiaries under the existing share option plans of the Company.The share options under the Share Option Plan 2023 have a term of ten years (unless contractually reduced in the offer to a beneficiary)  are generally not transferable and can in principle not be exercised prior to the first day of the fourth calendar year following the calendar year in which the offer of share options is made to a beneficiary. The share options of the members of the executive management will vest on the third anniversary of the date of offer  while the share options of the personnel members will in principle vest gradually over a period over approximately four years unless decided otherwise. Each share option gives the right to subscribe to one new ordinary Biocartis share. Should the share options be exercised  Biocartis will apply for the admission to trading of the resulting new shares on Euronext Brussels. The share option as such will not be listed on any stock market.The reports prepared by the board of directors and the Company‚Äôs statutory auditor (in accordance with Article 7:198 juncto Articles 7:180 and 7:191 of the Belgian Companies and Associations Code) in the framework of the creation of the Share Option Plan 2023 can be consulted on the website of the Company.--- END ---More information:e-mail: ir@biocartis.com@Biocartis_www.linkedin.com/BiocartisAbout BiocartisWith its revolutionary and proprietary Idylla‚Ñ¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idylla‚Ñ¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idylla‚Ñ¢'s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idylla‚Ñ¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idylla‚Ñ¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.0,1.0,0.0,negative,0.0,0.17,0.83,True,English,"['New Share Option Plan', 'Share Option Plans', 'Biocartis Group NV', 'Press release', 'Outstanding Pool', 'one new ordinary Biocartis share', 'faster, informed treatment decisions', 'key unmet clinical needs', 'U.S. Securities Act', 'existing share option plans', 'New Share Option Plan', 'innovative molecular diagnostics company', 'resulting new shares', 'Polymerase Chain Reaction', 'fastest growing segment', 'molecular diagnostics market', 'fourth calendar year', 'proprietary Idylla‚Ñ¢ platform', '8.3 million share options', 'accurate molecular information', 'molecular diagnostic tests', 'Biocartis Group NV', 'The Idylla‚Ñ¢ platform', 'individual Biocartis product', 'United States Securities', 'future personnel members', '435.270 share options', 'molecular testing', 'stock market', 'product labeling', 'future events', 'The Biocartis', 'PRESS RELEASE', 'REGULATED INFORMATION', 'Outstanding Pool', 'Euronext Brussels', 'authorized capital', 'executive management', 'subscription rights', 'potential increase', 'ten years', 'first day', 'third anniversary', 'four years', 'statutory auditor', 'Belgian Companies', 'Associations Code', 'More information', 'personalized medicine', 'real-time PCR', 'based system', 'minimum amount', 'expanding menu', 'liver cancer', 'other countries', 'Idylla‚Ñ¢ trademark', 'intended uses', 'Exchange Commission', 'financial condition', 'same time', 'universal access', 'Forward-looking statements', 'current expectations', 'Company directors', '24 February', '07:00 CET', 'Mechelen', 'Belgium', 'BCART', 'board', 'framework', 'order', 'subsidiaries', 'purpose', 'executives', 'interests', 'shareholders', 'opportunity', 'value', 'beneficiaries', 'term', 'offer', 'beneficiary', 'principle', 'date', 'period', 'trading', 'reports', 'accordance', 'Article', '198 juncto', 'creation', 'website', 'mail', 'revolutionary', 'patients', 'world', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'trademarks', 'Europe', 'logo', 'applicable', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibility', 'violation', 'invitation', 'sale', 'purchase', 'America', 'registration', 'exemption', 'beliefs', 'opinions', 'projections', 'results', 'operations', 'liquidity', 'performance', 'prospects', 'growth', 'strategies', 'industry', 'nature']",2023-02-24,2023-02-25,marketscreener.com
19249,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2614956/0/en/Press-release-Biocartis-Group-NV-Biocartis-Creates-New-Share-Option-Plan-and-Cancels-Outstanding-Pool-under-Existing-Share-Option-Plans.html,Press release Biocartis Group NV: Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option Plans,PRESS RELEASE - REGULATED INFORMATION  24 February 2023  07:00 CET  Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing......,English DutchPRESS RELEASE - REGULATED INFORMATION24 February 2023  07:00 CETBiocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option PlansMechelen  Belgium  24 February 2023 ‚Äì Biocartis Group NV (the ‚ÄòCompany‚Äô or ‚ÄòBiocartis‚Äô)  an innovative molecular diagnostics company (Euronext Brussels: BCART)  today announces that its board of directors created  within the framework of the authorized capital  8.3 million share options (each share option having the form of a subscription right) under a new share option plan  called the ‚ÄòShare Option Plan 2023‚Äô  in order to enable the Company to offer the share options to current and future personnel members and members of the executive management of the Company and/or its subsidiaries.The purpose of the Share Option Plan 2023 is to create a plan of subscription rights for shares of the Company which will allow the Company to attract  encourage  motivate and retain personnel and executives  and to align their interests with the interests of the Company and its shareholders by giving them the opportunity to share in the potential increase in the value of the Company. At the same time  the Company will cancel 435.270 share options which have not yet been offered to  and accepted by  the beneficiaries under the existing share option plans of the Company.The share options under the Share Option Plan 2023 have a term of ten years (unless contractually reduced in the offer to a beneficiary)  are generally not transferable and can in principle not be exercised prior to the first day of the fourth calendar year following the calendar year in which the offer of share options is made to a beneficiary. The share options of the members of the executive management will vest on the third anniversary of the date of offer  while the share options of the personnel members will in principle vest gradually over a period over approximately four years unless decided otherwise. Each share option gives the right to subscribe to one new ordinary Biocartis share. Should the share options be exercised  Biocartis will apply for the admission to trading of the resulting new shares on Euronext Brussels. The share option as such will not be listed on any stock market.The reports prepared by the board of directors and the Company‚Äôs statutory auditor (in accordance with Article 7:198 juncto Articles 7:180 and 7:191 of the Belgian Companies and Associations Code) in the framework of the creation of the Share Option Plan 2023 can be consulted on the website of the Company.--- END ---More information:e-mail: ir@biocartis.com@Biocartis_www.linkedin.com/BiocartisAbout BiocartisWith its revolutionary and proprietary Idylla‚Ñ¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idylla‚Ñ¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idylla‚Ñ¢'s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idylla‚Ñ¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idylla‚Ñ¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.0,1.0,0.0,mixed,0.2,0.11,0.69,True,English,"['New Share Option Plan', 'Share Option Plans', 'Biocartis Group NV', 'Press release', 'Outstanding Pool', 'one new ordinary Biocartis share', 'faster, informed treatment decisions', 'key unmet clinical needs', 'U.S. Securities Act', 'existing share option plans', 'New Share Option Plan', 'innovative molecular diagnostics company', 'resulting new shares', 'Polymerase Chain Reaction', 'fastest growing segment', 'molecular diagnostics market', 'fourth calendar year', 'proprietary Idylla‚Ñ¢ platform', '8.3 million share options', 'accurate molecular information', 'molecular diagnostic tests', 'Biocartis Group NV', 'The Idylla‚Ñ¢ platform', 'individual Biocartis product', 'United States Securities', 'future personnel members', '435.270 share options', 'molecular testing', 'stock market', 'product labeling', 'future events', 'The Biocartis', 'English Dutch', 'PRESS RELEASE', 'REGULATED INFORMATION', 'Outstanding Pool', 'Euronext Brussels', 'authorized capital', 'executive management', 'subscription rights', 'potential increase', 'ten years', 'first day', 'third anniversary', 'four years', 'statutory auditor', 'Belgian Companies', 'Associations Code', 'More information', 'personalized medicine', 'real-time PCR', 'based system', 'minimum amount', 'expanding menu', 'liver cancer', 'other countries', 'Idylla‚Ñ¢ trademark', 'Exchange Commission', 'financial condition', 'same time', 'universal access', 'Forward-looking statements', 'current expectations', '24 February', '07:00 CET', 'Mechelen', 'Belgium', 'BCART', 'board', 'directors', 'framework', 'order', 'subsidiaries', 'purpose', 'executives', 'interests', 'shareholders', 'opportunity', 'value', 'beneficiaries', 'term', 'offer', 'beneficiary', 'principle', 'date', 'period', 'trading', 'reports', 'accordance', 'Article', '198 juncto', 'creation', 'website', 'mail', 'revolutionary', 'patients', 'world', 'sample', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'trademarks', 'Europe', 'logo', 'applicable', 'uses', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibility', 'violation', 'invitation', 'sale', 'purchase', 'America', 'registration', 'exemption', 'beliefs', 'opinions', 'projections', 'results', 'operations', 'liquidity', 'performance', 'prospects', 'growth', 'strategies', 'industry', 'nature']",2023-02-24,2023-02-25,globenewswire.com
19250,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2615484/0/en/Information-on-the-Total-Number-of-Voting-Rights-Denominator-following-Conversion-Notice-from-NEGMA.html,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA   Negma Group Investment Ltd. has converted 80......,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMANegma Group Investment Ltd. has converted 80 convertible bonds in Oxurion resulting in a EUR 200 000 capital increase. This is part of Negma Group Investment Ltd.‚Äôs EUR 15 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven  BELGIUM  Boston  MA  US ‚Äì February 24  2023 ‚Äì 07.00 PM CET ‚Äì In accordance with article 15 of the Belgian Act of May 2  2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions  Oxurion NV (Euronext Brussels: OXUR) (the ‚ÄúCompany‚Äù or ‚ÄúOxurion‚Äù)  announces the below information  following the issuance of 20 491 803 new ordinary shares on February 20  2023  for a total amount of EUR 200 000  as the result of the conversion of 80 class B convertible bonds  pursuant to the Capital Commitment entered into with Negma Group Investment Ltd.Following completion of the capital increase through the conversion of the convertible bonds  the total number of shares issued by Oxurion amounts to 584 702 740  outstanding ordinary shares carrying voting rights (compared to 564 210 937 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.Therefore  Oxurion publishes the following updated information:Share capital (EUR) 77 706 161.32 Total number of securities with voting rights (all ordinary shares) 584 702 740 Total number of ordinary shares (= denominator) 584 702 740 Number of outstanding  granted rights to subscribe to securities carrying voting rights not yet issued: 694 000 subscription rights (‚ÄúSRs‚Äù) issued on November 20  2017  entitling their holders to subscribe to a total number of 694 000 securities carrying voting rights (all ordinary shares);60 000 SRs issued on December 23  2020  entitling their holders to subscribe to a total number of 60 000 securities carrying voting rights (all ordinary shares);976 874 SRs issued on April 14  2021  entitling their holders to subscribe to a total number of 976 874 securities carrying voting rights (all ordinary shares);534 688 SRs issued on September 22  2021  entitling their holders to subscribe to a total number of 534 688 securities carrying voting rights (all ordinary shares);582 248 SRs issued on December 30  2021  entitling their holders to subscribe to a total number of 582 248 securities carrying voting rights (all ordinary shares); and100 convertible bonds issued on December 20  2021  entitling their holders (Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company  Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.  on November 21  2021.ENDAbout OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered ‚Äúforward-looking‚Äù. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company‚Äôs Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMicha√´l DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com USConway CommunicationsMary T. Conwaymtconway@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com1 Press release Oxurion  06/04/2021  Press release Oxurion  02/09/2022 and Press release Oxurion  25/01/2023Attachments,neutral,0.0,1.0,0.0,mixed,0.25,0.12,0.62,True,English,"['Total Number', 'Voting Rights', 'Conversion Notice', 'Information', 'Denominator', 'NEGMA', 'potent plasma kallikrein inhibitor', 'Negma Group Investment Ltd.', 'EUR 15 million Capital Commitment1', '80 class B convertible bonds', 'Pontifax Medison Finance', 'next generation standard', 'diabetic macular edema', 'EUR 200,000 capital increase', 'Kreos Capital VI', 'potential new standard', 'potential market opportunities', 'care ophthalmic therapies', 'Such forward-looking statements', '20,491,803 new ordinary shares', 'outstanding ordinary shares', 'Israel) L.P.', '80 convertible bonds', '100 convertible bonds', 'Share capital', 'regulated market', 'new information', 'drug candidate', 'Belgian Act', 'major participations', 'miscellaneous provisions', 'Euronext Brussels', 'total amount', 'Loan Facility', 'retinal disorders', 'leading cause', 'working-age people', 'important role', 'successful development', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'press release', 'current expectations', 'future events', 'other reason', 'other factors', 'actual results', 'Annual Report', 'Voting Rights', '694,000 subscription rights', 'Total Number', 'updated information', 'More information', 'Important information', 'Additional information', 'vision loss', 'other conditions', 'novel therapeutic', 'various risks', 'biopharmaceutical company', 'The Company', 'Conversion Notice', 'Oxurion NV', 'DME patients', 'Denominator', 'back', 'eye', 'Leuven', 'BELGIUM', 'Boston', 'February', '07.00 PM', 'accordance', 'article', 'May', 'disclosure', 'issuers', 'issuance', 'completion', 'calculation', 'percentages', 'shareholdings', 'securities', 'SRs', 'November', 'holders', 'December', 'April', 'September', 'UK', 'Cayman', 'terms', 'Agreement', 'Limited', 'treatment', 'THR-149', 'uncertainties', 'assurance', 'obligation', 'business', 'offer', 'invitation', 'sale', 'purchase', 'assets', 'jurisdiction']",2023-02-24,2023-02-25,globenewswire.com
19251,EuroNext,NewsApi.org,https://www.marketscreener.com/news/latest/Corn-and-wheat-hit-multi-week-lows-on-U-S-export-concerns--43082357/?utm_medium=RSS&utm_content=20230224,Corn and wheat hit multi-week lows on U.S. export concerns,(marketscreener.com) Chicago Board of Trade cornfutures set a six-week low on Friday while wheat hit its lowestin more than four weeks on concern over competition for globalexport business  analysts said. Prospects for robust 2023 corn production in the U‚Ä¶,"*Grain markets pressured by Black Sea export deal hopes*Weak wheat futures help to drag down corn  traders say*Weekly U.S. export sales meet analyst estimatesCHICAGO  Feb 24 (Reuters) - Chicago Board of Trade corn futures set a six-week low on Friday while wheat hit its lowest in more than four weeks on concern over competition for global export business  analysts said.Prospects for robust 2023 corn production in the United States  along with broader economic worries  also hung over grain futures.On the first anniversary of Russia's invasion of major grains producer Ukraine  traders largely expect an extension of the Black Sea grain deal that was struck last year. The agreement facilitated the flow of Ukrainian crops such as wheat and corn to world buyers and increased competition for other suppliers.""The flow of cheap wheat out of the Black Sea region has been stiff competition for corn "" said Tomm Pfitzenmaier  analyst for Summit Commodity Brokerage in Iowa.The most active CBOT corn contract was down 7-1/4 cents at $6.52 a bushel by 11:15 a.m. CST (1715 GMT) after falling for a second day to its lowest price since Jan. 12.Wheat was down 22-1/2 cents at $7.28 a bushel  after touching its lowest since Jan. 24 at $7.25-1/2.Compared with the day before Russia's invasion last year  wheat futures are down about 18% and corn futures are down 4%.In Paris  Euronext wheat fell to a one-month low on Friday  pressured by export competition from Russia and expectations that the shipping corridor from Ukraine will continue.CBOT soybeans also eased  with the most active contract down 6 cents at $15.21-1/4 a bushel. Soybeans earlier touched their lowest since Feb. 15 at $15.17-1/2.The United States faces competition for soybean export sales from cheaper suppliers in Brazil  traders said.U.S. soybean export sales were 556 600 tonnes in the week ended Feb. 16  the U.S. Department of Agriculture said. Analysts had expected 300 000 to 1.15 million tonnes.Weekly U.S. export sales totaled 418 900 tonnes for wheat and 848 800 tonnes for corn  within estimates. (Reporting by Tom Polansek in Chicago Additional reporting by Gus Trompiz in Paris and Naveen Thukral in Singapore Editing by David Goodman)",negative,0.0,0.46,0.54,negative,0.03,0.2,0.77,True,English,"['U.S. export concerns', 'multi-week lows', 'Corn', 'wheat', 'Weekly U.S. export sales', 'U.S. soybean export sales', 'Black Sea export deal', 'Black Sea grain deal', 'U.S. Department', 'active CBOT corn contract', 'Black Sea region', 'global export business', 'broader economic worries', 'major grains producer', 'Summit Commodity Brokerage', 'robust 2023 corn production', 'The United States', '300,000 to 1.15 million tonnes', 'Trade corn futures', 'Weak wheat futures', 'active contract', 'export competition', 'grain futures', 'Grain markets', 'CBOT soybeans', 'four weeks', 'first anniversary', 'Ukrainian crops', 'world buyers', 'other suppliers', 'Tomm Pfitzenmaier', 'lowest price', 'shipping corridor', 'cheaper suppliers', 'Tom Polansek', 'Additional reporting', 'Gus Trompiz', 'Naveen Thukral', 'David Goodman', 'cheap wheat', 'Euronext wheat', 'second day', 'stiff competition', 'Chicago Board', 'analyst estimates', '556,600 tonnes', '900 tonnes', '848,800 tonnes', 'traders', 'Reuters', 'six', 'Friday', 'concern', 'analysts', 'Prospects', 'Russia', 'invasion', 'Ukraine', 'extension', 'agreement', 'flow', 'Iowa', 'bushel', 'Jan.', 'Paris', 'expectations', 'Feb.', 'Brazil', 'Agriculture', 'Singapore', '11:15']",2023-02-24,2023-02-25,marketscreener.com
19252,EuroNext,NewsApi.org,https://www.marketscreener.com/news/latest/Corn-and-wheat-hit-multi-week-lows-on-U-S-export-concerns--43083356/?utm_medium=RSS&utm_content=20230224,Corn and wheat hit multi-week lows on U.S. export concerns,(marketscreener.com) Chicago Board of Trade cornfutures set a six-week low on Friday while wheat hit its lowestlevel in more than four weeks on concern over competition forglobal export business  analysts said. Technical selling helped fuel the sell-off  ‚Ä¶,"*Hopes for Black Sea export deal pressure CBOT grains*Tumbling wheat futures help drag down corn*CBOT wheat  corn have dropped since Ukraine war beganCHICAGO  Feb 24 (Reuters) - Chicago Board of Trade corn futures set a six-week low on Friday while wheat hit its lowest level in more than four weeks on concern over competition for global export business  analysts said.Technical selling helped fuel the sell-off  along with prospects for robust 2023 corn production in the United States and broader economic worries.On the first anniversary of Russia's invasion of major grains producer Ukraine  traders largely expect an extension of the Black Sea grain deal that facilitated the flow of Ukrainian crops to world buyers. Struck last year  the agreement has increased competition for suppliers of wheat and corn.Russian President Vladimir Putin spoke to Turkish counterpart Tayyip Erdogan about the deal on Friday.""The flow of cheap wheat out of the Black Sea region has been stiff competition for corn "" said Tomm Pfitzenmaier  analyst for Summit Commodity Brokerage in Iowa.The most active CBOT corn contract closed 10 cents lower at $6.49-1/4 per bushel and hit its lowest price since Jan. 10. Wheat settled down 28-3/4-cents at $7.21-3/4 per bushel and hit its lowest price since Jan. 23.Compared with the day before Russia's invasion last year  wheat futures are down about 18% and corn futures are down about 5%.Ukrainian President Volodymyr Zelenskiy on Friday welcomed some elements of a Chinese proposal for a ceasefire but said only the country where a war is being fought should be the initiator of a peace plan.In Paris  Euronext wheat fell to a one-month low under pressure from export competition from Russia and expectations the shipping corridor from Ukraine will continue.CBOT soybeans also eased  with the most active contract down 8 cents at $15.19-1/4. The contract hit its lowest price since Feb. 15.The United States faces competition for soybean export sales from cheaper supplies in Brazil  while traders have largely dialed in crop losses in drought-hit Argentina  analysts said. (Reporting by Tom Polansek in Chicago Additional reporting by Gus Trompiz in Paris and Naveen Thukral in Singapore Editing by David Goodman and Matthew Lewis)",negative,0.0,0.46,0.54,mixed,0.13,0.2,0.67,True,English,"['U.S. export concerns', 'multi-week lows', 'Corn', 'wheat', 'Black Sea export deal pressure', 'Russian President Vladimir Putin', 'Turkish counterpart Tayyip Erdogan', 'Black Sea grain deal', 'Ukrainian President Volodymyr Zelenskiy', 'Black Sea region', 'active CBOT corn contract', 'global export business', 'soybean export sales', 'broader economic worries', 'Summit Commodity Brokerage', 'major grains producer', 'robust 2023 corn production', 'The United States', 'Trade corn futures', 'Tumbling wheat futures', 'active contract', 'CBOT grains', 'Ukrainian crops', 'export competition', 'CBOT soybeans', 'CBOT wheat', 'lowest level', 'four weeks', 'Technical selling', 'first anniversary', 'world buyers', 'Tomm Pfitzenmaier', 'lowest price', 'Chinese proposal', 'peace plan', 'one-month low', 'shipping corridor', 'cheaper supplies', 'crop losses', 'Tom Polansek', 'Additional reporting', 'Gus Trompiz', 'Naveen Thukral', 'David Goodman', 'Matthew Lewis', 'cheap wheat', 'Euronext wheat', 'stiff competition', 'Chicago Board', 'Ukraine war', 'Hopes', 'Reuters', 'six-week', 'Friday', 'concern', 'analysts', 'sell-off', 'prospects', 'invasion', 'traders', 'extension', 'flow', 'Struck', 'agreement', 'suppliers', 'Iowa', 'bushel', 'Jan.', 'elements', 'ceasefire', 'country', 'initiator', 'Paris', 'expectations', 'Feb.', 'Brazil', 'drought-hit', 'Argentina', 'Singapore']",2023-02-24,2023-02-25,marketscreener.com
19253,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/dsm---delivery-of-shares-301755713.html,DSM - delivery of shares,This is a press release by Koninklijke DSM N.V. (Royal DSM)  pursuant to the provisions of Sections 13 paragraphs 1 and 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree) in connection with the public offer by Danube A‚Ä¶,This is a press release by Koninklijke DSM N.V. (Royal DSM)  pursuant to the provisions of Sections 13 paragraphs 1 and 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree) in connection with the public offer by Danube AG (to be renamed DSM-Firmenich AG) for all the issued and outstanding ordinary shares in the capital of DSM (the Exchange Offer). This press release does not constitute an offer  or any solicitation of any offer  to buy or subscribe for any securities. This press release is not for general release  publication or distribution  in whole or in part  in or into  directly or indirectly  the United States or any other jurisdiction where such release  publication or distribution would violate applicable laws or regulations.HEERLEN  Netherlands  Feb. 24  2023 /PRNewswire/ -- Following the Offering Circular published on 22 November 2022  Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.Pursuant to commitments entered into prior to issuing the Offering Circular  DSM has on 24 February 2023  delivered 18 050 ordinary shares to employees in view of settling the exercise of an equivalent number of stock options granted under the respective DSM Incentive Plan (average exercise price ‚Ç¨51.94). On the date hereof  the total number of issued and outstanding DSM ordinary shares is 173 144 715. As a consequence of the delivery included herein  the number of outstanding DSM ordinary shares increased by 0.0104%.DSMRoyal DSM is a global  purpose-led company in Health  Nutrition & Bioscience  applying science to improve the health of people  animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic  environmental and societal value for all its stakeholders ‚Äì customers  employees  shareholders  and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.Or find us on:LinkedIn: http://www.linkedin.com/company/3108Twitter: http://www.twitter.com/DSMFacebook: http://www.facebook.com/DSMcompanyYouTube: http://www.youtube.com/user/dsmcompanyFor more informationDSM Media Relations Gareth Mead tel. +31 (0) 45 5782420 email media.contacts@dsm.com DSM Investor Relations Dave Huizing tel. +31 (0) 45 5782864 email investor.relations@dsm.comForward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations  estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release  unless required by law. The English language version of the press release is leading.Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpgSOURCE Royal DSM,neutral,0.02,0.98,0.0,mixed,0.26,0.09,0.65,True,English,"['DSM', 'delivery', 'shares', 'DSM Media Relations Gareth Mead', 'DSM Investor Relations Dave Huizing', 'Koninklijke DSM N.V.', 'respective DSM Incentive Plan', 'Dutch public offer rules', 'outstanding DSM ordinary shares', 'outstanding ordinary shares', 'Public Takeover Bids', 'English language version', 'future (financial) performance', 'average exercise price', 'global, purpose-led company', 'SOURCE Royal DSM', '18,050 ordinary shares', 'treasury shares', 'Dutch Decree', 'actual performance', 'Sections 13 paragraphs', 'biedingen Wft', 'Danube AG', 'Exchange Offer', 'United States', 'other jurisdiction', 'applicable laws', 'Offering Circular', 'share units', 'stock options', 'brighter lives', 'biggest challenges', 'economic, environmental', 'societal value', 'Euronext Amsterdam', 'current expectations', 'many factors', 'press release', 'general release', 'equivalent number', 'total number', 'Forward-looking statements', 'Such statements', 'More information', 'provisions', 'connection', 'capital', 'solicitation', 'securities', 'publication', 'distribution', 'part', 'regulations', 'HEERLEN', 'Netherlands', '22 November', 'transactions', 'accordance', 'delivery', 'employees', 'view', 'vesting', 'commitments', '24 February', 'date', 'consequence', 'Health', 'Nutrition', 'Bioscience', 'people', 'animals', 'planet', 'products', 'solutions', 'world', 'stakeholders', 'customers', 'shareholders', 'society', 'LinkedIn', 'Twitter', 'Facebook', 'DSMcompany', 'YouTube', 'position', 'estimates', 'projections', 'readers', 'risks', 'uncertainties', 'obligation', 'Logo', '0.0']",2023-02-24,2023-02-25,prnewswire.co.uk
19254,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2615419/0/en/ALTUVIIIO-approved-by-the-U-S-FDA-this-positive-event-triggers-impairment-reversal-positively-impacting-2022-IFRS-net-income-no-change-on-business-net-income-non-IFRS.html,ALTUVIIIO‚Ñ¢ approved by the U.S. FDA: this positive event triggers impairment reversal  positively impacting 2022 IFRS net income; no change on business net income (non-IFRS),FDA approves once-weekly ALTUVIIIO‚Ñ¢  a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive...,English FrenchFDA approves once-weekly ALTUVIIIO‚Ñ¢  a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal  impacting 2022 IFRS net income; no change on business net income (non-IFRS)Filing of the 2022 U.S. Form 20-F and French ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù containing the Annual Financial ReportParis  February 24  2023. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù containing its Annual Financial Report with the French market regulator Autorit√© des march√©s financiers (AMF).On February 22  2023  the US Food and Drug Administration (FDA) approved ALTUVIIIOTM. This confirms the significant increase of value of the asset. That decision  which occurred prior to the filing of the French Document d‚Äôenregistrement universel and of the Annual Report on Form 20-F  resulted in an adjustment to IFRS net income for the year ended December 31  2022 as presented in the Sanofi press release issued on February 3  2023. The adjustment consisted of the reversal of ‚Ç¨2 154 million of impairment losses against the intangible assets associated with the Eloctate franchise  in accordance with IAS 36 (Impairment of Assets); the assets had been partially written down in 2019. The adjustment is presented within the line item Impairment of intangible assets in the consolidated income statement; the net impact after tax is a gain of ‚Ç¨1 651 million. Cash flows are not impacted by the adjustment. Following the adjustment  for the year ended December 31  2022  IFRS net income amounts to ‚Ç¨8 371 million (versus ‚Ç¨6 720 million as per the press release of February 3  2023); earnings per share (IFRS EPS) amounts to ‚Ç¨6.69 (versus ‚Ç¨5.37 as per the press release of February 3  2023); and total equity amounts to ‚Ç¨75 152 million (versus ‚Ç¨73 512 million as per the press release of February 3  2023).Business net income (a non-IFRS financial measure) for the year ended December 31  2022 is unchanged  as is the amount of the dividend proposed by the Board of Directors held on February 2  2023.Updated IFRS figures for 2022 Financial Statements1Q4 2022 Change Changeat CER 2022 Change Changeat CER IFRS net sales reported ‚Ç¨10 725m +7.3% +2.6% ‚Ç¨42 997m +13.9% +7.0% IFRS net income reported ‚Ç¨3 111m +175.1% _ ‚Ç¨8 371m +34.5% ‚Äî IFRS EPS reported ‚Ç¨2.48 +175.9% _ ‚Ç¨6.69 +34.6% ‚Äî Free cash flow(2) ‚Ç¨2 546m +0.2% _ ‚Ç¨8 483m +4.8% ‚Äî Business operating income ‚Ç¨2 724m +20.7% +15.0% ‚Ç¨13 040m +21.7% +13.3% Business net income(1) ‚Ç¨2 141m +23.8% +17.6% ‚Ç¨10 341m +25.9% +17.0% Business EPS(1) ‚Ç¨1.71 +23.9% +17.4% ‚Ç¨8.26 +25.9% +17.1%Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9 of February 3  2023 Press Release). (1) In order to facilitate an understanding of operational performance  Sanofi comments on the business net income statement. Business net income is a non-IFRS financial measure (definition in Appendix 9 of February 3  2023 Press Release). The reconciliation of reported IFRS net income to business net income is set forth in the 2022 U.S. Form 20-F page 62 and French ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù page 142; (2) Free cash flow is a non-IFRS financial measure (definition in Appendix 9 of February 3  2023 Press Release).These documents are available on the company‚Äôs website: https://www.sanofi.com/en/investors/reports-and-publications/financial-and-csr-reports.In addition  the Form 20-F is available on the website of the SEC (www.sec.gov) and the ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù is available on the website of the AMF (www.amf-france.org). A hard copy of these documents  each of which contains our complete audited financial statements  may be received free of charge  upon request.About SanofiWe are an innovative global healthcare company  driven by one purpose: we chase the miracles of science to improve people‚Äôs lives. Our team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comEvan Berland | +1 215 432 0234 | evan.berland@sanofi.comKate Conway | + 1 508 364 4931 | kate.conway@sanofi.comInvestor RelationsEva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.comArnaud Del√©pine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comCorentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comTarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comUpdated vs. February 3  2023 press releaseAttachment,neutral,0.25,0.57,0.18,mixed,0.37,0.25,0.38,True,English,"['U.S. FDA', 'business net income', '2022 IFRS net income', 'positive event', 'impairment reversal', 'ALTUVIIIO‚Ñ¢', 'change', 'des march√©s financiers', 'innovative global healthcare company', 'business net income statement', 'CER IFRS net sales', 'consolidated income statement', 'U.S. Securities', 'factor VIII therapy', 'life-changing treatment options', 'life-saving vaccine protection', 'Arnaud Del√©pine', 'Business operating income', 'Free cash flow', 'significant bleed protection', 'constant exchange rates', 'SNY Media Relations', '2022 U.S. Form', 'French market regulator', 'Q4 2022 Change Change', '2022 IFRS net income', 'IFRS financial measure', 'Annual Financial Report', 'CER 2022 Change Change', 'Sanofi press release', 'Annual Report', 'Business EPS', 'net impact', '2022 Financial Statements1', 'Cash flows', 'Exchange Commission', 'significant increase', 'Investor Relations', 'IFRS EPS', 'IFRS figures', 'English French', 'Form 20-F', 'new class', 'hemophilia A', 'positive event', 'Enregistrement Universel', 'US Food', 'Drug Administration', 'Eloctate franchise', 'line item', 'total equity', 'operational performance', 'F page', 'hard copy', 'one purpose', 'social responsibility', 'Corentine Driancourt', 'Nathalie Pham', 'French ‚ÄúDocument', 'French Document', 'impairment losses', 'intangible assets', 'Sandrine Guendoul', 'Evan Berland', 'Kate Conway', 'Eva Schaefer-Jansen', 'Tarik Elgoutni', 'sec.gov', 'impairment reversal', 'Victor Rouault', 'Felix Lauscher', 'FDA', 'ALTUVIIIO‚Ñ¢', 'Filing', 'Paris', 'February', 'AMF', 'ALTUVIIIOTM', 'value', 'decision', 'adjustment', 'year', 'December', 'accordance', 'IAS', 'tax', 'gain', 'earnings', 'share', 'amount', 'Board', 'Directors', 'Changes', 'definition', 'Appendix', 'order', 'understanding', 'reconciliation', 'documents', 'website', 'investors', 'reports', 'publications', 'csr', 'addition', 'org', 'complete', 'charge', 'request', 'miracles', 'science', 'people', 'lives', 'team', '100 countries', 'practice', 'medicine', 'impossible', 'millions', 'sustainability', 'center', 'ambitions', 'EURONEXT', 'NASDAQ']",2023-02-24,2023-02-25,globenewswire.com
19255,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/GALP-ENERGIA-SGPS-S-A-35373/news/Galp-Energia-SGPS-S-A-informs-about-weekly-report-on-share-repurchase-transactions-43082394/?utm_medium=RSS&utm_content=20230224,Galp Energia SGPS S A : informs about weekly report on share repurchase transactions,(marketscreener.com)   February 24  2023   Weekly report on share repurchases   In the context of the share repurchase programme of Galp Energia SGPS  SA's ordinary shares with the purpose to reduce the issued share capital  the Company informs about ‚Ä¶,"February 24  2023Weekly report on share repurchasesIn the context of the share repurchase programme of Galp Energia SGPS  SA's ordinary shares with the purpose to reduce the issued share capital  the Company informs about the transactions occurred during the period from 20 February 2023 to 24 February 2023 (inclusive).According to the information provided by the intermediary appointed to make the purchases  Galp has acquired shares in Euronext Lisbon regulated market  as detailed in the table below (aggregated information):Day Number of Shares Weighted Average Price (‚Ç¨/sh) Transactions Amount (‚Ç¨k) 20/02/2023 183 995 ‚Ç¨11.6900 ‚Ç¨2 151 21/02/2023 190 166 ‚Ç¨11.5129 ‚Ç¨2 189 22/02/2023 226 306 ‚Ç¨11.3102 ‚Ç¨2 560 23/02/2023 156 194 ‚Ç¨11.5175 ‚Ç¨1 799 24/02/2023 129 726 ‚Ç¨11.5903 ‚Ç¨1 504Galp has currently 1 412 755 treasury shares (equivalent to 0.17% of the share capital)  which were bought for an aggregate amount of ‚Ç¨16.4 m.All the detailed information regarding Galp's buyback programmes  including the details on daily trades  are available on our website  here.Galp Energia  SGPS  S.A.Investor Relations: Contacts: Website: www.galp.com/corp/en/ Otelo Ruivo  Director Tel: +351 21 724 08 66 Email: investor.relations@galp.com Jo√£o G. Pereira Teresa Toscano Address: Reuters: GALP.LS Tommaso Fornaciari Rua Tom√°s da Fonseca  Bloomberg: GALP PL C√©sar Teixeira Torre A  1600-209 Lisbon  PortugalThis document may include forward-looking statements. All statements other than statements of historical facts are  or may be deemed to be  forward-looking statements. Forward-looking statements express future expectations that are based on management's expectations and assumptions as of the date they are disclosed and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in such those statements. Accordingly  neither Galp nor any other person can assure that its future results  performance or events will meet those expectations  nor assume any responsibility for the accuracy and completeness of the forward-looking statements. Forward-looking statements include  among other things  statements concerning the potential exposure of Galp to market risks and statements expressing management's expectations  beliefs  estimates  forecasts  projections  and assumptions. These forward-looking statements may generally be identified by the use of the future  gerund or conditional tense or the use of terms and phrases such as ""aim""  ""ambition""  ""anticipate""  ""believe""  ""consider""  ""could""  ""develop""  ""envision""  ""estimate""  ""expect""  ""goals""  ""intend""  ""may''  ""objectives""  ""outlook""  ""plan""  ""potential""  ""probably""  ""project""  ""pursue""  ""risks""  ""schedule""  ""seek""  ""should""  ""target""  ""think""  ""will"" or the negative of these terms and similar terminology. This document may include data and information provided by third parties  which are not publicly available. Such data and information should not be interpreted as advice and you should not rely on it for any purpose. You may not copy or use this data and information except as expressly permitted by those third parties in writing. To the fullest extent permitted by law  those third parties accept no responsibility for your use of such data and information except as specified in a written agreement you may have entered into with those third parties for the provision of such data and information. Galp and its respective representatives  agents  employees or advisers do not intend to  and expressly disclaim any duty  undertaking or obligation to  make or disseminate any supplement  amendment  update or revision to any of the information  opinions or forward-looking statements contained in this document to reflect any change in events  conditions or circumstances. This document does not constitute investment advice nor forms part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or otherwise acquire securities of Galp or any of its subsidiaries or affiliates in any jurisdiction or an inducement to engage in any investment activity in any jurisdiction.",neutral,0.0,1.0,0.0,negative,0.0,0.2,0.8,True,English,"['Galp Energia SGPS S A', 'share repurchase transactions', 'weekly report', 'LS Tommaso Fornaciari Rua Tom√°s da Fonseca', 'GALP PL C√©sar Teixeira Torre A', 'Jo√£o G. Pereira Teresa Toscano', 'Euronext Lisbon regulated market', 'S.A.', 'share repurchase programme', 'Galp Energia SGPS', 'market risks', 'share repurchases', 'share capital', 'Weekly report', 'Day Number', 'Average Price', 'aggregate amount', 'buyback programmes', 'daily trades', 'Otelo Ruivo', 'historical facts', 'actual results', 'other person', 'future results', 'other things', 'potential exposure', 'future, gerund', 'conditional tense', 'similar terminology', 'third parties', 'fullest extent', 'written agreement', 'respective representatives', 'investment activity', 'unknown risks', 'forward-looking statements', 'ordinary shares', 'Transactions Amount', '1,412,755 treasury shares', 'investment advice', 'future expectations', 'Such data', 'detailed information', 'Investor Relations', '9 Lisbon', 'GALP.', 'February', 'context', 'purpose', 'Company', 'period', 'intermediary', 'table', 'details', 'website', 'Contacts', 'Director', 'Email', 'Address', 'Reuters', 'Bloomberg', 'Portugal', 'document', 'management', 'assumptions', 'date', 'uncertainties', 'performance', 'events', 'responsibility', 'accuracy', 'completeness', 'beliefs', 'estimates', 'forecasts', 'projections', 'use', 'terms', 'phrases', 'aim', 'ambition', 'objectives', 'outlook', 'plan', 'schedule', 'writing', 'law', 'provision', 'agents', 'employees', 'advisers', 'duty', 'undertaking', 'obligation', 'supplement', 'amendment', 'revision', 'opinions', 'change', 'conditions', 'circumstances', 'forms', 'offer', 'solicitation', 'securities', 'subsidiaries', 'affiliates', 'jurisdiction', 'inducement', '1600']",2023-02-24,2023-02-25,marketscreener.com
19256,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/WOLTERS-KLUWER-6291/news/Wolters-Kluwer-powers-innovation-in-clinical-education-with-new-Lippincott-solutions-43080518/?utm_medium=RSS&utm_content=20230224,Wolters Kluwer powers innovation in clinical education with new Lippincott solutions,(marketscreener.com) Lippincott Medical Procedures and Lippincott Connect Courseware help educators shape the next generation of healthcare workershttps://www.marketscreener.com/quote/stock/WOLTERS-KLUWER-6291/news/Wolters-Kluwer-powers-innovation-in-clinic‚Ä¶,Lippincott Medical Procedures and Lippincott Connect Courseware help educators shape the next generation of healthcare workersWolters Kluwer Health today announced the launch of Lippincott¬Æ Medical Procedures  a new clinical point of care solution to better prepare novice clinicians  and Lippincott¬Æ Connect Courseware  aimed at improving the educational process for both students and teachers. These new offerings support learning wherever and whenever it is convenient ‚Äì building on Lippincott‚Äôs full suite of essential medical products  from books and journals to digital solutions.Assignability  feedback  and insights becomes easier for faculty and studentsLippincott Connect Courseware provides faculty ‚Äì teaching anatomy  physiotherapy  occupational therapy  exercise science  and Intro clinical courses ‚Äì with better insights on what students are mastering or misunderstanding in their course by tracking performance across proficiency quizzes and adaptive learning questions. Additionally  faculty can create assignments containing a variety of engaging videos  images  and media that generate instant feedback and remediation for students to optimize their learning journey.Students can test their learning with quizzes  highlight and take notes on key passages of the textbook  and view engaging videos and media. Lippincott Connect Courseware also gives students access to and improves learning practices with the most trusted educational content  helping them transition to the workplace more smoothly. Key titles in the digital learning solution include Motor Control: Translating Research into Clinical Practice; Exercise Physiology: For Health  Fitness  and Performance; Bates‚Äô Guide to Physical Examination and History Taking; and Moore‚Äôs Clinically Oriented Anatomy.Students and residents get real-world ready by safely mastering common medical proceduresBased on research conducted with hundreds of program directors  clinical department chairs  attending physicians  and residents  Lippincott Medical Procedures is an easy-to-use  comprehensive  evidence-based resource that supports procedural training in internal medicine rotations  Physician Assistant programs  and residency programs. Program directors must ensure that residents can perform core procedures  such as point-of-care ultrasounds  line insertions  and wound care. Additionally  institutions can track usage for streamlined reporting to educational accrediting bodies.This new solution provides a comprehensive procedural training collection with step-by-step techniques for over 60 core medical procedures performed in a hospital or ambulatory setting. Presenting engaging  just-in-time content that shares the ‚Äúhow‚Äù and ‚Äúwhy‚Äù behind specific procedures allows for additional learning moments beyond the time spent in clinicals. Being able to access video tutorials  alongside ‚Äúpearls‚Äù and ‚Äúpitfalls‚Äù helps build confidence and provides practical insight that better prepares novice clinicians to perform procedures safely. Mastering common medical procedures prior to residency can help with a smooth transition into practice.‚ÄúAs caseloads for medical professionals continue to grow and become more complex  the need for new clinicians to be as practice ready as possible is more important than ever. Our goal is to leverage the power of technology to help achieve that vision ‚Äù said Vikram Savkar  Senior Vice President & General Manager  Medicine Segment  Health Learning  Research & Practice at Wolters Kluwer. ‚ÄúLippincott Medical Procedures and Lippincott Connect Courseware showcase the continual evolution of medical education to meet the demand in today‚Äôs landscape.‚ÄùWolters Kluwer Health provides trusted clinical technology and evidence-based solutions that engage clinicians  patients  researchers  and students in effective decision-making and outcomes across healthcare. The division of Wolters Kluwer supports clinical effectiveness  learning and research  clinical surveillance and compliance  as well as data solutions.About Wolters KluwerWolters Kluwer (EURONEXT: WKL) is a global leader in professional information  software solutions  and services for the healthcare; tax and accounting; governance  risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.Wolters Kluwer reported 2022 annual revenues of ‚Ç¨5.5 billion. The group serves customers in over 180 countries  maintains operations in over 40 countries  and employs approximately 20 000 people worldwide. The company is headquartered in Alphen aan den Rijn  the Netherlands.For more information  visit www.wolterskluwer.com  follow us on Twitter  Facebook  LinkedIn  and YouTube.For more information about our solutions  visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealthView source version on businesswire.com: https://www.businesswire.com/news/home/20230224005012/en/,neutral,0.04,0.96,0.0,positive,0.85,0.15,0.0,True,English,"['new Lippincott solutions', 'Wolters Kluwer', 'clinical education', 'innovation', 'Alphen aan den Rijn', 'comprehensive procedural training collection', 'comprehensive, evidence-based resource', 'Senior Vice President', 'deep domain knowledge', 'Lippincott Connect Courseware', 'Lippincott¬Æ Connect Courseware', 'essential medical products', 'educational accrediting bodies', 'Intro clinical courses', 'clinical department chairs', 'internal medicine rotations', 'Physician Assistant programs', 'common medical procedures', 'Lippincott Medical Procedures', 'Lippincott¬Æ Medical Procedures', 'trusted educational content', 'adaptive learning questions', 'additional learning moments', '60 core medical procedures', 'new clinical point', 'trusted clinical technology', 'digital learning solution', 'Wolters Kluwer Health', 'core procedures', 'medical professionals', 'medical education', 'educational process', 'specific procedures', 'new solution', 'clinical effectiveness', 'clinical surveillance', 'Medicine Segment', 'care solution', 'digital solutions', 'evidence-based solutions', 'new offerings', 'Health Learning', 'next generation', 'full suite', 'occupational therapy', 'exercise science', 'learning journey', 'key passages', 'learning practices', 'Key titles', 'Motor Control', 'Exercise Physiology', 'Bates‚Äô Guide', 'Physical Examination', 'program directors', 'residency programs', 'care ultrasounds', 'line insertions', 'wound care', 'step techniques', 'ambulatory setting', 'time content', 'video tutorials', 'practical insight', 'smooth transition', 'new clinicians', 'Vikram Savkar', 'General Manager', 'continual evolution', 'effective decision-making', 'global leader', 'regulatory sectors', 'critical decisions', '2022 annual revenues', 'source version', 'data solutions', 'software solutions', 'expert solutions', 'Clinical Practice', 'novice clinicians', 'engaging videos', 'proficiency quizzes', 'instant feedback', 'healthcare workers', 'professional information', 'educators', 'launch', 'students', 'teachers', 'books', 'journals', 'Assignability', 'insights', 'faculty', 'anatomy', 'performance', 'assignments', 'variety', 'images', 'media', 'notes', 'textbook', 'access', 'workplace', 'Research', 'Fitness', 'History', 'Moore', 'residents', 'real-world', 'hundreds', 'physicians', 'institutions', 'usage', 'streamlined', 'reporting', 'hospital', 'clinicals', 'pearls', 'pitfalls', 'confidence', 'caseloads', 'need', 'goal', 'power', 'vision', 'demand', 'today', 'landscape', 'patients', 'outcomes', 'compliance', 'EURONEXT', 'WKL', 'services', 'tax', 'accounting', 'governance', 'risk', 'legal', 'customers', 'group', '180 countries', 'operations', '40 countries', '20,000 people', 'company', 'Netherlands', 'Twitter', 'Facebook', 'LinkedIn', 'YouTube', 'wolterskluwer', 'WKHealth', 'businesswire']",2023-02-24,2023-02-25,marketscreener.com
19257,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BEACONSMIND-AG-118892242/news/Beaconsmind-AG-Further-Expands-Business-Activities-in-the-Hotspot-Segment-by-Acquiring-DSL-Solution-43073205/?utm_medium=RSS&utm_content=20230224,Beaconsmind AG Further Expands Business Activities in the Hotspot Segment by Acquiring DSL Solution Provider Netopsie,(marketscreener.com) The total purchase price of EUR 500 000 consists of a cash payment of EUR 200 000 immediately upon completion of the transaction and a payment of EUR 300 000 over a period of 5 yearsThe transaction is fully financed by the current li‚Ä¶,"Regulatory News:Publication of inside information pursuant to Article 17 of the EU Market Abuse Regulation (MAR)beaconsmind AG (ISIN: CH0451123589 - Ticker: 81D) (Paris:MLBMD) acquires 100% of the shares of Ingenieurb√ºro Netopsie via its subsidiary FREDERIX Hotspot. With the acquisition of Netopsie  beaconsmind is continuing to expand its business activities in the related hotspot segment in line with its strategy.Netopsie is a developer and provider of in-house DSL  TV  LAN and WLAN solutions. The company's products support customers in networking  digitalisation and building of high-performance infrastructures. The solutions are used in hospitality  healthcare  education  retail  cities and municipalities and sports venues  among others.The total price for the acquisition of Netopsie is EUR 500 000. EUR 200 000 of this amount will be paid immediately upon conclusion of the contract and a further EUR 300 000 over a period of five years. Following the acquisition  FREDERIX will have full access to Netopsie's broad customer base  including accounts such as TUI  with TUI Blue and Robinson Club  as well as to Netopsie's cash flows. Netopsie is financially sound  debt-free and cash flow-positive. The company has had sales revenues of EUR 650 000 and an EBITDA of EUR 100 000 in 2022. beaconsmind will fully consolidate Netopsie's corporate figures after the acquisition and anticipates high synergy effects and cross-selling potentials with significant growth potential.Explanatory partNetopsie DSL and Netopsie Koaxial are solutions to quickly and easily build a network and provide internet in every room  e.g. in a hospital or nursing home  without having to lay new cables. In addition  the company supports the planning and realisation of complex infrastructure solutions for the connection of modern IOT solutions. Through this transformative acquisition  beaconsmind will significantly expand its value chain and massively diversify its customer and revenue base. Customers will in future have access to both technology and solutions for the related Bluetooth low-energy and hotspot WiFi  as well as being able to offer data management and feedback. The offering will be enhanced by eKomi's SaaS review platform  which provides end-to-end solutions for B2B customers.Stefan Gerecke  the current CEO of Netopsie  will play an important role at FREDERIX with a long-term commitment to build the new solution vertical for FREDERIX.Jonathan Sauppe  CEO of beaconsmind subsidiary FREDERIX: ""The acquisition of Netopsie is an important milestone for our company. I am very pleased to welcome Stefan Gerecke to the FREDERIX team. This acquisition will allow us to expand our product offering in the related hotspot area and offer our customers an even more comprehensive value chain. In addition  we are significantly expanding our existing customer network through Netopsie's customer base  enabling us to offer our solutions to an even broader portfolio of customers.""Michael Ambros  Deputy CEO of beaconsmind  Founder and CEO of eKomi: ""eKomi has been looking for coherent B2B solutions to add more point-of-sales offerings to its current review and email signature platform. As a shareholder and board member of beaconsmind and FREDERIX  it's really exciting to see the hotspot vertical expand further with the acquisition of Netopsie. We are planning to pursue further accretive acquisition opportunities and also intend to go deeper into the value chain  with further plans to be revealed in due course.""About beaconsmindFounded in 2015 in Switzerland  beaconsmind AG is a pioneer in the field of location-based marketing (LBM) software for retail chains. By fitting stores with Bluetooth beacons that precisely locate and identify customers  and by integrating its Software Suite  beaconsmind opens a brand-new channel for retailers to interact with their customers. Thanks to its solution  retailers can converge digital and physical shopping and address the convenience gaps of each. The shares of the company (ISIN: CH0451123589 ‚Äì Ticker: MLBMD) are listed on the Frankfurt Stock Exchange with XETRA trading and on Euronext in Paris.For more information  please visit www.beaconsmind.com.About FREDERIXFREDERIX is a Hannover  Germany  based provider for corporate Wifi solutions (FREDERIX Hotspot) and a developer of smart  cloud-based W-LAN hotspot technologies (FREDERIX Cloud Wifi) with Lidl global account as a major customer. The company offers products that help the clients in the networking  control and monitoring of WLAN networks  enabling them to gain new insights  new contact points with their customers and real added value for both.About NetopsieNetopsie is a provider of in-house Digital Subscriber Line (DSL) solutions and a developer of comprehensive solutions for different industries. The company provides products that aid clients in the management  control  and monitoring of DSL networks. Netopsie DSL offers a streamlined and efficient solution for building networks and delivering internet access and additional services to every location without the need for additional cabling. This technology can be implemented in hotels  hospitals  nursing homes  sports facilities  and other types of facilities.About eKomieKomi Holdings with its group companies  affiliates and partners is Europe's premiere & largest independent provider of transaction-based reviews & ratings with specialist expertise in intelligent feedback systems in social commerce and customer evaluation for businesses operating across a wide range of sectors. Headquartered in Berlin  eKomi has offices in Amsterdam  Auckland  Berlin  Brisbane  Cape Town  Dubai  Hannover  Kyiv  Lahore  Lisbon  London  Los Angeles and Madrid while cooperating with an extensive network of partners around the globe.View source version on businesswire.com: https://www.businesswire.com/news/home/20230223006042/en/",neutral,0.0,1.0,0.0,mixed,0.72,0.13,0.15,True,English,"['DSL Solution Provider', 'Beaconsmind AG', 'Business Activities', 'Hotspot Segment', 'Netopsie', 'smart, cloud-based W-LAN hotspot technologies', 'EU Market Abuse Regulation', 'house Digital Subscriber Line', 'high synergy effects', 'significant growth potential', 'email signature platform', 'Frankfurt Stock Exchange', 'Lidl global account', 'related Bluetooth low-energy', 'SaaS review platform', 'new contact points', 'real added value', 'related hotspot segment', 'related hotspot area', 'complex infrastructure solutions', 'modern IOT solutions', 'broad customer base', 'new solution vertical', 'coherent B2B solutions', 'comprehensive value chain', 'accretive acquisition opportunities', 'Ingenieurb√ºro Netopsie', 'existing customer network', 'corporate Wifi solutions', 'FREDERIX Cloud Wifi', 'corporate figures', 'new cables', 'current review', 'Bluetooth beacons', 'new insights', 'comprehensive solutions', 'revenue base', 'major customer', 'Regulatory News', 'business activities', 'WLAN solutions', 'high-performance infrastructures', 'sports venues', 'total price', 'five years', 'Robinson Club', 'cash flows', 'sales revenues', 'cross-selling potentials', 'Explanatory part', 'Stefan Gerecke', 'important role', 'long-term commitment', 'Jonathan Sauppe', 'important milestone', 'broader portfolio', 'Michael Ambros', 'sales offerings', 'board member', 'due course', 'location-based marketing', 'LBM) software', 'Software Suite', 'brand-new channel', 'physical shopping', 'convenience gaps', 'XETRA trading', 'different industries', 'efficient solution', 'additional services', 'FREDERIX Hotspot', 'DSL) solutions', 'full access', 'WLAN networks', 'B2B customers', 'inside information', 'TUI Blue', 'data management', 'end solutions', 'current CEO', 'product offering', 'Deputy CEO', 'retail chains', 'DSL networks', 'FREDERIX team', 'transformative acquisition', 'Netopsie Koaxial', 'internet access', 'Netopsie DSL', 'beaconsmind subsidiary', 'beaconsmind AG', 'Publication', 'Article', 'Ticker', 'Paris', 'MLBMD', 'shares', 'strategy', 'developer', 'provider', 'TV', 'company', 'products', 'networking', 'digitalisation', 'building', 'hospitality', 'healthcare', 'education', 'cities', 'municipalities', 'others', 'amount', 'conclusion', 'contract', 'period', 'accounts', 'EBITDA', 'room', 'planning', 'realisation', 'connection', 'future', 'technology', 'feedback', 'eKomi', 'Founder', 'shareholder', 'plans', 'Switzerland', 'pioneer', 'field', 'stores', 'retailers', 'Euronext', 'Hannover', 'Germany', 'clients', 'control', 'monitoring', 'streamlined']",2023-02-24,2023-02-25,marketscreener.com
19258,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SANOFI-4698/news/ALTUVIIIO-trade-approved-by-the-U-S-FDA-this-positive-event-triggers-impairment-reversal-positiv-43081661/?utm_medium=RSS&utm_content=20230224,ALTUVIIIO‚Ñ¢ approved by the U.S. FDA: this positive event triggers impairment reversal  positively impacting 2022 IFRS net income; no change on business net income (non-IFRS),(marketscreener.com) FDA approves once-weekly ALTUVIIIO‚Ñ¢  a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal  impacting 2022 IFRS net income; no change on business net‚Ä¶,FDA approves once-weekly ALTUVIIIO‚Ñ¢  a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal  impacting 2022 IFRS net income; no change on business net income (non-IFRS)Filing of the 2022 U.S. Form 20-F and French ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù containing the Annual Financial ReportParis  February 24  2023. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù containing its Annual Financial Report with the French market regulator Autorit√© des march√©s financiers (AMF).On February 22  2023  the US Food and Drug Administration (FDA) approved ALTUVIIIOTM. This confirms the significant increase of value of the asset. That decision  which occurred prior to the filing of the French Document d‚Äôenregistrement universel and of the Annual Report on Form 20-F  resulted in an adjustment to IFRS net income for the year ended December 31  2022 as presented in the Sanofi press release issued on February 3  2023. The adjustment consisted of the reversal of ‚Ç¨2 154 million of impairment losses against the intangible assets associated with the Eloctate franchise  in accordance with IAS 36 (Impairment of Assets); the assets had been partially written down in 2019. The adjustment is presented within the line item Impairment of intangible assets in the consolidated income statement; the net impact after tax is a gain of ‚Ç¨1 651 million. Cash flows are not impacted by the adjustment. Following the adjustment  for the year ended December 31  2022  IFRS net income amounts to ‚Ç¨8 371 million (versus ‚Ç¨6 720 million as per the press release of February 3  2023); earnings per share (IFRS EPS) amounts to ‚Ç¨6.69 (versus ‚Ç¨5.37 as per the press release of February 3  2023); and total equity amounts to ‚Ç¨75 152 million (versus ‚Ç¨73 512 million as per the press release of February 3  2023).Business net income (a non-IFRS financial measure) for the year ended December 31  2022 is unchanged  as is the amount of the dividend proposed by the Board of Directors held on February 2  2023.Updated IFRS figures for 2022 Financial Statements1Q4 2022 Change Changeat CER 2022 Change Changeat CER IFRS net sales reported ‚Ç¨10 725m +7.3% +2.6% ‚Ç¨42 997m +13.9% +7.0% IFRS net income reported ‚Ç¨3 111m +175.1% _ ‚Ç¨8 371m +34.5% ‚Äî IFRS EPS reported ‚Ç¨2.48 +175.9% _ ‚Ç¨6.69 +34.6% ‚Äî Free cash flow(2) ‚Ç¨2 546m +0.2% _ ‚Ç¨8 483m +4.8% ‚Äî Business operating income ‚Ç¨2 724m +20.7% +15.0% ‚Ç¨13 040m +21.7% +13.3% Business net income(1) ‚Ç¨2 141m +23.8% +17.6% ‚Ç¨10 341m +25.9% +17.0% Business EPS(1) ‚Ç¨1.71 +23.9% +17.4% ‚Ç¨8.26 +25.9% +17.1%Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9 of February 3  2023 Press Release). (1) In order to facilitate an understanding of operational performance  Sanofi comments on the business net income statement. Business net income is a non-IFRS financial measure (definition in Appendix 9 of February 3  2023 Press Release). The reconciliation of reported IFRS net income to business net income is set forth in the 2022 U.S. Form 20-F page 62 and French ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù page 142; (2) Free cash flow is a non-IFRS financial measure (definition in Appendix 9 of February 3  2023 Press Release).These documents are available on the company‚Äôs website: https://www.sanofi.com/en/investors/reports-and-publications/financial-and-csr-reports.In addition  the Form 20-F is available on the website of the SEC (www.sec.gov) and the ‚ÄúDocument d‚ÄôEnregistrement Universel‚Äù is available on the website of the AMF (www.amf-france.org). A hard copy of these documents  each of which contains our complete audited financial statements  may be received free of charge  upon request.About SanofiWe are an innovative global healthcare company  driven by one purpose: we chase the miracles of science to improve people‚Äôs lives. Our team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comEvan Berland | +1 215 432 0234 | evan.berland@sanofi.comKate Conway | + 1 508 364 4931 | kate.conway@sanofi.comInvestor RelationsEva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.comArnaud Del√©pine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comCorentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comTarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comUpdated vs. February 3  2023 press releaseAttachment,neutral,0.25,0.57,0.18,mixed,0.33,0.2,0.47,True,English,"['U.S. FDA', 'business net income', '2022 IFRS net income', 'positive event', 'impairment reversal', 'ALTUVIIIO‚Ñ¢', 'change', 'des march√©s financiers', 'innovative global healthcare company', 'business net income statement', 'CER IFRS net sales', 'U.S. Securities', 'factor VIII therapy', 'life-changing treatment options', 'life-saving vaccine protection', 'Arnaud Del√©pine', 'Business operating income', 'Free cash flow', 'significant bleed protection', 'constant exchange rates', 'SNY Media Relations', '2022 U.S. Form', 'French market regulator', 'Q4 2022 Change Change', 'IFRS financial measure', '2022 IFRS net income', 'Annual Financial Report', 'CER 2022 Change Change', 'Sanofi press release', 'Annual Report', 'Business EPS', 'net impact', '2022 Financial Statements1', 'Cash flows', 'Exchange Commission', 'significant increase', 'Investor Relations', 'IFRS EPS', 'IFRS figures', 'Form 20-F', 'new class', 'hemophilia A', 'positive event', 'Enregistrement Universel', 'US Food', 'Drug Administration', 'Eloctate franchise', 'line item', 'total equity', 'operational performance', 'F page', 'hard copy', 'one purpose', 'social responsibility', 'Corentine Driancourt', 'French ‚ÄúDocument', 'French Document', 'impairment losses', 'intangible assets', 'Sandrine Guendoul', 'Evan Berland', 'Kate Conway', 'Eva Schaefer-Jansen', 'Tarik Elgoutni', 'impairment reversal', 'Victor Rouault', 'Felix Lauscher', 'Nathalie Pham', 'FDA', 'ALTUVIIIO‚Ñ¢', 'Filing', 'Paris', 'February', 'AMF', 'ALTUVIIIOTM', 'value', 'decision', 'adjustment', 'year', 'December', 'accordance', 'IAS', 'tax', 'gain', 'earnings', 'share', 'amount', 'Board', 'Directors', 'Changes', 'definition', 'Appendix', 'order', 'understanding', 'reconciliation', 'documents', 'website', 'investors', 'reports', 'publications', 'csr', 'addition', 'org', 'complete', 'charge', 'request', 'miracles', 'science', 'people', 'lives', 'team', '100 countries', 'practice', 'medicine', 'millions', 'sustainability', 'center', 'ambitions', 'EURONEXT', 'NASDAQ']",2023-02-24,2023-02-25,marketscreener.com
19259,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2614971/0/en/BGHL-GBP-NAV-s.html,BGHL (GBP): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED   Ordinary Shares  The Directors of Boussard & Gavaudan Holding...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 23 Feb 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.2812 ¬£ 24.0467 Estimated MTD return 0.06 % 0.15 % Estimated YTD return -1.76 % -1.55 % Estimated ITD return 172.81 % 140.47 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 22.00 N/A Premium/discount to estimated NAV -19.36 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.99 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 297 058 126 294 Held in treasury 800 N/A Shares Issued 12 297 858 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 239.4131 Class GBP A Shares (estimated) ¬£ 128.3609The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL', 'GBP', 'NAV', 'A Liquidity Enhancement Agreement Euro Shares Sterling Shares', 'The Class B Euro Shares', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'BGHL Ordinary Shares Euro Shares', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'Sterling Shares Shares', 'Euro Shares Amsterdam', 'A N/A Range', 'US Investment Company Act', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', '800 N/A Shares', 'BG Fund NAV', 'The Shares', 'Dutch Authority', 'Price N', 'Emmanuel Gavaudan', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'Number', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-02-24,2023-02-25,globenewswire.com
19260,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/HYDROGENE-DE-FRANCE-124047110/news/Hydrogene-De-France-HDF-Energy-lays-the-foundation-stone-of-its-high-power-hydrogen-fuel-cell-43081150/?utm_medium=RSS&utm_content=20230224,Hydrog√®ne De France :  HDF Energy lays the foundation stone of its high-power hydrogen fuel cell plant near Bordeaux (France),(marketscreener.com)  Bordeaux   24 February 2023 ‚Äì HDF Energy is delighted to announce the start of construction work on the world's first mass production plant for high-power hydrogen fuel cells. Representing a major technological and industrial breakthro‚Ä¶,"Bordeaux (France)  24 February 2023 ‚Äì HDF Energy (Hydrog√®ne de France) is delighted to announce the start of construction work on the world's first mass production plant for high-power hydrogen fuel cells. Representing a major technological and industrial breakthrough  the plant  which has been pre-notified as an IPCEI[1]  will supply the French domestic and international markets in heavy marine and rail mobility and electricity generation for energy grids. Located on the site of the former Ford factory in Blanquefort near Bordeaux  the new plant will contribute to the reindustrialisation of France and Europe  the creation of local jobs and the exportation of French technology.The foundation stone ceremony for the high-power fuel cell plant took place on Friday  24 February 2023 in Blanquefort near Bordeaux (France) in the presence of Damien Havard  CEO and founder of HDF Energy  Hanane El Hamraoui  VP Industry  and local public authorities.A bold industrial projectHDF Energy is building its 7 000 m¬≤ plant on a four-hectare plot of land located on the site of the former Ford factory. Delivery of the building is scheduled for late 2023  after which the Company's headquarters will be transferred to Blanquefort.When production begins in 2024  HDF initially plans to manufacture 1.5 MW fuel cells before gradually ramping their unit capacity up to 10 MW. Blanquefort will be the world's first mass production plant for high-power hydrogen fuel cells. 80% of production volume will be exported.In 2024  production capacity will reach 100 MW of fuel cells per year  representing over 100 direct jobs. HDF plans to establish 70% of its supply chain at regional  national and European level. As such  the HDF Energy plant will contribute to the industrial renewal of this regional landmark by installing cutting-edge technology.The high-power fuel cells manufactured here will serve the markets in heavy marine and rail mobility and electricity generation for energy grids. The Company has already signed a number of strategic partnerships for projects involving hydrogen-powered freight locomotives and large vessel propulsion and auxiliary power systems.To coincide with this occasion  HDF Energy also signed a memorandum of understanding with Ter√©ga Solutions and Hype to cooperate on the development of hydrogen mobility in the Bordeaux region. Under the agreement  the parties will review the possibility of launching a joint venture tasked with deploying green hydrogen distribution stations in order to accelerate and scale up the use of heavy and light hydrogen mobility in the region.Project pre-notified as an IPCEI (Important Project of Common European Interest)In October 2022  after two years of cooperation with government departments  the French government selected the HDF Energy project as an IPCEI and pre-notified the application to the European Commission. The Company is awaiting the Commission's approval due this summer in order to step up its industrial project and transform the plant into a gigafactory  thereby generating over 500 jobs in this regional industrial area.Moreover  HDF Energy has received since 2018 significant financial support from the Regional Council of Aquitaine which allowed the Company to start its industrial activity.An environmentally sustainable plantFor its construction and operation  the plant is subject to BREEAM certification  an international standard for assessing the environmental impact of a building in order to promote greener architecture. The following criteria will be monitored during plant operation: energy management  water management  waste recovery  access to sustainable transport and occupants' health and well-being.Moreover  the fuel cell is a clean technology whose sole emission is steam. Fuel cells have a 20-year lifespan and the Company has already provided for their future recycling.ABOUT HDF ENERGYHDF Energy is a global pioneer in high-power hydrogen power plants. The Company designs and develops power plants that generate non-intermittent  non-polluting renewable energy  day and night. In addition  HDF Energy organises the financing  construction and operation of these power plants through SPVs.HDF is the designer of Renewstable¬Æ  its flagship model of multi-megawatt power plants producing firm power from an intermittent renewable energy source (wind or solar) and massive energy storage in the form of green hydrogen generated on site.HDF Energy is also an industrial company which will mass produce  from 2024  the most strategic component of its power plants - high-power fuel cells - in its plant near Bordeaux. Already a major supplier of electricity for energy grids  this industrial activity will also allow HDF Energy to serve the heavy marine and rail mobility markets. Alongside its strategic partners  the Company develops projects involving hydrogen-powered freight locomotives and large vessel propulsion and auxiliary power systems.The Company operates on five continents and is developing a business portfolio currently worth over ‚Ç¨5 billion.HDF Energy is listed in Euronext Compartment B.More information about HDF Energy here:www.hdf-energy.comContactsInvestors relations Press relations Margaux ROUILLARD+ 33 (0)1 53 67 36 32hdf-energy@actus.fr Serena BONI+33 (0)4 72 18 04 92sboni@actus.fr[1] Important Project of Common European InterestThis publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: lWxqlpWalJubym+caJtoaZVjaZhkmZaZm2rKnGablpiVmHKSyG+WmJyXZnBpm25s- Check this key: https://www.security-master-key.com.Unregulated information:Full and original press release in PDF: https://www.actusnews.com/news/78696-hdf_cp-_pose-premiere-pierre_en.pdfReceive by email the next press releases of the company by registering on www.actusnews.com  it's free¬© 2023 ActusNews",neutral,0.0,1.0,0.0,positive,0.83,0.17,0.0,True,English,"['high-power hydrogen fuel cell plant', 'Hydrog√®ne De', 'HDF Energy', 'foundation stone', 'France', 'Bordeaux', 'intermittent, non-polluting renewable energy', 'intermittent renewable energy source', 'green hydrogen distribution stations', 'high-power hydrogen fuel cells', 'first mass production plant', 'high-power hydrogen power plants', 'high-power fuel cell plant', 'high-power fuel cells', 'Hydrog√®ne de', 'former Ford factory', 'foundation stone ceremony', 'Hanane El Hamraoui', 'hydrogen-powered freight locomotives', 'large vessel propulsion', 'Ter√©ga Solutions', 'significant financial support', 'light hydrogen mobility', 'auxiliary power systems', 'local public authorities', 'massive energy storage', 'Common European Interest', 'multi-megawatt power plants', '1.5 MW fuel cells', 'regional industrial area', 'bold industrial project', 'rail mobility markets', 'HDF Energy plant', 'HDF Energy project', 'firm power', 'production volume', 'production capacity', 'energy grids', 'energy management', 'European level', 'regional landmark', 'Regional Council', 'industrial breakthrough', 'new plant', '7,000 m¬≤ plant', 'industrial renewal', 'industrial activity', 'sustainable plant', 'Important Project', 'local jobs', 'major technological', 'French domestic', 'international markets', 'French technology', 'Damien Havard', 'VP Industry', 'four-hectare plot', 'unit capacity', 'supply chain', 'cutting-edge technology', 'strategic partnerships', 'joint venture', 'two years', 'government departments', 'French government', 'BREEAM certification', 'international standard', 'environmental impact', 'greener architecture', 'following criteria', 'water management', 'waste recovery', 'sustainable transport', ""occupants' health"", 'clean technology', 'sole emission', '20-year lifespan', 'future recycling', 'global pioneer', 'flagship model', 'strategic component', 'major supplier', 'five continents', 'business portfolio', 'European Commission', 'industrial company', 'heavy marine', 'electricity generation', '100 direct jobs', 'plant operation', 'The Company', 'construction work', 'Bordeaux region', '10 MW', '100 MW', '500 jobs', 'France', 'start', 'world', 'IPCEI', 'site', 'Blanquefort', 'reindustrialisation', 'creation', 'place', 'Friday', 'February', 'presence', 'CEO', 'founder', 'Delivery', 'building', 'late', 'headquarters', 'number', 'projects', 'occasion', 'memorandum', 'understanding', 'Hype', 'development', 'agreement', 'parties', 'possibility', 'order', 'use', 'October', 'cooperation', 'application', 'approval', 'gigafactory', 'Aquitaine', 'access', 'well', 'being', 'steam', 'night', 'addition', 'financing', 'SPVs', 'designer', 'Renewstable¬Æ', 'wind', 'solar', 'produce']",2023-02-24,2023-02-25,marketscreener.com
19261,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDI-36044/news/BGHL-EUR-NAV-s-43073953/?utm_medium=RSS&utm_content=20230224,BGHL (EUR): NAV(s),(marketscreener.com) ¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like...https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDI-36044/news/BGHL‚Ä¶,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 23 Feb 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.2812 ¬£ 24.0467 Estimated MTD return 0.06 % 0.15 % Estimated YTD return -1.76 % -1.55 % Estimated ITD return 172.81 % 140.47 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 22.00 N/A Premium/discount to estimated NAV -19.36 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.99 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 297 058 126 294 Held in treasury 800 N/A Shares Issued 12 297 858 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 239.4131 Class GBP A Shares (estimated) ¬£ 128.3609The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL', 'EUR', 'NAV', 'A Liquidity Enhancement Agreement Euro Shares Sterling Shares', 'The Class B Euro Shares', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'BGHL Ordinary Shares Euro Shares', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'Sterling Shares Shares', 'Euro Shares Amsterdam', 'A N/A Range', 'US Investment Company Act', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', '800 N/A Shares', 'BG Fund NAV', 'The Shares', 'Dutch Authority', 'Price N', 'Emmanuel Gavaudan', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'Number', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-02-24,2023-02-25,marketscreener.com
19262,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/IREIT-GLOBAL-17646737/news/IREIT-Global-Press-Release-190-KB-43073144/?utm_medium=RSS&utm_content=20230224,IREIT Global : Press Release (190 KB),(marketscreener.com)   IREIT Global Group Pte. Ltd.      1 Wallich Street #15-03 Guoco Tower Singapore 078881 Main 6718 0590 www.ireitglobal.com   Media Release   IREIT's gross revenue grew 18.2% in FY2022 on full-year contribution from acquisit‚Ä¶,"IREIT Global Group Pte. Ltd. (as Manager of IREIT Global) 1 Wallich Street #15-03 Guoco Tower Singapore 078881 Main (65) 6718 0590 www.ireitglobal.com Media Release IREIT's gross revenue grew 18.2% in FY2022 on full-year contribution from acquisitions FY2022 gross revenue and net property income rose by 18.2% and 14.9% respectively year-on-year on full-year contribution from acquisitionsyear-on-year on full-year contribution from acquisitions Income available for distribution increased 0.8% year-on-year to ‚Ç¨34.6 million but distribution per unit was down 8.2% to 2.69 ‚Ç¨ centsyear-on-year to ‚Ç¨34.6 million but distribution per unit was down 8.2% to 2.69 ‚Ç¨ cents Weighted average lease expiry improved to 5.0 years as at 31 December 2022 from 3.8 years a year ago due to lease renewals and new leases secured during the yearAggregate leverage remained low at 32.0%  with substantially all of the bank borrowings hedged and no refinancing requirements until 2026. Interest coverage ratio at a healthy 7.9 timesManager proactively engaging IREIT's existing tenants to retain them as well as focusing on filling up the vacant spaces at the portfolio assetsReceived green certifications for 15 properties under IREIT's French portfolio  with the remaining 12 properties on track to attain their certifications by first quarter of 2023 SINGAPORE | 23 FEBRUARY 2023 For immediate release IREIT Global (""IREIT"")  a Europe-focused real estate investment trust managed by IREIT Global Group Pte. Ltd. (the ""Manager"")  is pleased to report the financial results for the second half year and financial year ended 31 December 2022 (""2H2022"" and ""FY2022""  respectively). Gross revenue for 2H2022 increased by 10.7% year-on-year to ‚Ç¨31.6 million  while net property income rose by 5.2% to ‚Ç¨24.4 million over the same period. The increase was mainly due to the contribution from the acquisitions of the French portfolio and Parc Cugat in 3Q2021  step-up rents and CPI indexation. Income available for distribution was impacted mainly by higher property operating expenses related to higher portfolio vacancy  higher tax costs  and management fees payable 100% in cash (versus 50% in cash for FY2021). As a Joint Sponsors of IREIT Global: Page 1 of 6IREIT Global Group Pte. Ltd. (as Manager of IREIT Global) 1 Wallich Street #15-03 Guoco Tower Singapore 078881 Main (65) 6718 0590 www.ireitglobal.com Media Release result  income available for distribution for 2H2022 decreased by 14.7% year-on-year to ‚Ç¨16.4 million  while the distribution per unit (""DPU"") amounted to 1.28 ‚Ç¨ cents  down 14.7% year-on-year. For FY2022  gross revenue came in at ‚Ç¨61.7 million  up 18.2% year-on-year  whereas net property income was 14.9% higher at ‚Ç¨48.8 million. In addition  income available for distribution was largely flat at ‚Ç¨34.6 million and DPU for the full-year registered 2.69 ‚Ç¨ cents  representing a decrease of 8.2% year-on-year. Based on the closing unit price of S$0.505 as at 30 December 2022  the FY2022 DPU translates to a healthy distribution yield of 7.6%. (1) Portfolio occupancy was down to 88.3% as at 31 December 2022 from 95.7% a year ago  due mainly to Darmstadt Campus being vacant since December 2022 with the departure of its sole tenant  Deutsche Telekom. This contributed partially to the 2.5% year-on-year decline in IREIT's portfolio valuation to ‚Ç¨950.5 million as at 31 December 2022  and may have some impact on IREIT's future distributions. Mr Louis d'Estienne d'Orves  Chief Executive Officer of the Manager  said  ""We are pleased to grow the gross revenue of IREIT's portfolio  delivering growth of 18.2% year-on-year. We will continue to proactively engage our existing tenants to retain them  as well as focus on filling up the vacant spaces at IREIT's portfolio assets in 2023. At the same time  on the environmental  social and governance (""ESG"") front  we are working to improve the energy efficiency and marketability of IREIT's portfolio. To this end  we have successfully attained green certifications for 15 properties under IREIT's French portfolio  with the remaining 12 properties on track to receive their certifications by the first quarter of 2023. We will continue to strive to make a positive impact on the communities that IREIT operates in while creating long-term value for Unitholders."" IREIT's weighted average lease expiry (""WALE"") improved to 5.0 years as at 31 December 2022 from 3.8 years a year ago  as a result of the six-year lease extension for 100% of Bonn Campus and the 12-year major new lease for approximately 5 300 sqm data centre space at Sant Cugat Green during the year. In addition  IREIT will continue to benefit from higher rents due to rising inflation as its portfolio leases have rental escalation clauses pegged to CPI  while the high level of hedging on its existing bank borrowings will cushion IREIT from any impact due to rising interest rates. Notably  IREIT's aggregate leverage as at 31 December 2022 remained low at 32.0%  with substantially all of the bank borrowings hedged and no (1) Based on S$1.4331 per ‚Ç¨ as at 30 December 2022 as extracted from MAS website Joint Sponsors of IREIT Global: Page 2 of 6IREIT Global Group Pte. Ltd. (as Manager of IREIT Global) 1 Wallich Street #15-03 Guoco Tower Singapore 078881 Main (65) 6718 0590 www.ireitglobal.com Media Release refinancing requirements until 2026. Interest coverage ratio was also at a healthy level of 7.9 times. On the investment front  the repricing of assets may also bring about attractive opportunities  allowing IREIT to diversify and strengthen its long-term income streams. The Manager is actively exploring various avenues to broaden IREIT's funding sources so that it is well- positioned to pursue such investment opportunities as and when they arise. Half Year Ended 31 December Financial Year Ended 31 December 2H2022 2H2021 Variance FY2022 FY2021 Variance Actual Actual (%) Actual Actual (%) Gross revenue (‚Ç¨ '000) 31 580 28 521 10.7 61 650 52 167 18.2 Net property income (‚Ç¨ '000) 24 362 23 155 5.2 48 797 42 482 14.9 Income available for 16 414 19 237 (14.7) 34 647 34 386 0.8 distribution (‚Ç¨ '000) Income to be distributed to 14 772 17 313 (14.7) 31 182 30 947 0.8 Unitholders (‚Ç¨ '000) Distribution per Unit 2H2022 2H2021 Variance (%) FY2022 FY2021 Variance (%) - ‚Ç¨ cents 1.28 (1) 1.50 (2) (14.7) 2.69 (1) 2.93 (2) (8.2) Total issued Units as at 31 December 2022 was 1 155 891 421 (31 December 2021: 1 154 591 595). IREIT issued 11 372 868 new Units pursuant to an equity placement offering on 30 June 2021 and 201 137 870 new Units pursuant to an equity preferential offering on 21 July 2021. ABOUT IREIT GLOBAL www.ireitglobal.com | SGX Main Board Listing IREIT Global (SGX-UD1U) which was listed on 13 August 2014  is the first Singapore-listed real estate investment trust with the investment strategy of principally investing  directly or indirectly  in a portfolio of income-producing real estate in Europe which is used primarily for office  retail and industrial (including logistics) purposes  as well as real estate-related assets. Joint Sponsors of IREIT Global: Page 3 of 6IREIT Global Group Pte. Ltd. (as Manager of IREIT Global) 1 Wallich Street #15-03 Guoco Tower Singapore 078881 Main (65) 6718 0590 www.ireitglobal.com Media Release IREIT Global's current portfolio comprises five freehold office properties in Germany  five freehold office properties in Spain and 27 freehold retail properties in France. IREIT Global is managed by IREIT Global Group Pte. Ltd. (the ""Manager"")  which is jointly owned by Tikehau Capital and City Developments Limited (""CDL""). Tikehau Capital is global alternative asset management group listed in France  while CDL is a leading global real estate company listed in Singapore. ABOUT TIKEHAU CAPITAL www.tikehaucapital.com | Paris Euronext  Compartment A Listing Tikehau Capital is a global alternative asset management group with ‚Ç¨38.8 billion of assets under management as at 31 December 2022. Tikehau Capital has developed a wide range of expertise across four asset classes (private debt  real assets  private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Tikehau Capital is a founder-led team with a distinctive business model  a strong balance sheet  proprietary global deal flow and a track record of backing high-quality companies and executives. Deeply rooted in the real economy  Tikehau Capital provides bespoke and innovative alternative financing solutions to the companies it invests in and seeks to create long-term value for its investors  while generating positive impacts on society. Leveraging its strong equity base (‚Ç¨3.1 billion of shareholders' equity as at 31 December 2022)  Tikehau Capital invests in its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners  Tikehau Capital is guided by a strong entrepreneurial spirit and DNA  shared by its 742 employees across its 14 offices in Europe  Asia and North America. Tikehau Capital is listed on compartment A of the regulated Euronext Paris market (ISIN: FR0013230612; Ticker: TKO.FP). Joint Sponsors of IREIT Global: Page 4 of 6",neutral,0.0,1.0,0.0,mixed,0.58,0.28,0.14,True,English,"['IREIT Global', 'Press Release', ""Mr Louis d'Estienne d'Orves"", 'Europe-focused real estate investment trust', 'IREIT Global Group Pte. Ltd.', '5,300 sqm data centre space', 'higher property operating expenses', '12-year major new lease', 'average lease expiry', 'Interest coverage ratio', 'higher tax costs', 'Chief Executive Officer', 'six-year lease extension', 'rental escalation clauses', 'rising interest rates', 'Guoco Tower Singapore', 'net property income', 'higher portfolio vacancy', 'Sant Cugat Green', 'closing unit price', 'healthy 7.9 times Manager', 'second half year', 'healthy distribution yield', 'existing bank borrowings', 'Media Release result', 'FY2022 gross revenue', 'lease renewals', 'new leases', 'higher rents', 'Parc Cugat', 'rising inflation', 'existing tenants', 'immediate release', '1 Wallich Street', 'refinancing requirements', 'vacant spaces', 'first quarter', 'financial results', 'same period', 'step-up rents', 'management fees', 'Joint Sponsors', 'Darmstadt Campus', 'sole tenant', 'Deutsche Telekom', 'future distributions', 'same time', 'ESG"") front', 'energy efficiency', 'long-term value', 'Bonn Campus', 'high level', 'portfolio assets', 'French portfolio', 'Portfolio occupancy', 'portfolio valuation', 'portfolio leases', 'green certifications', 'full-year contribution', 'remaining 12 properties', 'CPI indexation', 'aggregate leverage', 'positive impact', 'financial year', 'year decline', 'FY2022 DPU', '15 properties', 'acquisitions', '31 December', 'track', '23 FEBRUARY', '2H2022', 'increase', '3Q2021', 'cash', 'FY2021', 'Page', 'addition', '2.69 ‚Ç¨ cents', 'decrease', '30 December', 'departure', 'growth', 'social', 'governance', 'marketability', 'end', 'communities', 'Unitholders', 'WALE', '5.0 years', 'hedging', '1.28 ‚Ç¨']",2023-02-24,2023-02-25,marketscreener.com
19263,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/fda-approves-once-weekly-efanesoctocog-alfa-a-new-class-of-high-sustained-factor-viii-therapy-for-haemophilia-a-swedish-orphan-biovitrum-ab-301755196.html,FDA approves once-weekly efanesoctocog alfa  a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB,STOCKHOLM  Feb. 24  2023 /PRNewswire/ -- Sobi¬Æ today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl]  a first-in-class  high-sustained factor VIII ‚Ä¶,"STOCKHOLM  Feb. 24  2023 /PRNewswire/ -- Sobi¬Æ today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl]  a first-in-class  high-sustained factor VIII replacement therapy for adults and children with haemophilia A. Efanesoctocog alfa is the first and only haemophilia A treatment that provides patients with normal to near-normal factor VIII activity levels for a significant part of the week with once-weekly dosing  resulting in superior protection from bleeds compared to existing factor VIII prophylaxis.Haemophilia A is a rare  genetic disorder in which the ability of a person's blood to clot is impaired due to a lack of factor VIII. Haemophilia A occurs in about one in 5 000 male births annually  and more rarely in females. People with haemophilia can experience bleeding episodes that can cause pain  irreversible joint damage and life-threatening haemorrhages. Despite advancements in treatment made in recent years  a large unmet medical need still exists and requires further improvement in the standard of care.""This approval marks an important clinical advancement for the haemophilia community because we have an option that can achieve higher levels of factor activity with a single weekly dose "" said Lynn Malec  MD  Medical Director of Comprehensive Center for Bleeding Disorders and Associate Investigator at Versiti Blood Research Institute  and Associate Professor of Medicine and Pediatrics at The Medical College of Wisconsin  US. ""By maintaining high levels of factor activity throughout the week  patients can be confident in the bleed protection efanesoctocog alfa offers.""""On behalf of Sobi I'd like to congratulate our co-development partner Sanofi on this great achievement "" said Anders Ullman  Head of Research & Development and Medical Affairs  Chief Medical Officer at Sobi. ""This is a major milestone in our collaboration as we work towards providing access to this important new treatment for people living with haemophilia A around the world.""The FDA approval is primarily based on data from the pivotal XTEND-1 phase 3 study recently published in The New England Journal of Medicine. Once-weekly efanesoctocog alfa met the primary endpoint  providing significant improvements in bleed protection for people with severe haemophilia A with median and mean annualised bleeding rates (ABR) of 0.00 (interquartile range: 0.00-1.04) and 0.71 (95% confidence interval: 0.52-0.97)  respectively. Efanesoctocog alfa met the key secondary endpoint with a significant reduction of 77% in ABR versus prior factor prophylaxis based on an intra-patient comparison. Efanesoctocog alfa prophylaxis with 50IU/kg/week provided mean factor VIII activity greater than 40% for the majority of the week with a trough activity of 15% on day seven  and these levels were associated with a low bleed risk.Additional data showed prevention of joint bleeds with a median annualised joint bleeding rate of 0 (Q1  Q3: 0.0  1.0). Treatment with efanesoctocog alfa provided 100% resolution of target joints  which are joints that have recurrent bleeds (e.g.  knee  ankle  or elbow). In adults and adolescents  efanesoctocog alfa had a favourable safety profile and there were no signs of factor VIII inhibitor development.Efanesoctocog alfa is indicated in the US for routine prophylaxis  on-demand treatment and control of bleeding episodes  and perioperative management of bleeding. The recommended weekly dose of 50 IU/kg is intended for prophylaxis in patients of all ages and the same dose can be administered according to needs in different clinical settings. Efanesoctocog alfa is expected to be commercially available in the US starting in the second quarter of 2023 and will be marketed as ALTUVIIIO‚Ñ¢ in Sanofi territories.The FDA evaluated the application under Priority Review  which is granted to therapies that have the potential to provide significant improvements in the treatment  diagnosis  or prevention of serious conditions.Regulatory submission in the EU will follow the availability of final data from the XTEND-Kids paediatric study in the first half of 2023. The European Commission granted orphan designation in June 2019.About efanesoctocog alfaEfanesoctocog alfa (formerly BIVV001) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for most of the week  extending bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN¬Æ polypeptides to potentially extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling  which is believed to impose a half-life limitation on current factor VIII therapies. It is approved as ALTUVIIIO [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the US. It is not approved in any country outside the US.About the Sanofi and Sobi collaborationSobi and Sanofi collaborate on the development and commercialisation of Alprolix¬Æ and Elocta¬Æ/Eloctate¬Æ. The companies also collaborate on the development and commercialisation of efanesoctocog alfa or ALTUVIIIO in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe  North Africa  Russia and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.SanofiSanofi are an innovative global healthcare company  driven by one purpose: to chase the miracles of science to improve people's lives. Their team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the centre of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.Sobi¬ÆSobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology  immunology and specialty care  Sobi has approximately 1 600 employees across Europe  North America  the Middle East  Asia and Australia. In 2022  revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com  LinkedIn and YouTube.ContactsFor details on how to contact the Sobi Investor Relations Team  please click here. For Sobi Media contacts  click here.Swedish Orphan Biovitrum AB (publ)Postal address SE-112 76 Stockholm  SwedenPhone: 46 8 697 20 00www.sobi.comThe following files are available for download:https://mb.cision.com/Main/14266/3722707/1872777.pdf FDA approves once-weekly efanesoctocog alfaSOURCE Swedish Orphan Biovitrum AB",neutral,0.0,1.0,0.0,mixed,0.17,0.16,0.67,True,English,"['high-sustained factor VIII therapy', 'Swedish Orphan Biovitrum AB', 'efanesoctocog alfa', 'new class', 'haemophilia A', 'FDA', 'high-sustained factor VIII replacement therapy', 'investigational recombinant factor VIII therapy', 'median annualised joint bleeding rate', 'normal factor VIII activity levels', 'pivotal XTEND-1 phase 3 study', 'current factor VIII therapies', 'innovative Fc fusion technology', 'mean annualised bleeding rates', 'large unmet medical need', 'mean factor VIII activity', 'The New England Journal', 'von Willebrand factor ceiling', 'existing factor VIII prophylaxis', 'factor VIII inhibitor development', 'near-normal factor activity levels', 'Versiti Blood Research Institute', 'haemophilia A. Efanesoctocog alfa', 'Fc-VWF-XTEN Fusion Protein-ehtl', 'irreversible joint damage', 'prior factor prophylaxis', 'rare, genetic disorder', 'important clinical advancement', 'low bleed risk', 'favourable safety profile', 'different clinical settings', 'The European Commission', 'The Medical College', 'Chief Medical Officer', 'key secondary endpoint', 'important new treatment', 'efanesoctocog alfa offers', 'single weekly dose', 'Efanesoctocog alfa prophylaxis', 'weekly efanesoctocog alfa', 'The FDA approval', 'Antihemophilic Factor', 'joint bleeds', 'trough activity', 'higher levels', 'Medical Director', 'high levels', 'Medical Affairs', 'bleeding episodes', 'Bleeding Disorders', 'routine prophylaxis', 'primary endpoint', 'weekly dosing', 'development partner', 'same dose', 'Drug Administration', 'significant part', '5,000 male births', 'life-threatening haemorrhages', 'recent years', 'Lynn Malec', 'Comprehensive Center', 'Associate Investigator', 'Associate Professor', 'great achievement', 'Anders Ullman', 'major milestone', 'significant improvements', 'interquartile range', 'significant reduction', 'intra-patient comparison', 'recurrent bleeds', 'perioperative management', 'second quarter', 'Priority Review', 'serious conditions', 'Regulatory submission', 'orphan designation', 'XTEN¬Æ polypeptides', 'half-life limitation', 'haemophilia community', 'severe haemophilia', 'Additional data', 'final data', 'target joints', 'demand treatment', 'first half', 'Sanofi territories', 'superior protection', 'US Food', 'PRNewswire', 'Sobi¬Æ', 'adults', 'children', 'only', 'patients', 'ability', 'person', 'lack', 'females', 'People', 'pain', 'advancements', 'standard', 'care', 'option', 'MD', 'Medicine', 'Pediatrics', 'Wisconsin', 'behalf', 'Head', 'collaboration', 'access', 'world', 'ABR', '50IU/kg', 'majority', 'day', 'seven', 'prevention', '100% resolution', 'knee', 'ankle', 'elbow', 'adolescents', 'signs', 'control', '50 IU', 'needs', 'ALTUVIIIO‚Ñ¢', 'application', 'potential', 'diagnosis', 'June', 'novel', 'region', 'time', 'circulation', 'country']",2023-02-24,2023-02-25,prnewswire.co.uk
19264,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2615384/0/en/Press-release-New-Phase-3-data-presented-at-WORLDSymposium-reinforce-Nexviazyme-avalglucosidase-alfa-as-potential-new-standard-of-care-for-all-people-living-with-late-onset-Pompe-d.html,Press release: New Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease,New Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease,English FrenchNew Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe diseaseParis  February 24  2023. Today  at WORLDSymposiumTM  data from the Phase 3 COMET study long-term extension showed sustained treatment effect of Nexviazyme¬Æ (avalglucosidase alfa) over nearly three years in late-onset Pompe disease (LOPD) patients who were treatment-na√Øve as well as those who switched from long-time standard of care  alglucosidase alfa  during the 96-week extension period. Additionally  a separate analysis of respiratory function showed clinical benefit over two years for patients who switched to Nexviazyme regardless of prior response to alglucosidase alfa.Priya S. Kishnani  MDC.L. and Su Chen Professor of Pediatrics; Medical Director  YT and Alice Chen Pediatrics Genetics and Genomics Center; and Division Chief  Medical Genetics  Duke University Medical Center‚ÄúThe results presented at the 2023 WORLDSymposium continue to build on the data from the clinical trials on the value and long-term impact Nexviazyme may provide for a wide variety of people living with late-onset Pompe disease  from newly diagnosed patients to those who have been previously treated with alglucosidase alfa. Further  when examining patients treated with Nexviazyme who switched from using alglucosidase alfa  these data show clinical benefit both for patients who were stable on alglucosidase alfa and those who experienced sub-optimal response or decline.‚ÄùBill SiboldGlobal Head of Specialty Care  Sanofi‚ÄúThese long-term data over nearly three years add to the robust body of evidence that consistently shows the clinical benefit and durability of effect of treatment with Nexviazyme for both treatment-experienced and treatment-na√Øve people living with late-onset Pompe disease. We continue to learn from our 20 years of experience in Pompe disease and build on our findings in an effort to advance the standard of care.‚ÄùNexviazyme is a monotherapy approved in the US and other markets for the treatment of LOPD. It is also approved for infantile-onset Pompe disease (IOPD) in certain markets outside of the US.Nexviazyme maintained treatment effect at 145 weeksThe Phase 3 COMET trial enrolled 100 previously untreated LOPD patients who were randomized to receive either Nexviazyme (20 mg/kg) or alglucosidase alfa (20 mg/kg) every two weeks for 49 weeks during the double-blind primary analysis period. During the open-label extension period  long-term efficacy and safety outcomes were assessed up to 145 weeks in patients who continued their treatment with Nexviazyme (n=51)  as well as those who switched to treatment with Nexviazyme from alglucosidase alfa (n=44) at the conclusion of the primary analysis period (Week 49).After nearly three years (145 weeks)  changes from baseline (least squares mean [standard error]) showed:Patients who received continuous Nexviazyme treatment for 145 weeks experienced sustained improvements in respiratory and motor function  showing a 1.40 (1.21) point improvement in forced vital capacity (FVC) percent-predicted and an average increase of 20.65 (9.60) meters in walking distance as measured by the six-minute walk test (6MWT)  respectively  compared to baseline.Patients who switched from alglucosidase alfa to Nexviazyme treatment during the extension period experienced stabilization of treatment effect  showing a 1.18 (1.32) point improvement in FVC percent-predicted and an average increase of 0.29 (10.42) meters in walking distance (6MWT)  compared to baseline.The safety profile during treatment with Nexviazyme was comparable between both study groups (those who started Nexviazyme in the primary analysis period and those who switched to Nexviazyme during the extension period). No new safety signals were observed in patients who switched from alglucosidase alfa to Nexviazyme during the extension period. Across both Nexviazyme treatment groups  five patients discontinued treatment during the extension period due to six adverse events (AEs); four were treatment-related (ocular hyperemia  erythema  urticaria  respiratory distress)  and two were non-treatment-related (acute myocardial infarction  pancreatic adenocarcinoma).Clinical benefits seen over two years for patients who switched to NexviazymeSubgroup analyses were also performed to assess respiratory function outcomes for the 44 patients who switched to Nexviazyme in the long-term extension period of the Phase 3 COMET study. Patients were divided into two subgroups  responders (n=14) and non-responders (n=30) based on individual responses to initial treatment with alglucosidase alfa  as measured by the change in FVC percent-predicted (ŒîFVC %predicted/year) pre- (baseline-week 49) and post-switch (week 49-week 145). Findings showed clinical benefits over two years following switch to Nexviazyme regardless of prior response to alglucosidase alfa:Patients who responded to alglucosidase alfa treatment in the primary analysis period had increased respiratory function (ŒîFVC slope  4.67¬±1.28%/yr  p<0.001)  which was maintained throughout the extension period with Nexviazyme treatment (ŒîFVC slope  0.14¬±0.94%/yr  p=0.88).Patients who did not respond to alglucosidase alfa treatment in the primary analysis period had reduced respiratory function while taking alglucosidase alfa (ŒîFVC slope  -2.12¬±0.87%/yr  p=0.016); however  switching to Nexviazyme halted this decline in the extension period (ŒîFVC slope  0.15¬±0.61%/yr  p=0.81).About Pompe diseasePeople living with Pompe disease have low levels of the enzyme acid alpha-glucosidase (GAA)  which results in build-up of glycogen in muscle cells throughout the body  leading to irreversible damage to skeletal and cardiac muscles.Pompe disease can present as infantile-onset Pompe disease (IOPD)  the most severe form of the disease with rapid onset in infancy  or late-onset Pompe disease (LOPD)  which progressively damages muscles over time. If left untreated  IOPD can lead to heart failure and death within the first year of life  while people living with LOPD may require mechanical ventilation to help with breathing or a wheelchair to assist with mobility as the disease progresses.About Nexviazyme (avalglucosidase alfa)Nexviazyme (avalglucosidase alfa) is an enzyme replacement therapy (ERT) designed to target the mannose-6-phosphate (M6P) receptor  the key pathway for uptake and transport of ERT. Nexviazyme aims to help improve uptake and enhance glycogen clearance in target tissues with an average 15-fold higher level of M6P moieties as compared to alglucosidase alfa  the comparator therapy in the pivotal study. Nexviazyme is approved in multiple markets around the world for the treatment of people living with Pompe disease  including the United States  the European Union  Japan  Canada  Switzerland  Australia  Brazil  Argentina  Taiwan  the United Arab Emirates  South Korea and the United Kingdom  with specific indications varying by country. In Europe  the medicine is marketed under the brand name Nexviadyme.About SanofiWe are an innovative global healthcare company  driven by one purpose: we chase the miracles of science to improve people‚Äôs lives. Our team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comKate Conway | + 1 508 364 4931 | kate.conway@sanofi.comInvestor RelationsEva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.comArnaud Del√©pine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comCorentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comTarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comSanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995  as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions  statements regarding plans  objectives  intentions  and expectations with respect to future financial results  events  operations  services  product development and potential  and statements regarding future performance. Forward-looking statements are generally identified by the words ‚Äúexpects‚Äù  ‚Äúanticipates‚Äù  ‚Äúbelieves‚Äù  ‚Äúintends‚Äù  ‚Äúestimates‚Äù  ‚Äúplans‚Äù and similar expressions. Although Sanofi‚Äôs management believes that the expectations reflected in such forward-looking statements are reasonable  investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties  many of which are difficult to predict and generally beyond the control of Sanofi  that could cause actual results and developments to differ materially from those expressed in  or implied or projected by  the forward-looking information and statements. These risks and uncertainties include among other things  the uncertainties inherent in research and development  future clinical data and analysis  including post marketing  decisions by regulatory authorities  such as the FDA or the EMA  regarding whether and when to approve any drug  device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates  the fact that product candidates if approved may not be commercially successful  the future approval and commercial success of therapeutic alternatives  Sanofi‚Äôs ability to benefit from external growth opportunities  to complete related transactions and/or obtain regulatory clearances  risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation  trends in exchange rates and prevailing interest rates  volatile economic and market conditions  cost containment initiatives and subsequent changes thereto  and the impact that COVID-19 will have on us  our customers  suppliers  vendors  and other business partners  and the financial condition of any one of them  as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly  and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi  including those listed under ‚ÄúRisk Factors‚Äù and ‚ÄúCautionary Statement Regarding Forward-Looking Statements‚Äù in Sanofi‚Äôs annual report on Form 20-F for the year ended December 31  2022. Other than as required by applicable law  Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.Attachment,neutral,0.0,0.96,0.04,mixed,0.19,0.17,0.63,True,English,"['New Phase 3 data', 'potential new standard', 'late-onset Pompe disease', 'Press release', 'avalglucosidase alfa', 'WORLDSymposium‚Ñ¢', 'Nexviazyme¬Æ', 'care', 'people', 'Duke University Medical Center', 'Alice Chen Pediatrics Genetics', 'double-blind primary analysis period', '100 previously untreated LOPD patients', 'Su Chen Professor', 'Priya S. Kishnani', 'Phase 3 COMET trial', 'six-minute walk test', 'six adverse events', 'acute myocardial infarction', 'late-onset Pompe disease', 'infantile-onset Pompe disease', 'Phase 3 COMET study', 'new safety signals', '96-week extension period', 'open-label extension period', 'potential new standard', 'treatment-na√Øve people', 'New Phase 3 data', 'long-term extension period', 'respiratory function outcomes', 'sustained treatment effect', 'continuous Nexviazyme treatment', 'alglucosidase alfa treatment', 'Medical Genetics', 'Nexviazyme treatment groups', 'study groups', 'separate analysis', 'Genomics Center', 'safety outcomes', 'Medical Director', 'sustained improvements', 'motor function', 'safety profile', 'long-term impact', 'long-term efficacy', 'avalglucosidase alfa', 'English French', 'long-time standard', 'clinical benefit', 'prior response', 'C.L.', 'Division Chief', 'clinical trials', 'wide variety', 'sub-optimal response', 'Bill Sibold', 'Global Head', 'robust body', 'least squares', 'standard error', '1.40 (1.21) point improvement', 'vital capacity', 'average increase', 'walking distance', '1.18 (1.32) point improvement', 'ocular hyperemia', 'respiratory distress', 'Subgroup analyses', 'two subgroups', 'individual responses', 'three years', 'two years', 'initial treatment', 'long-term data', 'other markets', 'five patients', 'Specialty Care', 'FVC percent', 'to 145 weeks', '20 years', '44 patients', 'Nexviazyme¬Æ', 'Nexviazyme (20', '49 weeks', 'WORLDSymposium‚Ñ¢', 'Paris', 'February', 'WORLDSymposiumTM', 'MD', 'YT', 'results', '2023 WORLDSymposium', 'value', 'decline', 'Sanofi', 'evidence', 'durability', 'treatment-experienced', 'findings', 'effort', 'monotherapy', 'IOPD', 'conclusion', 'changes', 'baseline', '20.65 (9.60) meters', 'stabilization', '0.29 (10.42) meters', 'AEs', 'urticaria', 'pancreatic', 'responders', 'switch']",2023-02-24,2023-02-25,globenewswire.com
19265,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SANOFI-4698/news/Press-release-New-Phase-3-data-presented-at-WORLDSymposium-trade-reinforce-Nexviazyme-avalglucos-43081278/?utm_medium=RSS&utm_content=20230224,Press release: New Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease,(marketscreener.com) New Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ as potential new standard of care for all people living with late-onset Pompe disease Paris  February 24  2023. Today  at WORLDSymposiumTM  data from the Phase 3 COMET st‚Ä¶,New Phase 3 data presented at WORLDSymposium‚Ñ¢ reinforce Nexviazyme¬Æ (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe diseaseParis  February 24  2023. Today  at WORLDSymposiumTM  data from the Phase 3 COMET study long-term extension showed sustained treatment effect of Nexviazyme¬Æ (avalglucosidase alfa) over nearly three years in late-onset Pompe disease (LOPD) patients who were treatment-na√Øve as well as those who switched from long-time standard of care  alglucosidase alfa  during the 96-week extension period. Additionally  a separate analysis of respiratory function showed clinical benefit over two years for patients who switched to Nexviazyme regardless of prior response to alglucosidase alfa.Priya S. Kishnani  MDC.L. and Su Chen Professor of Pediatrics; Medical Director  YT and Alice Chen Pediatrics Genetics and Genomics Center; and Division Chief  Medical Genetics  Duke University Medical Center‚ÄúThe results presented at the 2023 WORLDSymposium continue to build on the data from the clinical trials on the value and long-term impact Nexviazyme may provide for a wide variety of people living with late-onset Pompe disease  from newly diagnosed patients to those who have been previously treated with alglucosidase alfa. Further  when examining patients treated with Nexviazyme who switched from using alglucosidase alfa  these data show clinical benefit both for patients who were stable on alglucosidase alfa and those who experienced sub-optimal response or decline.‚ÄùBill SiboldGlobal Head of Specialty Care  Sanofi‚ÄúThese long-term data over nearly three years add to the robust body of evidence that consistently shows the clinical benefit and durability of effect of treatment with Nexviazyme for both treatment-experienced and treatment-na√Øve people living with late-onset Pompe disease. We continue to learn from our 20 years of experience in Pompe disease and build on our findings in an effort to advance the standard of care.‚ÄùNexviazyme is a monotherapy approved in the US and other markets for the treatment of LOPD. It is also approved for infantile-onset Pompe disease (IOPD) in certain markets outside of the US.Nexviazyme maintained treatment effect at 145 weeksThe Phase 3 COMET trial enrolled 100 previously untreated LOPD patients who were randomized to receive either Nexviazyme (20 mg/kg) or alglucosidase alfa (20 mg/kg) every two weeks for 49 weeks during the double-blind primary analysis period. During the open-label extension period  long-term efficacy and safety outcomes were assessed up to 145 weeks in patients who continued their treatment with Nexviazyme (n=51)  as well as those who switched to treatment with Nexviazyme from alglucosidase alfa (n=44) at the conclusion of the primary analysis period (Week 49).After nearly three years (145 weeks)  changes from baseline (least squares mean [standard error]) showed:Patients who received continuous Nexviazyme treatment for 145 weeks experienced sustained improvements in respiratory and motor function  showing a 1.40 (1.21) point improvement in forced vital capacity (FVC) percent-predicted and an average increase of 20.65 (9.60) meters in walking distance as measured by the six-minute walk test (6MWT)  respectively  compared to baseline.Patients who switched from alglucosidase alfa to Nexviazyme treatment during the extension period experienced stabilization of treatment effect  showing a 1.18 (1.32) point improvement in FVC percent-predicted and an average increase of 0.29 (10.42) meters in walking distance (6MWT)  compared to baseline.The safety profile during treatment with Nexviazyme was comparable between both study groups (those who started Nexviazyme in the primary analysis period and those who switched to Nexviazyme during the extension period). No new safety signals were observed in patients who switched from alglucosidase alfa to Nexviazyme during the extension period. Across both Nexviazyme treatment groups  five patients discontinued treatment during the extension period due to six adverse events (AEs); four were treatment-related (ocular hyperemia  erythema  urticaria  respiratory distress)  and two were non-treatment-related (acute myocardial infarction  pancreatic adenocarcinoma).Clinical benefits seen over two years for patients who switched to NexviazymeSubgroup analyses were also performed to assess respiratory function outcomes for the 44 patients who switched to Nexviazyme in the long-term extension period of the Phase 3 COMET study. Patients were divided into two subgroups  responders (n=14) and non-responders (n=30) based on individual responses to initial treatment with alglucosidase alfa  as measured by the change in FVC percent-predicted (ŒîFVC %predicted/year) pre- (baseline-week 49) and post-switch (week 49-week 145). Findings showed clinical benefits over two years following switch to Nexviazyme regardless of prior response to alglucosidase alfa:Patients who responded to alglucosidase alfa treatment in the primary analysis period had increased respiratory function (ŒîFVC slope  4.67¬±1.28%/yr  p<0.001)  which was maintained throughout the extension period with Nexviazyme treatment (ŒîFVC slope  0.14¬±0.94%/yr  p=0.88).Patients who did not respond to alglucosidase alfa treatment in the primary analysis period had reduced respiratory function while taking alglucosidase alfa (ŒîFVC slope  -2.12¬±0.87%/yr  p=0.016); however  switching to Nexviazyme halted this decline in the extension period (ŒîFVC slope  0.15¬±0.61%/yr  p=0.81).About Pompe diseasePeople living with Pompe disease have low levels of the enzyme acid alpha-glucosidase (GAA)  which results in build-up of glycogen in muscle cells throughout the body  leading to irreversible damage to skeletal and cardiac muscles.Pompe disease can present as infantile-onset Pompe disease (IOPD)  the most severe form of the disease with rapid onset in infancy  or late-onset Pompe disease (LOPD)  which progressively damages muscles over time. If left untreated  IOPD can lead to heart failure and death within the first year of life  while people living with LOPD may require mechanical ventilation to help with breathing or a wheelchair to assist with mobility as the disease progresses.About Nexviazyme (avalglucosidase alfa)Nexviazyme (avalglucosidase alfa) is an enzyme replacement therapy (ERT) designed to target the mannose-6-phosphate (M6P) receptor  the key pathway for uptake and transport of ERT. Nexviazyme aims to help improve uptake and enhance glycogen clearance in target tissues with an average 15-fold higher level of M6P moieties as compared to alglucosidase alfa  the comparator therapy in the pivotal study. Nexviazyme is approved in multiple markets around the world for the treatment of people living with Pompe disease  including the United States  the European Union  Japan  Canada  Switzerland  Australia  Brazil  Argentina  Taiwan  the United Arab Emirates  South Korea and the United Kingdom  with specific indications varying by country. In Europe  the medicine is marketed under the brand name Nexviadyme.About SanofiWe are an innovative global healthcare company  driven by one purpose: we chase the miracles of science to improve people‚Äôs lives. Our team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comKate Conway | + 1 508 364 4931 | kate.conway@sanofi.comInvestor RelationsEva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.comArnaud Del√©pine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comCorentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comTarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comSanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995  as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions  statements regarding plans  objectives  intentions  and expectations with respect to future financial results  events  operations  services  product development and potential  and statements regarding future performance. Forward-looking statements are generally identified by the words ‚Äúexpects‚Äù  ‚Äúanticipates‚Äù  ‚Äúbelieves‚Äù  ‚Äúintends‚Äù  ‚Äúestimates‚Äù  ‚Äúplans‚Äù and similar expressions. Although Sanofi‚Äôs management believes that the expectations reflected in such forward-looking statements are reasonable  investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties  many of which are difficult to predict and generally beyond the control of Sanofi  that could cause actual results and developments to differ materially from those expressed in  or implied or projected by  the forward-looking information and statements. These risks and uncertainties include among other things  the uncertainties inherent in research and development  future clinical data and analysis  including post marketing  decisions by regulatory authorities  such as the FDA or the EMA  regarding whether and when to approve any drug  device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates  the fact that product candidates if approved may not be commercially successful  the future approval and commercial success of therapeutic alternatives  Sanofi‚Äôs ability to benefit from external growth opportunities  to complete related transactions and/or obtain regulatory clearances  risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation  trends in exchange rates and prevailing interest rates  volatile economic and market conditions  cost containment initiatives and subsequent changes thereto  and the impact that COVID-19 will have on us  our customers  suppliers  vendors  and other business partners  and the financial condition of any one of them  as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly  and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi  including those listed under ‚ÄúRisk Factors‚Äù and ‚ÄúCautionary Statement Regarding Forward-Looking Statements‚Äù in Sanofi‚Äôs annual report on Form 20-F for the year ended December 31  2022. Other than as required by applicable law  Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.Attachment,neutral,0.0,0.96,0.04,mixed,0.14,0.19,0.67,True,English,"['New Phase 3 data', 'potential new standard', 'late-onset Pompe disease', 'Press release', 'avalglucosidase alfa', 'WORLDSymposium‚Ñ¢', 'Nexviazyme¬Æ', 'care', 'people', 'Phase 3 COMET study long-term extension', 'Duke University Medical Center', 'Alice Chen Pediatrics Genetics', 'double-blind primary analysis period', '100 previously untreated LOPD patients', 'Phase 3 COMET trial', 'Su Chen Professor', 'Priya S. Kishnani', 'six-minute walk test', 'six adverse events', 'acute myocardial infarction', 'late-onset Pompe disease', 'infantile-onset Pompe disease', '96-week extension period', 'open-label extension period', 'new safety signals', 'long-term extension period', 'New Phase 3 data', 'potential new standard', 'treatment-na√Øve people', 'up to 145 weeks', 'respiratory function outcomes', 'sustained treatment effect', 'continuous Nexviazyme treatment', 'alglucosidase alfa treatment', 'study groups', 'Medical Genetics', 'Nexviazyme treatment groups', 'separate analysis', 'Genomics Center', 'safety outcomes', 'long-term impact', 'long-term efficacy', 'Medical Director', 'sustained improvements', 'long-term data', 'safety profile', 'motor function', 'avalglucosidase alfa', 'long-time standard', 'clinical benefit', 'prior response', 'C.L.', 'Division Chief', 'clinical trials', 'wide variety', 'sub-optimal response', 'Bill Sibold', 'Global Head', 'robust body', 'least squares', 'standard error', '1.40 (1.21) point improvement', 'vital capacity', 'average increase', 'walking distance', '1.18 (1.32) point improvement', 'ocular hyperemia', 'respiratory distress', 'Subgroup analyses', 'two subgroups', 'individual responses', 'three years', 'two years', 'initial treatment', 'other markets', 'five patients', 'Specialty Care', 'FVC percent', '20 years', '49 weeks', '44 patients', 'Nexviazyme¬Æ', 'Nexviazyme (20', 'WORLDSymposium‚Ñ¢', 'Paris', 'February', 'WORLDSymposiumTM', 'MD', 'YT', 'results', '2023 WORLDSymposium', 'value', 'decline', 'Sanofi', 'evidence', 'durability', 'treatment-experienced', 'findings', 'effort', 'monotherapy', 'IOPD', 'conclusion', 'changes', 'baseline', '20.65 (9.60) meters', 'stabilization', '0.29 (10.42) meters', 'AEs', 'urticaria', 'pancreatic', 'responders', 'switch']",2023-02-24,2023-02-25,marketscreener.com
19266,EuroNext,NewsApi.org,https://www.prnewswire.com/news-releases/fda-approves-once-weekly-efanesoctocog-alfa-a-new-class-of-high-sustained-factor-viii-therapy-for-haemophilia-a-swedish-orphan-biovitrum-ab-301755196.html,FDA approves once-weekly efanesoctocog alfa  a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB,STOCKHOLM  Feb. 24  2023 /PRNewswire/ -- Sobi¬Æ today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl]  a first-in-class  high-sustained factor VIII ‚Ä¶,"STOCKHOLM  Feb. 24  2023 /PRNewswire/ -- Sobi¬Æ today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl]  a first-in-class  high-sustained factor VIII replacement therapy for adults and children with haemophilia A. Efanesoctocog alfa is the first and only haemophilia A treatment that provides patients with normal to near-normal factor VIII activity levels for a significant part of the week with once-weekly dosing  resulting in superior protection from bleeds compared to existing factor VIII prophylaxis.Haemophilia A is a rare  genetic disorder in which the ability of a person's blood to clot is impaired due to a lack of factor VIII. Haemophilia A occurs in about one in 5 000 male births annually  and more rarely in females. People with haemophilia can experience bleeding episodes that can cause pain  irreversible joint damage and life-threatening haemorrhages. Despite advancements in treatment made in recent years  a large unmet medical need still exists and requires further improvement in the standard of care.""This approval marks an important clinical advancement for the haemophilia community because we have an option that can achieve higher levels of factor activity with a single weekly dose "" said Lynn Malec  MD  Medical Director of Comprehensive Center for Bleeding Disorders and Associate Investigator at Versiti Blood Research Institute  and Associate Professor of Medicine and Pediatrics at The Medical College of Wisconsin  US. ""By maintaining high levels of factor activity throughout the week  patients can be confident in the bleed protection efanesoctocog alfa offers.""""On behalf of Sobi I'd like to congratulate our co-development partner Sanofi on this great achievement "" said Anders Ullman  Head of Research & Development and Medical Affairs  Chief Medical Officer at Sobi. ""This is a major milestone in our collaboration as we work towards providing access to this important new treatment for people living with haemophilia A around the world.""The FDA approval is primarily based on data from the pivotal XTEND-1 phase 3 study recently published in The New England Journal of Medicine. Once-weekly efanesoctocog alfa met the primary endpoint  providing significant improvements in bleed protection for people with severe haemophilia A with median and mean annualised bleeding rates (ABR) of 0.00 (interquartile range: 0.00-1.04) and 0.71 (95% confidence interval: 0.52-0.97)  respectively. Efanesoctocog alfa met the key secondary endpoint with a significant reduction of 77% in ABR versus prior factor prophylaxis based on an intra-patient comparison. Efanesoctocog alfa prophylaxis with 50IU/kg/week provided mean factor VIII activity greater than 40% for the majority of the week with a trough activity of 15% on day seven  and these levels were associated with a low bleed risk.Additional data showed prevention of joint bleeds with a median annualised joint bleeding rate of 0 (Q1  Q3: 0.0  1.0). Treatment with efanesoctocog alfa provided 100% resolution of target joints  which are joints that have recurrent bleeds (e.g.  knee  ankle  or elbow). In adults and adolescents  efanesoctocog alfa had a favourable safety profile and there were no signs of factor VIII inhibitor development.Efanesoctocog alfa is indicated in the US for routine prophylaxis  on-demand treatment and control of bleeding episodes  and perioperative management of bleeding. The recommended weekly dose of 50 IU/kg is intended for prophylaxis in patients of all ages and the same dose can be administered according to needs in different clinical settings. Efanesoctocog alfa is expected to be commercially available in the US starting in the second quarter of 2023 and will be marketed as ALTUVIIIO‚Ñ¢ in Sanofi territories.The FDA evaluated the application under Priority Review  which is granted to therapies that have the potential to provide significant improvements in the treatment  diagnosis  or prevention of serious conditions.Regulatory submission in the EU will follow the availability of final data from the XTEND-Kids paediatric study in the first half of 2023. The European Commission granted orphan designation in June 2019.About efanesoctocog alfaEfanesoctocog alfa (formerly BIVV001) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for most of the week  extending bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN¬Æ polypeptides to potentially extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling  which is believed to impose a half-life limitation on current factor VIII therapies. It is approved as ALTUVIIIO [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the US. It is not approved in any country outside the US.About the Sanofi and Sobi collaborationSobi and Sanofi collaborate on the development and commercialisation of Alprolix¬Æ and Elocta¬Æ/Eloctate¬Æ. The companies also collaborate on the development and commercialisation of efanesoctocog alfa or ALTUVIIIO in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe  North Africa  Russia and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.SanofiSanofi are an innovative global healthcare company  driven by one purpose: to chase the miracles of science to improve people's lives. Their team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the centre of our ambitions. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY.Sobi¬ÆSobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology  immunology and specialty care  Sobi has approximately 1 600 employees across Europe  North America  the Middle East  Asia and Australia. In 2022  revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com  LinkedIn and YouTube.ContactsFor details on how to contact the Sobi Investor Relations Team  please click here. For Sobi Media contacts  click here.Swedish Orphan Biovitrum AB (publ)Postal address SE-112 76 Stockholm  SwedenPhone: 46 8 697 20 00www.sobi.comThe following files are available for download:https://mb.cision.com/Main/14266/3722707/1872777.pdf FDA approves once-weekly efanesoctocog alfaSOURCE Swedish Orphan Biovitrum AB",neutral,0.0,1.0,0.0,mixed,0.17,0.16,0.67,True,English,"['high-sustained factor VIII therapy', 'Swedish Orphan Biovitrum AB', 'efanesoctocog alfa', 'new class', 'haemophilia A', 'FDA', 'high-sustained factor VIII replacement therapy', 'investigational recombinant factor VIII therapy', 'median annualised joint bleeding rate', 'normal factor VIII activity levels', 'pivotal XTEND-1 phase 3 study', 'current factor VIII therapies', 'innovative Fc fusion technology', 'mean annualised bleeding rates', 'large unmet medical need', 'mean factor VIII activity', 'The New England Journal', 'von Willebrand factor ceiling', 'existing factor VIII prophylaxis', 'factor VIII inhibitor development', 'near-normal factor activity levels', 'Versiti Blood Research Institute', 'haemophilia A. Efanesoctocog alfa', 'Fc-VWF-XTEN Fusion Protein-ehtl', 'irreversible joint damage', 'prior factor prophylaxis', 'rare, genetic disorder', 'important clinical advancement', 'low bleed risk', 'favourable safety profile', 'different clinical settings', 'The European Commission', 'The Medical College', 'Chief Medical Officer', 'key secondary endpoint', 'important new treatment', 'efanesoctocog alfa offers', 'single weekly dose', 'Efanesoctocog alfa prophylaxis', 'weekly efanesoctocog alfa', 'The FDA approval', 'Antihemophilic Factor', 'joint bleeds', 'trough activity', 'higher levels', 'Medical Director', 'high levels', 'Medical Affairs', 'bleeding episodes', 'Bleeding Disorders', 'routine prophylaxis', 'primary endpoint', 'weekly dosing', 'development partner', 'same dose', 'Drug Administration', 'significant part', '5,000 male births', 'life-threatening haemorrhages', 'recent years', 'Lynn Malec', 'Comprehensive Center', 'Associate Investigator', 'Associate Professor', 'great achievement', 'Anders Ullman', 'major milestone', 'significant improvements', 'interquartile range', 'significant reduction', 'intra-patient comparison', 'recurrent bleeds', 'perioperative management', 'second quarter', 'Priority Review', 'serious conditions', 'Regulatory submission', 'orphan designation', 'XTEN¬Æ polypeptides', 'half-life limitation', 'haemophilia community', 'severe haemophilia', 'Additional data', 'final data', 'target joints', 'demand treatment', 'first half', 'Sanofi territories', 'superior protection', 'US Food', 'PRNewswire', 'Sobi¬Æ', 'adults', 'children', 'only', 'patients', 'ability', 'person', 'lack', 'females', 'People', 'pain', 'advancements', 'standard', 'care', 'option', 'MD', 'Medicine', 'Pediatrics', 'Wisconsin', 'behalf', 'Head', 'collaboration', 'access', 'world', 'ABR', '50IU/kg', 'majority', 'day', 'seven', 'prevention', '100% resolution', 'knee', 'ankle', 'elbow', 'adolescents', 'signs', 'control', '50 IU', 'needs', 'ALTUVIIIO‚Ñ¢', 'application', 'potential', 'diagnosis', 'June', 'novel', 'region', 'time', 'circulation', 'country']",2023-02-24,2023-02-25,prnewswire.com
19267,EuroNext,NewsApi.org,https://www.prnewswire.com/news-releases/legrand-north-america-announces-opening-of-newest-distribution-center-in-dayton-301755606.html,LEGRAND NORTH AMERICA ANNOUNCES OPENING OF NEWEST DISTRIBUTION CENTER IN DAYTON,Electrical Giant Expands Footprint In Centrally Located Western Ohio. The Resulting New Distribution Network Will Allow For The Majority Of Customer Base To Be Within A 2-Day Transit Time. DAYTON  Ohio  Feb. 24  2023 /PRNewswire/ -- Legrand¬Æ  a world leader i‚Ä¶,"Electrical Giant Expands Footprint In Centrally Located Western Ohio. The Resulting New Distribution Network Will Allow For The Majority Of Customer Base To Be Within A 2-Day Transit Time.DAYTON  Ohio  Feb. 24  2023 /PRNewswire/ -- Legrand¬Æ   a world leader in electrical  digital infrastructure  and connected solutions  has officially opened a larger operations facility in the Dayton area. This latest opening will provide over 200 new jobs to the Dayton area and enhance the company's ability to serve its customers quicker in shipment times across all of America.LEGRAND NORTH AMERICA ANNOUNCES OPENING OF NEWEST DISTRIBUTION CENTER IN DAYTONThe 625 000 square-feet operations facility  located at 2200 Douglas Way  Union OH  is a state-of-the-art distribution center that will enhance the company's ability to meet the growing demand for electrical and digital building infrastructures as well as connected solutions across America. The facility features technology and equipment that will increase production and maintain quality control  ensuring that customers receive the best products available.Legrand is committed to sustainability  and the opening of the Dayton facility supports that commitment through various approaches. Notably  the building is on track to receive Green Globes Level One Certification. In addition  the new centrally located facility  coupled with existing West Coast and Southern Distribution centers will service customers more efficiently reducing freight and carbon emissions.This latest expansion will bring new jobs to Dayton  with Legrand hiring for positions ranging from production and warehouse to office and management. This growth is a testament to Legrand's commitment to providing exceptional customer service and delivering high-quality solutions to customers.Each aspect of the facility features and highlights Legrand's notable brands including:Architectural and industrial lighting from Kenall  Finelite  OCL  and Pinnacle.Automated window shades from Legrand Commercial Shading.Electrical wiring devices from Legrand's radiant Collection and Cablofil wire management.Data room outfitted with Legrand Minkels technology.Productivity enabling technologies from Legrand's AV division  such as Middle Atlantic  Chief  Vaddio  Da-Lite  C2G.As a result  this facility truly showcases Legrand's deep expertise in the space and creates a highly functional environment for its employees.""We are thrilled to expand our footprint in Dayton and continue to support the thriving community "" said Dan Carsten  Vice President of Operational Excellence and Logistics of Legrand North America. ""Our goal is to provide our customers with the highest quality products and exceptional customer service  and this our newest facility will allow us to do this.""""Our investment into Montgomery County worked to develop the site for long-term sustainability by putting the site into production  generating taxes into the community  and further strengthening the economy through job creation "" said Matt Gaston  Vice President of Development at NorthPoint Development. ""The expansion of Legrand's operations into Montgomery County further supports the thriving community here in Dayton  as well as the region as a whole.""About Legrand and Legrand  North and Central AmericaLegrand is the global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for commercial  industrial  and residential markets makes it a benchmark for customers worldwide. The Group harnesses technological and societal trends with lasting impacts on buildings with the purpose of improving life by transforming the spaces where people live  work and meet with electrical  digital infrastructures and connected solutions that are simple  innovative and sustainable. Drawing on an approach that involves all teams and stakeholders  Legrand is pursuing its strategy of profitable and responsible growth driven by acquisitions and innovation  with a steady flow of new offerings‚Äîincluding products with enhanced value in use (faster expanding segments: data centers  connected offerings and energy efficiency programs). Legrand reported sales of ‚Ç¨7.0 billion in 2021. The company is listed on Euronext Paris and is notably a component stock of the CAC 40 and CAC 40 ESG indexes. (code ISIN FR0010307819). https://www.legrand.us/SOURCE Legrand",neutral,0.0,1.0,0.0,positive,0.81,0.19,0.0,True,English,"['LEGRAND NORTH AMERICA ANNOUNCES', 'NEWEST DISTRIBUTION CENTER', 'OPENING', 'DAYTON', 'Green Globes Level One Certification', 'LEGRAND NORTH AMERICA ANNOUNCES', '2-Day Transit Time', 'art distribution center', 'existing West Coast', 'faster expanding segments', 'energy efficiency programs', 'exceptional customer service', 'NEWEST DISTRIBUTION CENTER', 'Southern Distribution centers', 'digital building infrastructures', 'New Distribution Network', 'electrical, digital infrastructure', 'Electrical wiring devices', 'Cablofil wire management', 'CAC 40 ESG indexes', 'Legrand Commercial Shading', 'highest quality products', 'larger operations facility', '625,000 square-feet operations facility', 'Central America Legrand', 'Legrand Minkels technology', 'Customer Base', 'quality control', 'data centers', 'newest facility', '200 new jobs', 'new offerings', 'Electrical Giant', 'world leader', 'shipment times', '2200 Douglas Way', 'Union OH', 'growing demand', 'best products', 'various approaches', 'carbon emissions', 'notable brands', 'industrial lighting', 'window shades', 'radiant Collection', 'Data room', 'AV division', 'Middle Atlantic', 'deep expertise', 'functional environment', 'Dan Carsten', 'Vice President', 'Operational Excellence', 'Montgomery County', 'job creation', 'Matt Gaston', 'global specialist', 'comprehensive offering', 'residential markets', 'The Group', 'societal trends', 'lasting impacts', 'steady flow', 'enhanced value', 'connected offerings', 'Euronext Paris', 'component stock', 'code ISIN', 'facility features', 'connected solutions', 'high-quality solutions', 'thriving community', 'SOURCE Legrand', 'Western Ohio', 'latest expansion', 'long-term sustainability', 'NorthPoint Development', 'responsible growth', 'Dayton area', 'latest opening', 'Dayton facility', 'Legrand¬Æ', 'Footprint', 'Majority', 'Feb.', 'PRNewswire', 'company', 'customers', 'equipment', 'production', 'commitment', 'track', 'addition', 'freight', 'positions', 'warehouse', 'office', 'testament', 'aspect', 'highlights', 'Architectural', 'Kenall', 'Finelite', 'OCL', 'Pinnacle', 'Productivity', 'technologies', 'Chief', 'Vaddio', 'Da-Lite', 'C2G', 'result', 'space', 'employees', 'Logistics', 'goal', 'investment', 'site', 'taxes', 'economy', 'region', 'benchmark', 'technological', 'buildings', 'purpose', 'life', 'people', 'teams', 'stakeholders', 'strategy', 'profitable', 'acquisitions', 'innovation', 'sales']",2023-02-24,2023-02-25,prnewswire.com
19268,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/VINCI-4725/news/Description-of-the-2023-2024-treasury-share-buy-back-programme-submitted-by-the-Board-of-Directors-43081904/?utm_medium=RSS&utm_content=20230224,Description of the 2023-2024 treasury share buy-back programme submitted by the Board of Directors for the approval of the Combined General Meeting of Shareholders of 13 April 2023,(marketscreener.com) French public limited company with share capital of ‚Ç¨1 476 302 545.00 Registered office: 1973 boulevard de la D√©fense  F-92000 Nanterre 552 037 806 RCS Nanterre www.vinci.com _____________________________________________________ Descripti‚Ä¶,Description of the 2023-2024 treasury share buy-back programme submitted by the Board of Directors for the approval of the Combined General Meeting of Shareholders of 13 April 2023 02/24/2023 | 11:46am EST Send by mail :Name : First name : From * : To * : (You can enter multiple email addresses separated by commas) Message : * Required fields French public limited company (soci√©t√© anonyme) with share capital of ‚Ç¨1 476 302 545.00 Registered office: 1973 boulevard de la D√©fense  F-92000 Nanterre 552 037 806 RCS Nanterre www.vinci.com _____________________________________________________ Description of the 2023-2024 treasury share buy-back programme submitted by the Board of Directors for the approval of the Combined General Meeting of Shareholders of 13 April 2023 _________________________________________________________________________ I-Summary The shares concerned by the 2023-2024 buy-back programme are VINCI shares listed for trading in the A Compartment of the regulated market of NYSE Euronext in Paris under ISIN code FR0000125486.The programme offers the possibility of purchasing shares up to a maximum of 10% of the number of shares making up the Company‚Äôs share capital over a period of 18 months from 13 April 2023 to 12 October 2024 (see duration of programme below). This limit is based on the number of shares making up the share capital at the time of the purchases. Since the programme provides for the possibility of using derivatives in performing it  the treasury shares that the Company could purchase through the exercise of the share purchase options that it may have bought previously will be included in the calculation of the maximum number of shares authorised over the 18-month duration of the programme  at the time of the purchase of these share purchase options  and not at the time of their exercise  if any. Maximum purchase price : ‚Ç¨140.: ‚Ç¨140. Maximum amount of purchases authorised : ‚Ç¨4 billion.: ‚Ç¨4 billion. The purchase cost of any derivatives used by the Company in connection with the programme shall be recognised in the maximum amount authorised at the time they are put in place. The amount relating to the price of any treasury shares acquired through the exercise of share purchase options shall only be recognised at the time of their exercise. Additional amounts that may be allocated to the liquidity agreement shall be recognised in the maximum amount of purchases authorised.Objectives : (1) disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law  share and/or share purchase option allocation plans; (2) cancellation of shares; (3) delivery of shares pursuant to the exercise of the rights attached to securities giving access to the share capital; (4) transfers of shares for payment or exchange purposes  in particular in connection with transactions involving external growth; (5) ensuring market liquidity under a liquidity agreement that complies with a code of ethics recognised by the Autorit√© des March√©s Financiers (AMF  the French financial markets regulator) and entrusted to an investment service provider acting independently; and (6) implementation of any market practice  any objective or any transaction that would be accepted under laws or regulations in force or by the AMF with respect to share buy-back programmes.: (1) disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law  share and/or share purchase option allocation plans; (2) cancellation of shares; (3) delivery of shares pursuant to the exercise of the rights attached to securities giving access to the share capital; (4) transfers of shares for payment or exchange purposes  in particular in connection with transactions involving external growth; (5) ensuring market liquidity under a liquidity agreement that complies with a code of ethics recognised by the Autorit√© des March√©s Financiers (AMF  the French financial markets regulator) and entrusted to an investment service provider acting independently; and (6) implementation of any market practice  any objective or any transaction that would be accepted under laws or regulations in force or by the AMF with respect to share buy-back programmes. Duration of the programme : 18 months from the approval of the Combined Shareholders‚Äô General Meeting of 13 April 2023  i.e. until 12 October 2024. II-Objectives of the 2023-2024 share buy-back programme: use of shares purchased VINCI wishes to implement a new share buy-back programme with the objectives described below. 1. Disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law  share and/or share purchase option allocation plans  including disposals to any approved service provider appointed to design  implement and manage any employee savings UCITS or similar employee savings structure on behalf of the VINCI Group  and pledges of shares as guarantees under employee savings plans. 2. Cancellation  as part of the Company‚Äôs financial policy  of the shares thus purchased  subject to the adoption of the fifteenth resolution of the 13 April 2023 Shareholders‚Äô General Meeting. 3. Fulfilment of obligations to transfer or exchange shares pursuant to the exercise of the rights attached to securities giving access to the Company‚Äôs share capital. 4. Transfers of shares for payment or exchange purposes  in particular in connection with transactions involving external growth. 5. Market-making through a liquidity agreement that complies with a code of ethics recognised by the AMF and entrusted to an investment service provider acting independently. 6. Implementation of any market practice  any objective or any transaction that would be accepted under laws or regulations in force or by the AMF with respect to share buy-back programmes. The shares purchased and retained by VINCI shall not carry any voting rights and shall not give right to the payment of dividends. The Company reserves the right to use derivatives in implementing this new programme. Furthermore  in compliance with the applicable legal and regulatory provisions  including those relating to stock exchange disclosure requirements  it reserves the right to carry out authorised reallocations of shares purchased in view of one of the programme‚Äôs objectives to one or more of its other objectives  or to sell them on-market or off-market through an investment service provider acting independently. III-Legal framework This programme is within the framework of the provisions of Articles L.22-10-62 et seq. and Articles L.225-210 to L.225-212 of the French Commercial Code and shall be submitted on 13 April 2023 to VINCI‚Äôs Shareholders‚Äô General Meeting  acting in accordance with the quorum and majority requirements for ordinary (tenth resolution) and extraordinary (fifteenth resolution) shareholders‚Äô meetings: Tenth resolution Renewal of the delegation of powers to the Board of Directors in view of the purchase by the Company of its own shares The Shareholders‚Äô General Meeting  having taken note of (a) the Report of the Board of Directors and (b) the description of the new 2023-2024 share buy-back programme  in accordance with the provisions of Articles L.22-10-62 et seq. and Articles L.225-210 et seq. of the French Commercial Code as well as European regulation 596/2014 of 16 April 2014 on market abuse  authorises the Board of Directors  with the ability to sub-delegate such powers  within the limits provided for by law and regulations  on one or more occasions  on the stock market or otherwise  including by blocks of shares or through the use of options or derivatives  to purchase the Company‚Äôs shares for the conduct of the following: 1. disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law  share and/or share purchase option allocation plans  including any disposals to any approved service provider appointed for the design  implementation and management of any employee savings UCITS or similar structure on behalf of the VINCI Group  and pledges of shares as guarantee under employee savings plans; 2. cancellation  as part of the Company‚Äôs financial policy  of the shares thus purchased  subject to the adoption of the fifteenth resolution hereunder; 3. transfers or exchanges of shares upon the exercise of the rights attached to securities giving access to the Company‚Äôs share capital; 4. retention and future delivery for payment or exchange purposes in connection with transactions involving external growth; 5. ensuring market liquidity within the framework of a liquidity agreement that complies with a code of ethics recognised by the Autorit√© des March√©s Financiers and entrusted to an investment service provider acting independently; 6. implementation of any market practice  any objective or any transaction that may be accepted by laws or regulations or in force or by the Autorit√© des March√©s Financiers in respect of share buy-back programmes. The maximum purchase price per share is set at ‚Ç¨140. The maximum number of shares purchased by virtue of this authorisation shall not exceed 10% of the share capital. This limit is calculated at the time of the purchases and the maximum amount of shares thus purchased shall not exceed ‚Ç¨4 billion. The share purchase price shall be adjusted by the Board of Directors in the event of transactions involving the Company‚Äôs capital in compliance with the conditions provided for by the applicable regulations. In particular  in the event of a capital increase through the capitalisation of reserves and the allotment of performance shares  the price specified above shall be adjusted by a multiplier equal to the ratio of the number of shares making up the share capital before the transaction to the number of shares after the transaction. The acquisition  disposal  transfer  allotment or exchange of these shares may be carried out by any means that are authorised or that may become authorised by regulations in force  either on-market or off-market  including block transactions or through the use of derivatives  in particular through share purchase options in accordance with the regulations in force. There is no restriction on the proportion of the share buy-back programme that may be carried out through block transactions. These transactions may be carried out at any time in compliance with the current regulations  except during a public offering period. The Shareholders‚Äô General Meeting grants full powers to the Board of Directors  including the ability to delegate such powers  so that  in compliance with the applicable legal and regulatory provisions  including those on stock exchange disclosure requirements  it may proceed with the authorised reallocations of the shares purchased in view of one of the programme‚Äôs objectives to one or more of its other objectives  or sell them on-market or off-market  it being specified that these reallocations and disposals may concern shares purchased pursuant to previously authorised share buy-back programmes. The Shareholders‚Äô General Meeting grants full powers to the Board of Directors  including the ability to delegate such powers  for the purpose of placing stock market orders  signing any deed of purchase  sale or transfer  entering into any agreement  carrying out any necessary adjustments  making all declarations and completing all formalities. This authorisation is granted for a period of 18 months from the date of this Shareholders‚Äô General Meeting. It renders ineffective and replaces the authorisation granted by the Shareholders‚Äô General Meeting on 12 April 2022 in its tenth resolution. Fifteenth resolution Renewal of the authorisation granted to the Board of Directors in view of the reduction of the share capital through cancellation of VINCI shares held in treasury The Shareholders‚Äô General Meeting  voting under the quorum and majority conditions required for Extraordinary Shareholders‚Äô General Meetings  having considered the Report of the Board of Directors and the Special Report of the Statutory Auditors  in accordance with the provisions of Article L.22-10-62 of the French Commercial Code  authorises the Board of Directors to cancel  at its sole discretion  on one or more occasions  within the limit of 10% of the number of shares making up the share capital on the date when the Board of Directors takes a decision to cancel and over successive periods of 24 months for the determination of this limit  the shares purchased by virtue of the authorisations granted to the Company to purchase its own shares  and to proceed with a reduction in share capital equivalent to that amount. The Shareholders‚Äô General Meeting establishes the validity of this authorisation at 26 months as from the date of the present Meeting and grants full powers to the Board of Directors  including the powers to delegate such powers  to take all decisions necessary for the cancellation of shares and reduction of the share capital  to recognise the difference between the purchase price and the nominal value of the shares in the reserve account of its choice  including the account for ‚Äúshare premiums arising on contributions or mergers‚Äù  to perform all actions  formalities or declarations to finalise the reductions in capital which may be carried out by virtue of this authorisation  and to amend the Company‚Äôs Articles of Association accordingly. This authorisation renders ineffective and replaces the authorisation granted by the Shareholders‚Äô General Meeting on 12 April 2022 in its fifteenth resolution. IV-Arrangements 1. Maximum proportion of the share capital that may be acquired and maximum amount payable by VINCI The maximum proportion of the share capital that VINCI may acquire is 10% of the share capital on the date of the Combined Shareholders‚Äô General Meeting. However  in the event of a change in the share capital after that date  the authorisation granted by the General Meeting would apply to 10% of the new share capital. The maximum purchase price per share is set at ‚Ç¨140. The maximum total amount of capital that may be allocated to share purchases by virtue of this programme amounts to ‚Ç¨4 billion. This maximum amount shall apply for all transactions carried out from 13 April 2023 over the duration of the programme: purchases of treasury shares  acquisitions of derivatives on treasury shares  treasury share subscriptions through the exercise of derivatives previously put in place  additional amounts that may be allocated to the liquidity agreement. The Company reserves the right to use the entire programme. VINCI shall ensure that it does not directly or indirectly exceed the buy-back ceiling of 10% of the share capital authorised by the Shareholders‚Äô General Meeting over the programme‚Äôs 18-month term. It shall furthermore ensure that it does not own at any time  directly or indirectly  more than 10% of its share capital. Moreover  the share buy-back programme shall not have any significant impact on VINCI‚Äôs free float  which amounted to 82.4% of the share capital on 31 December 2022. The amount of the Company‚Äôs available reserves  which was ‚Ç¨29 144 million at 31 December 2022  is  as required by law  higher than the amount of the share buy-back programme. 2. Share buy-back arrangements Shares may be purchased fully or partly by any means that are authorised or that may become authorised by regulations in force  either on-market or off-market  including block transactions or through the use of derivatives  including through share purchase options in accordance with regulations in force. The Company shall be careful not to increase the volatility of its share price if it uses derivatives. These transactions may be carried out at any time in compliance with the current regulations  except during a public offering period. The proposed authorisation submitted to the General Meeting does not restrict the proportion of the programme that may be carried out through the acquisition of blocks of shares. 3. Duration and timeframe of the share purchase and cancellation programme Share purchases may be carried out over a period of 18 months following the date of the Shareholders‚Äô General Meeting  i.e. from 13 April 2023 until 12 October 2024. Pursuant to paragraph 4 of Article L.22-10-62 of the French Commercial Code  the shares purchased can only be cancelled up to a limit of 10% of the share capital over successive rolling periods of 24 months. 4. Use of derivatives VINCI reserves the right to use derivatives for the implementation of this programme in order to cover  under current regulations  option positions that it has taken separately (such as share subscription or purchase options granted or issued debt securities giving access to the share capital). Information on the use of derivatives on treasury shares is systematically provided to the Board of Directors. Board of Directors of VINCI and  by delegation of the Board of Directors  ________________________ Xavier Huillard Chairman and Chief Executive Officer le 23 February 2023 This document  which constitutes the 2023-2024 share buy-back programme submitted for the approval of VINCI‚Äôs Shareholders‚Äô General Meeting on 13 April 2023  is available free of charge on request from: VINCI Shareholder Relations Department 1973 boulevard de la D√©fense  F-92000 Nanterre. It is available online on the VINCI website (www.vinci.com) and has been filed with the Autorit√© des March√©s Financiers. Attachment 20230130_Descriptif_PRA_2023-2024_VAAll news about VINCI 02/24 Description of the 2023-2024 treasury share buy-back programme submitted by the Board .. GL 02/23 Vinci : 2022 Cofiroute financial report - English PU 02/23 Vinci : ASF Annual financial report at 31 December 2022 - English PU 02/23 Vinci : ASF Annual financial report at 31 December 2022 - French PU 02/21 VINCI : RBC reaffirms its Buy rating MD 02/20 Disclosure of transactions in own shares From February 13th to February 17th  2023 GL 02/20 Disclosure of transactions in own shares From February 13th to February 17th  2023 GL 02/20 VINCI : UBS maintains a Buy rating MD 02/17 VINCI : JP Morgan reaffirms its Buy rating MD 02/16 VINCI : UBS reaffirms its Buy rating MD Analyst Recommendations on VINCI 02/21 VINCI : RBC reaffirms its Buy rating MD 02/20 VINCI : UBS maintains a Buy rating MD 02/17 VINCI : JP Morgan reaffirms its Buy rating MD,neutral,0.0,1.0,0.0,neutral,0.0,0.99,0.0,True,English,"['2023-2024 treasury share buy-back programme', 'Combined General Meeting', 'Description', 'Board', 'Directors', 'approval', 'Shareholders', '13 April', '1973 boulevard de la D√©fense', 'share purchase option allocation plans', '2023-2024 treasury share buy-back programme', 'des March√©s Financiers', 'French financial markets regulator', '2023-2024 share buy-back programme', 'new share buy-back programme', 'French public limited company', 'Combined Shareholders‚Äô General Meeting', '2023-2024 buy-back programme', 'Combined General Meeting', 'share purchase options', 'share ownership plan', 'multiple email addresses', 'soci√©t√© anonyme', 'VINCI Group companies', 'investment service provider', 'Maximum purchase price', 'buy-back programmes', 'savings plans', 'purchase cost', 'share capital', 'treasury shares', 'A Compartment', 'regulated market', 'NYSE Euronext', 'Additional amounts', 'liquidity agreement', 'foreign law', 'exchange purposes', 'external growth', 'market liquidity', 'market practice', 'company officers', 'Maximum amount', 'VINCI shares', 'First name', 'RCS Nanterre', 'eligible employees', 'ISIN code', 'maximum number', '18-month duration', 'Company shares', '2000 Nanterre', 'Description', 'Board', 'Directors', 'approval', '13 April', 'commas', 'Message', 'fields', 'Summary', 'trading', 'Paris', 'possibility', 'period', '18 months', '12 October', 'time', 'purchases', 'derivatives', 'exercise', 'calculation', 'connection', 'place', 'Objectives', 'disposals', 'transfers', 'context', 'cancellation', 'delivery', 'rights', 'securities', 'access', 'payment', 'transactions', 'ethics', 'AMF', 'implementation', 'laws', 'regulations', 'force', 'respect', 'use']",2023-02-24,2023-02-25,marketscreener.com
19269,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/24/2615439/0/en/Description-of-the-2023-2024-treasury-share-buy-back-programme-submitted-by-the-Board-of-Directors-for-the-approval-of-the-Combined-General-Meeting-of-Shareholders-of-13-April-2023.html,Description of the 2023-2024 treasury share buy-back programme submitted by the Board of Directors for the approval of the Combined General Meeting of Shareholders of 13 April 2023,French public limited company (soci√©t√© anonyme) with share capital of ‚Ç¨1 476 302 545.00  Registered office: 1973 boulevard de la D√©fense  F-92000 Nanterre...,English FrenchFrench public limited company (soci√©t√© anonyme) with share capital of ‚Ç¨1 476 302 545.00Registered office: 1973 boulevard de la D√©fense  F-92000 Nanterre552 037 806 RCS Nanterrewww.vinci.com_____________________________________________________Description of the 2023-2024 treasury share buy-back programmesubmitted by the Board of Directorsfor the approval of the Combined General Meeting of Shareholders of 13 April 2023_________________________________________________________________________I-SummaryThe shares concerned by the 2023-2024 buy-back programme are VINCI shares listed for trading in the A Compartment of the regulated market of NYSE Euronext in Paris under ISIN code FR0000125486.The programme offers the possibility of purchasing shares up to a maximum of 10% of the number of shares making up the Company‚Äôs share capital over a period of 18 months from 13 April 2023 to 12 October 2024 (see duration of programme below). This limit is based on the number of shares making up the share capital at the time of the purchases.Since the programme provides for the possibility of using derivatives in performing it  the treasury shares that the Company could purchase through the exercise of the share purchase options that it may have bought previously will be included in the calculation of the maximum number of shares authorised over the 18-month duration of the programme  at the time of the purchase of these share purchase options  and not at the time of their exercise  if any.Maximum purchase price : ‚Ç¨140.: ‚Ç¨140. Maximum amount of purchases authorised : ‚Ç¨4 billion.: ‚Ç¨4 billion. The purchase cost of any derivatives used by the Company in connection with the programme shall be recognised in the maximum amount authorised at the time they are put in place. The amount relating to the price of any treasury shares acquired through the exercise of share purchase options shall only be recognised at the time of their exercise. Additional amounts that may be allocated to the liquidity agreement shall be recognised in the maximum amount of purchases authorised.Objectives : (1) disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law  share and/or share purchase option allocation plans; (2) cancellation of shares; (3) delivery of shares pursuant to the exercise of the rights attached to securities giving access to the share capital; (4) transfers of shares for payment or exchange purposes  in particular in connection with transactions involving external growth; (5) ensuring market liquidity under a liquidity agreement that complies with a code of ethics recognised by the Autorit√© des March√©s Financiers (AMF  the French financial markets regulator) and entrusted to an investment service provider acting independently; and (6) implementation of any market practice  any objective or any transaction that would be accepted under laws or regulations in force or by the AMF with respect to share buy-back programmes.: (1) disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law  share and/or share purchase option allocation plans; (2) cancellation of shares; (3) delivery of shares pursuant to the exercise of the rights attached to securities giving access to the share capital; (4) transfers of shares for payment or exchange purposes  in particular in connection with transactions involving external growth; (5) ensuring market liquidity under a liquidity agreement that complies with a code of ethics recognised by the Autorit√© des March√©s Financiers (AMF  the French financial markets regulator) and entrusted to an investment service provider acting independently; and (6) implementation of any market practice  any objective or any transaction that would be accepted under laws or regulations in force or by the AMF with respect to share buy-back programmes. Duration of the programme : 18 months from the approval of the Combined Shareholders‚Äô General Meeting of 13 April 2023  i.e. until 12 October 2024.II-Objectives of the 2023-2024 share buy-back programme: use of shares purchasedVINCI wishes to implement a new share buy-back programme with the objectives described below.1. Disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law  share and/or share purchase option allocation plans  including disposals to any approved service provider appointed to design  implement and manage any employee savings UCITS or similar employee savings structure on behalf of the VINCI Group  and pledges of shares as guarantees under employee savings plans.2. Cancellation  as part of the Company‚Äôs financial policy  of the shares thus purchased  subject to the adoption of the fifteenth resolution of the 13 April 2023 Shareholders‚Äô General Meeting.3. Fulfilment of obligations to transfer or exchange shares pursuant to the exercise of the rights attached to securities giving access to the Company‚Äôs share capital.4. Transfers of shares for payment or exchange purposes  in particular in connection with transactions involving external growth.5. Market-making through a liquidity agreement that complies with a code of ethics recognised by the AMF and entrusted to an investment service provider acting independently.6. Implementation of any market practice  any objective or any transaction that would be accepted under laws or regulations in force or by the AMF with respect to share buy-back programmes.The shares purchased and retained by VINCI shall not carry any voting rights and shall not give right to the payment of dividends.The Company reserves the right to use derivatives in implementing this new programme.Furthermore  in compliance with the applicable legal and regulatory provisions  including those relating to stock exchange disclosure requirements  it reserves the right to carry out authorised reallocations of shares purchased in view of one of the programme‚Äôs objectives to one or more of its other objectives  or to sell them on-market or off-market through an investment service provider acting independently.III-Legal frameworkThis programme is within the framework of the provisions of Articles L.22-10-62 et seq. and Articles L.225-210 to L.225-212 of the French Commercial Code and shall be submitted on 13 April 2023 to VINCI‚Äôs Shareholders‚Äô General Meeting  acting in accordance with the quorum and majority requirements for ordinary (tenth resolution) and extraordinary (fifteenth resolution) shareholders‚Äô meetings:Tenth resolutionRenewal of the delegation of powers to the Board of Directors in view of the purchase by the Company of its own sharesThe Shareholders‚Äô General Meeting  having taken note of (a) the Report of the Board of Directors and (b) the description of the new 2023-2024 share buy-back programme  in accordance with the provisions of Articles L.22-10-62 et seq. and Articles L.225-210 et seq. of the French Commercial Code as well as European regulation 596/2014 of 16 April 2014 on market abuse  authorises the Board of Directors  with the ability to sub-delegate such powers  within the limits provided for by law and regulations  on one or more occasions  on the stock market or otherwise  including by blocks of shares or through the use of options or derivatives  to purchase the Company‚Äôs shares for the conduct of the following:1. disposals or transfers of Company shares to eligible employees and/or company officers of VINCI Group companies in the context of savings plans or any share ownership plan governed by French or foreign law  share and/or share purchase option allocation plans  including any disposals to any approved service provider appointed for the design  implementation and management of any employee savings UCITS or similar structure on behalf of the VINCI Group  and pledges of shares as guarantee under employee savings plans;2. cancellation  as part of the Company‚Äôs financial policy  of the shares thus purchased  subject to the adoption of the fifteenth resolution hereunder;3. transfers or exchanges of shares upon the exercise of the rights attached to securities giving access to the Company‚Äôs share capital;4. retention and future delivery for payment or exchange purposes in connection with transactions involving external growth;5. ensuring market liquidity within the framework of a liquidity agreement that complies with a code of ethics recognised by the Autorit√© des March√©s Financiers and entrusted to an investment service provider acting independently;6. implementation of any market practice  any objective or any transaction that may be accepted by laws or regulations or in force or by the Autorit√© des March√©s Financiers in respect of share buy-back programmes.The maximum purchase price per share is set at ‚Ç¨140. The maximum number of shares purchased by virtue of this authorisation shall not exceed 10% of the share capital. This limit is calculated at the time of the purchases and the maximum amount of shares thus purchased shall not exceed ‚Ç¨4 billion.The share purchase price shall be adjusted by the Board of Directors in the event of transactions involving the Company‚Äôs capital in compliance with the conditions provided for by the applicable regulations. In particular  in the event of a capital increase through the capitalisation of reserves and the allotment of performance shares  the price specified above shall be adjusted by a multiplier equal to the ratio of the number of shares making up the share capital before the transaction to the number of shares after the transaction.The acquisition  disposal  transfer  allotment or exchange of these shares may be carried out by any means that are authorised or that may become authorised by regulations in force  either on-market or off-market  including block transactions or through the use of derivatives  in particular through share purchase options in accordance with the regulations in force. There is no restriction on the proportion of the share buy-back programme that may be carried out through block transactions.These transactions may be carried out at any time in compliance with the current regulations  except during a public offering period.The Shareholders‚Äô General Meeting grants full powers to the Board of Directors  including the ability to delegate such powers  so that  in compliance with the applicable legal and regulatory provisions  including those on stock exchange disclosure requirements  it may proceed with the authorised reallocations of the shares purchased in view of one of the programme‚Äôs objectives to one or more of its other objectives  or sell them on-market or off-market  it being specified that these reallocations and disposals may concern shares purchased pursuant to previously authorised share buy-back programmes.The Shareholders‚Äô General Meeting grants full powers to the Board of Directors  including the ability to delegate such powers  for the purpose of placing stock market orders  signing any deed of purchase  sale or transfer  entering into any agreement  carrying out any necessary adjustments  making all declarations and completing all formalities.This authorisation is granted for a period of 18 months from the date of this Shareholders‚Äô General Meeting. It renders ineffective and replaces the authorisation granted by the Shareholders‚Äô General Meeting on 12 April 2022 in its tenth resolution.Fifteenth resolutionRenewal of the authorisation granted to the Board of Directors in view of the reduction of the share capital through cancellation of VINCI shares held in treasuryThe Shareholders‚Äô General Meeting  voting under the quorum and majority conditions required for Extraordinary Shareholders‚Äô General Meetings  having considered the Report of the Board of Directors and the Special Report of the Statutory Auditors  in accordance with the provisions of Article L.22-10-62 of the French Commercial Code  authorises the Board of Directors to cancel  at its sole discretion  on one or more occasions  within the limit of 10% of the number of shares making up the share capital on the date when the Board of Directors takes a decision to cancel and over successive periods of 24 months for the determination of this limit  the shares purchased by virtue of the authorisations granted to the Company to purchase its own shares  and to proceed with a reduction in share capital equivalent to that amount.The Shareholders‚Äô General Meeting establishes the validity of this authorisation at 26 months as from the date of the present Meeting and grants full powers to the Board of Directors  including the powers to delegate such powers  to take all decisions necessary for the cancellation of shares and reduction of the share capital  to recognise the difference between the purchase price and the nominal value of the shares in the reserve account of its choice  including the account for ‚Äúshare premiums arising on contributions or mergers‚Äù  to perform all actions  formalities or declarations to finalise the reductions in capital which may be carried out by virtue of this authorisation  and to amend the Company‚Äôs Articles of Association accordingly.This authorisation renders ineffective and replaces the authorisation granted by the Shareholders‚Äô General Meeting on 12 April 2022 in its fifteenth resolution.IV-Arrangements1. Maximum proportion of the share capital that may be acquired and maximum amount payable by VINCIThe maximum proportion of the share capital that VINCI may acquire is 10% of the share capital on the date of the Combined Shareholders‚Äô General Meeting. However  in the event of a change in the share capital after that date  the authorisation granted by the General Meeting would apply to 10% of the new share capital.The maximum purchase price per share is set at ‚Ç¨140.The maximum total amount of capital that may be allocated to share purchases by virtue of this programme amounts to ‚Ç¨4 billion. This maximum amount shall apply for all transactions carried out from 13 April 2023 over the duration of the programme: purchases of treasury shares  acquisitions of derivatives on treasury shares  treasury share subscriptions through the exercise of derivatives previously put in place  additional amounts that may be allocated to the liquidity agreement.The Company reserves the right to use the entire programme.VINCI shall ensure that it does not directly or indirectly exceed the buy-back ceiling of 10% of the share capital authorised by the Shareholders‚Äô General Meeting over the programme‚Äôs 18-month term.It shall furthermore ensure that it does not own at any time  directly or indirectly  more than 10% of its share capital.Moreover  the share buy-back programme shall not have any significant impact on VINCI‚Äôs free float  which amounted to 82.4% of the share capital on 31 December 2022.The amount of the Company‚Äôs available reserves  which was ‚Ç¨29 144 million at 31 December 2022  is  as required by law  higher than the amount of the share buy-back programme.2. Share buy-back arrangementsShares may be purchased fully or partly by any means that are authorised or that may become authorised by regulations in force  either on-market or off-market  including block transactions or through the use of derivatives  including through share purchase options in accordance with regulations in force. The Company shall be careful not to increase the volatility of its share price if it uses derivatives.These transactions may be carried out at any time in compliance with the current regulations  except during a public offering period.The proposed authorisation submitted to the General Meeting does not restrict the proportion of the programme that may be carried out through the acquisition of blocks of shares.3. Duration and timeframe of the share purchase and cancellation programmeShare purchases may be carried out over a period of 18 months following the date of the Shareholders‚Äô General Meeting  i.e. from 13 April 2023 until 12 October 2024.Pursuant to paragraph 4 of Article L.22-10-62 of the French Commercial Code  the shares purchased can only be cancelled up to a limit of 10% of the share capital over successive rolling periods of 24 months.4. Use of derivativesVINCI reserves the right to use derivatives for the implementation of this programme in order to cover  under current regulations  option positions that it has taken separately (such as share subscription or purchase options granted or issued debt securities giving access to the share capital). Information on the use of derivatives on treasury shares is systematically provided to the Board of Directors.Board of Directors of VINCIand  by delegation of the Board of Directors ________________________Xavier HuillardChairman and Chief Executive Officerle 23 February 2023This document  which constitutes the 2023-2024 share buy-back programme submitted for the approval of VINCI‚Äôs Shareholders‚Äô General Meeting on 13 April 2023  is available free of charge on request from:VINCI Shareholder Relations Department1973 boulevard de la D√©fense  F-92000 Nanterre.It is available online on the VINCI website (www.vinci.com) and has been filed with the Autorit√© des March√©s Financiers.Attachment,neutral,0.0,1.0,0.0,neutral,0.01,0.98,0.02,True,English,"['2023-2024 treasury share buy-back programme', 'Combined General Meeting', 'Description', 'Board', 'Directors', 'approval', 'Shareholders', '13 April', 'share purchase option allocation plans', 'des March√©s Financiers', '2023-2024 treasury share buy-back programme', 'similar employee savings structure', 'French financial markets regulator', 'Combined Shareholders‚Äô General Meeting', '2023-2024 share buy-back programme', 'new share buy-back programme', 'French public limited company', 'Combined General Meeting', '2023-2024 buy-back programme', 'employee savings plans', 'share purchase options', 'soci√©t√© anonyme', 'la D√©fense', 'employee savings UCITS', 'share ownership plan', 'investment service provider', 'VINCI Group companies', 'Maximum purchase price', 'purchase cost', 'buy-back programmes', 'financial policy', 'share capital', 'English French', 'treasury shares', 'Registered office', 'A Compartment', 'regulated market', 'NYSE Euronext', 'Additional amounts', 'liquidity agreement', 'foreign law', 'exchange purposes', 'external growth', 'market liquidity', 'market practice', 'company officers', 'Maximum amount', 'RCS Nanterre', 'VINCI shares', 'eligible employees', 'ISIN code', 'maximum number', '18-month duration', 'Company shares', '1973 boulevard', 'Description', 'Board', 'Directors', 'approval', '13 April', 'I-Summary', 'trading', 'Paris', 'possibility', 'period', '18 months', '12 October', 'time', 'purchases', 'derivatives', 'exercise', 'calculation', 'connection', 'place', 'Objectives', 'disposals', 'transfers', 'context', 'cancellation', 'delivery', 'rights', 'securities', 'access', 'payment', 'transactions', 'ethics', 'AMF', 'implementation', 'laws', 'regulations', 'force', 'respect', 'use', 'behalf', 'pledges', 'guarantees', 'adoption']",2023-02-24,2023-02-25,globenewswire.com
19270,EuroNext,NewsApi.org,https://salesandmarketingnetwork.com/news_release_bs.html?ID=2047915,News for Medical Independent Sales Representatives and Medical Distributors: FDA approves once-weekly efanesoctocog alfa  a new class of high-sustained factor VIII therapy for haemophilia A: Swedish O,STOCKHOLM  Feb. 24  2023 -- (Healthcare Sales & Marketing Network) -- Sobi¬Æ today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl]  a first-... Biop‚Ä¶,"BiopharmaceuticalsFDANews Release - February 24  2023FDA approves once-weekly efanesoctocog alfa  a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum ABSTOCKHOLM  Feb. 24  2023 -- (Healthcare Sales & Marketing Network) -- Sobi¬Æ today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl]  a first-in-class  high-sustained factor VIII replacement therapy for adults and children with haemophilia A. Efanesoctocog alfa is the first and only haemophilia A treatment that provides patients with normal to near-normal factor VIII activity levels for a significant part of the week with once-weekly dosing  resulting in superior protection from bleeds compared to existing factor VIII prophylaxis.Haemophilia A is a rare  genetic disorder in which the ability of a person's blood to clot is impaired due to a lack of factor VIII. Haemophilia A occurs in about one in 5 000 male births annually  and more rarely in females. People with haemophilia can experience bleeding episodes that can cause pain  irreversible joint damage and life-threatening haemorrhages. Despite advancements in treatment made in recent years  a large unmet medical need still exists and requires further improvement in the standard of care.""This approval marks an important clinical advancement for the haemophilia community because we have an option that can achieve higher levels of factor activity with a single weekly dose "" said Lynn Malec  MD  Medical Director of Comprehensive Center for Bleeding Disorders and Associate Investigator at Versiti Blood Research Institute  and Associate Professor of Medicine and Pediatrics at The Medical College of Wisconsin  US. ""By maintaining high levels of factor activity throughout the week  patients can be confident in the bleed protection efanesoctocog alfa offers.""""On behalf of Sobi I'd like to congratulate our co-development partner Sanofi on this great achievement "" said Anders Ullman  Head of Research & Development and Medical Affairs  Chief Medical Officer at Sobi. ""This is a major milestone in our collaboration as we work towards providing access to this important new treatment for people living with haemophilia A around the world.""The FDA approval is primarily based on data from the pivotal XTEND-1 phase 3 study recently published in The New England Journal of Medicine. Once-weekly efanesoctocog alfa met the primary endpoint  providing significant improvements in bleed protection for people with severe haemophilia A with median and mean annualised bleeding rates (ABR) of 0.00 (interquartile range: 0.00-1.04) and 0.71 (95% confidence interval: 0.52-0.97)  respectively. Efanesoctocog alfa met the key secondary endpoint with a significant reduction of 77% in ABR versus prior factor prophylaxis based on an intra-patient comparison. Efanesoctocog alfa prophylaxis with 50IU/kg/week provided mean factor VIII activity greater than 40% for the majority of the week with a trough activity of 15% on day seven  and these levels were associated with a low bleed risk.Additional data showed prevention of joint bleeds with a median annualised joint bleeding rate of 0 (Q1  Q3: 0.0  1.0). Treatment with efanesoctocog alfa provided 100% resolution of target joints  which are joints that have recurrent bleeds (e.g.  knee  ankle  or elbow). In adults and adolescents  efanesoctocog alfa had a favourable safety profile and there were no signs of factor VIII inhibitor development.Efanesoctocog alfa is indicated in the US for routine prophylaxis  on-demand treatment and control of bleeding episodes  and perioperative management of bleeding. The recommended weekly dose of 50 IU/kg is intended for prophylaxis in patients of all ages and the same dose can be administered according to needs in different clinical settings. Efanesoctocog alfa is expected to be commercially available in the US starting in the second quarter of 2023 and will be marketed as ALTUVIIIO¬ô in Sanofi territories.The FDA evaluated the application under Priority Review  which is granted to therapies that have the potential to provide significant improvements in the treatment  diagnosis  or prevention of serious conditions.Regulatory submission in the EU will follow the availability of final data from the XTEND-Kids paediatric study in the first half of 2023. The European Commission granted orphan designation in June 2019.About efanesoctocog alfaEfanesoctocog alfa (formerly BIVV001) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for most of the week  extending bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN¬Æ polypeptides to potentially extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling  which is believed to impose a half-life limitation on current factor VIII therapies. It is approved as ALTUVIIIO [Antihemophilic Factor (Recombinant)  Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the US. It is not approved in any country outside the US.About the Sanofi and Sobi collaborationSobi and Sanofi collaborate on the development and commercialisation of Alprolix¬Æ and Elocta¬Æ/Eloctate¬Æ. The companies also collaborate on the development and commercialisation of efanesoctocog alfa or ALTUVIIIO in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe  North Africa  Russia and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.SanofiSanofi are an innovative global healthcare company  driven by one purpose: to chase the miracles of science to improve people's lives. Their team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the centre of our ambitions. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY.Sobi¬ÆSobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology  immunology and specialty care  Sobi has approximately 1 600 employees across Europe  North America  the Middle East  Asia and Australia. In 2022  revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com  LinkedIn and YouTube.Source: Swedish Orphan BiovitrumIssuer of this News Release is solely responsible for its content.Please address inquiries directly to the issuing company.",neutral,0.0,1.0,0.0,mixed,0.26,0.17,0.57,True,English,"['high-sustained factor VIII therapy', 'Medical Independent Sales Representatives', 'Medical Distributors', 'efanesoctocog alfa', 'new class', 'haemophilia A', 'Swedish O', 'News', 'FDA', 'high-sustained factor VIII replacement therapy', 'investigational recombinant factor VIII therapy', 'median annualised joint bleeding rate', 'normal factor VIII activity levels', 'pivotal XTEND-1 phase 3 study', 'high-sustained factor VIII therapy', 'innovative Fc fusion technology', 'mean annualised bleeding rates', 'Swedish Orphan Biovitrum AB', 'mean factor VIII activity', 'large unmet medical need', 'von Willebrand factor ceiling', 'existing factor VIII prophylaxis', 'The New England Journal', 'factor VIII inhibitor development', 'near-normal factor activity levels', 'Versiti Blood Research Institute', 'haemophilia A. Efanesoctocog alfa', 'Fc-VWF-XTEN Fusion Protein-ehtl', 'irreversible joint damage', 'prior factor prophylaxis', 'rare, genetic disorder', 'important clinical advancement', 'low bleed risk', 'favourable safety profile', 'different clinical settings', 'The European Commission', 'The Medical College', 'Chief Medical Officer', 'key secondary endpoint', 'FDA News Release', 'efanesoctocog alfa offers', 'important new treatment', 'single weekly dose', 'Efanesoctocog alfa prophylaxis', 'weekly efanesoctocog alfa', 'The FDA approval', 'haemophilia A treatment', 'Antihemophilic Factor', 'joint bleeds', 'trough activity', 'new class', 'orphan designation', 'higher levels', 'Medical Director', 'high levels', 'Medical Affairs', 'bleeding episodes', 'Bleeding Disorders', 'routine prophylaxis', 'primary endpoint', 'weekly dosing', 'development partner', 'haemophilia community', 'severe haemophilia', 'same dose', 'Healthcare Sales', 'Marketing Network', 'Drug Administration', 'significant part', '5,000 male births', 'life-threatening haemorrhages', 'recent years', 'Lynn Malec', 'Comprehensive Center', 'Associate Investigator', 'Associate Professor', 'great achievement', 'Anders Ullman', 'major milestone', 'significant improvements', 'interquartile range', 'significant reduction', 'intra-patient comparison', 'recurrent bleeds', 'perioperative management', 'second quarter', 'Priority Review', 'serious conditions', 'Regulatory submission', 'XTEN¬Æ polypeptides', 'demand treatment', 'Additional data', 'final data', 'target joints', 'Sanofi territories', 'first half', 'US Food', 'superior protection', 'Biopharmaceuticals', 'February', 'Feb.', 'Sobi¬Æ', 'adults', 'children', 'patients', 'ability', 'person', 'lack', 'females', 'People', 'pain', 'advancements', 'standard', 'option', 'MD', 'Medicine', 'Pediatrics', 'Wisconsin', 'behalf', 'Head', 'collaboration', 'access', 'world', 'ABR', '50IU/kg', 'majority', 'day', 'seven', 'prevention', '100% resolution', 'knee', 'ankle', 'elbow', 'adolescents', 'signs', 'control', '50 IU', 'needs', 'ALTUVIIIO', 'application', 'potential', 'diagnosis', 'June', 'novel', 'region', 'time', 'circulation']",2023-02-24,2023-02-25,salesandmarketingnetwork.com
19271,EuroNext,Twitter API,Twitter,Euronext has no plans to copy rivals with cloud computing deal - Yahoo News https://t.co/LpjMEfubs8 #cloudcomputing‚Ä¶ https://t.co/Ca1JOFpQ3A,nan,Euronext has no plans to copy rivals with cloud computing deal - Yahoo News https://t.co/LpjMEfubs8 #cloudcomputing‚Ä¶ https://t.co/Ca1JOFpQ3A,neutral,0.11,0.87,0.02,neutral,0.11,0.87,0.02,True,English,"['cloud computing deal', 'Yahoo News', 'Euronext', 'plans', 'rivals', 'LpjMEfubs8', 'Ca1JOFpQ3A', 'cloud computing deal', 'Yahoo News', 'Euronext', 'plans', 'rivals', 'LpjMEfubs8', 'Ca1JOFpQ3A']",2023-02-25,2023-02-25,Unknown
19272,EuroNext,Twitter API,Twitter,Euronext in talks to buy Allfunds  conditional on shareholder approval https://t.co/g3o0wsPCeo #finance #financial #finanzas #finanza,nan,Euronext in talks to buy Allfunds  conditional on shareholder approval https://t.co/g3o0wsPCeo #finance #financial #finanzas #finanza,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['shareholder approval', 'Euronext', 'talks', 'Allfunds', 'finanzas', 'shareholder approval', 'Euronext', 'talks', 'Allfunds', 'finanzas']",2023-02-25,2023-02-25,Unknown
19273,EuroNext,Twitter API,Twitter,@paulturner2012 L'Arche Green N.VOwnership. Heineken Holding N.V is a public company listed on the NYSE Euronext‚Ä¶ https://t.co/Y8T1MR0U84,nan,@paulturner2012 L'Arche Green N.VOwnership. Heineken Holding N.V is a public company listed on the NYSE Euronext‚Ä¶ https://t.co/Y8T1MR0U84,neutral,0.11,0.89,0.01,neutral,0.11,0.89,0.01,True,English,"['Heineken Holding N.V', 'public company', 'paulturner2012', 'Y8T1MR0U84', 'Heineken Holding N.V', 'public company', 'paulturner2012', 'Y8T1MR0U84']",2023-02-25,2023-02-25,Unknown
19274,EuroNext,Twitter API,Twitter,This Week in European Tech: Slava Ukraini  Volocopter tops up Series E round  Euronext chases ‚Ç¨5.5 billion Allfunds‚Ä¶ https://t.co/ZDuM5HmYXk,nan,This Week in European Tech: Slava Ukraini  Volocopter tops up Series E round  Euronext chases ‚Ç¨5.5 billion Allfunds‚Ä¶ https://t.co/ZDuM5HmYXk,neutral,0.09,0.86,0.04,neutral,0.09,0.86,0.04,True,English,"['Series E round', 'European Tech', 'Slava Ukraini', 'Volocopter', 'Euronext', 'ZDuM5HmYXk', 'Series E round', 'European Tech', 'Slava Ukraini', 'Volocopter', 'Euronext', 'ZDuM5HmYXk']",2023-02-25,2023-02-25,Unknown
19275,EuroNext,Twitter API,Twitter,Fireside Friday with... Euronext‚Äôs Stephane Boujnah‚ÄØ - The TRADE https://t.co/qhgtJEKy4f,nan,Fireside Friday with... Euronext‚Äôs Stephane Boujnah‚ÄØ - The TRADE https://t.co/qhgtJEKy4f,neutral,0.04,0.96,0.01,neutral,0.04,0.96,0.01,True,English,"['Stephane Boujnah', 'The TRADE', 'Fireside', 'Euronext', 'qhgtJEKy4f', 'Stephane Boujnah', 'The TRADE', 'Fireside', 'Euronext', 'qhgtJEKy4f']",2023-02-25,2023-02-25,Unknown
